Darrell Wilson

All Publications

• Sustained Continuous Glucose Monitor Use in Low-Income Youth with Type 1 Diabetes Following Insurance Coverage Supports Expansion of Continuous Glucose Monitor Coverage for All. Diabetes technology & therapeutics Prahalad, P., Addala, A., Buckingham, B., Wilson, D. M., Maahs, D. M. 2018

  View details for PubMedID 30020810

• Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents PEDIATRIC DIABETES Forlenza, G. P., Raghinaru, D., Cameron, F., Bequette, B., Chase, H., Wadwa, R., Maahs, D. M., Jost, E., Ly, T. T., Wilson, D. M., Norlander, L., Ekhlaspour, L., Min, H., Clinton, P., Njeru, N., Lum, J. W., Kollman, C., Beck, R. W., Buckingham, B. A., In-Home Closed-Loop IHCL Study Grp 2018; 19 (3): 420–28

  Abstract

  The primary objective of this trial was to evaluate the feasibility, safety, and efficacy of a predictive hyperglycemia and hypoglycemia minimization (PHHM) system vs predictive low glucose suspension (PLGS) alone in optimizing overnight glucose control in children 6 to 14 years old.Twenty-eight participants 6 to 14 years old with T1D duration ≥1 year with daily insulin therapy ≥12 months and on insulin pump therapy for ≥6 months were randomized per night into PHHM mode or PLGS-only mode for 42 nights. The primary outcome was percentage of time in sensor-measured range 70 to 180 mg/dL in the overnight period.The addition of automated insulin delivery with PHHM increased time in target range (70-180 mg/dL) from 66 ± 11% during PLGS nights to 76 ± 9% during PHHM nights (P<.001), without increasing hypoglycemia as measured by time below various thresholds. Average morning blood glucose improved from 176 ± 28 mg/dL following PLGS nights to 154 ± 19 mg/dL following PHHM nights (P<.001).The PHHM system was effective in optimizing overnight glycemic control, significantly increasing time in range, lowering mean glucose, and decreasing glycemic variability compared to PLGS alone in children 6 to 14 years old.

  View details for PubMedID 29159870

• Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes. Diabetes care Spaic, T., Driscoll, M., Raghinaru, D., Buckingham, B. A., Wilson, D. M., Clinton, P., Chase, H. P., Maahs, D. M., Forlenza, G. P., Jost, E., Hramiak, I., Paul, T., Bequette, B. W., Cameron, F., Beck, R. W., Kollman, C., Lum, J. W., Ly, T. T. 2017; 40 (3): 359-366

  Abstract

  The objective of this study was to determine the safety, feasibility, and efficacy of a predictive hyperglycemia and hypoglycemia minimization (PHHM) system compared with predictive low-glucose insulin suspension (PLGS) alone in overnight glucose control.A 42-night trial was conducted in 30 individuals with type 1 diabetes in the age range 15-45 years. Participants were randomly assigned each night to either PHHM or PLGS and were blinded to the assignment. The system suspended the insulin pump on both the PHHM and PLGS nights for predicted hypoglycemia but delivered correction boluses for predicted hyperglycemia on PHHM nights only. The primary outcome was the percentage of time spent in a sensor glucose range of 70-180 mg/dL during the overnight period.The addition of automated insulin delivery with PHHM increased the time spent in the target range (70-180 mg/dL) from 71 ± 10% during PLGS nights to 78 ± 10% during PHHM nights (P < 0.001). The average morning blood glucose concentration improved from 163 ± 23 mg/dL after PLGS nights to 142 ± 18 mg/dL after PHHM nights (P < 0.001). Various sensor-measured hypoglycemic outcomes were similar on PLGS and PHHM nights. All participants completed 42 nights with no episodes of severe hypoglycemia, diabetic ketoacidosis, or other study- or device-related adverse events.The addition of a predictive hyperglycemia minimization component to our existing PLGS system was shown to be safe, feasible, and effective in overnight glucose control.

  View details for DOI 10.2337/dc16-1794

  View details for PubMedID 28100606

• Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial LANCET El-Khatib, F. H., Balliro, C., Hillard, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M. J., Malkani, S., Lock, J. P., Harlan, D. M., Clinton, P., Frank, E., Wilson, D. M., DeSalvo, D., Norlander, L., Ly, T., Buckingham, B. A., Diner, J., Dezube, M., Young, L. A., Goley, A., Kirkman, M. S., Buse, J. B., Zheng, H., Selagamsetty, R. R., Damiano, E. R., Russell, S. J. 2017; 389 (10067): 369-380

  Abstract

  The safety and effectiveness of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has not been shown in a free-living, home-use setting. We aimed to assess whether bihormonal bionic pancreas initialised only with body mass can safely reduce mean glycaemia and hypoglycaemia in adults with type 1 diabetes who were living at home and participating in their normal daily routines without restrictions on diet or physical activity.We did a random-order crossover study in volunteers at least 18 years old who had type 1 diabetes and lived within a 30 min drive of four sites in the USA. Participants were randomly assigned (1:1) in blocks of two using sequentially numbered sealed envelopes to glycaemic regulation with a bihormonal bionic pancreas or usual care (conventional or sensor-augmented insulin pump therapy) first, followed by the opposite intervention. Both study periods were 11 days in length, during which time participants continued all normal activities, including athletics and driving. The bionic pancreas was initialised with only the participant's body mass. Autonomously adaptive dosing algorithms used data from a continuous glucose monitor to control subcutaneous delivery of insulin and glucagon. The coprimary outcomes were the mean glucose concentration and time with continuous glucose monitoring (CGM) glucose concentration less than 3·3 mmol/L, analysed over days 2-11 in participants who completed both periods of the study. This trial is registered with ClinicalTrials.gov, number NCT02092220.We randomly assigned 43 participants between May 6, 2014, and July 3, 2015, 39 of whom completed the study: 20 who were assigned to bionic pancreas first and 19 who were assigned to the comparator first. The mean CGM glucose concentration was 7·8 mmol/L (SD 0·6) in the bionic pancreas period versus 9·0 mmol/L (1·6) in the comparator period (difference 1·1 mmol/L, 95% CI 0·7-1·6; p<0·0001), and the mean time with CGM glucose concentration less than 3·3 mmol/L was 0·6% (0·6) in the bionic pancreas period versus 1·9% (1·7) in the comparator period (difference 1·3%, 95% CI 0·8-1·8; p<0·0001). The mean nausea score on the Visual Analogue Scale (score 0-10) was greater during the bionic pancreas period (0·52 [SD 0·83]) than in the comparator period (0·05 [0·17]; difference 0·47, 95% CI 0·21-0·73; p=0·0024). Body mass and laboratory parameters did not differ between periods. There were no serious or unexpected adverse events in the bionic pancreas period of the study.Relative to conventional and sensor-augmented insulin pump therapy, the bihormonal bionic pancreas, initialised only with participant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate counting. Larger and longer studies are needed to establish the long-term benefits and risks of automated glycaemic management with a bihormonal bionic pancreas.National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and National Center for Advancing Translational Sciences.

  View details for DOI 10.1016/S0140-6736(16)32567-3

  View details for PubMedID 28007348

• Variations in Brain Volume and Growth in Young Children With Type 1 Diabetes. Diabetes Mazaika, P. K., Weinzimer, S. A., Mauras, N., Buckingham, B., White, N. H., Tsalikian, E., Hershey, T., Cato, A., Aye, T., Fox, L., Wilson, D. M., Tansey, M. J., Tamborlane, W., Peng, D., Raman, M., Marzelli, M., Reiss, A. L. 2016; 65 (2): 476-485

  Abstract

  Early-onset type 1 diabetes may affect the developing brain during a critical window of rapid brain maturation. Structural MRI was performed on 141 children with diabetes (4-10 years of age at study entry) and 69 age-matched control subjects at two time points spaced 18 months apart. For the children with diabetes, the mean (±SD) HbA1c level was 7.9 ± 0.9% (63 ± 9.8 mmol/mol) at both time points. Relative to control subjects, children with diabetes had significantly less growth of cortical gray matter volume and cortical surface area and significantly less growth of white matter volume throughout the cortex and cerebellum. For the population with diabetes, the change in the blood glucose level at the time of scan across longitudinal time points was negatively correlated with the change in gray and white matter volumes, suggesting that fluctuating glucose levels in children with diabetes may be associated with corresponding fluctuations in brain volume. In addition, measures of hyperglycemia and glycemic variation were significantly negatively correlated with the development of surface curvature. These results demonstrate that early-onset type 1 diabetes has widespread effects on the growth of gray and white matter in children whose blood glucose levels are well within the current treatment guidelines for the management of diabetes.

  View details for DOI 10.2337/db15-1242

  View details for PubMedID 26512024

• Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes cAMP. Diabetes care Ly, T. T., Breton, M. D., Keith-Hynes, P., De Salvo, D., Clinton, P., Benassi, K., Mize, B., Chernavvsky, D., Place, J., Wilson, D. M., Kovatchev, B. P., Buckingham, B. A. 2014; 37 (8): 2310-2316

  Abstract

  To determine the safety and efficacy of an automated unified safety system (USS) in providing overnight closed-loop (OCL) control in children and adolescents with type 1 diabetes attending diabetes summer camps.RESEARCH DESIGN AND METHODS: The Diabetes Assistant (DIAS) USS used the Dexcom G4P glucose sensor (Dexcom) and t:slim insulin pump (Tandem Diabetes Care). An initial inpatient study was completed for 12 participants to evaluate safety. For the main camp study, 20 participants with type 1 diabetes were randomized to either OCL or sensor-augmented therapy (control conditions) per night over the course of a 5- to 6-day diabetes camp.RESULTS: Subjects completed 54 OCL nights and 52 control nights. On an intention-to-treat basis, with glucose data analyzed regardless of system status, the median percent time in range, from 70-150 mg/dL, was 62% (29, 87) for OCL nights versus 55% (25, 80) for sensor-augmented pump therapy (P = 0.233). A per-protocol analysis allowed for assessment of algorithm performance. The median percent time in range, from 70-150 mg/dL, was 73% (50, 89) for OCL nights (n = 41) versus 52% (24, 83) for control conditions (n = 39) (P = 0.037). There was less time spent in the hypoglycemic range <50, <60, and <70 mg/dL during OCL compared with the control period (P = 0.019, P = 0.009, and P = 0.023, respectively).CONCLUSIONS: The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.

  View details for DOI 10.2337/dc14-0147

  View details for PubMedID 24879841

• A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes DIABETES CARE Maahs, D. M., Calhoun, P., Buckingham, B. A., Chase, H. P., Hramiak, I., Lum, J., Cameron, F., Bequette, B. W., Aye, T., Paul, T., Slover, R., Wadwa, R. P., Wilson, D. M., Kollman, C., Beck, R. W. 2014; 37 (7): 1885-1891

  Abstract

  Overnight hypoglycemia occurs frequently in individuals with type 1 diabetes and can result in loss of consciousness, seizure, or even death. We conducted an in-home randomized trial to determine whether nocturnal hypoglycemia could be safely reduced by temporarily suspending pump insulin delivery when hypoglycemia was predicted by an algorithm based on continuous glucose monitoring (CGM) glucose levels.Following an initial run-in phase, a 42-night trial was conducted in 45 individuals aged 15-45 years with type 1 diabetes in which each night was assigned randomly to either having the predictive low-glucose suspend system active (intervention night) or inactive (control night). The primary outcome was the proportion of nights in which ≥1 CGM glucose values ≤60 mg/dL occurred.Overnight hypoglycemia with at least one CGM value ≤60 mg/dL occurred on 196 of 942 (21%) intervention nights versus 322 of 970 (33%) control nights (odds ratio 0.52 [95% CI 0.43-0.64]; P < 0.001). Median hypoglycemia area under the curve was reduced by 81%, and hypoglycemia lasting >2 h was reduced by 74%. Overnight sensor glucose was >180 mg/dL during 57% of control nights and 59% of intervention nights (P = 0.17), while morning blood glucose was >180 mg/dL following 21% and 27% of nights, respectively (P < 0.001), and >250 mg/dL following 6% and 6%, respectively. Morning ketosis was present <1% of the time in each arm.Use of a nocturnal low-glucose suspend system can substantially reduce overnight hypoglycemia without an increase in morning ketosis.

  View details for DOI 10.2337/dc13-2159

  View details for Web of Science ID 000338020400022

  View details for PubMedCentralID PMC4067393

• Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment DIABETES CARE Orban, T., Bundy, B., Becker, D. J., Dimeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., Moran, A., Peakman, M., Raskin, P., Russell, W. E., Schatz, D., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S. 2014; 37 (4): 1069-1075

  Abstract

  OBJECTIVE We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine whether there was persistence of effect. RESEARCH DESIGN AND METHODS Of 112 subjects (ages 6-36 years) with T1D, 77 received abatacept and 35 received placebo infusions intravenously for 27 infusions over 2 years. The primary outcome-baseline-adjusted geometric mean 2-h area under the curve (AUC) serum C-peptide during a mixed-meal tolerance test (MMTT) at 2 years-showed higher C-peptide with abatacept versus placebo. Subjects were followed an additional year, off treatment, with MMTTs performed at 30 and 36 months. RESULTS C-peptide AUC means, adjusted for age and baseline C-peptide, at 36 months were 0.217 nmol/L (95% CI 0.168-0.268) and 0.141 nmol/L (95% CI 0.071-0.215) for abatacept and placebo groups, respectively (P = 0.046). The C-peptide decline from baseline remained parallel with an estimated 9.5 months' delay with abatacept. Moreover, HbA1c levels remained lower in the abatacept group than in the placebo group. The slightly lower (nonsignificant) mean total insulin dose among the abatacept group reported at 2 years was the same as the placebo group by 3 years. CONCLUSIONS Costimulation modulation with abatacept slowed decline of β-cell function and improved HbA1c in recent-onset T1D. The beneficial effect was sustained for at least 1 year after cessation of abatacept infusions or 3 years from T1D diagnosis.

  View details for DOI 10.2337/dc13-0604

  View details for Web of Science ID 000333414700039

  View details for PubMedID 24296850

  View details for PubMedCentralID PMC3964491

• Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial LANCET Wherrett, D. K., Bundy, B., Becker, D. J., Dimeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., Monzavi, R., Moran, A., Orban, T., Palmer, J. P., Raskin, P., Rodriguez, H., Schatz, D., Wilson, D. M., Krischer, J. P., Skyler, J. S. 2011; 378 (9788): 319-327

  Abstract

  Glutamic acid decarboxylase (GAD) is a major target of the autoimmune response that occurs in type 1 diabetes mellitus. In animal models of autoimmunity, treatment with a target antigen can modulate aggressive autoimmunity. We aimed to assess whether immunisation with GAD formulated with aluminum hydroxide (GAD-alum) would preserve insulin production in recent-onset type 1 diabetes.Patients aged 3-45 years who had been diagnosed with type 1 diabetes for less than 100 days were enrolled from 15 sites in the USA and Canada, and randomly assigned to receive one of three treatments: three injections of 20 μg GAD-alum, two injections of 20 μg GAD-alum and one of alum, or 3 injections of alum. Injections were given subcutaneously at baseline, 4 weeks later, and 8 weeks after the second injection. The randomisation sequence was computer generated at the TrialNet coordinating centre. Patients and study personnel were masked to treatment assignment. The primary outcome was the baseline-adjusted geometric mean area under the curve (AUC) of serum C-peptide during the first 2 h of a 4-h mixed meal tolerance test at 1 year. Secondary outcomes included changes in glycated haemoglobin A(1c) (HbA(1c)) and insulin dose, and safety. Analysis included all randomised patients with known measurements. This trial is registered with ClinicalTrials.gov, number NCT00529399.145 patients were enrolled and treated with GAD-alum (n=48), GAD-alum plus alum (n=49), or alum (n=48). At 1 year, the 2-h AUC of C-peptide, adjusted for age, sex, and baseline C-peptide value, was 0·412 nmol/L (95% CI 0·349-0·478) in the GAD-alum group, 0·382 nmol/L (0·322-0·446) in the GAD-alum plus alum group, and 0·413 nmol/L (0·351-0·477) in the alum group. The ratio of the population mean of the adjusted geometric mean 2-h AUC of C-peptide was 0·998 (95% CI 0·779-1·22; p=0·98) for GAD-alum versus alum, and 0·926 (0·720-1·13; p=0·50) for GAD-alum plus alum versus alum. HbA(1c), insulin use, and the occurrence and severity of adverse events did not differ between groups.Antigen-based immunotherapy therapy with two or three doses of subcutaneous GAD-alum across 4-12 weeks does not alter the course of loss of insulin secretion during 1 year in patients with recently diagnosed type 1 diabetes. Although antigen-based therapy is a highly desirable treatment and is effective in animal models, translation to human autoimmune disease remains a challenge.US National Institutes of Health.

  View details for DOI 10.1016/S0140-6736(11)60895-7

  View details for Web of Science ID 000293615800029

  View details for PubMedID 21714999

• Persistence of Individual Variations in Glycated Hemoglobin Analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial DIABETES CARE Wilson, D. M., Xing, D., Cheng, J., Beck, R. W., Hirsch, I., Kollman, C., Laffel, L., Lawrence, J. M., Mauras, N., Ruedy, K. J., Tsalikian, E., Wolpert, H. 2011; 34 (6): 1315-1317

  Abstract

  To determine the individual persistence of the relationship between mean sensor glucose (MG) concentrations and hemoglobin A(1c) (A1C) from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (CGM) Randomized Trial.MG was calculated using CGM data for 3 months before A1C measurements at 3, 6, 9, and 12 months for the CGM group and at 9 and 12 months for the control group. An MG-to-A1C ratio was included in analysis for subjects who averaged ≥4 days/week of CGM use.Spearman correlations of the MG-to-A1C ratio between consecutive visits 3 months apart ranged from 0.70 to 0.79. The correlations for children and youth were slightly smaller than those for adults. No meaningful differences were observed by device type or change in A1C.Individual variations in the rate of hemoglobin glycation are persistent and contribute to the inaccuracy in estimating MGs calculated from A1C levels.

  View details for DOI 10.2337/dc10-1661

  View details for PubMedID 21505208

• Hemoglobin A(1c) and Mean Glucose in Patients With Type 1 Diabetes Analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial DIABETES CARE Wilson, D. M., Xing, D., Beck, R. W., Block, J., Bode, B., Fox, L. A., Hirsch, I., Kollman, C., Laffel, L., Ruedy, K. J., Steffes, M., Tamborlane, W. V. 2011; 34 (3): 540-544

  Abstract

  To determine the relationship between mean sensor glucose concentrations and hemoglobin A(1c) (HbA(1c)) values measured in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications laboratory at the University of Minnesota in a cohort of subjects with type 1 diabetes from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial.Near-continuous glucose sensor data (≥ 4 days/week) were collected for 3 months before a central laboratory-measured HbA(1c) was performed for 252 subjects aged 8-74 years, the majority of whom had stable HbA(1c) values (77% within ± 0.4% of the patient mean).The slope (95% CI) for mean sensor glucose concentration (area under the curve) versus a centrally measured HbA(1c) was 24.4 mg/dL (22.0-26.7) for each 1% change in HbA(1c), with an intercept of -16.2 mg/dL (-32.9 to 0.6). Although the slope did not vary with age or sex, there was substantial individual variability, with mean sensor glucose concentrations ranging from 128 to 187 mg/dL for an HbA(1c) of 6.9-7.1%. The root mean square of the errors between the actual mean sensor glucose concentration versus the value calculated using the regression equation was 14.3 mg/dL, whereas the median absolute difference was 10.1 mg/dL.There is substantial individual variability between the measured versus calculated mean glucose concentrations. Consequently, estimated average glucose concentrations calculated from measured HbA(1c) values should be used with caution.

  View details for DOI 10.2337/dc10-1054

  View details for Web of Science ID 000288145400002

  View details for PubMedID 21266647

  View details for PubMedCentralID PMC3041177

• Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data DIABETES Haller, M. J., Long, S., Blanchfield, J., Schatz, D. A., Skyler, J. S., Krischer, J. P., Bundy, B. N., Geyer, S. M., Warnock, M. V., Miller, J. L., Atkinson, M. A., Becker, D. J., Baidal, D. A., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Herold, K. C., Marks, J. B., Moran, A., Rodriguez, H., Russell, W. E., Wilson, D. M., Greenbaum, C. J., Type 1 Diabet TrialNet ATG-GCSF 2019; 68 (6): 1267–76

  View details for DOI 10.2337/db19-0057

  View details for Web of Science ID 000468311600015

• Low-dose Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1 Diabetes: Two Year Clinical Trial Data. Diabetes Haller, M. J., Long, S. A., Blanchfield, J. L., Schatz, D. A., Skyler, J. S., Krischer, J. P., Bundy, B. N., Geyer, S. M., Warnock, M. V., Miller, J. L., Atkinson, M. A., Becker, D. J., Baidal, D. A., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Herold, K. C., Marks, J. B., Moran, A., Rodriguez, H., Russell, W. E., Wilson, D. M., Greenbaum, C. J., Type 1 Diabetes TrialNet ATG-GCSF Study Group 2019

  Abstract

  A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG, 2.5mg/kg) preserved beta-cell function and reduced HbA1c for one year in new-onset type 1 diabetes. Subjects (N=89) were randomized to: 1) ATG and pegylated granulocyte-colony stimulating factor (GCSF); 2) ATG alone; or 3) placebo. Herein, we report two-year AUC C-peptide and HbA1c, pre-specified secondary endpoints, and potential immunologic correlates. The two-year mean mixed-meal tolerance test (MMTT)-stimulated AUC C-peptide, analyzed by ANCOVA adjusting for baseline C-peptide, age, and sex (N=82) with significance defined as one-sided p<0.025, was significantly higher in subjects treated with ATG versus placebo (p=0.00005) but not ATG/GCSF versus placebo (p=0.032). HbA1c was significantly reduced at 2-years in subjects treated with ATG (p=0.011) and ATG/GCSF (p=0.022) versus placebo. Flow-cytometric analyses demonstrated reduced circulating CD4:CD8 ratio, increased regulatory T cell (Treg): conventional CD4 T cell (Tconv) ratios, and increased PD-1+CD4+ T cells following low-dose ATG and ATG/GCSF. Low-dose ATG partially preserved beta-cell function and reduced HbA1c two years after therapy in new-onset type 1 diabetes. Future studies should determine whether low-dose ATG might prevent or delay the onset of type 1 diabetes.

  View details for PubMedID 30967424

• A Feasibility Study to Detect Neonatal Hypoglycemia in Infants of Diabetic Mothers Using Real-Time Continuous Glucose Monitoring DIABETES TECHNOLOGY & THERAPEUTICS Nally, L., Bondy, N., Doiev, J., Buckingham, B. A., Wilson, D. M. 2019; 21 (4): 170–76

  View details for DOI 10.1089/dia.2018.0337

  View details for Web of Science ID 000463602900003

• A Feasibility Study to Detect Neonatal Hypoglycemia in Infants of Diabetic Mothers Using Real-Time Continuous Glucose Monitoring. Diabetes technology & therapeutics Nally, L. M., Bondy, N., Doiev, J., Buckingham, B., Wilson, D. M. 2019

  Abstract

  BACKGROUND: Infants born to mothers with diabetes commonly experience asymptomatic hypoglycemia after birth. Continuous glucose monitors (CGM) can detect asymptomatic hypoglycemia in this population without the need for painful glucose checks.METHODS: Infants born after 34 weeks of gestation to mothers with diabetes had a CGM placed after birth. One group of infants was remotely monitored in real-time by research staff during the hospitalization, whereas another group wore a blinded CGM. In both groups, hospital standard-of-care (SOC) glucose checks were performed. Clinical staff and families were blinded to CGM data. For CGM readings <45mg/dL, research staff requested a verification blood glucose (BG) using the point-of-care glucometer.RESULTS: Sixteen infants were studied; 4 with a blinded CGM and 12 with remote monitoring (RM). When there were confirmatory hospital glucometer readings, the sensitivity of the CGM to detect hypoglycemia was 86% and the specificity was 91%. The positive predictive value was 55% and the negative predictive value was 98%. In the full cohort, hypoglycemia (<45mg/dL) was confirmed in 12 of 16 infants with 30 events at <12 hours of life (HOL), 3 events between 12 and 24 HOL, and 1 event at >48 HOL. In the RM group, CGM detected hypoglycemia five times when the infant was not due for a BG check based on the SOC. Overall, the CGM detected five false-positive alerts and six true-positive alerts for hypoglycemia. Only one hypoglycemic episode was missed by CGM in the RM group. Barriers to recruitment included fear of pain with glucose checks, concerns with CGM use, satisfaction with the hospital SOC, personal reasons independent of the study, and lack of interest in participating in research.CONCLUSIONS: Although there were barriers to recruitment and retention in the study, we conclude that CGM can provide added benefit for detecting hypoglycemia when used early after birth.

  View details for PubMedID 30839229

• Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes DIABETES CARE Triolo, T. M., Fouts, A., Pyle, L., Yu, L., Gottlieb, P. A., Steck, A. K., Greenbaum, C. J., Atkinson, M., Baidal, D., Battaglia, M., Becker, D., Bingley, P., Bosi, E., Buckner, J., Clements, M., Colman, P., DiMeglio, L., Gitelman, S., Goland, R., Gottlieb, P., Goland, R., Gottlieb, P., Herold, K., Knip, M., Krischer, J., Lernmark, A., Moore, W., Moran, A., Muir, A., Palmer, J., Peakman, M., Philipson, L., Raskin, P., Redondo, M., Rodriguez, H., Russell, W., Spain, L., Schatz, D. A., Sosenko, J., Wentworth, J., Wherrett, D., Wilson, D., Winter, W., Ziegler, A., Anderson, M., Antinozzi, P., Benoist, C., Blum, J., Bourcier, K., Chase, P., Clare-Salzler, M., Clynes, R., Eisenbarth, G., Fathman, C. G., Grave, G., Hering, B., Insel, R., Kaufman, F., Kay, T., Leschek, E., Mahon, J., Marks, J. B., Nanto-Salonen, K., Nepom, G., Orban, T., Parkman, R., Pescovitz, M., Peyman, J., Pugliese, A., Roep, B., Roncarolo, M., Savage, P., Simell, O., Sherwin, R., Siegelman, M., Skyler, J. S., Steck, A., Thomas, J., Trucco, M., Wagner, J., Krischer, J. P., Leschek, E., Rafkin, L., Bourcier, K., Cowie, C., Foulkes, M., Insel, R., Krause-Steinrauf, H., Lachin, J. M., Malozowski, S., Peyman, J., Ridge, J., Savage, P., Skyler, J. S., Zafonte, S. J., Rafkin, L., Sosenko, J. M., Kenyon, N. S., Santiago, Krischer, J. P., Bundy, B., Abbondondolo, M., Adams, T., Amado, D., Asif, Boonstra, M., Burroughs, C., Cuthbertson, D., Deemer, M., Eberhard, C., Fiske, S., Ford, J., Garmeson, J., Guillette, H., Geyer, S., Hays, B., Henderson, C., Henry, M., Heyman, K., Hsiao, B., Karges, C., Keaton, N., Kinderman, A., Law, P., Leinbach, A., Liu, S., Lloyd, J., Malloy, J., Maddox, K., Martin, J., Miller, J., Milliot, E., Moore, M., Muller, S., Nguyen, T., O'Donnell, R., Roberts, A., Sadler, K., Stavros, T., Tamura, R., Wood, K., Xu, P., Young, K., Alies, P., Badias, F., Baker, A., Bassi, M., Beam, C., Boulware, D., Bounmananh, L., Bream, S., Freeman, D., Gough, J., Ginem, J., Granger, M., Kieffer, M., Lane, P., Linton, C., Nallamshetty, L., Oduah, Parrimon, Y., Paulus, K., Pilger, J., Ramiro, J., Ritzie, A., Sharma, A., Shor, A., Song, X., Terry, A., Weinberger, J., Wootten, M., Lachin, J. M., Foulkes, M., Harding, P., Krause-Steinrauf, H., McDonough, S., McGee, P. F., Hess, K., Phoebus, D., Quinlan, S., Raiden, E., Batts, E., Buddy, C., Kirpatrick, K., Ramey, M., Shultz, A., Webb, C., Romesco, M., Fradkin, J., Leschek, E., Spain, L., Savage, P., Aas, S., Blumberg, E., Beck, G., Brillon, D., Gubitosi-Klug, R., Laffel, L., Vigersky, R., Wallace, D., Braun, J., Lernmark, A., Lo, B., Mitchell, H., Naji, A., Nerup, J., Orchard, T., Steffes, M., Tsiatis, A., Veatch, R., Zinman, B., Loechelt, B., Baden, L., Green, M., Weinberg, A., Marcovina, S., Palmer, J. P., Weinberg, A., Yu, L., Babu, S., Winter, W., Eisenbarth, G. S., Bingley, P., Clynes, R., DiMeglio, L., Eisenbarth, G., Hays, B., Leschek, E., Marks, J., Matheson, D., Rafkin, L., Rodriguez, H., Spain, L., Wilson, D., Redondo, M., Gomez, D., McDonald, A., Pena, S., Pietropaolo, M., Shippy, K., Batts, E., Brown, T., Buckner, J., Dove, A., Hammond, M., Hefty, D., Klein, J., Kuhns, K., Letlau, M., Lord, S., McCulloch-Olson, M., Miller, L., Nepom, G., Odegard, J., Ramey, M., Sachter, E., St Marie, M., Stickney, K., VanBuecken, D., Vellek, B., Webber, C., Allen, L., Bollyk, J., Hilderman, N., Ismail, H., Lamola, S., Sanda, S., Vendettuoli, H., Tridgell, D., Monzavi, R., Bock, M., Fisher, L., Halvorson, M., Jeandron, D., Kim, M., Wood, J., Geffner, M., Kaufman, F., Parkman, R., Salazar, C., Goland, R., Clynes, R., Cook, S., Freeby, M., Gallagher, P. M., Gandica, R., Greenberg, E., Kurland, A., Pollak, S., Wolk, A., Chan, M., Koplimae, L., Levine, E., Smith, K., Trast, J., DiMeglio, L., Blum, J., Evans-Molina, C., Hufferd, R., Jagielo, B., Kruse, C., Patrick, Rigby, M., Spall, M., Swinney, K., Terrell, J., Christner, L., Ford, L., Lynch, S., Menendez, M., Merrill, P., Pescovitz, M., Rodriguez, H., Alleyn, C., Baidal, D., Fay, S., Gaglia, J., Resnick, B., Szubowicz, S., Weir, G., Benjamin, R., Conboy, D., deManbey, A., Jackson, R., Jalahej, H., Orban, T., Ricker, A., Wolfsdorf, J., Zhang, H. H., Wilson, D., Aye, T., Baker, B., Barahona, K., Buckingham, B., Esrey, K., Esrey, T., Fathman, G., Snyder, R., Aneja, B., Chatav, M., Espinoza, O., Frank, E., Liu, J., Perry, J., Pyle, R., Rigby, A., Riley, K., Soto, A., Gitelman, S., Adi, S., Anderson, M., Berhel, A., Breen, K., Fraser, K., Gerard-Gonzalez, A., Jossan, P., Lustig, R., Moassesfar, S., Mugg, A., Ng, D., Prahalod, P., Rangel-Lugo, M., Sanda, S., Tarkoff, J., Torok, C., Wesch, R., Aslan, Buchanan, J., Cordier, J., Hamilton, C., Hawkins, L., Ho, T., Jain, A., Ko, K., Lee, T., Phelps, S., Rosenthal, S., Sahakitrungruang, T., Stehl, L., Taylor, L., Wertz, M., Wong, J., Philipson, L., Briars, R., Devine, N., Littlejohn, E., Grant, T., Gottlieb, P., Klingensmith, G., Steck, A., Alkanani, A., Bautista, K., Bedoy, R., Blau, A., Burke, B., Cory, L., Dang, M., Fitzgerald-Miller, L., Fouts, A., Gage, Garg, S., Gesauldo, P., Gutin, R., Hayes, C., Hoffman, M., Ketchum, K., Logsden-Sackett, N., Maahs, D., Messer, L., Meyers, L., Michels, A., Peacock, S., Rewers, M., Rodriguez, P., Sepulbeda, F., Sippl, R., Steck, A., Taki, Tran, B. K., Tran, T., Wadwa, R. P., Zeitler, P., Barker, J., Barry, S., Birks, L., Bomsburger, L., Bookert, T., Briggs, L., Burdick, P., Cabrera, R., Chase, P., Cobry, E., Conley, A., Cook, G., Daniels, J., DiDomenico, D., Eckert, J., Ehler, A., Eisenbarth, G., Fain, P., Fiallo-Scharer, R., Frank, N., Goettle, H., Haarhues, M., Harris, S., Horton, L., Hutton, J., Jeffrrey, J., Jenison, R., Jones, K., Kastelic, W., King, M. A., Lehr, D., Lungaro, J., Mason, K., Maurer, H., Nguyen, L., Proto, A., Realsen, J., Schmitt, K., Schwartz, M., Skovgaard, S., Smith, J., Vanderwel, B., Voelmle, M., Wagner, R., Wallace, A., Walravens, P., Weiner, L., Westerhoff, B., Westfall, E., Widmer, K., Wright, H., Schatz, D., Abraham, A., Atkinson, M., Cintron, M., Clare-Salzler, M., Ferguson, J., Haller, M., Hosford, J., Mancini, D., Rohrs, H., Silverstein, J., Thomas, J., Winter, W., Cole, G., Cook, R., Coy, R., Hicks, E., Lewis, N., Marks, J., Pugliese, A., Blaschke, C., Matheson, D., Pugliese, A., Sanders-Branca, N., Arce, R. A., Cisneros, M., Sabbag, S., Moran, A., Gibson, C., Fife, B., Hering, B., Kwong, C., Leschyshyn, J., Nathan, B., Pappenfus, B., Street, A., Boes, M. A., Eck, P. S., Finney, L., Fischer, A. T., Martin, A., Muzamhindo, J. C., Rhodes, M., Smith, J., Wagner, J., Wood, B., Becker, D., Delallo, K., Diaz, A., Elnyczky, B., Libman, Pasek, B., Riley, K., Trucco, M., Copemen, B., Gwynn, D., Toledo, F., Rodriguez, H., Bollepalli, S., Diamond, F., Eyth, E., Henson, D., Lenz, A., Shulman, D., Raskin, P., Adhikari, S., Dickson, B., Dunnigan, E., Lingvay, Pruneda, L., Ramos-Roman, M., Raskin, P., Rhee, C., Richard, J., Siegelman, M., Sturges, D., Sumpter, K., White, P., Alford, M., Arthur, J., Aviles-Santa, M. L., Cordova, E., Davis, R., Fernandez, S., Fordan, S., Hardin, T., Jacobs, A., Kaloyanova, P., Lukacova-Zib, Mirfakhraee, S., Mohan, A., Noto, H., Smith, O., Torres, N., Wherrett, D., Balmer, D., Eisel, L., Kovalakovska, R., Mehan, M., Sultan, F., Ahenkorah, B., Cevallos, J., Razack, N., Ricci, J. M., Rhode, A., Srikandarajah, M., Steger, R., Russell, W. E., Black, M., Brendle, F., Brown, A., Moore, D., Pittel, E., Robertson, A., Shannon, A., Thomas, J. W., Herold, K., Feldman, L., Sherwin, R., Tamborlane, W., Weinzimer, S., Toppari, J., Kallio, T., Karkkainen, M., Mantymaki, E., Niininen, T., Nurmi, B., Rajala, P., Romo, M., Suomenrinne, S., Nanto-Salonen, K., Simell, O., Simell, T., Bosi, E., Battaglia, M., Bianconi, E., Bonfanti, R., Grogan, P., Laurenzi, A., Martinenghi, S., Meschi, F., Pastore, M., Falqui, L., Muscato, T. M., Viscardi, M., Bingley, P., Castleden, H., Farthing, N., Loud, S., Matthews, C., McGhee, J., Morgan, A., Pollitt, J., Elliot-Jones, R., Wheaton, C., Knip, M., Siljander, H., Suomalainen, H., Colman, P., Healy, F., Mesfin, S., Redl, L., Wentworth, J., Willis, J., Farley, M., Harrison, L., Perry, C., Williams, F., Mayo, A., Paxton, J., Thompson, Volin, L., Fenton, C., Carr, L., Lemon, E., Swank, M., Luidens, M. K., Salgam, M., Sharma, Schade, D., King, C., Carano, R., Heiden, J., Means, N. D., Holman, L., Thomas, Madrigal, D., Muth, T., Martin, C. L., Plunkett, C., Ramm, C., Auchus, R. J., Lane, W., Avots, E., Buford, M., Hale, C., Hoyle, J., Lane, B., Muir, A., Shuler, S., Raviele, N., Ivie, E., Jenkins, M., Lindsley, K., Hansen, Fadoju, D. O., Felner, E., Bode, B., Hosey, R., Sax, J., Jefferies, C., Mannering, S., Prentis, R., She, J. X., Stachura, M., Hopkins, D., Williams, J., Steed, L., Asatapova, E., Nunez, S., Knight, S., Dixon, P., Ching, J., Donner, T., Longnecker, S., Abel, K., Arcara, K., Blackman, S., Clark, L., Cooke, D., Plotnick, L., Levin, P. A., Bromberger, L., Klein, K., Sadurska, K., Allen, C., Michaud, D., Snodgrass, H., Burghen, G., Chatha, S., Clark, C., Silverberg, J., Wittmer, C., Gardner, J., LeBoeuf, C., Bell, P., McGlore, O., Tennet, H., Alba, N., Carroll, M., Baert, L., Beaton, H., Cordell, E., Haynes, A., Reed, C., Lichter, K., McCarthy, P., McCarthy, S., Monchamp, T., Roach, J., Manies, S., Gunville, F., Marosok, L., Nelson, T., Ackerman, K., Rudolph, J., Stewart, M., McCormick, K., May, S., Falls, T., Barrett, T., Dale, K., Makusha, L., McTernana, C., K, P., Sullivan, K., Narendran, P., Robbie, J., Smith, D., Christensen, R., Koehler, B., Royal, C., Arthur, T., Houser, H., Renaldi, J., Watsen, S., Wu, P., Lyons, L., House, B., Yu, J., Holt, H., Nation, M., Vickers, C., Watling, R., Heptulla, R., Trast, J., Agarwal, C., Newell, D. J., Katikaneni, R., Gardner, C., A, D., Rio, A., Logan, H., Collier, C., Rishton, G., Whalley, A., Ali, S., Ramtoola, T., Quattrin, L., Mastrandea, A. J., House, M., Ecker, C., Huang, C., Gougeon, J., D, H., Pacuad, D., Dunger, J., May, C., O'Brien, C., Acerini, B., Salgin, A., Thankamony, R., Williams, J., Buse, G., Fuller, M., Duclos, J., Tricome, H., Brown, D., Pittard, D., Bowlby, A., Blue, T., Headley, S., Bendre, K., Lewis, K., Sutphin, C., Soloranzo, J., Puskaric, H., Madison, M., Rincon, M., Carlucci, R., B, S., Rusk, E., Tessman, D. M., Huffman, H., Abrams, B., Biederman, M. D., Jones, Leathers, W., Brickman, P., Petrie, D., Zimmerman, J., Howard, L., Miller, R., Alemzadeh, D., Mihailescu, R., Melgozza-Walker, N., Abdulla, C., Boucher-Berry, D., Ize-Ludlow, R., Levy, C., Swenson, B. N., Crimmins, D., Edler, T., Weis, C., Schultz, D., Rogers, D., Latham, C., Mawhorter, C., Switzer, W., Spencer, P., Konstantnopoulus, S., Broder, J., Klein, L., Knight, L., Szadek, G., Welnick, B., Thompson, R., Hoffman, A., Revell, J., Cherko, K., Carter, E., Gilson, J., Haines, G., Arthur, B., Bowen, W. B., Zipf, P., Graves, R. A., Lozano, D., Seiple, K., Spicer, A., Chang, J., Fregosi, J., Harbinson, C., Paulson, S., Stalters, P., Wright, D., Zlock, A. E., Freeth, J., Victory, H., Maheshwari, A., Maheshwari, T., Holmstrom, J., Bueno, R., Arguello, J., Ahern, L., Noreika, Watson, S., Hourse, P., Breyer, C., Kissel, Y., Nicholson, M., Pfeifer, S., Almazan, J., Bajaj, M., Quinn, K., Funk, J., McCance, E., Moreno, R., Veintimilla, A., Wells, J., Cook, S., Trunnel, J., Henske, S., Desai, K., Frizelis, F., Khan, R., Sjoberg, K., Allen, P. P., Manning, G., Hendry, B., Taylor, S., Jones, W., Strader, M. E., Bencomo, T., Bailey, L., Bedolla, C., Roldan, C., Moudiotis, B., Vaidya, C., Anning, S., Bunce, S., Estcourt, E., Folland, E., Gordon, C., Harrill, J., Ireland, J., Piper, L., Scaife, K., Sutton, S., Wilkins, M., Costelloe, J., Palmer, L., Casas, C., Miller, M., Burgard, C., Erickson, J., Hallanger-Johnson, P., Clark, W., Taylor, A., Lafferty, S., Gillett, C., Nolan, M., Pathak, L., Sondrol, T., Hjelle, S., Hafner, J., Kotrba, R., Hendrickson, A. P., Cemeroglu, T., Symington, M., Daniel, Y., Appiagyei-Dankah, D. C., Postellon, M. S., Racine, L., Kleis, K., Barnes, S. E., Godwin, H., McCullough, K., Shaheen, G., Buck, L., Noel, M. L., Warren, S., Weber, S. M., Parker, Gillespie, B. A., Nelson, C., Frost, J., Amrhein, E. C., Moreland, A., Hayes, J., Peggram, J., Aisenberg, M. E., Riordan, J., Zasa, E., Cummings, K., Scott, T., Pinto, A., Mokashi, K., McAssey, E., Helden, P., Hammond, L., Dinning, S., Rahman, S., Ray, C., Dimicri, S., Guppy, H., Nielsen, C. K., Vogel, C., Ariza, L., Morales, Y. T., Chang, R. A., Gabbay, L., Ambrocio, L., Manley, R., Nemery, W., Charlton, P., Smith, L., Kerr, B., Steindel-Kopp, M., Alamaguer, D., Liljenquist, G., Browning, T., Coughenour, M. B., Sulk, E., Tsalikan, M., Tansey, J., Cabbage, N., Dixit, S., Pasha, M., King, K., Adcock, H., Atterberry, L., Fox, K., Englert, N., Mauras, J., Permuy, K., Sikes, T., Berhe, B., Guendling, L., McLennan, L., Paganessi, C., Murphy, M. B., Draznin, M., Kamboj, S., Sheppard, Lewis, L., Coates, W., Moore, G., Babar, J., Bedard, D., Brenson-Hughes, J., Cernich, M., Clements, R., Duprau, S., Goodman, L., Hester, L., Huerta-Saenz, A., Karmazin, T., Letjen, S., Raman, D., Morin, W., Bestermann, E. J., Morawski, J. L., White, A., Brockmyer, R., Bays, S., Campbell, A., Stapleton, N., Stone, A., Donoho, H., Everett, H., Hensley, M., Johnson, C., Marshall, N., Skirvin, P., R, T., Williams, L., Ray, C., Wolverton, D. A., Nickels, C., Dothard, P. W., Speiser, M., Pellizzari, L., Bokor, K., Izuora, S., Abdelnour, P., Cummings, S., Paynor, M., Leahy, M., Riedl, S., Shockley, R., Saad, T., Briones, S., Casella, C., Herz, K., Walsh, J., Greening, F., Hay, S., Hunt, N., Sikotra, L., Simons, D. G., Karounos, R., Oremus, L., Dye, L., Myers, D., Ballard, W., Miers, R., Sparks, K. M., Thraikill, K., Edwards, J., Fowlkes, S., Kemp, A., Morales, L., Holland, L., Johnson, P., Paul, A., Ghatak, K., Phelen, H., Leyland, T., Henderson, D., Brenner, E., Oppenheimer, Mamkin, C., Moniz, C., Clarson, M., Lovell, A., Peters, Ruelas, D., Borut, D., Burt, M., Jordan, S., Castilla, P., Flores, M., Ruiz, L., Hanson, J., Green-Blair, R. J., Sheridan, K. A., Wintergerst, G., Pierce, A., Omoruyi, M., Foster, S., Kingery, A., Lunsford, Cervantes, T., Parker, P., Price, J., Urben, Doughty, H., Haydock, Parker, P., Bergman, S., Duncum, C., Rodda, A., Perelman, R., Calendo, C., Barrera, E., Arce-Nunez, Y., Martinez, M., De la Portilla, Cardenas, L., Garrido, M., Villar, R., Lorini, E., Calandra, G., D'Annuzio, K., Perri, N., Minuto, C., Rebora, R., Callegari, O., Ali, J., Kramer, B., Auble, S., Cabrera, P., Donohoue, R., Fiallo-Scharer, M., Hessner, P., Wolfgram, A., Kansra, N., Bettin, R., McCuller, A., Miller, S., Accacha, J., Corrigan, E., Fiore, R. L., Levine, T. A., Mahoney, C., Polychronakos, Gagne, H., Starkman, M., Fox, D., Chin, F., Melchionne, L. A., Silverman, Marshall, L., Cerracchio, J., Cruz, A., Viswanathan, J., Wilson, S., Chalew, S., Valley, S., Layburn, A., Lala, P., Clesi, M., Genet, G., Uwaifo, A., Charron, T., Allerton, W., Cefalu, L., Melendez-Ramirez, R., Richards, C., Alleyn, E., Gustafson, M., Lizanna, J., Wahlen, S., Aleiwe, M., Hansen, H., Wahlen, C. J., Levy, A., Bonaccorso, R., Rapaport, Y., Tomer, D., Chia, M., Goldis, L., Iazzetti, M., Klein, C., Levister, L., Waldman, E., Wallach, M. O., Regelmann, Z., Antal, M., Aranda, C., Reynholds, A., Vinik, P., Barlow, M., Bourcier, M. L., Nevoret, J., Couper, S., Beresford, N., Thalagne, H., Roper, J., Gibbons, J., Hill, S., Balleaut, C., Brennan, J., Ellis-Gage, L., Fear, T., Gray, L., Jones, C., McNerney, L., Pointer, N., Price, K., Few, D., Tomlinson, N., Leech, D., Wake, C., Owens, M., Burns, J., Wotherspoon, A., Murray, K., Short, G., Curry, S., Kelsey, J., Lawson, J., Porter, S., Stevens, E., Thomson, S., Winship, L., Wynn, E., Wiltshire, J., Krebs, P., Cresswell, H., Faherty, C., Ross, L., Denvir, J., Drew, T., Randell, P., Mansell, S. A., Bell, S., Butler, Y., Hooton, H., Navarra, A., Roper, G., Babington, L., Crate, H., Cripps, A., Ledlie, C., Moulds, R., Norton, B., Petrova, O., Silkstone, C., Smith, K., Ghai, M., Murray, Viswanathan, M., Henegan, O., Kawadry, J. A., Olson, L., Patterson, T., Ahmad, B., Flores, D., Domek, S., Domek, K., Copeland, M., George, J., Less, T., Davis, M., Short, A., Dwarakanathan, P., O'Donnell, B., Boerner, L., Larson, M., Phillips, M., Rendell, K., Larson, C., Smith, K., Zebrowski, L., Kuechenmeister, M., Thevarayapillai, M., Daniels, H., Speer, N., Forghani, R., Quintana, C., Reh, A., Bhangoo, P., Desrosiers, L., Ireland, T., Misla, C., Torres, S., Wells, J., Villar, M., Yu, D., Berry, D., Cook, J., Soder, A., Powell, M., Ng, M., Morrison, Z., Haslam, M., Lawson, B., Bradley, J., Courtney, C., Richardson, C., Watson, E., Keely, D., DeCurtis, M., Vaccarcello-Cruz, Z., Torres, K., Sandberg, H., Hsiang, B., Joy, D., McCormick, A., Powell, H., Jones, J., Bell, S., Hargadon, S., Hudson, M., Kummer, S., Sauder, E., Sutton, K., Gensel, R., Aguirre-Castaneda, Benavides, L. D., Hemp, S., Allen, J., Stear, E., Davis, T., Jones, A., Roberts, J. A., Dart, N., Paramalingam, L. E., Katz, L. N., Chaudhary, K. M., Murphy, S. M., Willi, B., Schwartzman, C., Kapadia, D., Larson, D., McClellan, G., Shaibai, L. A., Kelley, G., Villa, C., Kelley, R., Diamond, M., Kabbani, T., Dajani, F., Hoekstra, M., Magorno, J., Holst, Chauhan, N., Wilson, P., Bononi, M., Sperl, A., Millward, M., Eaton, L., Dean, J., Olshan, H., Renna, C., Milliard, B. L., Bacon, J. B., Quintos, L. S., Topor, S., Bialo, B., Bancroft, A. G., Soto, W., Lagarde, H., Lockemer, T., Vanderploeg, M. A., Ibrahim, M., Huie, Sanchez, R., Edelen, R., Marchiando, J., Palmer, T., Repas, M., Wasson, P., Auker, J., Culbertson, T., Kieffer, D., Voorhees, T., Borgwardt, L., DeRaad, K., Eckert, E., Isaacson, H., Kuhn, A., Carroll, M., Schubert, G., Francis, S., Hagan, T., Le, M., Penn, E., Wickham, C., Leyva, K., Rivera, J., Padilla, Rodriguez, N., Jospe, J., Czyzyk, B., Johnson, U., Nadgir, N., Marlen, G., Prakasam, C., Rieger, N., Glaser, E. C., Heiser, B., Harris, C., Foster, H., Slater, K., Wheeler, D. L., Donaldson, M., Murray, D. E., Hale, R., Tragus, D. R., Word, J., Lynch, L., Pankratz, W., Rogers, R., Newfield, S., Holland, M., Hashiguchi, M., Gottschalk, A., Philis-Tsimikas, R., Rosal, S., Franklin, S. M., Guardado, N., Bohannon, M., Garcia, T., Aguinaldo, J., Phan, Barraza, D., Cohen, J., Pinsker, U., Khan, J., Wiley, L., Jovanovic, P., Misra, M., Wright, D., Cohen, K., Huang, M., Skiles, S., Maxcy, C., Pihoker, K., Cochrane, J., Fosse, S., Kearns, M., Klingsheim, N., Wright, L., Viles, H., Smith, S., Heller, M., Cunningham, A., Daniels, L., Zeiden, J., Field, R., Walker, K. J., Griffin, L., Bartholow, C., Erickson, J., Howard, B., Krabbenhoft, C., Sandman, A., Vanveldhuizen, J., Wurlger, A., Zimmerman, K., Hanisch, L., Davis-Keppen, A., Cotterill, J., Kirby, M., Harris, A., Schmidt, C., Kishiyama, C., Flores, J., Milton, W., Martin, C., Whysham, A., Yerka, T., Freels, J. M., Hassing, J., Webster, R., Green, P., Carter, J., Galloway, D., Hoelzer, S., Roberts, S., Said, P., Sullivan, H. F., Allen, E., Reiter, E., Feinberg, C., Johnson, L. A., Newhook, D., Hagerty, N. H., White, L., Levandoski, J., Kyllo, M., Johnson, C., Benoit, P., Iyer, F., Diamond, H., Hosono, S., Jackman, L., Barette, P., Jones, Sills, S., Bzdick, J., Bulger, R., Weinstock, Douek, R., Andrews, G., Modgill, G., Gyorffy, L., Robin, N., Vaidya, S., Crouch, K., O'Brien, C., Thompson, N., Thorne, J., Blumer, J., Kalic, L., Klepek, J., Paulett, B., Rosolowski, J., Horner, M., Watkins, J. L., Casey, K., Carpenter, C., Burns, J., Horton, C., Pritchard, D., Soetaert, A. G., Wynne, C., Chin, O. Y., Molina, C., Patel, R., Senguttuvan, M., Wheeler, O., Furet, C., Steuhm, D. H., Jelley, S., Goudeau, L., Chalmers, D., Greer, C., Panagiotopoulos, D. L., Metzger, D., Nguyen, M., Horowitz, M. P., Christiansen, E., Glades, C., Morimoto, M., Macarewich, R., Norman, K., Patin, C., Vargas, A., Barbanica, A., Yu, P., Vaidyanathan, W., Osborne, R., Mehra, S., Kaster, S., Neace, J., Horner, G., Reeves, C., Cordrey, L., Marrs, T., Miller, S., Dowshen, D., Doyle, S., Walker, D., Catte, H., Dean, M., Drury-Brown, B., Hackman, M. C., Lee, S., Malkani, K., Cullen, K., Johnson, P., Hampton, M., McCarrell, C., Curtis, E., Paul, Z. Y., Type 1 Diabet TrialNet Study Grp 2019; 42 (2): 192–99

  Abstract

  There are variable reports of risk of concordance for progression to islet autoantibodies and type 1 diabetes in identical twins after one twin is diagnosed. We examined development of positive autoantibodies and type 1 diabetes and the effects of genetic factors and common environment on autoantibody positivity in identical twins, nonidentical twins, and full siblings.Subjects from the TrialNet Pathway to Prevention Study (N = 48,026) were screened from 2004 to 2015 for islet autoantibodies (GAD antibody [GADA], insulinoma-associated antigen 2 [IA-2A], and autoantibodies against insulin [IAA]). Of these subjects, 17,226 (157 identical twins, 283 nonidentical twins, and 16,786 full siblings) were followed for autoantibody positivity or type 1 diabetes for a median of 2.1 years.At screening, identical twins were more likely to have positive GADA, IA-2A, and IAA than nonidentical twins or full siblings (all P < 0.0001). Younger age, male sex, and genetic factors were significant factors for expression of IA-2A, IAA, one or more positive autoantibodies, and two or more positive autoantibodies (all P ≤ 0.03). Initially autoantibody-positive identical twins had a 69% risk of diabetes by 3 years compared with 1.5% for initially autoantibody-negative identical twins. In nonidentical twins, type 1 diabetes risk by 3 years was 72% for initially multiple autoantibody-positive, 13% for single autoantibody-positive, and 0% for initially autoantibody-negative nonidentical twins. Full siblings had a 3-year type 1 diabetes risk of 47% for multiple autoantibody-positive, 12% for single autoantibody-positive, and 0.5% for initially autoantibody-negative subjects.Risk of type 1 diabetes at 3 years is high for initially multiple and single autoantibody-positive identical twins and multiple autoantibody-positive nonidentical twins. Genetic predisposition, age, and male sex are significant risk factors for development of positive autoantibodies in twins.

  View details for DOI 10.2337/dc18-0288

  View details for Web of Science ID 000457193000013

  View details for PubMedID 30061316

  View details for PubMedCentralID PMC6341285

• Low-Dose Anti-Thymocyte Globulin (ATG) Preserves -Cell Function and Improves HbA(1c) in New-Onset Type 1 Diabetes DIABETES CARE Haller, M. J., Schatz, D. A., Skyler, J. S., Krischer, J. P., Bundy, B. N., Miller, J. L., Atkinson, M. A., Becker, D. J., Baidal, D., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Herold, K. C., Marks, J. B., Moran, A., Rodriguez, H., Russell, W., Wilson, D. M., Greenbaum, C. J., Type 1 Diabet TrialNet ATG-GCSF St 2018; 41 (9): 1917–25

  Abstract

  A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that 1) low-dose ATG/GCSF or 2) low-dose ATG alone would slow the decline of β-cell function in patients with new-onset T1D (duration <100 days).A three-arm, randomized, double-masked, placebo-controlled trial was performed by the Type 1 Diabetes TrialNet Study Group in 89 subjects: 29 subjects randomized to ATG (2.5 mg/kg intravenously) followed by pegylated GCSF (6 mg subcutaneously every 2 weeks for 6 doses), 29 to ATG alone (2.5 mg/kg), and 31 to placebo. The primary end point was mean area under the curve (AUC) C-peptide during a 2-h mixed-meal tolerance test 1 year after initiation of therapy. Significance was defined as one-sided P value < 0.025.The 1-year mean AUC C-peptide was significantly higher in subjects treated with ATG (0.646 nmol/L) versus placebo (0.406 nmol/L) (P = 0.0003) but not in those treated with ATG/GCSF (0.528 nmol/L) versus placebo (P = 0.031). HbA1c was significantly reduced at 1 year in subjects treated with ATG and ATG/GCSF, P = 0.002 and 0.011, respectively.Low-dose ATG slowed decline of C-peptide and reduced HbA1c in new-onset T1D. Addition of GCSF did not enhance C-peptide preservation afforded by low-dose ATG. Future studies should be considered to determine whether low-dose ATG alone or in combination with other agents may prevent or delay the onset of the disease.

  View details for DOI 10.2337/dc18-0494

  View details for Web of Science ID 000442337700017

  View details for PubMedID 30012675

  View details for PubMedCentralID PMC6105329

• A Feasibility Study to Detect Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring Nally, L. M., Bondy, N. W., Doiev, J., Buckingham, B., Wilson, D. AMER DIABETES ASSOC. 2018

  View details for DOI 10.2337/db18-906-P

  View details for Web of Science ID 000462825102177

• Familial Holoprosencephaly with Endocrine Dysgenesis JOURNAL OF PEDIATRICS Chang, M., Wilson, D. M., Maahs, D. M. 2018; 192: 98

  View details for Web of Science ID 000423353900019

• Impact of Early Diabetic Ketoacidosis on the Developing Brain. Diabetes care Aye, T., Mazaika, P. K., Mauras, N., Marzelli, M. J., Shen, H., Hershey, T., Cato, A., Weinzimer, S. A., White, N. H., Tsalikian, E., Jo, B., Reiss, A. L. 2018

  Abstract

  This study examined whether a history of diabetic ketoacidosis (DKA) is associated with changes in longitudinal cognitive and brain development in young children with type 1 diabetes.Cognitive and brain imaging data were analyzed from 144 children with type 1 diabetes, ages 4 to <10 years, who participated in an observational study of the Diabetes Research in Children Network (DirecNet). Participants were grouped according to history of DKA severity (none/mild or moderate/severe). Each participant had unsedated MRI scans and cognitive testing at baseline and 18 months.In 48 of 51 subjects, the DKA event occurred at the time of onset, at an average of 2.9 years before study entry. The moderate/severe DKA group gained more total and regional white and gray matter volume over the observed 18 months compared with the none/mild group. When matched by age at time of enrollment and average HbA1c during the 18-month interval, participants who had a history of moderate/severe DKA compared with none/mild DKA were observed to have significantly lower Full Scale Intelligence Quotient scores, cognitive performance on the Detectability and Commission subtests of the Conners' Continuous Performance Test II, and the Dot Locations subtest of the Children's Memory Scale.A single episode of moderate/severe DKA in young children at diagnosis is associated with lower cognitive scores and altered brain growth. Further studies are needed to assess whether earlier diagnosis of type 1 diabetes and prevention of DKA may reduce the long-term effect of ketoacidosis on the developing brain.

  View details for DOI 10.2337/dc18-1405

  View details for PubMedID 30573652

• 50 Years Ago in The Journal of Pediatrics: Familial Holoprosencephaly with Endocrine Dysgenesis. The Journal of pediatrics Chang, M., Wilson, D. M., Maahs, D. M. 2018; 192: 98

  View details for PubMedID 29246365

• Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes A Randomized Clinical Trial JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Greenbaum, C., Atkinson, M., Baidal, D., Battaglia, M., Bingley, P., Bosi, E., Buckner, J., Clements, M., Colman, P., DiMeglio, L., Evans-Molina, C., Gitelman, S., Goland, R., Gottlieb, P., Herold, K., Knip, M., Krischer, J., Lernmark, A., Moore, W., Moran, A., Muir, A., Palmer, J., Peakman, M., Philipson, L., Raskin, P., Redondo, M., Rodriguez, H., Russell, W., Spain, L., Schatz, D. A., Sosenko, J., Wherrett, D., Wilson, D., Winter, W., Ziegler, A., Anderson, M., Antinozzi, P., Benoist, C., Blum, J., Bourcier, K., Chase, P., Clare-Salzler, M., Clynes, R., Cowie, C., Eisenbarth, G., Fathman, C. G., Grave, G., Harrison, L., Hering, B., Insel, R., Jordan, S., Kaufman, F., Kay, T., Kenyon, N., Klines, R., Lachin, J., Leschek, E., Mahon, J., Marks, J. B., Monzavi, R., Nanto-Salonen, K., Nepom, G., Orban, T., Parkman, R., Pescovitz, M., Peyman, J., Pugliese, A., Ridge, J., Roep, B., Roncarolo, M., Savage, P., Simell, O., Sherwin, R., Siegelman, M., Skyler, J. S., Thomas, J., Trucco, M., Wagner, J., Bourcier, K., Greenbaum, C. J., Krischer, J. P., Leschek, E., Rafkin, L., Spain, L., Cowie, C., Foulkes, M., Insel, R., Krause-Steinrauf, H., Lachin, J. M., Malozowski, S., Peyman, J., Ridge, J., Savage, P., Skyler, J. S., Zafonte, S. J., Greenbaum, C. J., Rafkin, L., Sosenko, J., Skyler, J. S., Kenyon, N. S., Santiago, I., Krischer, J. P., Bundy, B., Abbondondolo, M., Adams, T., Asif, D., Boonstra, M., Boulware, D., Bundy, B., Burroughs, C., Cuthbertson, D., Eberhard, C., Fiske, S., Ford, J., Garmeson, J., Guillette, H., Geyer, S., Hays, B., Henderson, C., Henry, M., Heyman, K., Hsiao, B., Karges, C., Kinderman, A., Lane, L., Leinbach, A., Liu, S., Lloyd, J., Malloy, J., Maddox, K., Martin, J., Miller, J., Moore, M., Muller, S., Nguyen, T., O'Donnell, R., Parker, M., Pereyra, M. J., Reed, N., Roberts, A., Sadler, K., Stavros, T., Tamura, R., Wood, K., Xu, P., Young, K., Alies, P., Badias, F., Baker, A., Bassi, M., Beam, C., Boulware, D., Bounmananh, L., Bream, S., Deemer, M., Freeman, D., Gough, J., Ginem, J., Granger, M., Holloway, M., Kieffer, M., Lane, P., Law, P., Linton, C., Nallamshetty, L., Oduah, V., Parrimon, Y., Paulus, K., Pilger, J., Ramiro, J., Ritzie, A., Sharma, A., Shor, A., Song, X., Terry, A., Weinberger, J., Wootten, M., Lachin, J. M., Harding, M., Krause-Steinrauf, H., McDonough, S., Mcgee, P. F., Hess, K., Phoebus, D., Quinlan, S., Raiden, E., Fradkin, J., Leschek, E., Spain, L., Cowie, C., Malozowski, S., Savage, P., Beck, G., Blumberg, E., Gubitosi-Klug, R., Laffel, L., Veatch, R., Wallace, D., Braun, J., Brillon, D., Lernmark, A., Lo, B., Mitchell, H., Naji, A., Nerup, J., Orchard, T., Steffes, M., Tsiatis, A., Zinman, B., Loechelt, B., Baden, L., Green, M., Weinberg, A., Marcovina, S., Palmer, J. P., Weinberg, A., Yu, L., Winter, W., Shultz, A., Batts, E., Fitzpatrick, K., Ramey, M., Guerra, R., Webb, C., Caffey, F., Carr, L., Ergun-Longmire, B., Fenton, C., Giebner, D., Johnson, J., Maglionico, D., Marinelli, M., Martin, K., Minnozzi, E., Riley, W., Wilson, M., Gougeon, C., Ho, J., Huang, C., Pacaud, D., Virtanen, H., Craig, C., Ghatak, A., Henderson, T., Leyland, H., Padmore, K., Paul, P., Brickman, W., Halsey-Lyda, M., Petrie, P., Rizzo, D., Steuer, R., Suchyta, K., Torchen, L., Zimmerman, D., Bode, B., Dial, M., Gazaway, K., Hosey, R., Alkanani, A., Barker, J., Barr, M., Blau, A., Burdick, P., Burke, B., Chase, H., Drye, M., Eisenbarth, G., Escobar, E., Fitzgerald-Miller, L., Fouts, A., Gage, V., Gall, E., Goettle, H., Gottlieb, P., Harris, S., Ketchum, K., King, M., Klingensmith, G., Lehr, D., Lehr, J., Lewis, L., Logsden-Sackett, N., Lykens, J., Maahs, D., Michels, A., Pelletier, S., Rihanek, M., Rodriguez, P., Schauwecker, A., Simmons, K., Smith, J., Steck, A., Tran, B., Tran, T., Wadwa, P., Wagner, R., Wright, H., Betancourt, J., Bui, V., DeSalvo, D., Gomez, D., Jake, K., Lynds, J., McCartney, T., McDonald, A., Pena, S., Pietropaolo, M., Redondo, M., Shippy, K., Zheng, X., Allen, L., Batts, E., Brown, T., Buckner, J., Dove, A., Graziano, E., Greenbaum, C., Hao, W., Harrington, R., Hefty, D., Kang, D., Klein, J., Kuhns, K., Lamola, S., Lettau, M., Lord, S., Machmer, H., McCulloch-Olson, M., Miller, L., Odegard, J., Ramey, M., Romasco, M., Russell, B., Sachter, E., Sanda, S., Scheuffele, T., Shultz, A., Snavely, J., St Marie, M., Tobin, M., Tordillos, C., Tridgell, D., VanBuecken, D., Varner, K., Vellek, B., Vendettuoli, H., Vizzutti, M., Webber, C., Wickstrom, N., Ackerman, K., Gunville, F., Nelson, T., Aston, K., Barrett, T., Dale, K., Gray, Z., Kershaw, M., Makusha, L., McTernan, C., Okwu, F., Penny-Thomas, K., Surplice, I., Frattaroli, P., Gihawi, A., Kanumakala, S., Laycock, C., Ramsay, R., Symes, L., Wlazly, D., Healy, F., Bowden, K., Doughty, I., Haydock, H., Kennedy, K., Parker, V., Plimmer, N., Swart, L., Wood, C., Leyva, C., Padilla, J., Rodriguez, I., Ahmad, T., Bhatia, S., Conrad, S., Egli, C., Flores, B., Higa, A., Leong, K., Ng, V., Oakes, S., Olson, J., Blackmore, A., Bradley, B., Cooper, T., Courtney, J., Lawson, M., Richardson, C., Watson, C., Blind, J., Bowden, S., Bowen, B., Carter, K., Cecrle, M., Chaudhari, M., Cherko, J., Dyer, J., Ellis, K., Haines, J., Hapanowicz, C., Hardin, D., Henwood, M., Hoffman, R., Lamberjack, K., Leary, J., Lewis, S., Mhaskar, R., Rowe, S., Schoeginger, L., Stiltner, T., Bock, M., Castaneda, N., Fisher, L., Geffner, M., Gonzalez, M., Halvorson, M., Hisakado, M., Jeandron, D., Kaufman, F., Kwan, K., Marks, L., Medina, B., Miller, D., Monzavi, R., Ng, E., Parkman, R., Salazar, C., Tjauw, A., Wood, J., Woods, A., Xu, Y., Chalew, S., Daniels, J., Gomez, R., Lala, A., Layburn, S., Meyers, M., Sonnier, S., Valley, S., Ayala, N., Bhangoo, A., Bowen, S., Cervisi, J., Chase, Y., Clark, S., Daniels, M., Flannery, T., Forghani, N., Humphrey, L., Krause, G., Less, J., Lester, S., Magedman, G., Montgomery, K., Preasmyer, S., Quintana, R., Randhawa, R., Reh, C., Speer, H., Stockton, W., Sutton, F., Tran, A., Trihn, L., Tu, K., Varni, N., Ackermann, A., Capella, C., Clark, C., Gralewski, K., Hawkes, C., Kim, R., Katz, L., Liilii, R., McKenzie, O., Murphy, K., Norris, M., Orellana, J., Schwartzman, B., Sheth, S., Volpe, R., Willi, S., Healy, F., Heenan, H., Hodgman, S., Kendall, D., Logan, F., Lunt, H., Willis, J., Crimmins, N., Elder, D., Lagory, D., Schultz, C., Stamper, M., Weis, T., Armbruster, D., Klein, J., Konstantinopoulus, P., Latham, D., Markle, T., Mawhorter, C., Rizk, M., Rogers, D., Schmidt, N., Switzer, C., Bokor, L., DeMers, C., Pellizzari, M., Speiser, P., Clynes, R., Cook, S., Dinapoli, G., Eng, C., Engelman, H., Freeby, M., Gallagher, M., Gandica, R., Goland, R., Greenberg, E., Jezioro, J., Kurland, A., Leibel, N., Levine, E., Maher, C., Nieva, D., Parra, Z., Pollak, S., Pope, K., Ridder, R., Scotto, M., Softness, B., Uche, E., Williams, K., Wolk, A., Zhang, H., Burns, C., Casey, J., Doty, B., Horton, J., Moore, H., Pritchard, C., Wynne, A., Brown, L., Cordrey, C., Dowshen, S., Doyle, D., Kidd, G., Marrs, L., Miller, T., Reeves, G., Brousell, C., Healy, F., Hendry, G., Manning, P., Willis, J., Ali, A., Collier, H., Del Rio, A., Gardner, C., Logan, A., Patel, I., Ramtoola, S., Rishton, C., Robinson, D., Whalley, G., Childs, E., Dothard, C., Jordan, K., Batajoo, R., Kerrigan, J., Nickels, D., Tapiador, C., Van Audenhove, J., Wirthwein, E., Allen, C., Anderson, K., Michaud, D., Sadurska, K., Snodgrass, H., Antich, A., Brown, M., Clark-Stuart, T., Cossen, K., Fadoju, D., Felner, E., Greber, G., Ivie, E., Jenkins, M., Kwapil, L., Lindsley, K., Muir, A., Panagiotakopoulos, L., Raviele, N., Sanchez, W., Shuler, S., Davis, A., Gillespie, I., Kane, V., Koval, T., Manchester, T., Parker, S., Rulevitch, N., Weber, S., Healy, F., Amrhein, J., Frost, C., Hannah, D., Looper, L., Moreland, E., Nelson, B., Owens, C., Peggram, J., Phillips, J., Reifeis, E., Andel, A., Arrieta, P., Bena, P., Couch, R., Deol, S., Gordon, M., Lieberman, D., Martin, J., Neiley, R., Qureshi, S., Sadiasa, G., Baldwin, J., Helden, E., McAssey, K., Brunskill, C., Clarke, A., Collins, A., Dinning, L., Hammond, P., Idrees, T., Jones, H., Meredith, S., Moull, A., Rahman, S., Ray, S., Annillo, S., Briones, T., Saad, R., Adamsson, A., Iljamo, M., Jokipuu, S., Kallio, T., Karlsson, L., Kero, J., Leppanen, M., Mantymaki, E., Nanto-Salonen, K., Nurmi, B., Rajala, P., Romo, M., Rouhiainen, J., Ruohonen, E., Simell, O., Simell, S., Simell, T., Suomenrinne, S., Toppari, J., Torma, M., Wahlback, J., Cummings, E., Mokashi, A., Murphy, W., Pinto, T., Scott, K., Tiller, M., Allard, M., Anders, J., Blum, J., Book, B., Cox, D., Davies, V., DeYampert, L., DiMeglio, L., Dykstra, E., Effinger, J., Eugster, E., Evans-Molina, C., Ford, L., Fuqua, J., Haddad, N., Hannon, T., Hildinger, M., Hufferd, R., Imel, E., Jagielo, B., Johnson, A., Johnson, N., Kost, B., Kruse, C., Laskowski, P., Leung, E., Mantravadi, M., Melvin, E., Mirmira, R., Mott, L., Mullen, M., Murphy, R., Nabhan, Z., Nebesio, T., Newnum, A., Nicholson-Spall, M., Patrick, V., Pfeiffer, J., Purtlebaugh, D., Rigby, M., Sanchez, J., Sims, E., Swan, E., Acharya, S., Garvey, L., Stormer, J., Bzdick, S., Conboy, P., Doolittle, S., Izquierdo, R., Sills, I., Weinstock, R., Alleyn, C., Baidal, D., Bryant, N., Conboy, D., Demanbey, A., Fay, S., Gaglia, J., Jackson, R., Jalahej, H., Koshy, N., Krishfield, S., Migre, M., Montero, M., Orban, T., Resnick, B., Ricker, A., Szubowicz, S., Turley, J., Weir, G., Wolfsdorf, J., Zhang, H., Balapatebendi, M., Barradell, A., Brunskill, C., Cheney, S., Greening, J., Hay, F., Hunt, S., Punniyakodi, S., Sikotra, N., Sundaram, P., Thanawala, N., Voce, R., Biggs, J., Faherty, A., Healy, F., Jefferies, C., Mannering, S., Prentis, R., Willis, J., Baskerville, T., Cotterill, A., Harris, M., Healy, F., Kirby, J., Healy, F., Cheetham, T., Clark, Y., Cullen, K., Curry, G., Dixon, J., Leech, N., Logan, M., Owens, C., Porter, J., Richardson, V., Short, K., Thomson, E., Wake, D., Wotherspoon, J., Wynn, L., Brennan, C., Ellis-Gage, J., Fear, L., Few, K., Gibbons, J., Gray, T., Hill, J., Jones, L., McNerney, C., Oakley, S., Price, N., Rajan, S., Roper, H., Thalange, N., Tomlinson, D., Babington, G., Coupe, A., Crate, L., Denvir, L., Gazis, T., Hooton, Y., Mansell, P., Petrova, B., Saxton, M., Silkstone, O., Spick, D., Sudera, S., Alleyn, C., Cooper, J., Hall, S., Lizanna, M., Pandya, P., Ramsey, K., Ratti, P., Sanders, C., Stewart, S., Uwaifo, G., Ahmann, A., Bogan, C., Cain, N., Chambers, V., DeFrang, D., Fitch, R., Guttman-Bauman, I., Hanavan, K., Jahnke, K., Klopfenstein, B., Lester, L., Muhly, R., Nicol, L., Raymond, J., Wollam, B., Cooper, T., Cortes, L., Dingle, A., Duff, L., Elio, L., Fedorchenko, L., Goulet-Ingram, R., Gutierrez, J., Hollis, S., Hyderkhan, C., Hyderkhan, M., Kellogg, S., Klugh, S., Langarica, D., Leslie, C., Luna, J., Maceda, D., Miller, A., Nakhle, D., Nakhle, S., Neylon, E., O'Sullivan, M., Palal, B., Pedraza, S., Poynor, S., Ramiro, J., Ramos, M., Rosario, A., Sandry, S., Stricklin, K., Sushenko, N., Torres, P., Valle, M., Vernetti, N., Westerman, K., Alvi, S., Clapham, M., English, P., Greatrex, J., Khan, H., Millward, A., Storr, E., Dart, J., Healy, F., Jones, T., Baldwin, D., Bruckner, J., Conroy, C., Culbertson, J., Edelen, R., Ferkovich, M., Palmer, J., Voorhees, D., Wasson, M., Williams, A., Barbieri, K., Browning, G., Coughenour, T., Heagy, N., Judge, H., Liljenquist, D., Sulik, M., Connon, M., Abid, N., Beckett, R., Bell, P., Harvey, C., McFarland, M., McGlone, O., Tennet, H., Wells, B., Beamish, N., Cavan, D., Cooke, D., Graja, A., Nation, M., Sanders, P., Vickers, C., Walker, J., Watling, R., Healy, F., Estcourt, S., Foden, A., Gordon, E., Harrill, C., Ireland, J., Jones, N., Moudiotis, C., Piper, J., Scaife, L., Vaidya, B., Walton-Salih, E., Whitmore, H., Wilkins, S., Wilkinson, L., Battaglia, M., Belloni, C., Bianconi, E., Bolla, A., Bonfanti, R., Bonopane, M., Bosi, E., Corti, M., Costa, S., Falqui, L., Fontana, B., Galluccio, E., Grogan, P., Laurenzi, A., Lombardoni, C., Martinenghi, S., Meschi, F., Molinari, C., Molteni, L., Monti, L., Pastore, M., Privitera, D., Ragogna, F., Spadoni, S., Stabilini, A., Vecchione, F., Viscardi, M., Al Nofal, A., Albers, D., Austad, S., Austin, S., Bartholow, L., Brantz-Miller, A., Broadbent, M., Brosnahan, J., Cortes, G., Coyne, C., Davis-Keppen, L., Griffin, K., Hahn, D., Hanisch, K., Hanson, D., Hauge, C., Hein, T., Howard, J., Huber, C., Johnson, J., Karmazin, A., Keller, L., Kirschbaum, S., Klinghagen, R., Krabbenhoft, B., Krell, E., Meier, J., Olson, C., Prenger, S., Sandman, C., Shelso, J., Springman, C., Thompson, M., Vandermark, J., Vanveldhuizen, A., Wurgler, J., Zimmerman, A., Alving, E., Benitez, S., Bryant, S., Cochrane, K., DiBlasi, C., Fechner, P., Gama, K., Harry, J., Jacob, S., Kearns, S., Klingsheim, M., Knutzen, S., Kong, A., Koves, I., Loots, B., Malik, F., Mano, E., Martinez, O., Nandi-Munshi, D., Ness, K., O'Connor, R., Pihoker, C., Roth, C., Salehi, P., Semana, S., Sexton, A., Taplin, C., Yaptangco, M., Bull, J., Gormley, S., Jones, K., Redfearn, K., Shackleton, J., Smith, H., Strong, L., Thomas, L., Viles, L., Wright, N., Kordel, J., Agardh, C., Ahlkvist, L., Ask, M., Berggren, S., Borg, H., Gerardsson, J., Gustavsson, B., Hakansson, R., Hansen, M., Hansson, G., Jarvirova, M., Jonsdottir, B., Katsarou, A., Kulinski, M., Larsson, H., Lernmark, A., Lind, A., Lindstrom, M., Lundgren, M., Massadakis, T., Melin, J., Mestan, Z., Mulder, H., Nilsson, C., Rosengren, A., Salami, F., Skarstrand, H., Tekum-Amboh, E., Torn, C., Ulvenhag, U., Wimar, A., Arthur, T., Buchanan, M., Cardoni, C., Christensen, R., Filicetti, M., Gerrard, X., Haven, K., Ioli, M., Jackson, J., Jones, E., Kauk, K., Koehler, B., Nihill, K., Parra, B., Russell, N., Schott, S., Tawney, L., Taylor, L., Waldren, C., Watsen, S., Whitham, L., Atkins, M., Aye, T., Bachrach, L., Baker, B., Barahona, K., Berry, B., Buckingham, B., Chau, C., Crossen, S., DeSalvo, D., Espinoza, O., Esrey, T., Kumar, R., Ly, T., Nally, L., Patel, P., Seeley, H., Shah, A., Shah, S., Soto, A., Stenerson, M., Wilson, D., Kioroglo, Y., Mann, C., Marlen, N., Nadgir, U., Olsen-Wilson, K., Prakasam, G., Bunk, M., Chmiel, R., Fischer, F., Gavrisan, A., Haupt, F., Heinrich, M., Herbst, M., Hivner, S., Hofelich, A., Holzmaier, M., Kriesen, Y., Lagoda, N., Loebner, S., Maison, N., Mau, E., Peplow, C., Puff, R., Ramminger, C., Sebelefsky, C., Walter, M., Warncke, K., Ziegler, A., Zillmer, S., Babar, G., Bedard, J., Bloom, K., Broussard, J., Bruce, C., Cernich, J., Clements, M., Clifton, T., Craig, E., Drees, A., Duprau, R., Feldt, M., Fridlington, A., Goodman, S., Hess, K., Hester, L., Huseman, C., Karmazin, A., Kim, E., King, A., Kover, K., Luetjen, T., Martin, K., McDonough, R., Moore, W., Musick, T., Newman, K., Nichols, C., Peterson, K., Raman, S., Reddig, N., Swiderski, S., Tong, P., Turpin, A., Turpin, A., Ugrasbul, F., Watkins, D., Weigel, S., Whisenhunt, M., Wierson, J., Wilcox, R., Wolfe, D., Zacharko, P., Zebley, J., Albini, C., Bethin, K., Borowski, R., Buchlis, J., Ecker, M., Elsinghorst, H., Fourtner, S., Gartner, L., Gorman, E., House, A., Kraengel, K., Krolczyk, A., Majumdar, I., Marrone, A., Mastrandrea, L., Michalovic, S., Musial, W., Quattrin, T., Russell, M., Rychlicki, L., Shelat, T., Shine, B., Sickau, J., Van der Kloet, E., Young, B., Ahenkorah, B., Balmer, D., Bedford, M., Cevallos, J., Chapman, K., De Lima, S., Duong, T., Eisel, L., Fiset, J., Harrington, J., Kovalakovska, R., Mehan, M., Nguyen, H., Perro, B., Ricci, M., Ricci, M., Roode, A., Sriskandarajah, M., Steger, R., Sultan, F., Wherrett, D., Aslanov, R., Crummell, C., Hagerty, D., Newhook, L., Penney, S., Stokes, J., Beck, J., Copeland, K., George, M., Larson, S., Less, J., Lopez, C., Roof, A., Schanuel, J., Sparling, D., Tryggestad, J., Lee, M., Shaw, B., Bobik, C., Bollepalli, S., Brownstein, R., Diamond, F., Eyth, E., Henson, D., Iyer, P., Jorgensen, V., Martin, J., Norman, J., O'Brian, J., Rodriguez, H., Shulman, D., Smith, L., Steinbrueck, J., Terry, A., Tindell, S., Garza, A., Grohman, C., Hale, D., Kral, J., Tragus, R., Word, D., Barrett, T., Holloway, S., Lighton, B., Morgan, R., Narendran, P., Smith, D., Ambrose, M., Chin, C., Durazo, G., Gonzalez-Garcia, Z., Gordon, M., Hollis, M., Senguttuvan, R., Stuehm, C., Wheeler, M., Aitken, R., Bingley, P., Castleden, H., Farthing, N., Hughes, T., Loud, S., Matthews, C., Mcgee, J., Morgan, A., Munoz, P., Pollitt, J., Pope, C., Rouquette, C., Thorne, B., Baynham, S., Gardiner, S., Genereaux, D., Jantzen, C., Lai, J., Lutley, P., Mammon, B., Membreve, J., Metzger, D., Morrison, K., Nguyen, D., Panagiotopoulos, C., Ronsley, C., Roston, A., Suen, J., Abalos, M., Adi, S., Anderson, M., Auerback, G., Berhel, A., Bomberg, E., Breen, K., Buchanan, J., Cook, A., Cakmak, A., Ferrara, C., Fields, S., Finney, Z., Fraser, K., Gonzalez, A., Ghods, S., Gitelman, S., Hamid, L., Hamilton, C., Hawkins, L., Honrada, R., Huang, A., Jain, A., Jossan, P., Ko, K., Larocque, N., Lilley, B., Long, R., Lustig, D. R., Ly, E., Malik, A., Melaku, A., Moassesfar, S., Mugg, A., Ng, D., Ng, D., O'Brien, C., Perez, E., Phelps, S., Prahalod, P., Ramos, E., Lugo, M., Rodriguez, T., Arao, A., Demeterco-Berggren, C., Duong, J., Gottschalk, M., Hashiguchi, M., Kelly, T., Marinkovic, M., Marois, N., Newfield, R., Phillips, S., Rosenblum, D., Abdullah, N., Dunger, D., Gilbert, A., Guy, C., Hendricks, E., May, J., O'Brien, C., Salgin, B., Thankamony, A., Vyse, N., Watts, A., Whitehead, K., Whitehead, L., Willemsen, R., Williams, R., Wingate, D., Devine, N., Gannon, G., Grant, T., Letourneau, L., Littlejohn, E., Norstrom, M., O'Malley, T., Philipson, L., Abraham, A., Agustin, E., Albanese-O'Neill, A., Beltz, S., Clare-Salzler, M., Cole, G., Cook, R., Coy, R., Ferguson, J., Ferguson, R., Haller, M., Hicks, E., Hosford, J., Jacobsen, L., Johnson, M., Kahler, D., Kerr, N., Kimsey, R., Lucas, A., Meehan, C., Paguio, G., Rohrs, H., Schatz, D., Smith, M., Thomas, J., Towe, P., White, D., Winter, W., Zimmerman, C., Hamalainen, J., Harkonen, T., Helander, S., Hero, M., Hirvasniemi, M., Isoaho, K., Jaminki, S., Joutsjoki, L., Kalliola, P., Kararic, M., Knip, M., Koski, K., Koski, M., Koski, M. L., Koskinen, M., Kytola, J., Laamanen, T., Latva-Koivisto, M., Laurinen, S., Mustila, T., Nyblom, M., Ollila, I., Pekkola, M., Salonen, K., Selvenius, J., Siljamaki, S., Siljander, H., Snygg, S., Suomalainen, H., Suomi, A., Tuomaala, A., Cabbage, J., Coffey, J., Hobbs, T., Johnson, K., Martin, M., Rosazza, S., Tansey, M., Tsalikian, E., Deuser, A., Foster, M., Pierce, G., Rayborn, L., Rodriguez-Luna, M., Rush, H., Wintergerst, K., Bloomfield, E., Catte, D., Dean, H., Ferens, H., Kerr, L., Kozak, B., Maharaj, R., Marks, S., Minuk, L., Rossum, K., Sneesby, K., Stierman, T., Sucharov-Benarroch, A., Taback, S., Woo, V., Yakimoski, A., Allende, G., Arazo, L., Arce, R., Baidal, D., Blaschke, C., Marks, J., Matheson, D., Pugliese, A., Sanders-Branca, N., Snowhite, I., Burant, C., Chen, M., Haddad, A., Herman, W., Hooks, H., Martin, C., Menon, R., Pietropaolo, M., Pietropaolo, S., Plunkett, C., Pop-Busui, R., Soleimanpour, A., Surhigh, J., Thomas, I., Wood, M., Bartyzal, A., Christianson, T., Flaherty, N., Forlenza, G., Gibson, C., Halper, A., Halvorsen, T., Hamdoun, E., Helms, H., Kwong, C., Lee, C., Leschyshyn, J., Luke, D., McVean, J., Moran, T., Nathan, B., Nelson, B., Omann, T., Pappenfus, B., Parchem, B., Storo, K., Street, A., Sunni, M., Tafuri, M., Vang, N., Weingartner, D., Becker, D., DeLallo, K., Diaz, A., Elnyczky, B., Groscost, D., Baldauff, N., Hoffmann, P., Ismail, H., Klein, M., Lamm, V., Libman, I., McDowell, K., Minshall, V., Pasek, B., Riley, K., Shelleby, C., Sigmund, L., Smith, M., Tas, E., Trucco, M., Yates, C., Artman, H., Johnson, B., Jospe, N., Miller, A., Orlowski, C., Jackson, M., Johnson, B., Knight, L., Szadek, L., Thompson, B., Welnick, G., Al-Zubeidi, H., Bansal, S., Bissler, M., Carroll, L., Cockroft, J., Dourisseau, D., Ferry, R., Foster, C., Johnson, T., Kassim, N., Lee, K., Logan, B., Mazhar, G., McCommon, D., Moisan, A., Parish, M., Sands, C., Sinha, S., Smith, L., Thomas, A., Thompson, L., Trzil, J., Wilson, N., Green, L., Harden, T., Kreymer, R., Mohan, A., Pruneda, M., Raskin, P., Richard, J., Schnurr-Breen, L., Smith, O., Sturges, D., Torres, N., Ziemian, L., Allred, M., Baker, S., Calder, T., Dansie, P., Donaldson, D., Foster, C., Garcia, E., Jarrett, K., Langvardt, J., Lener, M., Lusted, K., Murray, M., Reynolds, L., Slater, H., Thompson, D., Underlin, K., Vickers, L., Wheeler, K., Bere, L., Clarson, C., Gallego, P., Lovell, M., Mahon, J., McCallum, J., Stein, R., Babington, B., Barnes, K., Black, M., Bremer, A., Brendle, F., Brown, A., Dixon, B., Frazier, E., Gregg, A., Moore, D., Mountz, G., Olayinka, K., Pittel, E., Robertson, A., Russell, W., Shah, K., Shannon, A., Thomas, J., Yoder, S., Anderson, T., Bailey, D., Basnet, D., Branch, M., Bruce, G., Francis, G., Hagan, S., Henderson, G., Khandan-Barani, M., King, T., Le, T., Lemmons, J., Miller, M., Nesgoda, L., Penn, M., Schmid, J., Shankar, R., Usry, M., Wickham, E., Banks, W., Brown, H., Constantino, M., Hutson, J., Kellum, G., Lagarde, W., Lewis, M., Lockemer, H., McLaughlin, T., Piszczak, M., Reif, S., Vanderploeg, T., Andaloro, E., Breen, C., Colman, P., Dalgleish, N., Fourlanos, S., Gellert, S., Harrison, L., Healy, F., Hong, E., Hsieh, C., Mesfin, S., Mohammed, E., Redl, L., Watson, K., Wentworth, J., Cresswell, P., Faherty, H., Gould, A., Healy, F., Krebs, J., Maister, C., Ross, C., Wiltshire, E., Beresford, S., Campbell, S., Cortis, L., Couper, J., Cranwell, A., Fairchild, J., Healy, F., Richichi, K., Abdelghany, O., Feldman, L., Forbes, N., Herold, K., Huang, Y., Kunze, K., Rink, L., Sherr, J., Sherwin, R., Tamborlane, W., Weinzimer, S., Wurtz, A., Yama, N., Young, L., Writing Comm Type Diabet 2017; 318 (19): 1891–1902

  Abstract

  Type 1 diabetes requires major lifestyle changes and carries increased morbidity and mortality. Prevention or delay of diabetes would have major clinical effect.To determine whether oral insulin delays onset of type 1 diabetes in autoantibody-positive relatives of patients with type 1 diabetes.Between March 2, 2007, and December 21, 2015, relatives with at least 2 autoantibodies, including insulin autoantibodies and normal glucose tolerance, were enrolled in Canada, the United States, Australia, New Zealand, the United Kingdom, Italy, Sweden, Finland, and Germany. The main study group (n = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than the threshold. The 55 patients in the secondary stratum 1 had an identical antibody profile as the main study group except they had first-phase insulin release that was lower than the threshold. Secondary strata 2 (n = 114) and strata 3 (n = 3) had different autoantibody profiles and first-phase insulin release threshold combinations. Follow-up continued through December 31, 2016.Randomization to receive 7.5 mg/d of oral insulin (n = 283) or placebo (n = 277), including participants in the main study group who received oral insulin (n = 203) or placebo (n = 186).The primary outcome was time to diabetes in the main study group. Significance was based on a 1-sided threshold of .05, and 1-sided 95% CIs are reported.Of a total of 560 randomized participants (median enrollment age, 8.2 years; interquartile range [IQR], 5.7-12.1 years; 170 boys [60%]; 90.7% white non-Hispanic; 57.6% with a sibling with type 1 diabetes), 550 completed the trial including 389 participants (median age, 8.4 years; 245 boys [63%]), 382 (96%) in the main study group. During a median follow-up of 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes was diagnosed in 58 participants (28.5%) in the oral insulin group and 62 (33%) in the placebo group. Time to diabetes was not significantly different between the 2 groups (hazard ratio [HR], 0.87; 95% CI, 0-1.2; P = .21). In secondary stratum 1 (n = 55), diabetes was diagnosed in 13 participants (48.1%) in the oral insulin group and in 19 participants (70.3%) in the placebo group. The time to diabetes was significantly longer with oral insulin (HR, 0.45; 95% CI, 0-0.82; P = .006). The HR for time to diabetes for the between-group comparisons for the 116 participants in the other secondary stratum was 1.03 (95% CI, 0-2.11; P = .53) and for the entire cohort of 560 participants was 0.83 (95% CI, 0-1.07; P = .11), which were not significantly different. The most common adverse event was infection (n = 254), with 134 events in the oral insulin group and 120 events in the placebo group, but no significant study-related adverse events occurred.Among autoantibody-positive relatives of patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not delay or prevent the development of type 1 diabetes over 2.7 years. These findings do not support oral insulin as used in this study for diabetes prevention.clinicaltrials.gov Identifier: NCT00419562.

  View details for DOI 10.1001/jama.2017.17070

  View details for Web of Science ID 000415870300019

  View details for PubMedID 29164254

  View details for PubMedCentralID PMC5798455

• Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials DIABETES CARE Nathan, B. M., Boulware, D., Geyer, S., Atkinson, M. A., Colman, P., Goland, R., Russell, W., Wentworth, J. M., Wilson, D. M., Evans-Molina, C., Wherrett, D., Skyler, J. S., Moran, A., Sosenko, J. M., Type 1 Diabet TrialNet Grp, Diabet Prevention Trial-Type 1 2017; 40 (11): 1494–99

  Abstract

  We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants.Two cohorts were analyzed: 1) baseline normoglycemic oral glucose tolerance tests (OGTTs) with an incident dysglycemic OGTT and 2) baseline Index60 <1.00 OGTTs with an incident Index60 ≥1.00 OGTT. Incident dysglycemic OGTTs were divided into those with (DYS/IND+) and without (DYS/IND-) concomitant Index60 ≥1.00. Incident Index60 ≥1.00 OGTTs were divided into those with (IND/DYS+) and without (IND/DYS-) concomitant dysglycemia.The cumulative incidence for type 1 diabetes was greater after IND/DYS- than after DYS/IND- (P < 0.01). Within the normoglycemic cohort, the cumulative incidence of type 1 diabetes was higher after DYS/IND+ than after DYS/IND- (P < 0.001), whereas within the Index60 <1.00 cohort, the cumulative incidence after IND/DYS+ and after IND/DYS- did not differ significantly. Among nonprogressors, type 1 diabetes risk at the last OGTT was greater for IND/DYS- than for DYS/IND- (P < 0.001). Hazard ratios (HRs) of DYS/IND- with age and 30- to 0-min C-peptide were positive (P < 0.001 for both), whereas HRs of type 1 diabetes with these variables were inverse (P < 0.001 for both). In contrast, HRs of IND/DYS- and type 1 diabetes with age and 30- to 0-min C-peptide were consistent (all inverse [P < 0.01 for all]).The findings suggest that incident dysglycemia without Index60 ≥1.00 is a suboptimal prediagnostic end point for type 1 diabetes. Measures that include both glucose and C-peptide levels, such as Index60 ≥1.00, appear better suited as prediagnostic end points.

  View details for PubMedID 28860125

• LEG LEAN MASS IS CORRELATED WITH BONE MINERAL DENSITY IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES Seeley, H., Long, J., Bachrach, L., Wilson, D. M., Leonard, M. KARGER. 2017: 418

  View details for Web of Science ID 000412595404225

• THE RISK OF PROGRESSION TO TYPE 1 DIABETES (T1D) IN INDIVIDUALS OF DIVERSE AGES WITH MULTIPLE AUTOANTIBODIES Jacobsen, L. M., Evans-Molina, C., Dimeglio, L. A., Goland, R., Wilson, D. M., Atkinson, M., Aye, T., Russell, W., Wentworth, J., Geyer, S., Boulware, D., Sosenko, J. KARGER. 2017: 23–24

  View details for Web of Science ID 000412595401039

• Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes. Journal of diabetes science and technology Calhoun, P. M., Buckingham, B. A., Maahs, D. M., Hramiak, I., Wilson, D. M., Aye, T., Clinton, P., Chase, P., Messer, L., Kollman, C., Beck, R. W., Lum, J. 2016; 10 (6): 1216-1221

  Abstract

  We developed a system to suspend insulin pump delivery overnight when the glucose trend predicts hypoglycemia. This predictive low-glucose suspend (PLGS) system substantially reduces nocturnal hypoglycemia without an increase in morning ketosis. Evaluation of hypoglycemia risk factors that could potentially influence the efficacy of the system remains critical for understanding possible problems with the system and identifying patients that may have the greatest benefit when using the system.The at-home randomized trial consisted of 127 study participants with hemoglobin A1c (A1C) of ≤8.5% (mmol/mol) for patients aged 4-14 years and ≤8.0% for patient aged 15-45 years. Factors assessed included age, gender, A1C, diabetes duration, daily percentage basal insulin, total daily dose of insulin (units/kg-day), bedtime BG, bedtime snack, insulin on board, continuous glucose monitor (CGM) rate of change (ROC), day of the week, time system activated, daytime exercise intensity, and daytime CGM-measured hypoglycemia.The PLGS system was effective in preventing hypoglycemia for each factor subgroup. There was no evidence that the PLGS system was more or less effective in preventing hypoglycemia in any one subgroup compared with the other subgroups based on that factor. In addition, the effect of the system on overnight hyperglycemia did not differ in subgroups.The PLGS system tested in this study effectively reduced hypoglycemia without a meaningful increase in hyperglycemia across a variety of factors.

  View details for PubMedID 27207890

• Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes PEDIATRIC DIABETES Dimeglio, L. A., Cheng, P., Beck, R. W., Kollman, C., Ruedy, K. J., Slover, R., Aye, T., Weinzimer, S. A., Bremer, A. A., Buckingham, B. 2016; 17 (4): 237-243

  Abstract

  Prior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time.Using data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled.Among 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p < 0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations.C-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.

  View details for DOI 10.1111/pedi.12271

  View details for Web of Science ID 000379831900001

  View details for PubMedID 25720763

• Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp DIABETES TECHNOLOGY & THERAPEUTICS Ly, T. T., Keenan, D. B., Roy, A., Han, J., Grosman, B., Cantwell, M., Kurtz, N., von Eyben, R., Clinton, P., Wilson, D. M., Buckingham, B. A. 2016; 18 (6): 377-384

  Abstract

  This study determined the feasibility and efficacy of an automated proportional-integral-derivative with insulin feedback (PID-IFB) controller in overnight closed-loop (OCL) control of children and adolescents with type 1 diabetes over multiple days in a diabetes camp setting.The Medtronic (Northridge, CA) Android™ (Google, Mountain View, CA)-based PID-IFB system consists of the Medtronic Minimed Revel™ 2.0 pump and Enlite™ sensor, a control algorithm residing on an Android phone, a translator, and remote monitoring capabilities. An inpatient study was completed for 16 participants to determine feasibility. For the camp study, subjects with type 1 diabetes were randomized to either OCL or sensor-augmented pump therapy (control conditions) per night for up to 6 nights at diabetes camp.During the camp study, 21 subjects completed 50 OCL nights and 52 control nights. Based on intention to treat, the median time spent in range, from 70 to 150 mg/dL, was greater during OCL at 66.4% (n = 55) versus 50.6% (n = 52) during the control period (P = 0.004). A per-protocol analysis allowed for assessment of algorithm performance with the median percentage time in range, 70-150 mg/dL, being 75.5% (n = 37) for OCL versus 47.6% (n = 32) for the control period (P < 0.001). There was less time spent in the hypoglycemic ranges <60 mg/dL and <70 mg/dL during OCL compared with the control period (P = 0.003 and P < 0.001, respectively).The PID-IFB controller is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.

  View details for DOI 10.1089/dia.2015.0431

  View details for PubMedID 27183197

• Outpatient Care Preceding Hospitalization for Diabetic Ketoacidosis PEDIATRICS Crossen, S. S., Wilson, D. M., Saynina, O., Sanders, L. M. 2016; 137 (6)

  Abstract

  To identify patterns of outpatient care associated with diabetic ketoacidosis (DKA) among pediatric patients with type 1 diabetes (T1D).Retrospective cohort study using Medicaid claims data from 2009 to 2012 for children with T1D enrolled ≥365 consecutive days in California Children's Services, a Title V program for low-income children with chronic disease. Outcome was DKA hospitalization >30 days after enrollment. Outpatient visits to primary care, endocrinology, pharmacies, and emergency departments (EDs) were assessed during the 6 months before an index date: either date of first DKA hospitalization or end of enrollment for those without DKA. Univariate and multivariate analysis was used to evaluate independent associations between DKA and outpatient care at clinically meaningful intervals preceding the index date.Among 5263 children with T1D, 16.7% experienced DKA during the study period. Patients with DKA were more likely to have had an ED visit (adjusted odds ratio [aOR] 3.99, 95% confidence interval [CI]: 2.60-6.13) or a nonpreventive primary care visit (aOR 1.35, 95% CI: 1.01-1.79) within 14 days before the index date, and less likely to have visited an endocrinologist (aOR 0.76, 95% CI: 0.65-0.89) within the preceding 120 days. Preventive visits and pharmacy claims were not associated with DKA.For children with T1D, recent ED visits and long intervals without subspecialty care are important signals of impending DKA. Combined with other known risk factors, these health-use indicators could be used to inform clinical and case management interventions that aim to prevent DKA hospitalizations.

  View details for DOI 10.1542/peds.2015-3497

  View details for PubMedID 27207491

• Is Pump Therapy for All with Type 1 Diabetes? DIABETES TECHNOLOGY & THERAPEUTICS Wilson, D. M. 2016; 18 (5): 280–81

  View details for PubMedID 27159783

• In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes. Pediatric diabetes Messer, L. H., Calhoun, P., Buckingham, B., Wilson, D. M., Hramiak, I., Ly, T. T., Driscoll, M., Clinton, P., Maahs, D. M. 2016: -?

  Abstract

  Overnight predictive low glucose suspend (PLGS) reduces hypoglycemia across all ages; however, there are no reports on behavior or experience differences across age groups, especially in pediatrics. As run-in for a subsequent randomized clinical trial (RCT), 127 subjects (50% male) ages 4-45 yr utilized the experimental PLGS system nightly for 5-10 nights (PLGS active phase). We analyzed the number of blood glucose (BG) checks and boluses given per age group. During the subsequent 42 night RCT phase, we analyzed sensor use, skin reactions, errors, and reasons why the experimental system was not used. In 821 nights of active PLGS, subjects ages 4-6 yr (and their parents) tested BG levels 75% of nights compared with 65% of nights (7-10 yr), 53% of nights (11-14 yr), 33% of nights (15-25 yr), and 28% of nights (26-45 yr), respectively (p < 0.001). Likewise, youngest subjects (and parents) administered insulin boluses 56% of nights during active PLGS use compared with 48%, 33%, 20%, and 25%, respectively (p < 0.001). This was unrelated to study requirements. During the RCT phase, subjects 4-6 yr experienced more frequent and severe skin reactions (p = 0.02), while adult subjects (26-45 yr) wore individual sensors a median of 26 h longer than the youngest subjects (p < 0.001). Technical problems with the sensor (errors, miscalibrations, etc.), traveling, and BG levels >270 at bedtime (study requirement) were primary contributors to non-system use. Understanding the different use patterns and challenges in pediatrics and adolescence is needed to direct patient education to optimize use of PLGS and future artificial pancreas systems.

  View details for DOI 10.1111/pedi.12395

  View details for PubMedID 27125223

  View details for PubMedCentralID PMC5086306

• Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes over 18 Months. Journal of the International Neuropsychological Society Cato, M. A., Mauras, N., Mazaika, P., Kollman, C., Cheng, P., Aye, T., Ambrosino, J., Beck, R. W., Ruedy, K. J., Reiss, A. L., Tansey, M., White, N. H., Hershey, T. 2016; 22 (3): 293-302

  Abstract

  Decrements in cognitive function may already be evident in young children with type 1 diabetes (T1D). Here we report prospectively acquired cognitive results over 18 months in a large cohort of young children with and without T1D.A total of 144 children with T1D (mean HbA1c: 7.9%) and 70 age-matched healthy controls (mean age both groups 8.5 years; median diabetes duration 3.9 years; mean age of onset 4.1 years) underwent neuropsychological testing at baseline and after 18-months of follow-up. We hypothesized that group differences observed at baseline would be more pronounced after 18 months, particularly in those T1D patients with greatest exposure to glycemic extremes.Cognitive domain scores did not differ between groups at the 18 month testing session and did not change differently between groups over the follow-up period. However, within the T1D group, a history of diabetic ketoacidosis (DKA) was correlated with lower Verbal IQ and greater hyperglycemia exposure (HbA1c area under the curve) was inversely correlated to executive functions test performance. In addition, those with a history of both types of exposure performed most poorly on measures of executive function.The subtle cognitive differences between T1D children and nondiabetic controls observed at baseline were not observed 18 months later. Within the T1D group, as at baseline, relationships between cognition (Verbal IQ and executive functions) and glycemic variables (chronic hyperglycemia and DKA history) were evident. Continued longitudinal study of this T1D cohort and their carefully matched healthy comparison group is planned.

  View details for DOI 10.1017/S1355617715001289

  View details for PubMedID 26786245

• IN-HOME OVERNIGHT PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) EXPERIENCE: DIFFERENCES ACROSS AGE GROUPS Messer, L. H., Calhoun, P., Buckingham, B. A., Wilson, D. M., Hramiak, I., Ly, T. T., Driscoll, M., Maahs, D. M. MARY ANN LIEBERT, INC. 2016: A47–A48

  View details for Web of Science ID 000369672700117

• INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PREDICTS INSULIN SENSITIVITY AND INSULIN AREA-UNDER-THE-CURVE IN OBESE, NONDIABETIC ADOLESCENTS ENDOCRINE PRACTICE Lee, P. D., Lustig, R. H., Lenders, C., Baillargeon, J., Wilson, D. M. 2016; 22 (2): 136-142

  Abstract

  To compare fasting insulin-like growth factor binding protein 1 (IGFBP-1) to other fasting indices as a surrogate marker of insulin sensitivity and resistance calculated from a 3-hour oral glucose tolerance test (oGTT).Fasting IGFBP-1 and oGTT were performed at 0 (n = 77), 52 (n = 54), and 100 (n = 38) weeks in a study investigating metformin treatment of obesity in adolescents. Insulin area-under-the-curve (IAUC) and the composite insulin sensitivity index (CISI) calculated from the oGTT were compared to fasting IGFBP-1, homeostasis model assessment-insulin resistance, and corrected insulin release at the glucose peak (CIRgp).IGFBP-1 and the ratio of IGFBP-1 to fasting insulin were significantly correlated with indices based on timed sampling, including IAUC, CISI, and CIRgp. In addition, a significant effect of IGFBP-1, but not IGFBP-1 to insulin at time zero, was observed for IAUC and CISI.Our results indicate that fasting IGFBP-1 may be a useful marker of insulin sensitivity and secretion.

  View details for DOI 10.4158/EP15885.OR

  View details for Web of Science ID 000377968200002

  View details for PubMedID 26484407

• Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective DIABETES-METABOLISM RESEARCH AND REVIEWS Bollyky, J. B., Xu, P., Butte, A. J., Wilson, D. M., Beam, C. A., Greenbaum, C. J. 2015; 31 (6): 588-594

  Abstract

  Type 1 diabetes (T1D) TrialNet is a National Institutes of Health-sponsored clinical trial network aimed at altering the disease course of T1D. The purpose of this study is to evaluate age-dependent heterogeneity in clinical, metabolic and immunologic characteristics of individuals with recent-onset T1D, to identify cohorts of interest and to aid in planning of future studies.Eight hundred eighty-three individuals with recent-onset T1D involved in five TrialNet studies were categorized by age as follows: ≥18 years, 12-17 years, 8-12 years and <8 years. Data were compared with healthy age-matched subjects in the National Health and Nutrition Examination Survey.Only 2.0% of the individuals overall were excluded from trial participation because of insufficient C-peptide values (<0.2 pmol/mL). A disproportionate number of these subjects were <8 years old. Leukopenia was present in 21.2% of individuals and lymphopenia in 11.6%; these frequencies were markedly higher than age-matched healthy National Health and Nutrition Examination Survey population. Of the cohort, 24.5% were overweight or obese. Neither high-risk human leukocyte antigen type DR3 nor DR4 was present in 31% of adults and 21% of children.The ability of recent-onset T1D patients to meet key entry criteria for TrialNet studies, including C-peptide >0.2 pmol/mL, varies by age. Lower C-peptide level requirements for younger participants and other aspects of heterogeneity of recent-onset T1D patients, such as white blood cell count abnormalities and body mass index should be considered in the design of future clinical studies. Copyright © 2015 John Wiley & Sons, Ltd.

  View details for DOI 10.1002/dmrr.2643

  View details for PubMedID 25689602

• Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis DIABETES CARE Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R., Wadwa, R. P., Wilson, D. M., Ly, T., Aye, T., Hramiak, I., Clarson, C., Stein, R., Gallego, P. H., Lum, J., Sibayan, J., Kollman, C., Beck, R. W. 2015; 38 (7): 1197-1204

  Abstract

  Nocturnal hypoglycemia can cause seizures and is a major impediment to tight glycemic control, especially in young children with type 1 diabetes. We conducted an in-home randomized trial to assess the efficacy and safety of a continuous glucose monitor-based overnight predictive low-glucose suspend (PLGS) system.In two age-groups of children with type 1 diabetes (11-14 and 4-10 years of age), a 42-night trial for each child was conducted wherein each night was assigned randomly to either having the PLGS system active (intervention night) or inactive (control night). The primary outcome was percent time <70 mg/dL overnight.Median time at <70 mg/dL was reduced by 54% from 10.1% on control nights to 4.6% on intervention nights (P < 0.001) in 11-14-year-olds (n = 45) and by 50% from 6.2% to 3.1% (P < 0.001) in 4-10-year-olds (n = 36). Mean overnight glucose was lower on control versus intervention nights in both age-groups (144 ± 18 vs. 152 ± 19 mg/dL [P < 0.001] and 153 ± 14 vs. 160 ± 16 mg/dL [P = 0.004], respectively). Mean morning blood glucose was 159 ± 29 vs. 176 ± 28 mg/dL (P < 0.001) in the 11-14-year-olds and 154 ± 25 vs. 158 ± 22 mg/dL (P = 0.11) in the 4-10-year-olds, respectively. No differences were found between intervention and control in either age-group in morning blood ketosis.In 4-14-year-olds, use of a nocturnal PLGS system can substantially reduce overnight hypoglycemia without an increase in morning ketosis, although overnight mean glucose is slightly higher.

  View details for DOI 10.2337/dc14-3053

  View details for PubMedID 26049549

• Large Doses of Vitamin D Fail to Increase 25-Hydroxyvitamin D Levels or to Alter Cardiovascular Risk Factors in Obese Adolescents: A Pilot Study. journal of adolescent health Shah, S., Wilson, D. M., Bachrach, L. K. 2015; 57 (1): 19-23

  Abstract

  Vitamin D deficiency and cardiometabolic risk factors are common in obese adolescents. Observational studies demonstrate an inverse relationship among serum 25-hydroxyvitamin D (25OHD) and obesity, insulin resistance, and inflammatory cytokines. This pilot study explores if vitamin D supplementation could reduce serum concentrations of inflammatory cytokines (interleukin [IL] 6, IL-10, tumor necrosis factor α), adiponectin, lipids, hemoglobin A1C, and high-sensitivity C-reactive protein (hs-CRP). A secondary aim was to determine the associations between baseline serum 25OHD concentrations and body mass index (BMI), hs-CRP, inflammatory cytokines, and lipids.Overweight and obese adolescents enrolled in this 24-week, randomized, double-blind study were given 150,000 IU ergocalciferol or placebo at baseline and 12 weeks. Outcome measurements included serum 25OHD, inflammatory cytokines, adiponectin, hs-CRP, lipids, hemoglobin A1C, and BMI at baseline, 12, and 24 weeks.Of 40 participants, 31 (78%) completed the study. Mean ± standard error 25OHD levels were similar in vitamin D and placebo groups at baseline (19.6 ± 5.3 vs. 25.8 ± 10.8 ng/mL) and 24 weeks (20.1 ± 3.4 vs. 24.6 ± 8.4 ng/mL). Inflammatory and cardiovascular markers were not significantly different between groups at 24 weeks. Serum 25OHD at baseline was associated with BMI (r = -.44 [95% confidence interval, -.66 to -.15]) but not with other outcome measures.Supplementation with vitamin D at 150,000 IU every 3 months failed to increase serum 25OHD or alter inflammatory markers and lipids in overweight and obese youth. Further studies are needed to establish the dose of vitamin D required to increase 25OHD and determine potential effects on metabolic risk factors in obese teens.

  View details for DOI 10.1016/j.jadohealth.2015.02.006

  View details for PubMedID 25873553

• Factors Associated with Nocturnal Hypoglycemia in At-Risk Adolescents and Young Adults with Type 1 Diabetes DIABETES TECHNOLOGY & THERAPEUTICS Wilson, D. M., Calhoun, P. M., Maahs, D. M., Chase, H. P., Messer, L., Buckingham, B. A., Aye, T., Clinton, P. K., Hramiak, I., Kollman, C., Beck, R. W. 2015; 17 (6): 385-391

  Abstract

  Hypoglycemia remains an impediment to good glycemic control, with nocturnal hypoglycemia being particularly dangerous. Information on major contributors to nocturnal hypoglycemia remains critical for understanding and mitigating risk.Continuous glucose monitoring (CGM) data for 855 nights were studied, generated by 45 subjects 15-45 years of age with hemoglobin A1c (HbA1c) levels of ≤8.0% who participated in a larger randomized study. Factors assessed for potential association with nocturnal hypoglycemia (CGM measurement of <60 mg/dL for ≥30 min) included bedtime blood glucose (BG), exercise intensity, bedtime snack, insulin on board, day of the week, previous daytime hypoglycemia, age, gender, HbA1c level, diabetes duration, daily basal insulin, and daily insulin dose.Hypoglycemia occurred during 221 of 885 (25%) nights and was more frequent with younger age (P<0.001), lower HbA1c levels (P=0.006), medium/high-intensity exercise during the preceding day (P=0.003), and the occurrence of antecedent daytime hypoglycemia (P=0.001). There was a trend for lower bedtime BG levels to be associated with more frequent nocturnal hypoglycemia (P=0.10). Bedtime snack, before bedtime insulin bolus, weekend versus weekday, gender, and daily basal and bolus insulin were not associated with nocturnal hypoglycemia.Awareness that HbA1c level, exercise, bedtime BG level, and daytime hypoglycemia are all modifiable factors associated with nocturnal hypoglycemia may help patients and providers decrease the risk of hypoglycemia at night. Risk for nocturnal hypoglycemia increased in a linear fashion across the range of variables, with no clear-cut thresholds to guide clinicians or patients for any particular night.

  View details for DOI 10.1089/dia.2014.0342

  View details for PubMedID 25761202

• The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months DIABETES CARE Sosenko, J. M., Skyler, J. S., Beam, C. A., Boulware, D., Mahon, J. L., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Matheson, D., Herold, K. C., Palmer, J. P. 2015; 38 (5): 940-942

  Abstract

  We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

  View details for DOI 10.2337/dc14-2787

  View details for Web of Science ID 000353505600040

  View details for PubMedID 25758770

• Longitudinal Assessment of Neuroanatomical and Cognitive Differences in Young Children With Type 1 Diabetes: Association With Hyperglycemia DIABETES Mauras, N., Mazaika, P., Buckingham, B., Weinzimer, S., White, N. H., Tsalikian, E., Hershey, T., Cato, A., Cheng, P., Kollman, C., Beck, R. W., Ruedy, K., Aye, T., Fox, L., Arbelaez, A. M., Wilson, D., Tansey, M., Tamborlane, W., Peng, D., Marzelli, M., Winer, K. K., Reiss, A. L. 2015; 64 (5): 1770-1779

  Abstract

  Significant regional differences in gray and white matter volume and subtle cognitive differences between young diabetic and nondiabetic children have been observed. Here, we assessed whether these differences change over time and the relation with dysglycemia. Children ages 4 to <10 years with (n = 144) and without (n = 72) type 1 diabetes (T1D) had high-resolution structural MRI and comprehensive neurocognitive tests at baseline and 18 months and continuous glucose monitoring and HbA1c performed quarterly for 18 months. There were no differences in cognitive and executive function scores between groups at 18 months. However, children with diabetes had slower total gray and white matter growth than control subjects. Gray matter regions (left precuneus, right temporal, frontal, and parietal lobes and right medial-frontal cortex) showed lesser growth in diabetes, as did white matter areas (splenium of the corpus callosum, bilateral superior-parietal lobe, bilateral anterior forceps, and inferior-frontal fasciculus). These changes were associated with higher cumulative hyperglycemia and glucose variability but not with hypoglycemia. Young children with T1D have significant differences in total and regional gray and white matter growth in brain regions involved in complex sensorimotor processing and cognition compared with age-matched control subjects over 18 months, suggesting that chronic hyperglycemia may be detrimental to the developing brain.

  View details for DOI 10.2337/db14-1445

  View details for PubMedID 25488901

• beta Cell death and dysfunction during type 1 diabetes development in at-risk individuals JOURNAL OF CLINICAL INVESTIGATION Herold, K. C., Usmani-Brown, S., Ghazi, T., Lebastchi, J., Beam, C. A., Bellin, M. D., Ledizet, M., Sosenko, J. M., Krischer, J. P., Palmer, J. P. 2015; 125 (3): 1163-1173

  Abstract

  Role of the funding source: Funding from the NIH was used for support of the participating clinical centers and the coordinating center. The funding source did not participate in the collection or the analysis of the data.The β cell killing that characterizes type 1 diabetes (T1D) is thought to begin years before patients present clinically with metabolic decompensation; however, this primary pathologic process of the disease has not been measured.Here, we measured β cell death with an assay that detects β cell-derived unmethylated insulin (INS) DNA. Using this assay, we performed an observational study of 50 participants from 2 cohorts at risk for developing T1D from the TrialNet Pathway to Prevention study and of 4 subjects who received islet autotransplants.In at-risk subjects, those who progressed to T1D had average levels of unmethylated INS DNA that were elevated modestly compared with those of healthy control subjects. In at-risk individuals that progressed to T1D, the observed increases in unmethylated INS DNA were associated with decreases in insulin secretion, indicating that the changes in unmethylated INS DNA are indicative of β cell killing. Subjects at high risk for T1D had levels of unmethylated INS DNA that were higher than those of healthy controls and higher than the levels of unmethylated INS DNA in the at-risk progressor and at-risk nonprogressor groups followed for 4 years. Evaluation of insulin secretory kinetics also distinguished high-risk subjects who progressed to overt disease from those who did not.We conclude that a blood test that measures unmethylated INS DNA serves as a marker of active β cell killing as the result of T1D-associated autoimmunity. Together, the data support the concept that β cell killing occurs sporadically during the years prior to diagnosis of T1D and is more intense in the peridiagnosis period.Clinicaltrials.gov NCT00097292.Funding was from the NIH, the Juvenile Diabetes Research Foundation, and the American Diabetes Association.

  View details for DOI 10.1172/JCI78142

  View details for Web of Science ID 000350616500030

  View details for PubMedID 25642774

• HYPOGLYCEMIA REDUCTION WITH CLOSED-LOOP SYSTEMS BY AGE Chase, H. P., Maahs, D., Wadwa, P., Buckingham, B., Wilson, D., Ly, T., Lum, J., Calhoun, P., Raghinaru, D., Cameron, F., Bequette, B. W., Hramiak, I., Beck, R., J D R F Home Closed-Loop Study Grp MARY ANN LIEBERT, INC. 2015: A4

  View details for Web of Science ID 000349317500011

• Electrochemiluminescence Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk DIABETES TECHNOLOGY & THERAPEUTICS Miao, D., Steck, A. K., Zhang, L., Guyer, K. M., Jiang, L., Armstrong, T., Muller, S. M., Krischer, J., Rewers, M., Yu, L. 2015; 17 (2): 119-127

  Abstract

  We recently developed new electrochemiluminescence (ECL) insulin autoantibody (IAA) and glutamic acid decarboxylase 65 autoantibody (GADA) assays that discriminate high-affinity, high-risk diabetes-specific autoantibodies from low-affinity, low-risk islet autoantibodies (iAbs) detected by radioassay (RAD). Here, we report a further validation of the ECL-IAA and -GADA assays in 3,484 TrialNet study participants. The ECL assay and RAD were congruent in those with prediabetes and in subjects with multiple autoantibodies, but only 24% (P<0.0001) of single RAD-IAA-positive and 46% (P<0.0001) of single RAD-GADA-positive were confirmed by the ECL-IAA and -GADA assays, respectively. During a follow-up (mean, 2.4 years), 51% of RAD-IAA-positive and 63% of RAD-GADA-positive subjects not confirmed by ECL became iAb negative, compared with only 17% of RAD-IAA-positive (P<0.0001) and 15% of RAD-GADA-positive (P<0.0001) subjects confirmed by ECL assays. Among subjects with multiple iAbs, diabetes-free survival was significantly shorter if IAA or GADA was positive by ECL and negative by RAD than if IAA or GADA was negative by ECL and positive by RAD (P<0.019 and P<0.0001, respectively). Both positive and negative predictive values in terms of progression to type 1 diabetes mellitus were superior for ECL-IAA and ECL-GADA, compared with RADs. The prevalence of the high-risk human leukocyte antigen-DR3/4, DQB1*0302 genotype was significantly higher in subjects with RAD-IAA or RAD-GADA confirmed by ECL. In conclusion, both ECL-IAA and -GADA are more disease-specific and better able to predict the risk of progression to type 1 diabetes mellitus than the current standard RADs.

  View details for DOI 10.1089/dia.2014.0186

  View details for Web of Science ID 000349009600008

  View details for PubMedID 25562486

• The impact of accelerometer use in exercise-associated hypoglycemia prevention in type 1 diabetes. Journal of diabetes science and technology Stenerson, M., Cameron, F., Payne, S. R., Payne, S. L., Ly, T. T., Wilson, D. M., Buckingham, B. A. 2015; 9 (1): 80-85

  Abstract

  Exercise-associated hypoglycemia is a common adverse event in people with type 1 diabetes. Previous in silico testing by our group demonstrated superior exercise-associated hypoglycemia mitigation when a predictive low glucose suspend (PLGS) algorithm was augmented to incorporate activity data. The current study investigates the effectiveness of an accelerometer-augmented PLGS algorithm in an outpatient exercise protocol. Subjects with type 1 diabetes on insulin pump therapy participated in two structured soccer sessions, one utilizing the algorithm and the other using the subject's regular basal insulin rate. Each subject wore their own insulin pump and a Dexcom G4™ Platinum continuous glucose monitor (CGM); subjects on-algorithm also wore a Zephyr BioHarness™ 3 accelerometer. The algorithm utilized a Kalman filter with a 30-minute prediction horizon. Activity and CGM readings were manually entered into a spreadsheet and at five-minute intervals, the algorithm indicated whether the basal insulin infusion should be on or suspended; any changes were then implemented by study staff. The rate of hypoglycemia during and after exercise (until the following morning) was compared between groups. Eighteen subjects (mean age 13.4 ± 3.7 years) participated in two separate sessions 7-22 days apart. The difference in meter blood glucose levels between groups at each rest period did not achieve statistical significance at any time point. Hypoglycemia during the session was recorded in three on-algorithm subjects, compared to six off-algorithm subjects. In the postexercise monitoring period, hypoglycemia occurred in two subjects who were on-algorithm during the session and four subjects who were off-algorithm. The accelerometer-augmented algorithm failed to prevent exercise-associated hypoglycemia compared to subjects on their usual basal rates. A larger sample size may have achieved statistical significance. Further research involving an automated system, a larger sample size, and an algorithm design that favors longer periods of pump suspension is necessary.

  View details for DOI 10.1177/1932296814551045

  View details for PubMedID 25231116

• Inpatient Trial of an Artificial Pancreas Based on Multiple Model Probabilistic Predictive Control with Repeated Large Unannounced Meals DIABETES TECHNOLOGY & THERAPEUTICS Cameron, F., Niemeyer, G., Wilson, D. M., Bequette, B. W., Benassi, K. S., Clinton, P., Buckingham, B. A. 2014; 16 (11): 728-734

  Abstract

  Closed-loop control of blood glucose levels in people with type 1 diabetes offers the potential to reduce the incidence of diabetes complications and reduce the patients' burden, particularly if meals do not need to be announced. We therefore tested a closed-loop algorithm that does not require meal announcement.A multiple model probabilistic predictive controller (MMPPC) was assessed on four patients, revised to improve performance, and then assessed on six additional patients. Each inpatient admission lasted for 32 h with five unannounced meals containing approximately 1 g/kg of carbohydrate per admission. The system used an Abbott Diabetes Care (Alameda, CA) Navigator(®) continuous glucose monitor (CGM) and Insulet (Bedford, MA) Omnipod(®) insulin pump, with the MMPPC implemented through the artificial pancreas system platform. The controller was initialized only with the patient's total daily dose and daily basal pattern.On a 24-h basis, the first cohort had mean reference and CGM readings of 179 and 167 mg/dL, respectively, with 53% and 62%, respectively, of readings between 70 and 180 mg/dL and four treatments for glucose values <70 mg/dL. The second cohort had mean reference and CGM readings of 161 and 142 mg/dL, respectively, with 63% and 78%, respectively, of the time spent euglycemic. There was one controller-induced hypoglycemic episode. For the 30 unannounced meals in the second cohort, the mean reference and CGM premeal, postmeal maximum, and 3-h postmeal values were 139 and 132, 223 and 208, and 168 and 156 mg/dL, respectively.The MMPPC, tested in-clinic against repeated, large, unannounced meals, maintained reasonable glycemic control with a mean blood glucose level that would equate to a mean glycated hemoglobin value of 7.2%, with only one controller-induced hypoglycemic event occurring in the second cohort.

  View details for DOI 10.1089/dia.2014.0093

  View details for Web of Science ID 000343419900006

  View details for PubMedID 25259939

  View details for PubMedCentralID PMC4201242

• A novel method to detect pressure-induced sensor attenuations (PISA) in an artificial pancreas. Journal of diabetes science and technology Baysal, N., Cameron, F., Buckingham, B. A., Wilson, D. M., Chase, H. P., Maahs, D. M., Bequette, B. W. 2014; 8 (6): 1091-1096

  Abstract

  Continuous glucose monitors (CGMs) provide real-time interstitial glucose concentrations that are essential for automated treatment of individuals with type 1 diabetes. Miscalibration, noise spikes, dropouts, or pressure applied to the site (e.g., lying on the site while sleeping) can cause inaccurate glucose signals, which could lead to inappropriate insulin dosing decisions. These studies focus on the problem of pressure-induced sensor attenuations (PISAs) that occur overnight and can cause undesirable pump shut-offs in a predictive low glucose suspend system. The algorithm presented here uses real-time CGM readings without knowledge of meals, insulin doses, activity, sensor recalibrations, or fingerstick measurements. The real-time PISA detection technique was tested on outpatient "in-home" data from a predictive low-glucose suspend trial with over 1125 nights of data. A total of 178 sets were created by using different parameters for the PISA detection algorithm to illustrate its range of available performance. The tracings were reviewed via a web-based analysis tool by an engineer with an extensive expertise on analyzing clinical datasets and ~3% of the CGM readings were marked as PISA events which were used as the gold standard. It is shown that 88.34% of the PISAs were successfully detected by the algorithm, and the percentage of false detections could be reduced to 1.70% by altering the algorithm parameters. Use of the proposed PISA detection method can result in a significant decrease in undesirable pump suspensions overnight, and may lead to lower overnight mean glucose levels while still achieving a low risk of hypoglycemia.

  View details for DOI 10.1177/1932296814553267

  View details for PubMedID 25316716

• Multicenter Closed-Loop/Hybrid Meal Bolus Insulin Delivery with Type 1 Diabetes DIABETES TECHNOLOGY & THERAPEUTICS Chase, H. P., Doyle, F. J., Zisser, H., Renard, E., Nimri, R., Cobelli, C., Buckingham, B. A., Maahs, D. M., Anderson, S., Magni, L., Lum, J., Calhoun, P., Kollman, C., Beck, R. W. 2014; 16 (10): 623-632

  Abstract

  This study evaluated meal bolus insulin delivery strategies and associated postprandial glucose control while using an artificial pancreas (AP) system.This study was a multicenter trial in 53 patients, 12-65 years of age, with type 1 diabetes for at least 1 year and use of continuous subcutaneous insulin infusion for at least 6 months. Four different insulin bolus strategies were assessed: standard bolus delivered with meal (n=51), standard bolus delivered 15 min prior to meal (n=40), over-bolus of 30% delivered with meal (n=40), and bolus purposely omitted (n=46). Meal carbohydrate (CHO) intake was 1 g of CHO/kg of body weight up to a maximum of 100 g for the first three strategies or up to a maximum of 50 g for strategy 4.Only three of 177 meals (two with over-bolus and one with standard bolus 15 min prior to meal) had postprandial blood glucose values of <60 mg/dL. Postprandial hyperglycemia (blood glucose level >180 mg/dL) was prolonged for all four bolus strategies but was shorter for the over-bolus (41% of the 4-h period) than the two standard bolus strategies (73% for each). Mean postprandial blood glucose level was 15.9 mg/dL higher for the standard bolus with meal compared with the prebolus (baseline-adjusted, P=0.07 for treatment effect over the 4-h period).The AP handled the four bolus situations safely, but at the expense of having elevated postprandial glucose levels in most subjects. This was most likely secondary to suboptimal performance of the algorithm.

  View details for DOI 10.1089/dia.2014.0050

  View details for Web of Science ID 000342561100003

  View details for PubMedID 25188375

  View details for PubMedCentralID PMC4183919

• Multicenter Closed-Loop Insulin Delivery Study Points to Challenges for Keeping Blood Glucose in a Safe Range by a Control Algorithm in Adults and Adolescents with Type 1 Diabetes from Various Sites DIABETES TECHNOLOGY & THERAPEUTICS Zisser, H., Renard, E., Kovatchev, B., Cobelli, C., Avogaro, A., Nimri, R., Magni, L., Buckingham, B. A., Chase, H. P., Doyle, F. J., Lum, J., Calhoun, P., Kollman, C., Dassau, E., Farret, A., Place, J., Breton, M., Anderson, S. M., Dalla Man, C., Del Favero, S., Bruttomesso, D., Filippi, A., Scotton, R., Phillip, M., Atlas, E., Muller, I., Miller, S., Toffanin, C., Raimondo, D. M., De Nicolao, G., Beck, R. W. 2014; 16 (10): 613-622

  Abstract

  The Control to Range Study was a multinational artificial pancreas study designed to assess the time spent in the hypo- and hyperglycemic ranges in adults and adolescents with type 1 diabetes while under closed-loop control. The controller attempted to keep the glucose ranges between 70 and 180 mg/dL. A set of prespecified metrics was used to measure safety.We studied 53 individuals for approximately 22 h each during clinical research center admissions. Plasma glucose level was measured every 15-30 min (YSI clinical laboratory analyzer instrument [YSI, Inc., Yellow Springs, OH]). During the admission, subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing by the controller.For adults, the mean of subjects' mean glucose levels was 159 mg/dL, and mean percentage of values 71-180 mg/dL was 66% overall (59% daytime and 82% overnight). For adolescents, the mean of subjects' mean glucose levels was 166 mg/dL, and mean percentage of values in range was 62% overall (53% daytime and 82% overnight). Whereas prespecified criteria for safety were satisfied by both groups, they were met at the individual level in adults only for combined daytime/nighttime and for isolated nighttime. Two adults and six adolescents failed to meet the daytime criterion, largely because of postmeal hyperglycemia, and another adolescent failed to meet the nighttime criterion.The control-to-range system performed as expected: faring better overnight than during the day and performing with variability between patients even after individualization based on patients' prior settings. The system had difficulty preventing postmeal excursions above target range.

  View details for DOI 10.1089/dia.2014.0066

  View details for Web of Science ID 000342561100002

  View details for PubMedID 25003311

  View details for PubMedCentralID PMC4183913

• Patterns of Nonverbal Behavior Associated with Truth and Deception: Illustrations from Three Experiments JOURNAL OF NONVERBAL BEHAVIOR Burgoon, J. K., Proudfoot, J. G., Schuetzler, R., Wilson, D. 2014; 38 (3): 325-354

  View details for DOI 10.1007/s10919-014-0181-5

  View details for Web of Science ID 000339722700005

• Accuracy evaluation of blood glucose monitoring systems in children on overnight closed-loop control. Journal of diabetes science and technology DeSalvo, D. J., Shanmugham, S., Ly, T. T., Wilson, D. M., Buckingham, B. A. 2014; 8 (5): 969-973

  Abstract

  This pilot study evaluated the difference in accuracy between the Bayer Contour® Next (CN) and HemoCue® (HC) glucose monitoring systems in children with type 1 diabetes participating in overnight closed-loop studies. Subjects aged 10-18 years old were admitted to a clinical research center and glucose values were obtained every 30 minutes overnight. Glucose values were measured using whole blood samples for CN and HC readings and results were compared to Yellow Springs Instrument (YSI) reference values obtained with plasma from the same sample. System accuracy was compared using mean absolute relative difference (MARD) and International Organization for Standardization (ISO) accuracy standards. A total of 28 subjects were enrolled in the study. Glucose measurements were evaluated at 457 time points. CN performed better than HC with an average MARD of 3.13% compared to 10.73% for HC (P < .001). With a limited sample size, CN met ISO criteria (2003 and 2013) at all glucose ranges while HC did not. CN performed very well, and would make an excellent meter for future closed-loop studies outside of a research center.

  View details for DOI 10.1177/1932296814532238

  View details for PubMedID 24876427

• A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes care Maahs, D. M., Calhoun, P., Buckingham, B. A., Chase, H. P., Hramiak, I., Lum, J., Cameron, F., Bequette, B. W., Aye, T., Paul, T., Slover, R., Wadwa, R. P., Wilson, D. M., Kollman, C., Beck, R. W. 2014; 37 (7): 1885-1891

  Abstract

  Overnight hypoglycemia occurs frequently in individuals with type 1 diabetes and can result in loss of consciousness, seizure, or even death. We conducted an in-home randomized trial to determine whether nocturnal hypoglycemia could be safely reduced by temporarily suspending pump insulin delivery when hypoglycemia was predicted by an algorithm based on continuous glucose monitoring (CGM) glucose levels.Following an initial run-in phase, a 42-night trial was conducted in 45 individuals aged 15-45 years with type 1 diabetes in which each night was assigned randomly to either having the predictive low-glucose suspend system active (intervention night) or inactive (control night). The primary outcome was the proportion of nights in which ≥1 CGM glucose values ≤60 mg/dL occurred.Overnight hypoglycemia with at least one CGM value ≤60 mg/dL occurred on 196 of 942 (21%) intervention nights versus 322 of 970 (33%) control nights (odds ratio 0.52 [95% CI 0.43-0.64]; P < 0.001). Median hypoglycemia area under the curve was reduced by 81%, and hypoglycemia lasting >2 h was reduced by 74%. Overnight sensor glucose was >180 mg/dL during 57% of control nights and 59% of intervention nights (P = 0.17), while morning blood glucose was >180 mg/dL following 21% and 27% of nights, respectively (P < 0.001), and >250 mg/dL following 6% and 6%, respectively. Morning ketosis was present <1% of the time in each arm.Use of a nocturnal low-glucose suspend system can substantially reduce overnight hypoglycemia without an increase in morning ketosis.

  View details for DOI 10.2337/dc13-2159

  View details for PubMedID 24804697

• Evolution of abnormal plasma glucagon responses to mixed-meal feedings in youth with type 1 diabetes during the first 2 years after diagnosis. Diabetes care Sherr, J., Tsalikian, E., Fox, L., Buckingham, B., Weinzimer, S., Tamborlane, W. V., White, N. H., Arbelaez, A. M., Kollman, C., Ruedy, K. J., Cheng, P., Beck, R. W. 2014; 37 (6): 1741-1744

  Abstract

  To examine the evolution of the dysregulated glucagon responses to mixed-meal tolerance tests (MMTTs) in youth with recent-onset type 1 diabetes (T1D).MMTTs were performed in 25 youth (9-18 years of age) with 1.5-12 months disease duration (year 1); 22 subjects were restudied 1 year later (year 2). Twenty nondiabetic (ND) control children were also studied.In T1D children, MMTT-stimulated increases in glucagon were significantly greater than that in ND children (median increments: year 1, 21 pg/mL [16-30]; year 2, 25 pg/mL [16-30]; ND, 9 pg/mL [5-16]; P = 0.001 and P < 0.001, respectively).In comparison with ND control children, exaggerated plasma glucagon responses to mixed-meal feedings are observed in youth with T1D within the first 2 years of diagnosis. Further studies to determine whether suppression of these abnormal responses may help to improve glycemic control are warranted.

  View details for DOI 10.2337/dc13-2612

  View details for PubMedID 24696460

• Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus PEDIATRIC DIABETES Arbelaez, A. M., Xing, D., Cryer, P. E., Kollman, C., Beck, R. W., Sherr, J., Ruedy, K. J., Tamborlane, W. V., Mauras, N., Tsalikian, E., Wilson, D. M., White, N. H. 2014; 15 (2): 127-134

  Abstract

  Glycemic control is limited by the barrier of hypoglycemia. Recurrent hypoglycemia impairs counterregulatory (CR) hormone responses to subsequent hypoglycemia.To determine the glucagon and epinephrine responses to insulin-induced hypoglycemia in adolescents with recent-onset type 1 diabetes mellitus (T1DM).We assessed the CR responses to hypoglycemia by performing a hyperinsulinemic (2.0 mU/kg/min), euglycemic (BG 90 mg/dL; 5.0 mmol/L)-hypoglycemic (BG 55 mg/dL; 3.0 mmol/L) clamp in 25 recent-onset (<1 yr duration) patients 9-18 yr old (mean ± SD: 13.4 ± 2.7) with T1DM and 16 non-diabetic controls 19-25 yr old (mean ± SD 23.3 ± 1.8). Twenty of the T1DM subjects were retested 1-yr (53 ± 3 wk) later.At the initial and 1-yr studies, peak glucagon (pGON) and incremental glucagon (ΔGON) during hypoglycemia were lower in the T1DM subjects [median pGON = 47 pg/mL (quartiles: 34, 72), ΔGON = 16 (4, 27) initially and pGON = 50 pg/mL (42, 70), ΔGON = 12 (9, 19) at 1-yr] than in controls [pGON = 93 pg/mL (60, 111); ΔGON = 38 pg/mL (19, 66), p = 0.01 and p = 0.004 for ΔGON at initial and 1-yr study, respectively]. In contrast, peak epinephrine (pEPI) and incremental epinephrine (ΔEPI) levels were similar in the T1DM (pEPI = 356 pg/mL (174, 797) and ΔEPI = 322 pg/mL (143, 781) initially and pEPI = 469 pg/mL (305, 595) and ΔEPI = 440 pg/mL (285, 574) at 1 yr) and in controls (pEPI = 383 pg/mL (329, 493) and ΔEPI = 336 pg/mL (298, 471) p = 0.97 and 0.21 for ΔEPI at initial and 1-yr study, respectively).Even within the first year of T1DM, glucagon responses to hypoglycemia are blunted but epinephrine responses are not, suggesting that the mechanisms involved in the loss of these hormonal responses, which are key components in pathophysiology of hypoglycemia-associated autonomic failure, are different.

  View details for DOI 10.1111/pedi.12070

  View details for Web of Science ID 000333060300007

  View details for PubMedID 23992543

  View details for PubMedCentralID PMC3858506

• OVERNIGHT GLUCOSE CONTROL WITH MODULAR CONTROL TO RANGE ALGORITHM IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES AT DIABETES CAMP Ly, T., De Salvo, D., Clinton, P., Breton, M. D., Chernavvsky, D., Mize, B., Keith-Hynes, P., Kovatchev, B. P., Wilson, D. M., Buckingham, B. A. MARY ANN LIEBERT, INC. 2014: A42

  View details for Web of Science ID 000331218000110

• Cognitive functioning in young children with type 1 diabetes. Journal of the International Neuropsychological Society Cato, M. A., Mauras, N., Ambrosino, J., Bondurant, A., Conrad, A. L., Kollman, C., Cheng, P., Beck, R. W., Ruedy, K. J., Aye, T., Reiss, A. L., White, N. H., Hershey, T. 2014; 20 (2): 238-247

  Abstract

  The aim of this study was to assess cognitive functioning in children with type 1 diabetes (T1D) and examine whether glycemic history influences cognitive function. Neuropsychological evaluation of 216 children (healthy controls, n = 72; T1D, n = 144) ages 4-10 years across five DirecNet sites. Cognitive domains included IQ, Executive Functions, Learning and Memory, and Processing Speed. Behavioral, mood, parental IQ data, and T1D glycemic history since diagnosis were collected. The cohorts did not differ in age, gender or parent IQ. Median T1D duration was 2.5 years and average onset age was 4 years. After covarying age, gender, and parental IQ, the IQ and the Executive Functions domain scores trended lower (both p = .02, not statistically significant adjusting for multiple comparisons) with T1D relative to controls. Children with T1D were rated by parents as having more depressive and somatic symptoms (p < .001). Learning and memory (p = .46) and processing speed (p = .25) were similar. Trends in the data supported that the degree of hyperglycemia was associated with Executive Functions, and to a lesser extent, Child IQ and Learning and Memory. Differences in cognition are subtle in young children with T1D within 2 years of onset. Longitudinal evaluations will help determine whether these findings change or become more pronounced with time. (JINS, 2014, 20, 238-247).

  View details for DOI 10.1017/S1355617713001434

  View details for PubMedID 24512675

• B-Lymphocyte Depletion With Rituximab and beta-Cell Function: Two-Year Results DIABETES CARE Pescovitz, M. D., Greenbaum, C. J., Bundy, B., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., Moran, A., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S. 2014; 37 (2): 453-459

  Abstract

  We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of β-cell function in recent-onset type 1 diabetes mellitus (T1DM) at 1 year. Subjects were followed further to determine whether there was persistence of effect.Eighty-seven subjects (aged 8-40 years) were randomly assigned to, and 81 received, infusions of rituximab or placebo on days 1, 8, 15, and 22. The primary outcome-baseline-adjusted mean 2-h area under the curve (AUC) serum C-peptide during a mixed-meal tolerance test (MMTT) at 1 year-showed higher C-peptide AUC with rituximab versus placebo. Subjects were further followed with additional MMTTs every 6 months.The rate of decline of C-peptide was parallel between groups but shifted by 8.2 months in rituximab-treated subjects. Over 30 months, AUC, insulin dose, and HbA1c were similar for rituximab and placebo. However, in evaluating change in C-peptide over the entire follow-up period, the rituximab group means were significantly larger as compared within assessment times with the placebo group means using a global test (P = 0.03). Odds ratio for loss of C-peptide to <0.2 nmol/L following rituximab was 0.565 (P = 0.064). B-lymphocytes recovered to baseline values by 18 months. Serum IgG levels were maintained in the normal range but IgM levels were depressed.Like several other immunotherapeutic approaches tested, in recent-onset T1DM, rituximab delays the fall in C-peptide but does not appear to fundamentally alter the underlying pathophysiology of the disease.

  View details for DOI 10.2337/dc13-0626

  View details for Web of Science ID 000331072800033

  View details for PubMedID 24026563

  View details for PubMedCentralID PMC3898764

• CLINICAL TRIAL OF AN ARTIFICIAL PANCREAS WITH LARGE UNANNOUNCED MEALS Cameron, F., Niemeyer, G., Wilson, D., Benasi, K., Clinton, P., Bequette, B. W., Buckingham, B. MARY ANN LIEBERT, INC. 2014: A24–A25

  View details for Web of Science ID 000331218000066

• OVERNIGHT CLOSED-LOOP CONTROL WITH A PROPORTIONAL-INTEGRAL-DERIVATIVE BASED ALGORITHM IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES AT DIABETES CAMP Ly, T., Clinton, P., Keenan, D. B., Roy, A., Han, J., Grosman, B., Cantwell, M., Kurtz, N., Wilson, D. M., Buckingham, B. A. MARY ANN LIEBERT, INC. 2014: A25

  View details for Web of Science ID 000331218000067

• Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia DIABETES TECHNOLOGY & THERAPEUTICS DeSalvo, D. J., Keith-Hynes, P., Peyser, T., Place, J., Caswell, K., Wilson, D. M., Harris, B., Clinton, P., Kovatchev, B., Buckingham, B. A. 2014; 16 (1): 1-7

  Abstract

  This study tested the feasibility and effectiveness of remote continuous glucose monitoring (CGM) in a diabetes camp setting.Twenty campers (7-21 years old) with type 1 diabetes were enrolled at each of three camp sessions lasting 5-6 days. On alternating nights, 10 campers were randomized to usual wear of a Dexcom (San Diego, CA) G4™ PLATINUM CGM system, and 10 were randomized to remote monitoring with the Dexcom G4 PLATINUM communicating with the Diabetes Assistant, a cell phone platform, to allow wireless transmission of CGM values. Up to 15 individual graphs and sensor values could be displayed on a single remote monitor or portable tablet. An alarm was triggered for values <70 mg/dL, and treatment was given for meter-confirmed hypoglycemia. The primary end point was to decrease the duration of hypoglycemic episodes <50 mg/dL.There were 320 nights of CGM data and 197 hypoglycemic events. Of the remote monitoring alarms, 79% were true (meter reading of <70 mg/dL). With remote monitoring, 100% of alarms were responded to, whereas without remote monitoring only 54% of alarms were responded to. The median duration of hypoglycemic events <70 mg/dL was 35 min without remote monitoring and 30 min with remote monitoring (P=0.078). Remote monitoring significantly decreased prolonged hypoglycemic events, eliminating all events <50 mg/dL lasting longer than 30 min as well as all events <70 mg/dL lasting more than 2 h.Remote monitoring is feasible at diabetes camps and effective in reducing the risk of prolonged nocturnal hypoglycemia. This technology will facilitate forthcoming studies to evaluate the efficacy of automated closed-loop systems in the camp setting.

  View details for DOI 10.1089/dia.2013.0139

  View details for PubMedID 24168317

• Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes Marzelli, M. J., Mazaika, P. K., Barnea-Goraly, N., Hershey, T., Tsalikian, E., Tamborlane, W., Mauras, N., White, N. H., Buckingham, B., Beck, R. W., Ruedy, K. J., Kollman, C., Cheng, P., Reiss, A. L. 2014; 63 (1): 343-353

  Abstract

  Studies of brain structure in type 1 diabetes (T1D) describe widespread neuroanatomical differences related to exposure to glycemic dysregulation in adults and adolescents. In this study, we investigate the neuroanatomical correlates of dysglycemia in very young children with early-onset T1D. Structural magnetic resonance images of the brain were acquired in 142 children with T1D and 68 age-matched control subjects (mean age 7.0 ± 1.7 years) on six identical scanners. Whole-brain volumetric analyses were conducted using voxel-based morphometry to detect regional differences between groups and to investigate correlations between regional brain volumes and measures of glycemic exposure (including data from continuous glucose monitoring). Relative to control subjects, the T1D group displayed decreased gray matter volume (GMV) in bilateral occipital and cerebellar regions (P < 0.001) and increased GMV in the left inferior prefrontal, insula, and temporal pole regions (P = 0.002). Within the T1D group, hyperglycemic exposure was associated with decreased GMV in medial frontal and temporal-occipital regions and increased GMV in lateral prefrontal regions. Cognitive correlations of intelligence quotient to GMV were found in cerebellar-occipital regions and medial prefrontal cortex for control subjects, as expected, but not for the T1D group. Thus, early-onset T1D affects regions of the brain that are associated with typical cognitive development.

  View details for DOI 10.2337/db13-0179

  View details for PubMedID 24170697

• The Impact of Accelerometer and Heart Rate Data on Hypoglycemia Mitigation in Type 1 Diabetes. Journal of diabetes science and technology Stenerson, M., Cameron, F., Wilson, D. M., Harris, B., Payne, S., Bequette, B. W., Buckingham, B. A. 2014; 8 (1): 64-69

  Abstract

  Aerobic exercise can lower blood glucose levels and alter insulin sensitivity both during and several hours after exercise, creating challenges for a closed-loop artificial pancreas. Predictive low glucose suspend (PLGS) algorithms are a first step toward an artificial pancreas, but few of these have been successfully applied to exercise. This study incorporates physical activity measurements from a combined accelerometer/heart rate monitor (HRM) to improve the performance of an existing PLGS algorithm at mitigating exercise-associated hypoglycemia in participants with type 1 diabetes. In all, 22 subjects with type 1 diabetes on insulin pump therapy were provided a combined accelerometer/HRM and (if not already using one) a continuous glucose monitor (CGM), then instructed to go about their everyday lives while wearing the devices. After the monitoring period, each subject's insulin pump, CGM, and accelerometer/HRM were downloaded and the data were used to augment an existing PLGS algorithm to incorporate activity. Using a computer simulator, the accelerometer-augmented algorithm was compared to the HRM-augmented algorithm to determine which was most effective at mitigating hypoglycemia. Mean length of monitoring was 4.9 days. Across all subjects, 11 061 CGM readings were recorded during the monitoring period. In the simulator analysis, the PLGS algorithm reduced hypoglycemia by 62%, compared to 71% and 74% reductions for the HRM-augmented and accelerometer-augmented algorithms, respectively; combined accelerometer and HRM augmentation provided a 76% reduction. In a simulated setting, the accelerometer-augmented pump suspension algorithm decreases the incidence of exercise-related hypoglycemia by a meaningful amount compared to the PLGS algorithm alone. Results also failed to justify the additional user burden of a HRM.

  View details for PubMedID 24876539

• Randomized Trial of Infusion Set Function: Steel Versus Teflon DIABETES TECHNOLOGY & THERAPEUTICS Patel, P. J., Benasi, K., Ferrari, G., Evans, M. G., Shanmugham, S., Wilson, D. M., Buckingham, B. A. 2014; 16 (1): 15-19

  Abstract

  This study compared infusion set function for up to 1 week using either a Teflon(®) (Dupont(™), Wilmington, DE) catheter or a steel catheter for insulin pump therapy in type 1 diabetes mellitus.Twenty subjects participating in a randomized, open-labeled, crossover study were asked to wear two Quick-Set(®) and two Sure-T(®) infusion sets (both from Medtronic Minimed, Northridge, CA) until the infusion set failed or was worn for 1 week. All subjects wore a MiniMed continuous glucose monitoring system for the duration of the study.One subject withdrew from the study. There were 38 weeks of Sure-T wear and 39 weeks of Quick-Set wear with no difference in the survival curves of the infusion sets. There was, however, a 15% initial failure rate with the Teflon infusion set. After 7 days, both types of infusion sets had a 64% failure rate. Overall, 30% failed because of hyperglycemia and a failed correction dose, 13% were removed for pain, 10% were pulled out by accident, 10% had erythema and/or induration of>10 mm, 5% fell out because of loss of adhesion, and 4% were removed for infection. The main predictor of length of wear was the individual subject. There was no increase in hyperglycemia or daily insulin requirements when an infusion set was successfully used for 7 days (n=25 of 77 weeks).We found no difference between steel and Teflon infusion sets in their function over 7 days, although 15% of Teflon sets failed because of kinking on insertion. The strongest predictor of prolonged 7-day infusion set function was the individual subject, not the type of infusion set.

  View details for DOI 10.1089/dia.2013.0119

  View details for Web of Science ID 000329298500003

  View details for PubMedID 24090124

  View details for PubMedCentralID PMC3887416

• Effectiveness of Early Intensive Therapy on beta-Cell Preservation in Type 1 Diabetes DIABETES CARE Buckingham, B., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., Weinzimer, S. A., Dimeglio, L. A., Bremer, A. A., Slover, R., Tamborlane, W. V. 2013; 36 (12): 4030-4035

  Abstract

  To assess effectiveness of inpatient hybrid closed-loop control (HCLC) followed by outpatient sensor-augmented pump (SAP) therapy initiated within 7 days of diagnosis of type 1 diabetes on the preservation of β-cell function at 1 year.Sixty-eight individuals (mean age 13.3 ± 5.7 years; 35% female, 92% Caucasian) were randomized to HCLC followed by SAP therapy (intensive group; N = 48) or to the usual-care group treated with multiple daily injections or insulin pump therapy (N = 20). Primary outcome was C-peptide concentrations during mixed-meal tolerance tests at 12 months.Intensive-group participants initiated HCLC a median of 6 days after diagnosis for a median duration of 71.3 h, during which median participant mean glucose concentration was 140 mg/dL (interquartile range 134-153 mg/dL). During outpatient SAP, continuous glucose monitor (CGM) use decreased over time, and at 12 months, only 33% of intensive participants averaged sensor use ≥6 days/week. In the usual-care group, insulin pump and CGM use were initiated prior to 12 months by 15 and 5 participants, respectively. Mean HbA1c levels were similar in both groups throughout the study. At 12 months, the geometric mean (95% CI) of C-peptide area under the curve was 0.43 (0.34-0.52) pmol/mL in the intensive group and 0.52 (0.32-0.75) pmol/mL in the usual-care group (P = 0.49). Thirty-seven (79%) intensive and 16 (80%) usual-care participants had a peak C-peptide concentration ≥0.2 pmol/mL (P = 0.30).In new-onset type 1 diabetes, HCLC followed by SAP therapy did not provide benefit in preserving β-cell function compared with current standards of care.

  View details for DOI 10.2337/dc13-1074

  View details for Web of Science ID 000327211500053

  View details for PubMedID 24130350

• Family, community and clinic collaboration to treat overweight and obese children: Stanford GOALS-A randomized controlled trial of a three-year, multi-component, multi-level, multi-setting intervention. Contemporary clinical trials Robinson, T. N., Matheson, D., Desai, M., Wilson, D. M., Weintraub, D. L., Haskell, W. L., McClain, A., McClure, S., A Banda, J., Sanders, L. M., Haydel, K. F., Killen, J. D. 2013; 36 (2): 421-435

  Abstract

  To test the effects of a three-year, community-based, multi-component, multi-level, multi-setting (MMM) approach for treating overweight and obese children.Two-arm, parallel group, randomized controlled trial with measures at baseline, 12, 24, and 36months after randomization.Seven through eleven year old, overweight and obese children (BMI≥85th percentile) and their parents/caregivers recruited from community locations in low-income, primarily Latino neighborhoods in Northern California.Families are randomized to the MMM intervention versus a community health education active-placebo comparison intervention. Interventions last for three years for each participant. The MMM intervention includes a community-based after school team sports program designed specifically for overweight and obese children, a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and a primary care behavioral counseling intervention linked to the community and home interventions. The active-placebo comparison intervention includes semi-annual health education home visits, monthly health education newsletters for children and for parents/guardians, and a series of community-based health education events for families.Body mass index trajectory over the three-year study. Secondary outcome measures include waist circumference, triceps skinfold thickness, accelerometer-measured physical activity, 24-hour dietary recalls, screen time and other sedentary behaviors, blood pressure, fasting lipids, glucose, insulin, hemoglobin A1c, C-reactive protein, alanine aminotransferase, and psychosocial measures.The Stanford GOALS trial is testing the efficacy of a novel community-based multi-component, multi-level, multi-setting treatment for childhood overweight and obesity in low-income, Latino families.

  View details for DOI 10.1016/j.cct.2013.09.001

  View details for PubMedID 24028942

• Outpatient Safety Assessment of an In-Home Predictive Low-Glucose Suspend System with Type 1 Diabetes Subjects at Elevated Risk of Nocturnal Hypoglycemia DIABETES TECHNOLOGY & THERAPEUTICS Buckingham, B. A., Cameron, F., Calhoun, P., Maahs, D. M., Wilson, D. M., Chase, H. P., Bequette, B. W., Lum, J., Sibayan, J., Beck, R. W., Kollman, C. 2013; 15 (8): 622-627

  Abstract

  Abstract Objective: Nocturnal hypoglycemia is a common problem with type 1 diabetes. In the home setting, we conducted a pilot study to evaluate the safety of a system consisting of an insulin pump and continuous glucose monitor communicating wirelessly with a bedside computer running an algorithm that temporarily suspends insulin delivery when hypoglycemia is predicted. Research Design and Methods: After the run-in phase, a 21-night randomized trial was conducted in which each night was randomly assigned 2:1 to have either the predictive low-glucose suspend (PLGS) system active (intervention night) or inactive (control night). Three predictive algorithm versions were studied sequentially during the study for a total of 252 intervention and 123 control nights. The trial included 19 participants 18-56 years old with type 1 diabetes (hemoglobin A1c level of 6.0-7.7%) who were current users of the MiniMed Paradigm(®) REAL-Time Revel™ System and Sof-sensor(®) glucose sensor (Medtronic Diabetes, Northridge, CA). Results: With the final algorithm, pump suspension occurred on 53% of 77 intervention nights. Mean morning glucose level was 144±48 mg/dL on the 77 intervention nights versus 133±57 mg/dL on the 37 control nights, with morning blood ketones >0.6 mmol/L following one intervention night. Overnight hypoglycemia was lower on intervention than control nights, with at least one value ≤70 mg/dL occurring on 16% versus 30% of nights, respectively, with the final algorithm. Conclusions: This study demonstrated that the PLGS system in the home setting is safe and feasible. The preliminary efficacy data appear promising with the final algorithm reducing nocturnal hypoglycemia by almost 50%.

  View details for DOI 10.1089/dia.2013.0040

  View details for PubMedID 23883408

• Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials LANCET Moran, A., Bundy, B., Becker, D. J., Dimeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., Sanda, S., Schatz, D., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S., Pickersgill, L., de Koning, E., Ziegler, A., Boeehm, B., Badenhoop, K., Schloot, N., Bak, J. F., Pozzilli, P., Mauricio, D., Donath, M. Y., Castano, L., Waegner, A., Lervang, H. H., Perrild, H., Mandrup-Poulsen, T. 2013; 381 (9881): 1905-1915

  Abstract

  Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.We did two randomised, placebo-controlled trials in two groups of patients with recent-onset type 1 diabetes and mixed-meal-tolerance-test-stimulated C peptide of at least 0·2 nM. Patients in the canakinumab trial were aged 6-45 years and those in the anakinra trial were aged 18-35 years. Patients in the canakinumab trial were enrolled at 12 sites in the USA and Canada and those in the anakinra trial were enrolled at 14 sites across Europe. Participants were randomly assigned by computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg) canakinumab or placebo monthly for 12 months or 100 mg anakinra or placebo daily for 9 months. Participants and carers were masked to treatment assignment. The primary endpoint was baseline-adjusted 2-h area under curve C-peptide response to the mixed meal tolerance test at 12 months (canakinumab trial) and 9 months (anakinra trial). Analyses were by intention to treat. These studies are registered with ClinicalTrials.gov, numbers NCT00947427 and NCT00711503, and EudraCT number 2007-007146-34.Patients were enrolled in the canakinumab trial between Nov 12, 2010, and April 11, 2011, and in the anakinra trial between Jan 26, 2009, and May 25, 2011. 69 patients were randomly assigned to canakinumab (n=47) or placebo (n=22) monthly for 12 months and 69 were randomly assigned to anakinra (n=35) or placebo (n=34) daily for 9 months. No interim analyses were done. 45 canakinumab-treated and 21 placebo-treated patients in the canakinumab trial and 25 anakinra-treated and 26 placebo-treated patients in the anakinra trial were included in the primary analyses. The difference in C peptide area under curve between the canakinumab and placebo groups at 12 months was 0·01 nmol/L (95% CI -0·11 to 0·14; p=0·86), and between the anakinra and the placebo groups at 9 months was 0·02 nmol/L (-0·09 to 0·15; p=0·71). The number and severity of adverse events did not differ between groups in the canakinumab trial. In the anakinra trial, patients in the anakinra group had significantly higher grades of adverse events than the placebo group (p=0·018), which was mainly because of a higher number of injection site reactions in the anakinra group.Canakinumab and anakinra were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes. Interleukin-1 blockade might be more effective in combination with treatments that target adaptive immunity in organ-specific autoimmune disorders.National Institutes of Health and Juvenile Diabetes Research Foundation.

  View details for DOI 10.1016/S0140-6736(13)60023-9

  View details for Web of Science ID 000320319500031

• Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes DIABETES CARE Sherr, J., Xing, D., Ruedy, K. J., Beck, R. W., Kollman, C., Buckingham, B., White, N. H., Fox, L., Tsalikian, E., Weinzimer, S., Arbelaez, A. M., Tamborlane, W. V. 2013; 36 (6): 1470-1476

  Abstract

  To examine the loss of glucagon response to hypoglycemia and its relationship with residual β-cell function early in the course of type 1 diabetes (T1D) in youth.Twenty-one youth with T1D duration <1 year (ages 8-18 years, T1D duration 6-52 weeks) underwent mixed-meal tolerance tests (MMTTs) to assess residual β-cell function and hypoglycemic clamps to assess glucagon responses to hypoglycemia. Glucagon responses to hypoglycemia in T1D subjects were compared with those in 12 nondiabetic young adults (ages 19-25 years).Peak MMTT-stimulated C-peptide levels (range 0.12-1.43) were ≥ 0.2 nmol/L in all but one T1D subject. As expected, the median of glucagon responses to hypoglycemia in the T1D subjects (18 pg/mL [interquartile range 7-32]) was significantly reduced compared with the responses in nondiabetic control subjects (38 pg/mL [19-66], P = 0.02). However, there was no correlation between the incremental increase in plasma glucagon during the hypoglycemic clamp and the incremental increase and peak plasma C-peptide level during the MMTT. Similarly, the seven T1D subjects who failed to achieve an increase in glucagon ≥ 12 pg/mL (i.e., 3 SD above baseline values) had C-peptide response ≥ 0.2 nmol/L (0.54-1.12), and the one T1D subject with peak stimulated <0.2 nmol/L had a 14 pg/mL increase in plasma glucagon in response to hypoglycemia.Impaired plasma glucagon responses to hypoglycemia are evident in youth with T1D during the first year of the disease. Moreover, defective and absent glucagon responses to hypoglycemia were observed in patients who retained clinically important residual endogenous β-cell function.

  View details for DOI 10.2337/dc12-1697

  View details for Web of Science ID 000321472600007

  View details for PubMedID 23288858

  View details for PubMedCentralID PMC3661789

• The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated Within 1 Week of Type 1 Diabetes Diagnosis DIABETES TECHNOLOGY & THERAPEUTICS Buckingham, B. A., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., Weinzimer, S. A., Dimeglio, L. A., Bremer, A. A., Slover, R., Cantwell, M., Tsalikian, E., Tansey, M. J., Coffey, J., Cabbage, J., Salamati, S., Mauras, N., Fox, L. A., Englert, K., Permuy, J., Sikes, K., Buckingham, B. A., Wilson, D. M., Clinton, P., Caswell, K., Weinzimer, S. A., Tamborlane, W. V., Sherr, J., Steffen, A., Weyman, K., Zgorski, M., Tichy, E., White, N. H., Arbelaez, A. M., Levandoski, L., Starnes, A., Skyler, J. S., Greenbaum, C. J., Kenyon, N. S., Rafkin, L., Santiago, I., Sosenko, J. M. 2013; 15 (5): 401-408

  View details for DOI 10.1089/dia.2013.0002

  View details for Web of Science ID 000318477700007

• A Cross-sectional Study of Osteocalcin and Body Fat Measures Among Obese Adolescents OBESITY Lenders, C. M., Lee, P. D., Feldman, H. A., Wilson, D. M., Abrams, S. H., Gitelman, S. E., Klish, W. J., Wertz, M. S., Taylor, G. A., Alongi, R. T., Chen, T. C., Holick, M. F. 2013; 21 (4): 808-814

  Abstract

  Osteocalcin (OCN), a marker of osteoblast activity, has been implicated in the regulation of energy metabolism by the skeleton and thus may affect body fat measures.To examine the relationships of OCN to body fat measures and whether they vary according to markers of energy and vitamin D metabolism.Data were obtained from 58 obese adolescents aged 13-17.9 years (38 females, 8 black or African-American). Total fat mass (FM) [dual X-ray absorptiometry (DXA)] and visceral adipose tissue (VAT) [computerized axial tomography (CT)] were calculated. Blood tests included leptin, OCN, 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), thyroid function tests, and triglycerides. Markers of glucose metabolism were obtained from fasting and OGTT samples.Adolescents with 25(OH)D <20 ng mL(-1) were considered deficient (n = 17/58); none had high PTH (PTH ≥ 65 pg mL(-1) ). OCN was associated with lower VAT (-84.27 ± 33.89 mm(2) ) and BMI (-0.10 ± 0.05 kg m(-2) ), not FM (P = 0.597) in a core model including age, sex, race, geographic latitude, summer, height z-score, and tanner stage. Adding 25(OH)D deficiency and PTH attenuated the inverse association of OCN to VAT. There was a significant interaction of OCN and 25(OH)D deficiency on FM (0.37 ± 0.18 kg, P = 0.041) and BMI (0.28 ± 0.10 kg m(-2) , P = 0.007) in this adjusted model, which was further explained by leptin. Adding A1C to the core model modified the relationship of OCN to VAT (-93.08 ± 35.05 mm(2) , P = 0.011), which was further explained by HOMA-IR. In summary, these findings provide initial evidence for a relationship between OCN and body fat measures that is dependent on energy metabolism and vitamin D status among obese adolescents.

  View details for DOI 10.1002/oby.20131

  View details for Web of Science ID 000322087800022

  View details for PubMedID 23712984

• Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet Moran, A., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., Sanda, S., Schatz, D., Wherrett, D. K., Wilson, D. M., Krischer, J. P., Skyler, J. S., Pickersgill, L., de Koning, E., Ziegler, A. G., Böehm, B., Badenhoop, K., Schloot, N., Bak, J. F., Pozzilli, P., Mauricio, D., Donath, M. Y., Castaño, L., Wägner, A., Lervang, H. H., Perrild, H., Mandrup-Poulsen, T., Pociot, F., Dinarello, C. A. 2013; 381 (9881): 1905–15

  Abstract

  Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.We did two randomised, placebo-controlled trials in two groups of patients with recent-onset type 1 diabetes and mixed-meal-tolerance-test-stimulated C peptide of at least 0·2 nM. Patients in the canakinumab trial were aged 6-45 years and those in the anakinra trial were aged 18-35 years. Patients in the canakinumab trial were enrolled at 12 sites in the USA and Canada and those in the anakinra trial were enrolled at 14 sites across Europe. Participants were randomly assigned by computer-generated blocked randomisation to subcutaneous injection of either 2 mg/kg (maximum 300 mg) canakinumab or placebo monthly for 12 months or 100 mg anakinra or placebo daily for 9 months. Participants and carers were masked to treatment assignment. The primary endpoint was baseline-adjusted 2-h area under curve C-peptide response to the mixed meal tolerance test at 12 months (canakinumab trial) and 9 months (anakinra trial). Analyses were by intention to treat. These studies are registered with ClinicalTrials.gov, numbers NCT00947427 and NCT00711503, and EudraCT number 2007-007146-34.Patients were enrolled in the canakinumab trial between Nov 12, 2010, and April 11, 2011, and in the anakinra trial between Jan 26, 2009, and May 25, 2011. 69 patients were randomly assigned to canakinumab (n=47) or placebo (n=22) monthly for 12 months and 69 were randomly assigned to anakinra (n=35) or placebo (n=34) daily for 9 months. No interim analyses were done. 45 canakinumab-treated and 21 placebo-treated patients in the canakinumab trial and 25 anakinra-treated and 26 placebo-treated patients in the anakinra trial were included in the primary analyses. The difference in C peptide area under curve between the canakinumab and placebo groups at 12 months was 0·01 nmol/L (95% CI -0·11 to 0·14; p=0·86), and between the anakinra and the placebo groups at 9 months was 0·02 nmol/L (-0·09 to 0·15; p=0·71). The number and severity of adverse events did not differ between groups in the canakinumab trial. In the anakinra trial, patients in the anakinra group had significantly higher grades of adverse events than the placebo group (p=0·018), which was mainly because of a higher number of injection site reactions in the anakinra group.Canakinumab and anakinra were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes. Interleukin-1 blockade might be more effective in combination with treatments that target adaptive immunity in organ-specific autoimmune disorders.National Institutes of Health and Juvenile Diabetes Research Foundation.

  View details for DOI 10.1016/S0140-6736(13)60023-9

  View details for PubMedID 23562090

• Detecting Sensor and Insulin Infusion Set Anomalies in an Artificial Pancreas American Control Conference (ACC) Baysal, N., Cameron, F., Buckingham, B. A., Wilson, D. M., Bequette, B. W. IEEE. 2013: 2929–2933

  View details for Web of Science ID 000327210203018

• White Matter Structural Differences in Young Children With Type 1 Diabetes: A Diffusion Tensor Imaging Study DIABETES CARE Aye, T., Barnea-Goraly, N., Ambler, C., Hoang, S., Schleifer, K., Park, Y., Drobny, J., Wilson, D. M., Reiss, A. L., Buckingham, B. A. 2012; 35 (11): 2167-2173

  Abstract

  To detect clinical correlates of cognitive abilities and white matter (WM) microstructural changes using diffusion tensor imaging (DTI) in young children with type 1 diabetes.Children, ages 3 to <10 years, with type 1 diabetes (n = 22) and age- and sex-matched healthy control subjects (n = 14) completed neurocognitive testing and DTI scans.Compared with healthy controls, children with type 1 diabetes had lower axial diffusivity (AD) values (P = 0.046) in the temporal and parietal lobe regions. There were no significant differences between groups in fractional anisotropy and radial diffusivity (RD). Within the diabetes group, there was a significant, positive correlation between time-weighted HbA(1c) and RD (P = 0.028). A higher, time-weighted HbA(1c) value was significantly correlated with lower overall intellectual functioning measured by the full-scale intelligence quotient (P = 0.03).Children with type 1 diabetes had significantly different WM structure (as measured by AD) when compared with controls. In addition, WM structural differences (as measured by RD) were significantly correlated with their HbA(1c) values. Additional studies are needed to determine if WM microstructural differences in young children with type 1 diabetes predict future neurocognitive outcome.

  View details for DOI 10.2337/dc12-0017

  View details for PubMedID 22966090

• Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm. Journal of diabetes science and technology Cameron, F., Wilson, D. M., Buckingham, B. A., Arzumanyan, H., Clinton, P., Chase, H. P., Lum, J., Maahs, D. M., Calhoun, P. M., Bequette, B. W. 2012; 6 (5): 1142-1147

  Abstract

  An insulin pump shutoff system can prevent nocturnal hypoglycemia and is a first step on the pathway toward a closed-loop artificial pancreas. In previous pump shutoff studies using a voting algorithm and a 1 min continuous glucose monitor (CGM), 80% of induced hypoglycemic events were prevented.The pump shutoff algorithm used in previous studies was revised to a single Kalman filter to reduce complexity, incorporate CGMs with different sample times, handle sensor signal dropouts, and enforce safety constraints on the allowable pump shutoff time.Retrospective testing of the new algorithm on previous clinical data sets indicated that, for the four cases where the previous algorithm failed (minimum reference glucose less than 60 mg/dl), the mean suspension start time was 30 min earlier than the previous algorithm. Inpatient studies of the new algorithm have been conducted on 16 subjects. The algorithm prevented hypoglycemia in 73% of subjects. Suspension-induced hyperglycemia is not assessed, because this study forced excessive basal insulin infusion rates.The new algorithm functioned well and is flexible enough to handle variable sensor sample times and sensor dropouts. It also provides a framework for handling sensor signal attenuations, which can be challenging, particularly when they occur overnight.

  View details for PubMedID 23063041

  View details for PubMedCentralID PMC3570849

• Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric diabetes Tsalikian, E., Fox, L., Weinzimer, S., Buckingham, B., White, N. H., Beck, R., Kollman, C., Xing, D., Ruedy, K. 2012; 13 (4): 301-307

  Abstract

  To examine the feasibility of continuous glucose monitoring (CGM) use in very young children with type 1 diabetes (T1D).Twenty-three children less than 4 yr of age with T1D were provided with a FreeStyle Navigator(®) (n = 21) or a Paradigm(®) (n = 2) CGM device. At baseline, mean age was 3.0 ± 0.8 yr, mean hemoglobin A1c (HbA1c) was 8.0 ± 0.8%, 10 were using an insulin pump and 13 were on multiple daily injections. CGM use was evaluated over a 6-month period.Three children dropped out of the study before the end of 6 months. Among the 20 children who completed 6 months of follow-up, CGM use in month 6 was ≥6 d/wk in 9 (45%), 4 ≤ 6 d/wk in 2 (10%), and <4 d/wk in 9 (45%). Skin reactions were minimal. Although there was no detectable change in mean HbA1c between baseline and 6 months (7.9 and 8.0%, respectively), there was a high degree of parental satisfaction with CGM as measured on the CGM satisfaction scale questionnaire. A high percentage of glucose values were in the hyperglycemic range, and biochemical hypoglycemia was infrequent.More than 40% of very young children were able to safely use CGM on a near-daily basis after 6 months. CGM demonstrated frequent hyperglycemic excursions, with a large variability in glucose readings. Although improvement in glycemic control was not detected in the group as a whole, parental satisfaction with CGM was high.

  View details for DOI 10.1111/j.1399-5448.2011.00837.x

  View details for PubMedID 22151826

• Achievement of Target A1C Levels With Negligible Hypoglycemia and Low Glucose Variability in Youth With Short-Term Type 1 Diabetes and Residual beta-Cell Function DIABETES CARE Sherr, J., Tamborlane, W. V., Xing, D., Tsalikian, E., Mauras, N., Buckingham, B., White, N. H., Arbelaez, A. M., Beck, R. W., Kollman, C., Ruedy, K. 2012; 35 (4): 817-820

  Abstract

  To determine exposure to hyper- and hypoglycemia using blinded continuous glucose monitoring (CGM) profiles in youth with type 1 diabetes (T1D) with residual β-cell function during the first year of insulin treatment.Blinded, 3-7 day CGM profiles were obtained in 16 short-term T1D patients (age 8-18 years, T1D duration 6-52 weeks) who had peak C-peptide levels ranging from 0.46 to 1.96 nmol/L during a mixed-meal tolerance test. Results in this short-term group were compared with those in 34 patients with well-controlled, longer-term T1D (duration ≥5 years), matched for age and A1C with the short-term T1D group, and with those in 26 age-matched nondiabetic individuals.Despite matching for A1C, and therefore similar mean sensor glucose levels in the two T1D groups, short-term T1D participants had a lower frequency of hypoglycemia (0.3 vs. 7.6%, P < 0.001), a trend toward less hyperglycemia (17 vs. 32%, P = 0.15), and a greater percentage in the target range (median 77 vs. 60%, P = 0.02). Indeed, the percentage of sensor glucose levels ≤70 mg/dL in the short-term T1D group (0.3%) did not differ from those in the nondiabetic group (1.7%, P = 0.73). The coefficient of variation of sensor glucose levels (an index of glucose variability) was lower in short-term vs. longer-term T1D participants (27 vs. 42%, respectively, P < 0.001).In youth with short-term T1D who retain residual β-cell function, there is negligible exposure to hypoglycemia and lower glucose variability than in youth with well-controlled T1D of longer duration.

  View details for DOI 10.2337/dc11-2190

  View details for Web of Science ID 000301959600027

  View details for PubMedID 22323414

  View details for PubMedCentralID PMC3308298

• A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children Aged 4 to < 10 Years DIABETES CARE Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C. 2012; 35 (2): 204-210

  Abstract

  Continuous glucose monitoring (CGM) has been demonstrated to improve glycemic control in adults with type 1 diabetes but less so in children. We designed a study to assess CGM benefit in young children aged 4 to 9 years with type 1 diabetes.After a run-in phase, 146 children with type 1 diabetes (mean age 7.5 ± 1.7 years, 64% on pumps, median diabetes duration 3.5 years) were randomly assigned to CGM or to usual care. The primary outcome was reduction in HbA(1c) at 26 weeks by ≥0.5% without the occurrence of severe hypoglycemia.The primary outcome was achieved by 19% in the CGM group and 28% in the control group (P = 0.17). Mean change in HbA(1c) was -0.1% in each group (P = 0.79). Severe hypoglycemia rates were similarly low in both groups. CGM wear decreased over time, with only 41% averaging at least 6 days/week at 26 weeks. There was no correlation between CGM use and change in HbA(1c) (r(s) = -0.09, P = 0.44). CGM wear was well tolerated, and parental satisfaction with CGM was high. However, parental fear of hypoglycemia was not reduced.CGM in 4- to 9-year-olds did not improve glycemic control despite a high degree of parental satisfaction with CGM. We postulate that this finding may be related in part to limited use of the CGM glucose data in day-to-day management and to an unremitting fear of hypoglycemia. Overcoming the barriers that prevent integration of these critical glucose data into day-to-day management remains a challenge.

  View details for DOI 10.2337/dc11-1746

  View details for Web of Science ID 000299856000004

  View details for PubMedID 22210571

  View details for PubMedCentralID PMC3263860

• The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring PEDIATRIC DIABETES Beck, R., Steffes, M., Xing, D., Ruedy, K., Mauras, N., Wilson, D. M., Kollman, C. 2011; 12 (8): 690-695

  Abstract

  To describe the interrelationships of glycemic control measures: hemoglobin A1c (HbA1c), glycated albumin, fructosamine, 1,5-anhydroglucitrol (1,5-AG), and continuous glucose monitoring (CGM) in children and adolescents with type 1 diabetes.In total, 26 subjects of age 4-17 had HbA1c measurement followed within 14 d by three laboratory measures of glycemia and the collection of CGM glucose data (N = 21).Glycated albumin and fructosamine levels had a higher correlation with each other than with HbA1c. The correlation of 1,5-AG with HbA1c was lower (absolute r value = 0.25). All four measures had a similar degree of correlation with CGM-measured mean glucose (absolute r value = 0.50-0.56) and with hyperglycemic area under the curve (AUC) at 180 mg/dL (0.50-0.60).Each of the four measures (i.e., HbA1c, glycated albumin, fructosamine, and 1,5-AG) had a similar correlation with mean glucose and hyperglycemic AUC-180. 1,5-AG did not correlate with hyperglycemic AUC-180 better than did HbA1c.

  View details for DOI 10.1111/j.1399-5448.2011.00764.x

  View details for Web of Science ID 000298170000004

  View details for PubMedID 21496193

  View details for PubMedCentralID PMC3193556

• The Feasibility of Detecting Neuropsychologic and Neuroanatomic Effects of Type 1 Diabetes in Young Children DIABETES CARE Aye, T., Reiss, A. L., Kesler, S., Hoang, S., Drobny, J., Park, Y., Schleifer, K., Baumgartner, H., Wilson, D. M., Buckingham, B. A. 2011; 34 (7): 1458-1462

  Abstract

  To determine if frequent exposures to hypoglycemia and hyperglycemia during early childhood lead to neurocognitive deficits and changes in brain anatomy.In this feasibility, cross-sectional study, young children, aged 3 to 10 years, with type 1 diabetes and age- and sex-matched healthy control (HC) subjects completed neuropsychologic (NP) testing and magnetic resonance imaging (MRI) scans of the brain.NP testing and MRI scanning was successfully completed in 98% of the type 1 diabetic and 93% of the HC children. A significant negative relationship between HbA1c and Wechsler Intelligence Scale for Children (WISC) verbal comprehension was observed. WISC index scores were significantly reduced in type 1 diabetic subjects who had experienced seizures. White matter volume did not show the expected increase with age in children with type 1 diabetes compared with HC children (diagnosis by age interaction, P=0.005). A similar trend was detected for hippocampal volume. Children with type 1 diabetes who had experienced seizures showed significantly reduced gray matter and white matter volumes relative to children with type 1 diabetes who had not experienced seizures.It is feasible to perform MRI and NP testing in young children with type 1 diabetes. Further, early signs of neuroanatomic variation may be present in this population. Larger cross-sectional and longitudinal studies of neurocognitive function and neuroanatomy are needed to define the effect of type 1 diabetes on the developing brain.

  View details for DOI 10.2337/dc10-2164

  View details for PubMedID 21562318

• The Use of Diffusion Tensor Imaging (DTI) in Young Children with Type 1 Diabetes Aye, T., Barnea-Goraly, N., Park, Y., Wilson, D. M., Reiss, A. L., Buckingham, B. A. AMER DIABETES ASSOC. 2011: A44–A45

  View details for Web of Science ID 000461640000162

• The Impact of Real Time Continuous Glucose Monitoring in the Classroom/School Environment Aye, T., Block, J. M., Buckingham, B. A., Wilson, D. M. AMER DIABETES ASSOC. 2011: A248

  View details for Web of Science ID 000461640001046

• Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial LANCET Orban, T., Bundy, B., Becker, D. J., Dimeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., Moran, A., Raskin, P., Rodriguez, H., Russell, W. E., Schatz, D., Wherrett, D., Wilson, D. M., Krischer, J. P., Skyler, J. S. 2011; 378 (9789): 412-419

  Abstract

  The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes.In this multicentre, double-blind, randomised controlled trial, patients aged 6-45 years recently diagnosed with type 1 diabetes were randomly assigned (2:1) to receive abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years. Computer-generated permuted block randomisation was used, with a block size of 3 and stratified by participating site. Neither patients nor research personnel were aware of treatment assignments. The primary outcome was baseline-adjusted geometric mean 2-h area-under-the-curve (AUC) serum C-peptide concentration after a mixed-meal tolerance test at 2 years' follow-up. Analysis was by intention to treat for all patients for whom data were available. This trial is registered at ClinicalTrials.gov, NCT00505375.112 patients were assigned to treatment groups (77 abatacept, 35 placebo). Adjusted C-peptide AUC was 59% (95% CI 6·1-112) higher at 2 years with abatacept (n=73, 0·378 nmol/L) than with placebo (n=30, 0·238 nmol/L; p=0·0029). The difference between groups was present throughout the trial, with an estimated 9·6 months' delay (95% CI 3·47-15·6) in C-peptide reduction with abatacept. There were few infusion-related adverse events (36 reactions occurred in 17 [22%] patients on abatacept and 11 reactions in six [17%] on placebo). There was no increase in infections (32 [42%] patients on abatacept vs 15 [43%] on placebo) or neutropenia (seven [9%] vs five [14%]).Co-stimulation modulation with abatacept slowed reduction in β-cell function over 2 years. The beneficial effect suggests that T-cell activation still occurs around the time of clinical diagnosis of type 1 diabetes. Yet, despite continued administration of abatacept over 24 months, the decrease in β-cell function with abatacept was parallel to that with placebo after 6 months of treatment, causing us to speculate that T-cell activation lessens with time. Further observation will establish whether the beneficial effect continues after cessation of abatacept infusions.US National Institutes of Health.

  View details for DOI 10.1016/S0140-6736(11)60886-6

  View details for Web of Science ID 000293615900032

  View details for PubMedID 21719096

• A closed-loop artificial pancreas based on risk management. Journal of diabetes science and technology Cameron, F., Bequette, B. W., Wilson, D. M., Buckingham, B. A., Lee, H., Niemeyer, G. 2011; 5 (2): 368-379

  Abstract

  Control algorithms that regulate blood glucose (BG) levels in individuals with type 1 diabetes mellitus face several fundamental challenges. Two of these are the asymmetric risk of clinical complications associated with low and high glucose levels and the irreversibility of insulin action when using only insulin. Both of these nonlinearities force a controller to be more conservative when uncertainties are high. We developed a novel extended model predictive controller (EMPC) that explicitly addresses these two challenges.Our extensions to model predictive control (MPC) operate in three ways. First, they explicitly minimize the combined risk of hypoglycemia and hyperglycemia. Second, they integrate the effect of prediction uncertainties into the risk. Third, they understand that future control actions will vary if measurements fall above or below predictions. Using the University of Virginia/Padova Simulator, we compared our novel controller (EMPC) against optimized versions of a proportional-integral-derivative (PID) controller, a traditional MPC, and a basal/bolus (BB) controller, as well as against published results of an independent MPC (IMPC). The BB controller was optimized retrospectively to serve as a bound on the possible performance.We tuned each controller, where possible, to minimize a published blood glucose risk index (BGRI). The simulated controllers (PID/MPC/EMPC/BB) provided BGRI values of 2.99/3.05/2.51/1.27 as compared to the published IMPC BGRI value of 4.10. These correspond to 73/79/84/92% of BG values lying in the euglycemic range (70-180 mg/dl), respectively, with mean BG levels of 151/156/147/140 mg/dl.The EMPC strategy extends MPC to explicitly address the issues of asymmetric glycemic risk and irreversible insulin action using estimated prediction uncertainties and an explicit risk function. This controller reduces the avoidable BGRI by 56% (p < .05) relative to a published MPC algorithm studied on a similar population.

  View details for PubMedID 21527108

• Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring DIABETES TECHNOLOGY & THERAPEUTICS Xing, D., Kollman, C., Beck, R. W., Tamborlane, W. V., Laffel, L., Buckingham, B. A., Wilson, D. M., Weinzimer, S., Fiallo-Scharer, R., Ruedy, K. J. 2011; 13 (3): 351-358

  Abstract

  AIMS AND HYPOTHESIS: The optimal duration and frequency of short-term continuous glucose monitoring (CGM) to reflect long-term glycemia have not been determined. The Juvenile Diabetes Research Foundation CGM randomized trials provided a large dataset of longitudinal CGM data for this type of analysis.The analysis included 185 subjects who had 334 3-month intervals of CGM data meeting specific criteria. For various glucose indices, correlations (r²) were computed for the entire 3-month interval versus selected sampling periods ranging from 3 to 15 days. Other computed agreement measures included median relative absolute difference, values within ± 10% and ± 20% of full value, and median absolute difference.As would be expected, the more days of glucose data that were sampled, the higher the correlation with the full 3 months of data. For 3 days of sampling, the r² value ranged from 0.32 to 0.47, evaluating mean glucose, percentage of values 71-180 mg/dL, percentage of values > 180 mg/dL, percentage of values ≤ 70 mg/dL, and coefficient of variation; in contrast, for 15 days of sampling, the r² values ranged from 0.66 to 0.75. The results were similar when the analysis intervals were stratified by age group (8-14, 15-24, and ≥ 25 years), by baseline hemoglobin A1c level (< 7.0% and ≥ 7.0%), and by CGM device type.Our data suggest that a 12-15-day period of monitoring every 3 months may be needed to optimally assess overall glucose control. Shorter periods of sampling can be useful, but the correlation with 3-month measures of glycemic control is lower.

  View details for DOI 10.1089/dia.2010.0156

  View details for Web of Science ID 000287798200009

  View details for PubMedID 21299401

• Factors Predictive of Severe Hypoglycemia in Type 1 Diabetes Analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset DIABETES CARE Fiallo-Scharer, R., Cheng, J., Beck, R. W., Buckingham, B. A., Chase, H. P., Kollman, C., Laffel, L., Lawrence, J. M., Mauras, N., Tamborlane, W. V., Wilson, D. M., Wolpert, H., Bode, B., Ruedy, K. J., Weinzimer, S., Xing, D. 2011; 34 (3): 586-590

  Abstract

  Identify factors predictive of severe hypoglycemia (SH) and assess the clinical utility of continuous glucose monitoring (CGM) to warn of impending SH.In a multicenter randomized clinical trial, 436 children and adults with type 1 diabetes were randomized to a treatment group that used CGM (N = 224), or a control group that used standard home blood glucose monitoring (N = 212) and completed 12 months of follow-up. After 6 months, the original control group initiated CGM while the treatment group continued use of CGM for 6 months. Baseline risk factors for SH were evaluated over 12 months of follow-up using proportional hazards regression. CGM-derived indices of hypoglycemia were used to predict episodes of SH over a 24-h time horizon.The SH rate was 17.9 per 100 person-years, and a higher rate was associated with the occurrence of SH in the prior 6 months and female sex. SH frequency increased eightfold when 30% of CGM values were ≤ 70 mg/dL on the prior day (4.5 vs. 0.5%; P < 0.001), but the positive predictive value (PPV) was low (<5%). Results were similar for hypoglycemic area under the curve and the low blood glucose index calculated by CGM.SH in the 6 months prior to the study was the strongest predictor of SH during the study. CGM-measured hypoglycemia over a 24-h span is highly associated with SH the following day (P < 0.001), but the PPV is low.

  View details for DOI 10.2337/dc10-1111

  View details for Web of Science ID 000288145400010

  View details for PubMedID 21266651

  View details for PubMedCentralID PMC3041185

• A Randomized Controlled Trial of Culturally Tailored Dance and Reducing Screen Time to Prevent Weight Gain in Low- Income African American Girls ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE Robinson, T. N., Matheson, D. M., Kraemer, H. C., Wilson, D. M., Obarzanek, E., Thompson, N. S., Alhassan, S., Spencer, T. R., Haydel, K. F., Fujimoto, M., Varady, A., Killen, J. D. 2010; 164 (11): 995-1004

  Abstract

  To test a 2-year community- and family-based obesity prevention program for low-income African American girls: Stanford GEMS (Girls' health Enrichment Multi-site Studies).Randomized controlled trial with follow-up measures scheduled at 6, 12, 18, and 24 months.Low-income areas of Oakland, California.African American girls aged 8 to 10 years (N=261) and their parents or guardians.Families were randomized to one of two 2-year, culturally tailored interventions: (1) after-school hip-hop, African, and step dance classes and a home/family-based intervention to reduce screen media use or (2) information-based health education.Changes in body mass index (BMI).Changes in BMI did not differ between groups (adjusted mean difference [95% confidence interval] = 0.04 [-0.18 to 0.27] per year). Among secondary outcomes, fasting total cholesterol level (adjusted mean difference, -3.49 [95% confidence interval, -5.28 to -1.70] mg/dL per year), low-density lipoprotein cholesterol level (-3.02 [-4.74 to -1.31] mg/dL per year), incidence of hyperinsulinemia (relative risk, 0.35 [0.13 to 0.93]), and depressive symptoms (-0.21 [-0.42 to -0.001] per year) decreased more among girls in the dance and screen time reduction intervention. In exploratory moderator analysis, the dance and screen time reduction intervention slowed BMI gain more than health education among girls who watched more television at baseline (P = .02) and/or those whose parents or guardians were unmarried (P = .01).A culturally tailored after-school dance and screen time reduction intervention for low-income, preadolescent African American girls did not significantly reduce BMI gain compared with health education but did produce potentially clinically important reductions in lipid levels, hyperinsulinemia, and depressive symptoms. There was also evidence for greater effectiveness in high-risk subgroups of girls.

  View details for PubMedID 21041592

• Validation of Measures of Satisfaction with and Impact of Continuous and Conventional Glucose Monitoring DIABETES TECHNOLOGY & THERAPEUTICS Hirsch, I. B., Gilliam, L. K., Fitzpatrick, K., Khakpour, D., Weinzimer, S. A., Tamborlane, W. V., Ives, B., Bosson-Heenan, J., Wolpert, H., Shetty, G., Atakov-Castillo, A., Giusti, J., O'Donnell, S., Ghiloni, S., Bode, B. W., O'Neil, K., Tolbert, L., Wysocki, T., Fox, L. A., Mauras, N., Englert, K., Permuy, J., Buckingham, B., Wilson, D. M., Block, J., Benassi, K., Tsalikian, E., Tansey, M., Kucera, D., Coffey, J., Cabbage, J., Laffel, L., Milaszewski, K., Pratt, K., Bismuth, E., Keady, J., Lawlor, M., Chase, H. P., Fiallo-Scharer, R., Wadwa, P., Messer, L., Gage, V., Burdick, P., Lawrence, J. M., Clemons, R., Maeva, M., Sattler, B., Beck, R. W., Ruedy, K. J., Kollman, C., Xing, D., Sibayan, J., Steffes, M., Bucksa, J. M., Nowicki, M. L., Van Hale, C., Makky, V., O'Grady, M., Huang, E., Basu, A., Meltzer, D. O., Zhao, L., Lee, J., Kowalski, A. J., Laffel, L., Tamborlane, W. V., Beck, R. W., Kowalski, A. J., Ruedy, K. J., Weinstock, R. S., Anderson, B. J., Kruger, D., Lavange, L., Rodriguez, H., Cheng, J. 2010; 12 (9): 679-684

  Abstract

  The evaluation of patient-reported outcomes (e.g. impact, satisfaction) is important in trials of continuous glucose monitoring (CGM). We evaluated psychometric properties of the CGM Satisfaction Scale (CGM-SAT) and the Glucose Monitoring Survey (GMS).CGM-SAT is a 44-item scale on which patients (n=224) or parents (n=102) rated their experience with CGM over the prior 6 months. GMS is a 22-item scale on which patients (n=447) or parents (n=221) rated the blood glucose monitoring system they were using (home glucose meter with or without CGM) at baseline and 6 months.The alpha coefficient for the CGM-SAT was > or = 0.94 for all respondents and for the GMS was > or = 0.84 for all respondents at baseline and 6 months. Parent-youth agreement was 0.52 for the CGM-SAT at 6 months and 0.24 and 0.20 for the GMS at baseline and 6 months for the Standard Care Group, respectively. Test-retest reliability of the GMS at 6 months for controls was r=0.76 for adult patients, 0.63 for pediatric patients, and 0.43 for parents. Factor analysis isolated measurement factors for the CGM-SAT labeled Benefits of CGM and Hassles of CGM, accounting for 33% and 9% of score variance, respectively. For the GMS, two factors emerged: Glucose Control and Social Complications, accounting for 28% and 9% of variance, respectively. Significant correlations of CGM-SAT with frequency of CGM use between 6 months and baseline and GMS with frequency of conventional daily self-monitoring of blood glucose at baseline support their convergent validity.The CGM-SAT and GMS are reliable and valid measures of patient-reported CGM outcomes.

  View details for DOI 10.1089/dia.2010.0015

  View details for Web of Science ID 000280883100001

  View details for PubMedID 20799388

  View details for PubMedCentralID PMC3045572

• Two New Unrelated Cases of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets with Alopecia Resulting from the Same Novel Nonsense Mutation in the Vitamin D Receptor Gene JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM Forghani, N., Lum, C., Krishnan, S., Wang, J., Wilson, D. M., Blackett, P. R., Malloy, P. J., Feldman, D. 2010; 23 (8): 843-850

  Abstract

  1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) an important regulator of bone homeostasis, mediates its actions by binding to the vitamin D receptor (VDR), a nuclear transcription factor. Mutations in the VDR cause the rare genetic disease hereditary vitamin D resistant rickets (HVDRR). In this study, we examined two unrelated young female patients who exhibited severe early onset rickets, hypocalcemia, and hypophosphatemia. Both patients had partial alopecia but with different unusual patterns of scant hair. Sequencing of the VDR gene showed that both patients harbored the same unique nonsense mutation that resulted in a premature stop codon (R50X). Skin fibroblasts from patient #1 were devoid of VDR protein and 1,25(OH)2D3 treatment of these cells failed to induce CYP24A1 gene expression, a marker of 1,25(OH)2D3 action. In conclusion, we identified a novel nonsense mutation in the VDR gene in two patients with HVDRR and alopecia. The mutation truncates the VDR protein and causes 1,25(OH)2D3 resistance.

  View details for PubMedID 21073129

• Analysis of Metformin Treatment for Adolescent Obesity at 48 Rather Than 24 Weeks After Treatment Cessation Reply ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE Wilson, D. M. 2010; 164 (7): 678-679

  View details for Web of Science ID 000279871600016

• Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring A safety net for the artificial pancreas DIABETES CARE Dassau, E., Cameron, F., Lee, H., Bequette, B. W., Zisser, H., Jovanovic, L., Chase, H. P., Wilson, D. M., Buckingham, B. A., Doyle, F. J. 2010; 33 (6): 1249-1254

  Abstract

  The purpose of this study was to develop an advanced algorithm that detects pending hypoglycemia and then suspends basal insulin delivery. This approach can provide a solution to the problem of nocturnal hypoglycemia, a major concern of patients with diabetes.This real-time hypoglycemia prediction algorithm (HPA) combines five individual algorithms, all based on continuous glucose monitoring 1-min data. A predictive alarm is issued by a voting algorithm when a hypoglycemic event is predicted to occur in the next 35 min. The HPA system was developed using data derived from 21 Navigator studies that assessed Navigator function over 24 h in children with type 1 diabetes. We confirmed the function of the HPA using a separate dataset from 22 admissions of type 1 diabetic subjects. During these admissions, hypoglycemia was induced by gradual increases in the basal insulin infusion rate up to 180% from the subject's own baseline infusion rate. RESULTS Using a prediction horizon of 35 min, a glucose threshold of 80 mg/dl, and a voting threshold of three of five algorithms to predict hypoglycemia (defined as a FreeStyle plasma glucose readings <60 mg/dl), the HPA predicted 91% of the hypoglycemic events. When four of five algorithms were required to be positive, then 82% of the events were predicted.The HPA will enable automated insulin-pump suspension in response to a pending event that has been detected prior to severe immediate complications.

  View details for DOI 10.2337/dc09-1487

  View details for Web of Science ID 000279304300020

  View details for PubMedID 20508231

  View details for PubMedCentralID PMC2875433

• Insulin Pumps in Young Children DIABETES TECHNOLOGY & THERAPEUTICS Fuld, K., Conrad, B., Buckingham, B., Wilson, D. M. 2010; 12: S67-S71

  Abstract

  Insulin infusion pump therapy has dramatically improved over the past 20 years and can now address some of the specific challenges related to toddlers with diabetes. We discuss both the non-randomized and randomized controlled trials comparing continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in this age group. There are advantages and disadvantages related to both CSII and MDI treatments, and ultimately the decision to use CSII should be individualized for each patient and family with the guidance of their diabetes team.

  View details for DOI 10.1089/dia.2009.0182

  View details for PubMedID 20515310

• Failure to Preserve beta-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes DIABETES CARE Gottlieb, P. A., Quinlan, S., Krause-Steinrauf, H., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D. A., Moran, A. M., Lachin, J. M., Skyler, J. S. 2010; 33 (4): 826-832

  Abstract

  This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes.A multi-center, randomized, placebo-controlled, double-masked trial was initiated by Type 1 Diabetes TrialNet at 13 sites in North America and Europe. Subjects diagnosed with type 1 diabetes and with sufficient C-peptide within 3 months of diagnosis were randomized to either MMF alone, MMF plus DZB, or placebo, and then followed for 2 years. The primary outcome was the geometric mean area under the curve (AUC) C-peptide from the 2-h mixed meal tolerance test.One hundred and twenty-six subjects were randomized and treated during the trial. The geometric mean C-peptide AUC at 2 years was unaffected by MMF alone or MMF plus DZB versus placebo. Adverse events were more frequent in the active therapy groups relative to the control group, but not significantly.Neither MMF alone nor MMF in combination with DZB had an effect on the loss of C-peptide in subjects with new-onset type 1 diabetes. Higher doses or more targeted immunotherapies may be needed to affect the autoimmune process.

  View details for DOI 10.2337/dc09-1349

  View details for Web of Science ID 000276793200029

  View details for PubMedID 20067954

  View details for PubMedCentralID PMC2845036

• Intraperitoneal Fat and Insulin Resistance in Obese Adolescents Glaser Pediatric Research Network Obesity Study Group OBESITY Wilson, D. M. 2010; 18 (2): 402-409

  View details for DOI 10.1038/oby.2009.261

  View details for Web of Science ID 000274208600029

• Metformin Extended Release Treatment of Adolescent Obesity A 48-Week Randomized, Double-Blind, Placebo-Controlled Trial With 48-Week Follow-up ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE Wilson, D. M., Abrams, S. H., Aye, T., Lee, P. D., Lenders, C., Lustig, R. H., Osganian, S. V., Feldman, H. A. 2010; 164 (2): 116-123

  Abstract

  Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported.To test the hypothesis that 48 weeks of daily metformin hydrochloride extended release (XR) therapy will reduce body mass index (BMI) in obese adolescents, as compared with placebo.Multicenter, randomized, double-blind, placebo-controlled clinical trial.The 6 centers of the Glaser Pediatric Research Network from October 2003 to August 2007.Obese (BMI > or = 95th percentile) adolescents (aged 13-18 years) were randomly assigned to the intervention (n = 39) or placebo groups. Intervention Following a 1-month run-in period, subjects following a lifestyle intervention program were randomized 1:1 to 48 weeks' treatment with metformin hydrochloride XR, 2000 mg once daily, or an identical placebo. Subjects were monitored for an additional 48 weeks. Main Outcome Measure Change in BMI, adjusted for site, sex, race, ethnicity, and age and metformin vs placebo.After 48 weeks, mean (SE) adjusted BMI increased 0.2 (0.5) in the placebo group and decreased 0.9 (0.5) in the metformin XR group (P = .03). This difference persisted for 12 to 24 weeks after cessation of treatment. No significant effects of metformin on body composition, abdominal fat, or insulin indices were observed.Metformin XR caused a small but statistically significant decrease in BMI when added to a lifestyle intervention program.clinicaltrials.gov Identifiers: NCT00209482 and NCT00120146.

  View details for PubMedID 20124139

• Consensus and Discordance in the Management of Growth Hormone-Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices Survey INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY Miller, B. S., Shulman, D. I., Shillington, A., Harshaw, Q., Wilson, D. M., Schwartz, D., Kappy, M., Bakker, B., Wyatt, D. 2010: 891571

  Abstract

  Our purpose was to determine pediatric endocrinologists' knowledge, attitudes, beliefs, and practices (KABPs) regarding recombinant human growth hormone (rhGH) treatment, examine care-related attitude consensus or discordance, and identify evidence-based practice gaps. We developed a survey for National Cooperative Growth Study (NCGS) investigators (N = 711) to elicit their KABPs regarding GH stimulation testing as a diagnostic tool, IGF-1 monitoring for safety and dosing guidance, and pubertal dosing. Responses were compared with NCGS data from the last 20 years. Comparison between survey responses and NCGS data revealed potential discrepancies between expressed opinions and actual practice. In conclusion, this KABP survey, combined with NCGS data, suggests changes over time in diagnostic and rhGH-related therapeutic practices. Variability and inconsistency exist between the survey responses and practice trends over time as reflected in the NCGS database. Further study is necessary to provide evidence to guide rhGH treatment decisions.

  View details for DOI 10.1155/2010/891571

  View details for Web of Science ID 000215855900053

  View details for PubMedID 20976269

  View details for PubMedCentralID PMC2952967

• Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function NEW ENGLAND JOURNAL OF MEDICINE Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., Skyler, J. S. 2009; 361 (22): 2143-2152

  Abstract

  The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes.We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included safety and changes in the glycated hemoglobin level and insulin dose.At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group. The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of decline in C-peptide levels in the rituximab group was significantly less than that in the placebo group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions appeared to be minimal with subsequent infusions. There was no increase in infections or neutropenia with rituximab.A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)

  View details for Web of Science ID 000272117800008

  View details for PubMedID 19940299

• Relation of body fat indexes to vitamin D status and deficiency among obese adolescents AMERICAN JOURNAL OF CLINICAL NUTRITION Lenders, C. M., Feldman, H. A., von Scheven, E., Merewood, A., Sweeney, C., Wilson, D. M., Lee, P. D., Abrams, S. H., Gitelman, S. E., Wertz, M. S., Klish, W. J., Taylor, G. A., Chen, T. C., Holick, M. F. 2009; 90 (3): 459-467

  Abstract

  Data on the relation between vitamin D status and body fat indexes in adolescence are lacking.The objective was to identify factors associated with vitamin D status and deficiency in obese adolescents to further evaluate the relation of body fat indexes to vitamin D status and deficiency.Data from 58 obese adolescents were obtained. Visceral adipose tissue (VAT) was measured by computed tomography. Dual-energy X-ray absorptiometry was used to measure total bone mineral content, bone mineral density, body fat mass (FM), and lean mass. Relative measures of body fat were calculated. Blood tests included measurements of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), osteocalcin, type I collagen C-telopeptide, hormones, and metabolic factors. Vitamin D deficiency was defined as 25(OH)D < 20 ng/mL. PTH elevation was defined as PTH > 65 ng/mL.The mean (+/-SD) age of the adolescents was 14.9 +/- 1.4 y; 38 (66%) were female, and 8 (14%) were black. The mean (+/-SD) body mass index (in kg/m(2)) was 36 +/- 5, FM was 40.0 +/- 5.5%, and VAT was 12.4 +/- 4.3%. Seventeen of the adolescents were vitamin D deficient, but none had elevated PTH concentrations. Bone mineral content and bone mineral density were within 2 SDs of national standards. In a multivariate analysis, 25(OH)D decreased by 0.46 +/- 0.22 ng/mL per 1% increment in FM (beta +/- SE, P = 0.05), whereas PTH decreased by 0.78 +/- 0.29 pg/mL per 1% increment in VAT (P = 0.01).To the best of our knowledge, our results show for the first time that obese adolescents with 25(OH)D deficiency, but without elevated PTH concentrations, have a bone mass within the range of national standards (+/-2 SD). The findings provide initial evidence that the distribution of fat may be associated with vitamin D status, but this relation may be dependent on metabolic factors. This study was registered at www.clinicaltrials.gov as NCT00209482, NCT00120146.

  View details for DOI 10.3945/ajcn.2008.27275

  View details for Web of Science ID 000269257300003

  View details for PubMedID 19640956

  View details for PubMedCentralID PMC2728638

• Duration of Nocturnal Hypoglycemia Before Seizures DIABETES CARE Buckingham, B., Wilson, D. M., Lecher, T., Hanas, R., Kaiserman, K., Cameron, F. 2008; 31 (11): 2110-2112

  Abstract

  Despite a high incidence of nocturnal hypoglycemia documented by the use of continuous glucose monitoring (CGM), there are no reports in the literature of nocturnal hypoglycemic seizures while a patient is wearing a CGM device.In this article, we describe four such cases and assess the duration of nocturnal hypoglycemia before the seizure.In the cases where patients had a nocturnal hypoglycemic seizure while wearing a CGM device, sensor hypoglycemia (<60 mg/dl) was documented on the CGM record for 2.25-4 h before seizure activity.Even with a subcutaneous glucose lag of 18 min when compared with blood glucose measurements, glucose sensors have time to provide clinically meaningful alarms. Current nocturnal hypoglycemic alarms need to be improved, however, since patients can sleep through the current alarm systems.

  View details for DOI 10.2337/dc08-0863

  View details for Web of Science ID 000260565000007

  View details for PubMedID 18694975

  View details for PubMedCentralID PMC2571056

• Continuous glucose monitoring and intensive treatment of type 1 diabetes NEW ENGLAND JOURNAL OF MEDICINE Tamborlane, W. V., Beck, R. W., Bode, B. W., Buckingham, B., Chase, H. P., Clemons, R., Fiallo-Scharer, R., Fox, L. A., Gilliam, L. K., Hirsch, I. B., Huang, E. S., Kollman, C., Kowalski, A. J., Laffel, L., Lawrence, J. M., Lee, J., Mauras, N., O'Grady, M., Ruedy, K. J., Tansey, M., Tsalikian, E., Weinzimer, S., Wilson, D. M., Wolpert, H., Wysocki, T., Xing, D. 2008; 359 (14): 1464-U65

  Abstract

  The value of continuous glucose monitoring in the management of type 1 diabetes mellitus has not been determined.In a multicenter clinical trial, we randomly assigned 322 adults and children who were already receiving intensive therapy for type 1 diabetes to a group with continuous glucose monitoring or to a control group performing home monitoring with a blood glucose meter. All the patients were stratified into three groups according to age and had a glycated hemoglobin level of 7.0 to 10.0%. The primary outcome was the change in the glycated hemoglobin level at 26 weeks.The changes in glycated hemoglobin levels in the two study groups varied markedly according to age group (P=0.003), with a significant difference among patients 25 years of age or older that favored the continuous-monitoring group (mean difference in change, -0.53%; 95% confidence interval [CI], -0.71 to -0.35; P<0.001). The between-group difference was not significant among those who were 15 to 24 years of age (mean difference, 0.08; 95% CI, -0.17 to 0.33; P=0.52) or among those who were 8 to 14 years of age (mean difference, -0.13; 95% CI, -0.38 to 0.11; P=0.29). Secondary glycated hemoglobin outcomes were better in the continuous-monitoring group than in the control group among the oldest and youngest patients but not among those who were 15 to 24 years of age. The use of continuous glucose monitoring averaged 6.0 or more days per week for 83% of patients 25 years of age or older, 30% of those 15 to 24 years of age, and 50% of those 8 to 14 years of age. The rate of severe hypoglycemia was low and did not differ between the two study groups; however, the trial was not powered to detect such a difference.Continuous glucose monitoring can be associated with improved glycemic control in adults with type 1 diabetes. Further work is needed to identify barriers to effectiveness of continuous monitoring in children and adolescents. (ClinicalTrials.gov number, NCT00406133.)

  View details for Web of Science ID 000259631700007

  View details for PubMedID 18779236

• Low-fat vs. high-fat bedtime snacks in children and adolescents with type 1 diabetes PEDIATRIC DIABETES Wilson, D., Chase, H. P., Kollman, C., Xing, D., Caswell, K., Tansey, M., Fox, L., Weinzimer, S., Beck, R., Ruedy, K., Tamborlane, W. 2008; 9 (4): 320-325

  Abstract

  The purpose of this study was to determine whether, in a group of children with type 1 diabetes using insulin pump, a prebedtime snack with a relatively high fat content provides greater protection from nocturnal hypoglycemia than a snack containing the same amount of carbohydrate and protein but a lower fat content.Ten subjects, aged 6 to <18 yr, in a trial evaluating the Abbott Navigator glucose sensor, agreed to this ancillary study. On 12 or more separate nights, each subject was randomized by a Web site to a carbohydrate-low-fat (30 g CHO, 2.5 g protein, and 1.3 g fat; 138 kcal) snack or a carbohydrate-high-fat (30 g CHO, 2 g protein, and 20 g fat; 320 kcal) snack. Subjects used their usual evening snack algorithm to determine the size (in 15-g carbohydrate increments) and insulin dosage.Average glucose on 128 valid study nights before snack was similar in both groups. The proportion of nights with hypoglycemia (a sensor or meter glucose value or=200 mg/dL and at least 50 mg/dL above baseline, 35% high fat vs. 30% low fat).There were no statistical differences between the high- and low-fat snacks on the frequency of hyperglycemia or hypoglycemia. This study highlights the feasibility of web-based research in patients' home environment.

  View details for DOI 10.1111/j.1399-5448.2008.00393.x

  View details for PubMedID 18768036

• Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator) PEDIATRIC DIABETES Buckingham, B., Xing, D., Weinzimer, S., Fiallo-Scharer, R., Kollman, C., Mauras, N., Tsalikian, E., Tamborlane, W., Wysocki, T., Ruedy, K., Beck, R. 2008; 9 (2): 142-147

  Abstract

  There are no published guidelines for use of real-time continuous glucose monitoring data by a patient; we therefore developed the DirecNet Applied Treatment Algorithm (DATA). The DATA provides algorithms for making diabetes management decisions using glucose values: (i) in real time which include the direction and rate of change of glucose levels, and (ii) retrospectively based on downloaded sensor data.To evaluate the use and effectiveness of the DATA in children with diabetes using a real-time continuous glucose sensor (the FreeStyle Navigator).Thirty children and adolescents (mean +/- standard deviation age = 11.2 +/- 4.1 yr) receiving insulin pump therapy.Subjects were instructed on use of the DATA and were asked to download their Navigator weekly to review glucose patterns. An Algorithm Satisfaction Questionnaire was completed at 3, 7, and 13 wk.At 13 wk, all of the subjects and all but one parent thought that the DATA gave good, clear directions for insulin dosing, and thought the guidelines improved their postprandial glucose levels. In responding to alarms, 86% of patients used the DATA at least 50% of the time at 3 wk, and 59% reported doing so at 13 wk. Similar results were seen in using the DATA to adjust premeal bolus doses of insulin.These results show the feasibility of implementing the DATA when real-time continuous glucose monitoring is initiated and support its use in future clinical trials of real-time continuous glucose monitoring.

  View details for DOI 10.1111/j.1399-5448.2007.00301.x

  View details for Web of Science ID 000255130400011

  View details for PubMedID 18221427

  View details for PubMedCentralID PMC2390770

• Relationship of A1C to glucose concentrations in children with type 1 diabetes - Assessments by high-frequency glucose determinations by sensors DIABETES CARE Wilson, D. M., Kollman, C., Xing, D., Fiallo-Scharer, R., Weinzimer, S., Steffes, M., Wysocki, T., Beck, R., Ruedy, K., Tamborlane, W. 2008; 31 (3): 381-385

  Abstract

  Despite the standing of A1C as the most validated and widely used measure for average glycemic control over time, the relationship between A1C and glucose concentrations is not completely understood. The purpose of this Diabetes Research in Children Network (DirecNet) study was to use continuous glucose monitoring data to examine the relationship between A1C and glucose in type 1 diabetes.Forty-eight youth enrolled in studies of the Navigator continuous glucose monitor were encouraged to wear the Navigator sensor at home continuously. A1C was measured at baseline, at 3 months, and at 6 months. Sensor glucose data were directly transmitted via the Internet, assuring that essentially all glucose values were analyzed.Subjects had a median of 112 h/week of Navigator data in the first 3 months and 115 h/week in the second 3 months. The slope of mean glucose over the previous 3 months versus A1C was only 18 mg/dl per 1.0% A1C. Individually, there was substantial variation in the relationship between mean glucose and A1C. A1C was not associated with glucose lability after controlling for mean glucose. Measures of an individual's rate of glycation were moderately correlated at the 3- and 6-month visits.As the chemistry of glycation would predict, we found no evidence to contradict the simple hypothesis that A1C directly reflects mean glucose over time. There is, however, substantial variability in individual mean glucose concentrations for a given A1C. Transforming reliable A1C values into calculated mean glucose values would, when applied to an individual, introduce substantial error.

  View details for DOI 10.2337/dc07-1835

  View details for Web of Science ID 000253801100001

  View details for PubMedID 18056888

• Stanford GEMS phase 2 obesity prevention trial for low-income African-American girls: Design and sample baseline characteristics CONTEMPORARY CLINICAL TRIALS Robinson, T. N., Kraemer, H. C., Matheson, D. M., Obarzanek, E., Wilson, D. M., Haskell, W. L., Pruitt, L. A., Thompson, N. S., Haydel, K. F., Fujimoto, M., Varady, A., McCarthy, S., Watanabe, C., Killen, J. D. 2008; 29 (1): 56-69

  Abstract

  African-American girls and women are at high risk of obesity and its associated morbidities. Few studies have tested obesity prevention strategies specifically designed for African-American girls. This report describes the design and baseline findings of the Stanford GEMS (Girls health Enrichment Multi-site Studies) trial to test the effect of a two-year community- and family-based intervention to reduce weight gain in low-income, pre-adolescent African-American girls.Randomized controlled trial with measurements scheduled in girls' homes at baseline, 6, 12, 18 and 24 month post-randomization.Low-income areas of Oakland, CA.Eight, nine and ten year old African-American girls and their parents/caregivers.Girls are randomized to a culturally-tailored after-school dance program and a home/family-based intervention to reduce screen media use versus an information-based community health education Active-Placebo Comparison intervention. Interventions last for 2 years for each participant.Change in body mass index over the two-year study.Recruitment and enrollment successfully produced a predominately low-socioeconomic status sample. Two-hundred sixty one (261) families were randomized. One girl per family is randomly chosen for the analysis sample. Randomization produced comparable experimental groups with only a few statistically significant differences. The sample had a mean body mass index (BMI) at the 74 th percentile on the 2000 CDC BMI reference, and one-third of the analysis sample had a BMI at the 95th percentile or above. Average fasting total cholesterol and LDL cholesterol were above NCEP thresholds for borderline high classifications. Girls averaged low levels of moderate to vigorous physical activity, more than 3 h per day of screen media use, and diets high in energy from fat.The Stanford GEMS trial is testing the benefits of culturally-tailored after-school dance and screen-time reduction interventions for obesity prevention in low-income, pre-adolescent African-American girls.

  View details for DOI 10.1016/j.cct.2007.04.007

  View details for PubMedID 17600772

• Real-time continuous glucose monitoring. Current opinion in endocrinology, diabetes, and obesity Buckingham, B., Caswell, K., Wilson, D. M. 2007; 14 (4): 288-295

  Abstract

  To summarize the current literature on real-time continuous glucose monitors, focusing on devices that have been approved or are pending approval.Real-time continuous glucose sensors are new tools to assist in diabetes management. Several devices are currently being sold and additional monitors are expected to be available shortly. These sensors measure interstitial glucose - a distinct physiologic space when compared with the blood glucose. The ability to recognize trends in blood glucose levels provides a new paradigm for making insulin dose decisions and treating hypo- and hyperglycemia.Real-time continuous glucose monitoring systems are currently less accurate than home glucose meters, but provide information every 1-5 min throughout the day and night with alarms for hyper- and hypoglycemia, providing information on glucose trends and nocturnal glycemic excursions. Current real-time sensors are behavior modification tools. Thus, improvements in diabetes control depend on the willingness of patients to modify their diabetes management based on information provided by these devices.

  View details for PubMedID 17940454

• The medtronic MiniMed gold continuous glucose monitoring system: An effective means to discover hypo- and Hyperglycemia in children under 7 years of age DIABETES TECHNOLOGY & THERAPEUTICS Gandrud, L. M., Xing, D., Kollman, C., Block, J. M., Kunselman, B., Wilson, D. M., Buckingham, B. A. 2007; 9 (4): 307-316

  Abstract

  The glycemic patterns of children less than 7 years with type 1 diabetes have not been well studied using continuous glucose monitoring. Our goal was to assess the incidence of hypoglycemia as well as postprandial glycemic patterns in this age group utilizing continuous glucose monitoring.Nineteen children used the Medtronic MiniMed (Northridge, CA) CGMS System Gold on three to seven occasions over approximately 6 months.Nineteen children (nine girls and 10 boys; mean age 4.8 +/- 1.4 years, range 1.6-6.8 years) used the CGMS 102 times, providing 434 days of data; 79% of days were optimal based on CGMS Solutions software version 3.0. Mild hypoglycemia (glucose or=2 mg/dL/min following 50% of breakfasts. Children with hemoglobin A1c levels >or=8% had higher postprandial glucose concentrations. There was no significant advantage of continuous subcutaneous insulin infusion therapy over multiple daily injection therapy in decreasing postprandial hyperglycemia.CGMS tracings from young children with diabetes demonstrate frequent mild nocturnal hypoglycemia and significant postprandial hyperglycemia, with a rapid rise in glucose following the meal. The most rapid rate of rise and the most severe postprandial hyperglycemia occurred after breakfast.

  View details for DOI 10.1089/dia.2007.0026

  View details for PubMedID 17705686

• Glucose control in pediatric intensive care unit patients using an insulin-glucose algorithm DIABETES TECHNOLOGY & THERAPEUTICS Wintergerst, K. A., Deiss, D., Buckingham, B., Cantwell, M., Kache, S., Agarwal, S., Wilson, D. M., Steil, G. 2007; 9 (3): 211-222

  Abstract

  Control of hyperglycemia in adult medical and surgical intensive care units (ICUs) has been shown to dramatically decrease morbidity and mortality. Algorithms to achieve glycemic control in the ICU setting are evolving. We have evaluated the use of a discrete proportional-integral-derivative (PID) algorithm to control hyperglycemia in pediatric ICU (PICU) patients both with and without diabetes.Six PICU patients [four with diabetic ketoacidosis (DKA) and two with glucocorticoid-induced hyperglycemia] with glucose values >150 mg/dL were enrolled. Their hyperglycemia was managed with a PID algorithm that provided recommendations for both changes in the intravenous insulin infusion rate and the time to obtain the next discrete glucose value. Glucose targets were adjusted based on clinical circumstances.Patients (mean age 9.2 years; range 1.8-14 years) utilized the algorithm for a total of 454.4 h. Mean time to the initial glucose target was 8.7 h (range 1.3-15.1 h) in five patients. One subject with hyperosmolar DKA did not achieve target before discharge from the PICU, and another was at target when the algorithm was initiated. After the glucose target was achieved, the mean SD was 23.5 mg/dL, and glucose values were >40 mg/dL above target 13% of the time and <40 mg/dL below target 1% of the time. There were no glucose values <55 mg/dL.The PID algorithm safely and effectively controlled hyperglycemia in a PICU, despite multiple changes in intravenous fluids, steroid doses (including high-dose pulses), and hemodialysis.

  View details for DOI 10.1089/dia.2006.0031

  View details for Web of Science ID 000247337800002

  View details for PubMedID 17561791

• Impact of real-time continuous glucose monitoring on children and their families. Journal of diabetes science and technology Wilson, D. 2007; 1 (1): 142-145

  View details for PubMedID 19888396

• The accuracy of the FreeStyle navigator continuous glucose monitoring system in children with type 1 diabetes DIABETES CARE Wilson, D. M., Beck, R. W., Tamborlane, W. V., Dontchev, M. J., Kollman, C., Chase, P., Fox, L. A., Ruedy, K. J., Tsalikian, E., Weinzimer, S. A. 2007; 30 (1): 59-64

  Abstract

  To evaluate the accuracy and precision of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes.In 30 children with type 1 diabetes (mean age 11.2 +/- 4.1 years), the Navigator glucose values were compared with reference serum glucose values of blood samples obtained in an inpatient clinical research center and measured in a central laboratory using a hexokinase enzymatic method and in an outpatient setting with a FreeStyle meter. Median absolute difference (AD) and median relative absolute difference (RAD) were computed for sensor-reference and sensor-sensor pairs.The median AD and RAD were 17 mg/dl and 12%, respectively, for 1,811 inpatient sensor-reference pairs and 20 mg/dl and 14%, respectively, for 8,639 outpatient pairs. The median RAD between two simultaneous Navigator measurements (n = 1,971) was 13%. Ninety-one percent of sensors in the inpatient setting and 81% of sensors in the outpatient setting had a median RAD < or = 20%.The Navigator's accuracy does not yet approach the accuracy of current-generation home glucose meters, but it is sufficient to believe that the device has the potential to be an important adjunct to treatment of youth with type 1 diabetes.

  View details for DOI 10.2337/dc06-1407

  View details for Web of Science ID 000243469800011

  View details for PubMedID 17192334

• Relative inaccuracy of the A1cNow in children with type 1 diabetes DIABETES CARE Fox, L., Dontchev, M., Ruedy, K., Beck, R., Kollman, C., Messer, L., Coffey, J., Wilson, D., Doyle, E., Tamborlane, W., Steffes, M. 2007; 30 (1): 135-137

  View details for DOI 10.2337/dc06-0972

  View details for Web of Science ID 000243469800023

  View details for PubMedID 17192346

  View details for PubMedCentralID PMC1978195

• Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes care Tsalikian, E., Kollman, C., Tamborlane, W. B., Beck, R. W., Fiallo-Scharer, R., Fox, L., Janz, K. F., Ruedy, K. J., Wilson, D., Xing, D., Weinzimer, S. A. 2006; 29 (10): 2200-2204

  Abstract

  Strategies for preventing hypoglycemia during exercise in children with type 1 diabetes have not been well studied. The Diabetes Research in Children Network (DirecNet) Study Group conducted a study to determine whether stopping basal insulin could reduce the frequency of hypoglycemia occurring during exercise.Using a randomized crossover design, 49 children 8-17 years of age with type 1 diabetes on insulin pump therapy were studied during structured exercise sessions on 2 days. On day 1, basal insulin was stopped during exercise, and on day 2 it was continued. Each exercise session, performed from approximately 4:00-5:00 p.m., consisted of four 15-min treadmill cycles at a target heart rate of 140 bpm (interspersed with three 5-min rest breaks over 75 min), followed by a 45-min observation period. Frequently sampled glucose concentrations (measured in the DirecNet Central Laboratory) were measured before, during, and after the exercise.Hypoglycemia (< or = 70 mg/dl) during exercise occurred less frequently when the basal insulin was discontinued than when it was continued (16 vs. 43%; P = 0.003). Hyperglycemia (increase from baseline of > or = 20% to > or = 200 mg/dl) 45 min after the completion of exercise was more frequent without basal insulin (27 vs. 4%; P = 0.002). There were no cases of abnormal blood ketone levels.Discontinuing basal insulin during exercise is an effective strategy for reducing hypoglycemia in children with type 1 diabetes, but the risk of hyperglycemia is increased.

  View details for PubMedID 17003293

• Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit PEDIATRICS Wintergerst, K. A., Buckingham, B., Gandrud, L., Wong, B. J., Kache, S., Wilson, D. M. 2006; 118 (1): 173-179

  Abstract

  We evaluated retrospectively plasma glucose levels and the degree of hypoglycemia, hyperglycemia, and glucose variability in a PICU and then assessed their association with hospital length of stay and mortality rates.Electronic medical records at the Packard Children's Hospital at Stanford University were reviewed retrospectively for all PICU admissions between March 1, 2003, and March 31, 2004. Patients with a known diagnosis of diabetes mellitus were excluded. The prevalence of hyperglycemia was defined with cutoff values of 110, 150, and 200 mg/dL. Hypoglycemia was defined as < or = 65 mg/dL. Glucose variability was assessed with a calculated glucose variability index.In 13 months, 1094 eligible admissions generated 18865 glucose values (median: 107 mg/dL; range: 13-1839 mg/dL). Patients in the highest maximal glucose quintile had a significantly longer median PICU length of stay, compared with those in the lowest quintile (7.5 days vs 1 day). Mortality rates increased as patients' maximal glucose levels increased, reaching 15.2% among patients with the greatest degree of hyperglycemia. Hypoglycemia was also prevalent, with 18.6% of patients (182 of 980 patients) having minimal glucose levels of < or = 65 mg/dL. There was an increased median PICU length of stay (9.5 days vs 1 day) associated with glucose values in the lowest minimal quintile, compared with those in the highest quintile. Hypoglycemia was correlated with mortality rates; 16.5% of patients with glucose levels of < or = 65 mg/dL died. Glucose variability also was associated with increased length of stay and mortality rates. In multivariate logistic regression analyses, glucose variability, taken with hyperglycemia and hypoglycemia, showed the strongest association with mortality rates.Hyperglycemia and hypoglycemia were prevalent in the PICU. Hypoglycemia, hyperglycemia, and, in particular, increased glucose variability were associated with increased morbidity (length of stay) and mortality rates.

  View details for DOI 10.1542/peds.2005-1819

  View details for PubMedID 16818563

• Definition of metabolic syndrome in preadolescent girls JOURNAL OF PEDIATRICS Chi, C. H., Wang, Y., Wilson, D. M., Robinson, T. N. 2006; 148 (6): 788-792

  Abstract

  To compare and contrast proposed definitions of metabolic syndrome in pediatrics, and to determine prevalence of metabolic syndrome in preadolescent females when applying different criteria.A literature review on definitions of metabolic syndrome and cardiovascular "risk factor clustering" in children and adolescents published in the past decade. Pediatric definitions of metabolic syndrome were then applied to a community-based study of 261 black preadolescent females (Girls Health Enrichment MultiSite studies [GEMS]) and a school-based, cross-sectional study of 240 ethnically-diverse preadolescent females (Girls Activity, Movement and Environmental Strategy [GAMES]) who had a baseline physical examination and fasting morning blood sample.Agreement among pediatric definitions of metabolic syndrome was poor. The prevalence of MS and cardiovascular risk factor clustering ranged from 0.4% to 23.0% for GEMS and 2.0% to 24.6% for GAMES with definitions adapted from the National Cholesterol Education Program Adult Treatment Panel III, and 0% to 15.3% for GEMS and 0.4% to 15.8% for GAMES using modified criteria from the World Health Organization.The prevalence of metabolic syndrome in preadolescent girls varies widely because of disagreement among proposed definitions of metabolic syndrome in pediatrics. Further investigation is needed to determine which metabolic factors and their respective cut points should be used to identify children at risk for development of clinical disease.

  View details for DOI 10.1016/j.jpeds.2006.01.048

  View details for PubMedID 16769388

• Evaluation of factors affecting CGMS calibration DIABETES TECHNOLOGY & THERAPEUTICS Buckingham, B. A., Kollman, C., Beck, R. W., Kalajian, A., Fiallo-Scharer, R., Tansey, M. J., Fox, L. A., Wilson, D. M., Weinzimer, S. A., Ruedy, K. J., Tamborlane, W. V. 2006; 8 (3): 318-325

  Abstract

  The optimal number/timing of calibrations entered into the CGMS (Medtronic MiniMed, Northridge, CA) continuous glucose monitoring system have not been previously described.Fifty subjects with Type 1 diabetes mellitus (10-18 years old) were hospitalized in a clinical research center for approximately 24 h on two separate days. CGMS and OneTouch Ultra meter (LifeScan, Milpitas, CA) data were obtained. The CGMS was retrospectively recalibrated using the Ultra data varying the number and timing of calibrations. Resulting CGMS values were compared against laboratory reference values.There was a modest improvement in accuracy with increasing number of calibrations. The median relative absolute deviation (RAD) was 14%, 15%, 13%, and 13% when using three, four, five, and seven calibration values, respectively (P < 0.001). Corresponding percentages of CGMS-reference pairs meeting the International Organisation for Standardisation criteria were 66%, 67%, 71%, and 72% (P < 0.001). Nighttime accuracy improved when daytime calibrations (pre-lunch and pre-dinner) were removed leaving only two calibrations at 9 p.m. and 6 a.m. (median difference, -2 vs. -9 mg/dL, P < 0.001; median RAD, 12% vs. 15%, P = 0.001). Accuracy was better on visits where the average absolute rate of glucose change at the times of calibration was lower. On visits with average absolute rates <0.5, 0.5 to <1.0, 1.0 to <1.5, and >or=1.5 mg/dL/min, median RAD values were 13% versus 14% versus 17% versus 19%, respectively (P = 0.05).Although accuracy is slightly improved with more calibrations, the timing of the calibrations appears more important. Modifying the algorithm to put less weight on daytime calibrations for nighttime values and calibrating during times of relative glucose stability may have greater impact on accuracy.

  View details for Web of Science ID 000242531200007

  View details for PubMedID 16800753

• Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Badaru, A., Wilson, D. M., Bachrach, L. K., Fechner, P., Gandrud, L. M., Durham, E., Wintergerst, K., Chi, C., Klein, K. O., Neely, E. K. 2006; 91 (5): 1862-1867

  Abstract

  Dosing of monthly depot leuprolide (DL) in central precocious puberty (CPP) varies considerably. U.S. practitioners use 7.5-15 mg, in contrast with the international standard of 3.75 mg. Pubertal suppression using the newer 3-month DL also has been reported from Europe. To date there have been no direct comparisons of these different DL doses.In an open 12-month protocol, we tested the efficacy of three DL doses (7.5 mg- and 3.75 mg-1 month and 11.25 mg-3 month) given sequentially to subjects treated for CPP. Primary outcome measures were stimulated gonadotropin (Gn) levels at 12-wk intervals. The null hypothesis was no difference among doses.Both existing and new patients with CPP received our standard therapy (DL 7.5 mg every 4 wk) for a minimum of 24 wk. In subjects with DL-stimulated LH 2 IU/liter or less, the dose was changed to 3.75 mg every 4 wk and evaluated 12 wk later. Subjects who met LH criteria (<4.5 IU/liter) on 3.75 mg then received a single dose of 11.25 mg-3 month and were reevaluated 12 wk later. Serum LH/FSH and sex steroids were obtained 40 min after DL injection.Thirty subjects were enrolled (20 naive; 24 girls, 6 boys), and 21 were evaluated on all three DL doses. DL-stimulated LH levels (mean +/- sd) were 1.30 +/- 0.74, 1.73 +/- 0.99, and 2.13 +/- 1.41 on 7.5 mg, 3.75 mg, and 11.25 mg-3 month, respectively (7.5 vs. 3.75 mg, P = 0.019; 7.5 mg vs. 11.25 mg-3 month, P = 0.004, Wilcoxon ranked sign test). Mean FSH levels were 2.86 +/- 1.91, 3.91 +/- 1.98, and 3.96 +/- 1.34, respectively (7.5 vs. 3.75 mg, P = 0.017; 7.5 mg vs. 11.25 mg-3 month, P = 0.020). No differences were detected in mean sex steroid levels.Stimulated LH and FSH levels were significantly higher during therapy with both the 3.75 mg and 11.25 mg-3 month depot leuprolide doses, compared with 7.5 mg, contradicting the null hypothesis of no difference. These data suggest that low-dose 1- and 3-month DL preparations are associated with persistently greater gonadal stimulation in most CPP patients, but the LH/FSH results were not corroborated by differences in sex steroid levels. Whether various DL doses lead to long-term therapeutic differences remains to be determined.

  View details for DOI 10.1210/jc.2005-1500

  View details for PubMedID 16449344

• Impact of exercise on overnight glycemic control in - Children with type 1 diabetes mellitus JOURNAL OF PEDIATRICS Tsalikian, E., Mauras, N., Beck, R. W., Tamborlane, W. V., Janz, K. F., Chase, H. P., Wysocki, T., Weinzimer, S. A., Buckingham, B. A., KOLLMAN, C., Xing, D. Y., Ruedy, K. J., Fiallo-Scharer, R., Fisher, J. H., Tallant, B., Tsalikian, E., Tansey, M. J., Larson, L. F., Coffey, J., Wysocki, T., Mauras, N., Fox, L. A., Bird, K., Lofton, K. L., Buckingham, B. A., Wilson, D. M., Block, J. M., Clinton, P., Doyle, E. A., Sikes, K., Kalajian, A., Stockdale, C. R., Steffes, M. W., Bucksa, J. M., Nowicki, M. L., Van Hale, C. A., Makky, V., Grave, G. D., Linder, B., Winer, K. K., Becker, D. M., Cox, C., Ryan, C. M., White, N. H., White, P. C. 2005; 147 (4): 528-534

  Abstract

  To examine the effect of exercise on overnight hypoglycemia in children with type 1 diabetes mellitus (T1DM).At 5 clinical sites, 50 subjects with T1DM (age 11 to 17 years) were studied in a clinical research center on 2 separate days. One day included an afternoon exercise session on a treadmill. On both days, frequently sampled blood glucose levels were measured at the DirecNet central laboratory. Insulin doses were similar on both days.During exercise, plasma glucose levels fell in almost all subjects; 11 (22%) developed hypoglycemia. Mean glucose level from 10 pm to 6 am was lower on the exercise day than on the sedentary day (131 vs 154 mg/dL; P=.003). Hypoglycemia developed overnight more often on the exercise nights than on the sedentary nights (P=.009), occurring on the exercise night only in 13 (26%), on the sedentary night only in 3 (6%), on both nights in 11 (22%), and on neither night in 23 (46%). Hypoglycemia was unusual on the sedentary night if the pre-bedtime snack glucose level was>130 mg/dL.These findings indicate that overnight hypoglycemia after exercise is common in children with T1DM and support the importance of modifying diabetes management after afternoon exercise to reduce the risk of hypoglycemia.

  View details for DOI 10.1016/j.jpeds.2005.04.065

  View details for Web of Science ID 000232865300024

  View details for PubMedID 16227041

• Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes technology & therapeutics Weinzimer, S. A., Beck, R. W., Chase, H. P., Fox, L. A., Buckingham, B. A., Tamborlane, W. V., Kollman, C., Coffey, J., Xing, D., Ruedy, K. J. 2005; 7 (5): 675-680

  Abstract

  The objective of this study was to assess how the accuracy of the FreeStyle Flash (Abbott Diabetes Care, Alameda, CA) meter compares with that of the One Touch Ultra (Lifescan, Milpitas, CA) home glucose meter (HGM).Fifty children with type 1 diabetes (T1D), 10-17 years old, were admitted for two separate 24-h periods to assess the effect of exercise on subsequent nocturnal hypoglycemia. Resulting data were used in a preplanned analysis of the accuracy of the Ultra and FreeStyle HGMs. Glucose levels were measured throughout the day and night and every 15-20 min during a standardized exercise protocol. Reference samples were assayed in a central laboratory using a hexokinase enzymatic method. These reference glucose measurements were paired with HGM values from venous blood obtained within +/- 5 min.The median relative absolute difference was 5% for both the Ultra and FreeStyle HGMs, and the percentages of pairs meeting the International Organisation for Standardization criteria were 99% and 98%, respectively. The FreeStyle tended to read slightly higher than the reference method (median difference = +3 mg/dL; P < 0.001), and there was trend in this direction for the Ultra (median difference = +2 mg/dL, P = 0.15). Sensitivities for detection of hypoglycemia (reference < or = 60 and HGM < or = 70 mg/dL) were 96% and 100% for the Ultra and FreeStyle, respectively, and corresponding false-positive rates were both 5%.In a controlled clinical setting using venous blood samples, both the Ultra and FreeStyle meters demonstrated a high degree of accuracy compared with the laboratory reference over a broad range of glucose concentrations in children with T1D.

  View details for PubMedID 16241867

• Real-time continuous glucose monitor use and patient selection: what have we learned and where are we going? Diabetes technology & therapeutics Wilson, D. M., Block, J. 2005; 7 (5): 788-791

  View details for PubMedID 16241884

• Youth and parent satisfaction with clinical use of the GlucoWatch G2 Biographer in the management of pediatric type 1 diabetes DIABETES CARE Wysocki, T., Beck, R. W., Tamborlane, W. V., Fiallo-Scharer, R., Tansey, M. J., Weinzimer, S. A., KOLLMAN, C., Ruedy, K. J., Xing, D. Y., Davis, B., Chase, H. P., Fiallo-Scharer, R., Fisher, J. H., Tallant, B., Tsalikian, E., Tansey, M. J., Larson, L. F., Coffey, J., Wysocki, T., Mauras, N., Fox, L. A., Bird, K., Lofton, K. L., Buckingham, B. A., Wilson, D. M., Block, J. M., Clinton, P., Weinzimer, S. A., Tamborlane, W. V., Doyle, E. A., Sikes, K., Beck, R. W., Ruedy, K. J., KOLLMAN, C., Xing, D. Y., Kalajian, A., Stockdale, C. R., Grave, G. D., Linder, B., Winer, K. K., Steffes, M. W., Bucksa, J. M., Nowicki, M. L., Van Hale, C. A., Becker, D. M., Cox, C., Ryan, C. M., White, N. H., White, P. C. 2005; 28 (8): 1929-1935

  Abstract

  A continuous glucose monitor satisfaction scale (CGM-SAT) was evaluated during a 6-month randomized controlled trial of the GlucoWatch G2 Biographer (GW2B) in youths with type 1 diabetes.At the end of the 6-month trial, 97 parents and 66 older children who had been randomized to the GW2B group completed the CGM-SAT, which assesses satisfaction on 37 items using a five-point Likert scale. Descriptive analysis, calculation of several reliability estimates, and assessment of concurrent validity were performed.The CGM-SAT demonstrated high internal reliability (Cronbach's alpha = 0.95 for parents and 0.94 for youths aged > or = 11 years), split-half reliability (rho = 0.91 for parents and 0.93 for youths), and parent-adolescent agreement (rho = 0.68, P < 0.001). Convergent validity was supported by marginally significant associations with treatment adherence and frequency of GW2B use. CGM-SAT scores did not correlate significantly with changes in treatment adherence, quality of life, or diabetes-related anxiety from baseline to 6 months. Mean scores on CGM-SAT items indicated that 81% of parental responses and 73% of youths' responses were less favorable than "neutral." Descriptive analysis indicated the GW2B requires substantial improvement before it can achieve widespread clinical utility and acceptance.The results supported the psychometric properties of the CGM-SAT. The CGM-SAT warrants further research use and cross-validation with other continuous glucose monitors. This study provides a benchmark for comparison with new glucose sensors.

  View details for Web of Science ID 000230869700013

  View details for PubMedID 16043734

• Diabetes self-management profile for flexible insulin regimens - Cross-sectional and longitudinal analysis of psychometric properties in a pediatric sample 64th Annual Meeting of the American-Diabetes-Association Wysocki, T., Xing, D. Y., Fiallo-Scharer, R., Doyle, E. A., Block, J. M., Tsalikian, E., Beck, R. W., Ruedy, K. J., KOLLMAN, C., Harris, M., Tamborlane, W. V. AMER DIABETES ASSOC. 2005: 2034–35

  View details for Web of Science ID 000230869700031

  View details for PubMedID 16043752

• A brief review of the use and utility of growth hormone stimulation testing in the NCGS: Do we need to do provocative GH testing? 18th Annual National Cooperative Growth Study/5th Annual National Cooperative Somatropin Surveillance Investigator Meeting Wilson, D. M., Frane, J. CHURCHILL LIVINGSTONE. 2005: S21–S25

  Abstract

  True growth hormone deficiency (GHD) in childhood, while rare, has major clinical consequences. GHD is often associated with other pituitary hormone deficiencies, so these children may require multiple hormonal replacement and close clinical follow-up to optimize their outcome. Growth hormone stimulation testing (GHST), as currently conducted, is not a reliable diagnostic tool. Both changes in growth hormone assay methodologies and increases in the diagnostic threshold contribute to the incorrect labeling of a substantial proportion of normal children as having idiopathic GHD. Fortunately, newer imaging technologies and laboratory tests form a more rational basis to diagnose true GHD. The use of GHST among GH-naive subjects (<20 years of age) enrolled in the National Cooperative Growth Study has declined over the past two decades, from a high of 89% between 1987 and 1989 to only 52% in 2002. Given that GH stimulation testing does not meaningfully aid in distinguishing those few children with true growth hormone deficiency from the much more common short normal child and that alternatives are now available, it is time to discontinue the routine use of GHST in children.

  View details for PubMedID 16039892

• Eight-point glucose testing versus the continuous glucose monitoring system in evaluation of glycemic control in type 1 diabetes JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Fiallo-Scharer, R., Xing, D. Y., Weinzimer, S., Buckingham, B., Mauras, N., Tansey, M., Chase, P., Beck, R., Ruedy, K., KOLLMAN, C., Tamborlane, W., Chase, H. P., Fiallo-Scharer, R., Fisher, J. H., Tallant, B., Tsalikian, E., Tansey, M. J., Larson, L. F., Coffey, J., Wysocki, T., Mauras, N., Fox, L. A., Bird, K., Lofton, K. L., Buckingham, B. A., Wilson, D. M., Block, J. M., Clinton, P., Weinzimer, S. A., Tamborlane, W. V., Doyle, E. A., Sikes, K., Beck, R. W., Ruedy, K. J., KOLLMAN, C., Xing, D. Y., Kalajian, A., Silvester, C. R., Steffes, M. W., Bucksa, J. M., Nowicki, M. L., Van Hale, C. A., Grave, G. D., Linder, B., Winer, K. K., Becker, D. M., Cox, C., Ryan, C. M., White, N. H., White, P. C. 2005; 90 (6): 3387-3391

  Abstract

  Advantages/disadvantages of continuous vs. discrete glucose monitoring are not well documented.Compare glucose profiles from home meters vs. continuous sensors.Randomized clinical trial conducted by the Diabetes Research in Children Network (DirecNet) to assess the utility of the GlucoWatch G2 Biographer.Home glucose measurements.Two hundred children (age, 7 to < 18 yr) with type 1 diabetes.At baseline, subjects were asked to wear the continuous glucose monitoring system (CGMS) sensor and perform meter tests at eight prespecified times of the day (eight-point testing) each for 3 d (2 d using both, 1 d eight-point testing only, 1 d CGMS only). Hemoglobin A1c was measured in a central laboratory.Six-month hemoglobin A1c. This analysis looked at baseline glucose profiles/hemoglobin A1c.Only 10% of subjects completed full eight-point testing for 3 d, but median CGMS use was 70 h. Mean glucose was lower when measured by the CGMS compared with eight-point testing (183 +/- 37 vs. 188 +/- 41 mg/dl; 10.2 +/- 2.1 vs.10.4 +/- 2.3 mmol/liter; P = 0.009), especially overnight (2400-0400 h; 174 vs. 199 mg/dl; 9.7 vs. 11.1 mmol/liter; P < 0.001). Associations of hemoglobin A1c with mean glucose were similar for eight-point testing [slope 23 mg/dl per 1% (1.3 mmol/liter); correlation 0.40; P < 0.001] and CGMS [slope 19 mg/dl per 1% (1.1 mmol/liter); correlation 0.39; P < 0.001]. Postprandial excursions were lower for eight-point testing vs. CGMS, especially after dinner (mean excursion -17 vs. 63 mg/dl; -1.0 vs. 3.5 mmol/liter; P < 0.001).Both methods gave similar mean glucose profiles and associations with hemoglobin A1c. Advantages of the CGMS were higher density of data and better detection of postprandial peaks. However, the CGMS may overestimate the frequency of low glucose levels, especially overnight.

  View details for DOI 10.1210/jc.2004-2510

  View details for Web of Science ID 000229351000036

  View details for PubMedID 15784705

• Response to nocturnal alarms using a real-time glucose sensor. Diabetes technology & therapeutics Buckingham, B., Block, J., Burdick, J., Kalajian, A., Kollman, C., Choy, M., Wilson, D. M., Chase, P. 2005; 7 (3): 440-447

  Abstract

  The objective of this study was to determine how subjects responded to alarms for hypo- and hyperglycemia while they were sleeping.Twenty subjects with type 1 diabetes (4-17 years old) were admitted to a clinical research center for approximately 24 h. Each subject wore two GlucoWatch G2 Biographers (GW2B) (Cygnus, Inc., Redwood City, CA) and was videotaped using an infrared camera from 9 p.m. to 7 a.m. The videotapes were reviewed to determine if the GW2B alarms were audible on the tape and to document the subject's response to the alarms. Because many alarms can occur surrounding a change in blood glucose, GW2B alarm "events" are defined as a one or more alarms separated from previous alarms by more than 30 min.Downloaded data from the biographers identified 240 individual alarms, 75% of which occurred while the subject was sleeping. Of the 240 alarms 68% were audible on the videotape. Subjects awoke to 29% of individual alarms and to 66% of alarm events. Subjects 4-6 years old responded to 17% of alarms, 7-11 year olds responded to 20% of alarms, adolescents responded to 53% of alarms, and parents responded to 37% of alarms. Subjects awoke to 40% of the first alarm during the night, but to only 28% of subsequent alarms. There were 11 events when the glucose was confirmed to be < or = 70 mg/dL, and in each case the subject was awoken. Fifty-five percent of alarm events occurred when there was no hypo- or hyperglycemia confirmed by a reference glucose value.Subjects awoke to 29% of individual alarms and to 66% of alarm events. Subjects awoke during all alarm events when hypoglycemia was confirmed, but there was a high incidence of false alarms.

  View details for PubMedID 15929675

• A randomized multicenter trial comparing the GlucoWatch Biographer with standard glucose monitoring in children with type 1 diabetes. Diabetes care Chase, H. P., Beck, R., Tamborlane, W., Buckingham, B., Mauras, N., Tsalikian, E., Wysocki, T., Weinzimer, S., Kollman, C., Ruedy, K., Xing, D. 2005; 28 (5): 1101-1106

  Abstract

  This study assesses whether use of the GlucoWatch G2 Biographer (GW2B) in addition to standard glucose monitoring lowers HbA(1c) and reduces hypoglycemia compared with standard glucose monitoring alone.In all, 200 subjects aged 7 to <18 years with type 1 diabetes were randomly assigned at five centers to standard glucose monitoring (usual care) or standard glucose monitoring plus GW2B use for 6 months. Study outcomes included HbA(1c) values obtained at 6 months and occurrence of severe hypoglycemia.The mean HbA(1c) at baseline was 8.0% in both groups; at 6 months, HbA(1c) was 7.9% in the usual care group and 8.1% in the GW2B group (95% CI for mean reduction in the GW2B group compared with the usual care group -0.4 to 0.1%; P = 0.15). A decrease in HbA(1c) of > or =0.5% was achieved in 21% of the usual care group and 28% of the GW2B group (P = 0.29). Severe hypoglycemia events occurred in 7% of the GW2B group and in 2% of the usual care group (P = 0.10). In the GW2B group, sensor use declined throughout the study from a mean value of 2.1 times/week in the 1st month to 1.5 times/week in the 6th month. Reasons given for declining use included skin irritation (76%), frequent skips (56%), excessive alarms (47%), and inaccurate readings (33%).Use of the GW2B in addition to standard glucose monitoring did not improve glycemic control or reduce the frequency of severe hypoglycemia. Skin reactions and other problems led to decreasing sensor use over time.

  View details for PubMedID 15855573

• Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: Results of a Diabetes Research in Children Network (DirecNet) Study PEDIATRIC DIABETES Tamborlane, W. V., KOLLMAN, C., Steffes, M. W., Ruedy, K. J., Xing, D. Y., Beck, R. W., Chase, H. P., Fox, L. A., Wilson, D. M., Tsalikian, E. 2005; 6 (1): 13-16

  Abstract

  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) high-performance liquid chromatography (HPLC) method for measuring hemoglobin A1c (HbA1c) serves as a reference standard against which other assays are compared. The DCA 2000 + Analyzer (Bayer Inc., Tarrytown, NY, USA), which uses an immunoassay, is a very popular device for measuring HbA1c levels in pediatric diabetes practices.To determine how HbA1c values measured with the DCA 2000 in a multisite, pediatric diabetes clinic setting compare with corresponding HbA1c values measured in the DCCT/EDIC laboratory.To examine this question, the Diabetes Research in Children Network (DirecNet) used the DCA 2000 in five clinical centers to measure baseline HbA1c levels in 200 youth with type 1 diabetes mellitus (T1DM) (aged 12.5 +/- 2.8 yr) who were participating in an outpatient clinical trial. At the same visit, an additional blood sample was obtained, refrigerated, and shipped to the DCCT/EDIC central laboratory for determination of HbA1c values.The central laboratory HbA1c value averaged 8.0 +/- 0.9% (mean +/- SD), with a median (25th and 75th quartiles) of 7.8% (7.3 and 8.5%, respectively). The DCA 2000 HbA1c values were strongly correlated (r = 0.94, p < 0.001), but significantly higher than DCCT/EDIC central laboratory values with a mean difference of +0.2% (95% confidence interval +0.14 to 0.23%, p < 0.001). There was some variation in the differences between DCA 2000 and central laboratory values at the five clinical centers (p < 0.001) with mean differences ranging between 0.0 and 0.3%, but differences between the two methods did not vary significantly by age or gender.Measurements of HbA1c by the DCA 2000 compare favorably with the DCCT/EDIC central laboratory method, albeit with slightly higher values.

  View details for Web of Science ID 000228222000004

  View details for PubMedID 15787896

• Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes technology & therapeutics Tansey, M. J., Beck, R. W., Buckingham, B. A., Mauras, N., Fiallo-Scharer, R., Xing, D., Killman, C., Tamborlane, W. V., Ruedy, K. J. 2005; 7 (1): 109-114

  Abstract

  We previously reported the results of an inpatient accuracy study in children with type 1 diabetes using the Continuous Glucose Monitoring System (CGMS, Medtronic MiniMed, Northridge, CA). During the course of that study, a new process was implemented for manufacturing the CGMS sensor. Accuracy from the resulting modified sensor used by only 14 children was significantly better than the original version [median relative absolute difference (RAD), 11% vs. 19%; P < 0.001]. Baseline data from a subsequent outpatient study provide an opportunity to further assess the accuracy of the modified sensor in a much larger sample of children with type 1 diabetes.As part of a randomized trial to assess the utility of the GlucoWatch G2 Biographer (Cygnus, Inc., Redwood City, CA), 200 children with type 1 diabetes were instructed to wear a CGMS for 48-72 h in an outpatient setting at baseline. Glucose measurements from a OneTouch UltraSmart (Lifescan, Inc., Milpitas, CA) home glucose meter were downloaded and used as reference values to calculate accuracy measures.The overall median RAD was 12%. Accuracy was better during hyperglycemia than during hypoglycemia (median RAD, 10% vs. 20%; P < 0.001) and on optimal versus non-optimal days but did not vary significantly by the number of calibrations entered.These data confirm the improved accuracy previously reported for the modified version of the CGMS sensor.

  View details for PubMedID 15738708

• A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes 63rd Annual Meeting of the American-Diabetes-Association Wilson, D. M., Buckingham, B. A., Kunselman, E. L., Sullivan, M. M., Paguntalan, H. U., Gitelman, S. E. AMER DIABETES ASSOC. 2005: 15–19

  Abstract

  Our goals were to determine if continuous subcutaneous insulin infusion (CSII), compared with those continuing multiple daily injections (MDIs), can be safely used in young children, if those on CSII will have superior glycemic control, if subjects using CSII will have less hypoglycemia for their level of control, and if families using CSII will report an improved quality of life.We conducted a randomized 1-year feasibility trial comparing CSII with continuing MDIs in preschool children with a history of type 1 diabetes for at least 6 months' duration. Prospective outcomes included measures of overall glycemic control (HbA1c and continuous glucose monitoring system), the incidence of severe hypoglycemia and diabetic ketoacidosis, the percent of glucose values below 3.9 mmol/l, and the parents' report of quality of life.The 19 subjects' ages ranged from 1.7 to 6.1 (mean 3.6) years, duration of diabetes ranged from 0.6 to 2.6 (mean 1.4) years, and baseline HbA1c ranged from 6.7 to 9.6% (mean 7.9%). Seven subjects were male. Nine subjects were randomized to start CSII and 10 to continue on MDI. All baseline characteristics were well balanced. Overall metabolic control, diabetes quality of life, and the incidence of hypoglycemia were similar in the two groups. No subject had diabetic ketoacidosis, while one subject in each group had an episode of severe hypoglycemia. No CSII subject discontinued using the pump during or after the study.CSII can be a safe and effective method to deliver insulin in young children.

  View details for PubMedID 15616227

• GlucoWatch G2 Biographer alarm reliability during hypoglycemia in children. Diabetes technology & therapeutics Tsalikian, E., Kollman, C., Mauras, N., Weinzimer, S., Buckingham, B., Xing, D., Beck, R., Ruedy, K., Tamborlane, W., Fiallo-Scharer, R. 2004; 6 (5): 559-566

  Abstract

  The GlucoWatch G2 Biographer (GW2B) (Cygnus, Inc., Redwood City, CA) provides near-continuous monitoring of glucose values in near real time. This device is equipped with two types of alarms to detect hypoglycemia. The hypoglycemia alarm is triggered when the current glucose measurement falls below the level set by the user. The "down alert" alarm is triggered when extrapolation of the current glucose trend anticipates hypoglycemia to occur within the next 20 min.We used data from an inpatient accuracy study to assess the performance of these alarms. During a 24-h clinical research center stay, 89 children and adolescents with Type 1 diabetes mellitus (3.5-17.7 years old) wore 174 GW2B devices and had frequent serum glucose determinations during the day and night.Sensitivity to detect hypoglycemia (reference glucose < or = 60 mg/dL) during an insulin-induced hypoglycemia test was 24% with the hypoglycemia alarm alone and 88% when combined with the down alert alarm. Overnight sensitivity from 11 p.m. to 6 a.m. was 23% with the hypoglycemia alarm alone and 77% when combined with the down alert alarm. For 16% of hypoglycemia alarms, the reference glucose was above 70 mg/dL for 30 min before and after the time of the alarm. For the two alarm types combined, the corresponding false-positive rate increased to 62%.The down alert alarm substantially improves the sensitivity of the GW2B to detect hypoglycemia at the price of a large increase in the false alarm rate. The utility of these alarms in the day-to-day management of children with diabetes remains to be determined.

  View details for PubMedID 15628809

• Assessing weight-related biochemical cardiovascular risk factors in African-American girls OBESITY RESEARCH Wilson, D. M., Wang, Y., Cullen, K. W., Baranowski, T., Himes, J. H., Gross, M., McClanahan, B. S., Robinson, T. N. 2004; 12: 73S-83S

  Abstract

  Hyperinsulinemia/insulin resistance is a risk factor for future type 2 diabetes. Fasting insulin and blood lipids serve as direct indicators of subsequent risk and as biochemical markers of metabolically significant adiposity. We examined the feasibility of obtaining fasting blood samples and report correlates of these biochemical markers in an understudied population sample.Fasting samples were requested from African-American girls, 8.00 to 10.99 years of age, for insulin, glucose, and lipid concentrations. Indices of insulin sensitivity and secretion were calculated and correlated with anthropometric, dietary, physical activity, and body composition data.Samples were obtained from 119 of 210 (57%) girls, varying from 5% to 86% across the four field centers. Glucose ranged from 71 to 104 mg/dL. Eleven percent had insulin concentrations >20 mU/liter. One girl had a triglyceride concentration >130 mg/dL. Thirteen percent had total cholesterol >200 mg/dL, whereas all subjects had high-density lipoprotein (HDL)-cholesterol of > or =35 mg/dL. Fourteen percent had low-density lipoprotein levels >130 mg/dL. Insulin concentrations showed consistently strong associations with measures of body weight (rs = 0.54 to 0.67); glucose, HDL, and LDL showed weaker correlations (rs = -0.11 to 0.22). Insulin concentration was highly correlated with indices of both insulin secretion and resistance (rs = 0.99).Fasting blood samples in young African-American girls were obtained with reasonable cooperation in three of the four field centers involved in this community-based study. Fasting insulin, glucose, LDL, and HDL concentrations may help evaluate future diabetes and cardiovascular risk in children of this age.

  View details for PubMedID 15489470

• Early sexual maturation, body composition, and obesity in African-American girls OBESITY RESEARCH Himes, J. H., Obarzanek, E., Baranowski, T., Wilson, D. M., Rochon, J., McClanahan, B. S. 2004; 12: 64S-72S

  Abstract

  To describe associations between sexual maturation and body composition in a sample of African-American girls who were participants in phase 1 pilot interventions of the Girls Health Enrichment Multisite Studies.Stature, weight, and waist circumference were measured. Pubic hair and breast development were assessed, and body composition was measured by DXA for 147 African-American girls who were 8 to 10 years of age from three field centers. Participants had BMI > or =25th percentile for age (one site) or BMI > or =50th percentile for age.Girls Health Enrichment Multisite Studies girls had greater BMI, fat mass, and percentage body fat than national norms and relatively earlier initiation of breast development and pubic hair. Increasing stages of breast development, but not stages of pubic hair, were related to increased stature, waist circumference, BMI, lean mass, fat mass, and percentage of body fat. Pubescent girls (breast stage > or = 2) were greater than six times as likely to be classified as at risk of overweight (BMI > or = 85th percentile) and greater than eight times as likely to be classified as overweight (BMI > or = 95th percentile) as prepubescent counterparts. Adjusted odds ratios for advanced breast development [breast stage > or = 2 (8 years) or > or = 3 (9 and 10 years)] were 3.6 for risk of overweight and for overweight compared to girls with average or less than average breast development.Sexual maturation is important to consider in understanding the classification of overweight and the development of obesity during adolescence. Breast development and pubic hair development should be considered separately for their associations with growth and body composition.

  View details for Web of Science ID 000224581800009

  View details for PubMedID 15489469

• Alternatives to growth hormone stimulation testing in children TRENDS IN ENDOCRINOLOGY AND METABOLISM Badaru, A., Wilson, D. M. 2004; 15 (6): 252-258

  Abstract

  Despite more than 40 years of pediatric growth hormone (GH) replacement, we are still limited in our ability to make a definitive diagnosis of GH deficiency (GHD) in children. Historically, GH stimulation tests (GHSTs) have been used to discriminate between GHD and idiopathic short stature. Over the years, increases in the peak diagnostic GH cutoffs and the proliferation of GH assays have fundamentally changed the nature of the GHST. In our opinion, today's GHSTs lack reproducibility and accuracy, are expensive, and can be dangerous. Moreover, newer diagnostic tools, such as high-resolution neuroimaging, measurements of serum insulin-like growth factor 1 and insulin-like growth factor-binding protein 3, and an increasing number of genetic tests, have emerged. We believe that it is no longer appropriate to use GHSTs to diagnose childhood GHD. Instead, diagnosis should be based on a combination of auxological, biochemical, neuroradiological and genetic considerations. Here, we examine the alternatives to the GHST that are currently available and literature that supports their use. We believe that these alternative methods should replace the GHST.

  View details for DOI 10.1016/j.tem.2004.06.004

  View details for PubMedID 15358277

• Is growth hormone stimulation testing in children still appropriate? GROWTH HORMONE & IGF RESEARCH Gandrud, L. M., Wilson, D. M. 2004; 14 (3): 185-194

  Abstract

  The diagnosis of growth hormone deficiency (GHD) historically has relied on measurement of growth hormone (GH) concentrations following stimulation, usually with a non-physiologic provocative agent. Despite the use of more specific GH assays, the peak concentration of GH below which a child is considered GH deficient has risen. We examine the pitfalls associated with GH stimulation tests, specifically, the lack of reliability and accuracy of these tests, and their inability to predict who will benefit from GH therapy. We recommend that GH stimulation tests no longer routinely be used for the diagnosis of GHD in children.

  View details for DOI 10.1016/j.ghir.2003.11.003

  View details for PubMedID 15125879

• Initiation of insulin glargine in children and adolescents with type I diabetes PEDIATRIC DIABETES Tan, C. Y., Wilson, D. M., Buckingham, B. 2004; 5 (2): 80-86

  Abstract

  Glargine (Lantus) is a recently approved, long-acting insulin analog that is increasingly being used in children with diabetes. The aim of this retrospective chart review was to summarize our experience in starting glargine in children and adolescents with diabetes. SUBJECTS AND STUDY METHODS: We reviewed the medical records of 71 children with type 1 diabetes (29 boys and 42 girls) who initiated glargine therapy to improve glycemic control between 1 June 2001 and 30 June 2002. Data were collected for 6 months before and 6 months after adding glargine.Subjects' mean age [+/-standard deviation (SD)] at diagnosis of diabetes was 7.5 +/- 4.1 yr. Mean age at initiation of glargine therapy was 11.5 +/- 4.9 yr. The total daily long-acting insulin dose decreased by about 20% after initiating glargine therapy. There were no significant differences in hemoglobin A1c (HbA1c) and blood glucose control prior to and after initiating glargine therapy (HbA1c at baseline 8.9 +/- 1.6% and HbA1c after 6 months of glargine therapy was 8.9 +/- 1.5%). Overall, blood glucose concentrations did not differ significantly throughout the study. Patients who switched to glargine because of nocturnal hypoglycemia had a 65% decrease in nocturnal blood glucose reading less than 50 mg/dL. There were three seizures in the first week after initiating glargine therapy.This retrospective study suggests that glargine is at least as effective as other long-acting insulins but that care must be taken during the conversion process to avoid hypoglycemia.

  View details for Web of Science ID 000223649200004

  View details for PubMedID 15189493

• Lack of accuracy of continuous glucose sensors in healthy, nondiabetic children: Results of the Diabetes Research in Children Network (DirecNet) Accuracy study JOURNAL OF PEDIATRICS Mauras, N., Beck, R. W., Ruedy, K. J., KOLLMAN, C., Tamborlane, W. V., Chase, P., Buckingham, B. A., Tsalikian, E., Weinzimer, S. A., Booth, A. D., Xing, D. Y. 2004; 144 (6): 770-775

  Abstract

  The workup of hypoglycemia requires frequent glucose sampling. We designed these studies to determine if the Continuous Glucose Monitoring System (CGMS) and the GlucoWatch G2 Biographer (GW2B) are sufficiently accurate to use in nondiabetic children. Study design Fifteen healthy children (aged 9-17 years, 11 boys) wore a GW2B and a CGMS during a 24-hour period, and reference serum glucose was measured hourly during the day and half-hourly overnight.Compared with the reference glucose, the median absolute difference in concentrations measured by the GW2B (487 pairs) was 13 mg/dL, and the difference measured by the CGMS was 17 mg/dL (668 pairs), with 30% and 42% of values using the GW2B and CGMS, respectively, deviating >20 mg/dL from the reference value. The GW2B reported values <60 mg/dL in 73% of subjects, the CGMS in 60% of subjects. In none of these episodes was serum glucose truly low. Spurious high glucose concentrations also were observed with the sensors. The mean reference glucose was lowest at 5 am (89 mg/dL) and highest at 11:30 pm (106 mg/dL) during the 24-hour period.Neither the CGMS nor the GW2B is accurate enough to establish population standards of the glycemic profile of healthy children and cannot be recommended in the workup of hypoglycemia in nondiabetic youth.

  View details for DOI 10.1016/j.jpeds.2004.03.042

  View details for Web of Science ID 000222047900017

  View details for PubMedID 15192625

• Performance of the DCA2000 for measurement of hemoglobin A1(c) levels in children with T1DM in a DirecNet outpatient clinical trial Tamborlane, W., Xing, D., Steffes, M., Kollman, C., Ruedy, K. J., Beck, R. W., Fiallo-Scharer, R., Fox, L., Wilson, D., Tsalikian, E., Diabetes Res Children Network INT PEDIATRIC RESEARCH FOUNDATION, INC. 2004: 138A

  View details for Web of Science ID 000220591100811

• Accuracy of the GlucoWatch G2 Biographer and the continuous glucose monitoring system during hypoglycemia - Experience of the Diabetes Research in Children Network DIABETES CARE Tsalikian, E., Beck, R. W., Tamborlane, W. V., Chase, P., Buckingham, B. A., Weinzimer, S. A., Mauras, N., Ruedy, K. J., KOLLMAN, C., Xing, D. Y., Fiallo-Scharer, R., Fisher, J. H., Tsalikian, E., Tansey, M. J., Larson, L. F., Wysocki, T., Gagnon, K. M., Todd, P., Wilson, D. M., Block, J. M., Kunselman, E. L., Tamborlane, W. V., Doyle, E. A., Moke, P. S., Labastie, L. M., Becker, D. M., Cox, C., Ryan, C. M., White, N. H., White, P. C., Steffes, M. W., Bucksa, J. M., Nowicki, M. L., Grave, G. D., Linder, B., Winer, K. K. 2004; 27 (3): 722-726

  Abstract

  The goal of this study was to assess the accuracy of the GlucoWatch G2 Biographer (GW2B) and the continuous glucose monitoring system (CGMS) during hypoglycemia in children and adolescents with type 1 diabetes.During a 24-h clinical research center stay, 91 children and adolescents with type 1 diabetes (aged 3.5-17.7 years) wore one or two CGMSs, and 89 of these subjects wore one or two GW2Bs. Frequent serum glucose determinations were made during the day, overnight, and during insulin-induced hypoglycemia resulting in 192 GW2B reference pairs and 401 CGMS reference pairs during hypoglycemia (reference glucose < or =60 mg/dl).During hypoglycemia, the median absolute difference between the 192 GW2B reference glucose pairs was 26 mg/dl and between the 401 CGMS reference glucose pairs was 19 mg/dl with 31 and 42%, respectively, of the sensor values within 15 mg/dl of the reference glucose. Sensitivity to detect hypoglycemia when the GW2B alarm level was set to 60 mg/dl was 23% with a false-alarm rate of 51%. Analyses suggested that modified CGMS sensors that became available in November 2002 might be more accurate than the original CGMS sensors (median absolute difference 15 vs. 20 mg/dl).These data show that the GW2B and the CGMS do not reliably detect hypoglycemia. Both of these devices perform better at higher glucose levels, suggesting they may be more useful in reducing HbA1c levels than in detecting hypoglycemia.

  View details for Web of Science ID 000189307400014

  View details for PubMedID 14988292

• Catch-up growth in severe juvenile hypothyroidism: Treatment with a GnRH analog JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM Teng, L., Bui, H., Bachrach, L., Lee, P., Gagne, N., Deal, C., Wilson, D. M. 2004; 17 (3): 345-354

  Abstract

  Anecdotal reports suggest that the addition of a gonadotropin releasing hormone (GnRH) analog (GnRHa) in addition to L-thyroxine (LT4) replacement may increase adult stature in children with severe longstanding hypothyroidism by prolonging the pubertal growth period. This retrospective chart review compares the height outcome and body mass index in 33 children (21 treated with LT4 alone and 12 treated with LT4 + GnRHa) with severe longstanding hypothyroidism and bone age delay. Seventeen controls and six GnRHa-treated patients were followed to adult height (BA >14 yr [F]/16 yr [M] and/or growth velocity < 2 cm/yr). At diagnosis, GnRHa-treated patients were 1) older and shorter for chronological age, and 2) more advanced in puberty and bone age. Despite these differences, at adult height, both groups had similar improvements in height Z scores, similar height deficits, and comparable adult heights. Changes in BMI Z score were similar for both groups. Our study suggests that the addition of GnRHa to LT4 may improve interval growth without imposing a risk of obesity in children with longstanding severe hypothyroidism.

  View details for Web of Science ID 000220670300009

  View details for PubMedID 15112911

• Use of the Cygnus GlucoWatch biographer at a diabetes camp PEDIATRICS Gandrud, L. M., Paguntalan, H. U., Van Wyhe, M. M., Kunselman, B. L., Leptien, A. D., Wilson, D. M., Eastman, R. C., Buckingham, B. A. 2004; 113 (1): 108-111

  Abstract

  Detection and prevention of nocturnal hypoglycemia is a major medical concern at diabetes camps.We conducted an open-label trial of the Cygnus GlucoWatch biographer to detect nocturnal hypoglycemia in a diabetes camp, a nonclinical environment with multiple activities.Forty-five campers (7-17 years old) wore a biographer. The biographer was placed on the arm at 6:00 PM, with the low alarm set to 85 mg/dL (4.7 mmol/L). Overnight glucose monitoring occurred per usual camp protocol. Counselors were to check and record blood glucose values if the biographer alarmed.Biographers were worn for 154 nights by 45 campers. After a 3-hour warm-up period, 67% of biographers were calibrated, of which 28% were worn the entire night (12 hours). Thirty-four percent of readings were skipped because of: "data errors" (65%), sweat (20%), and temperature change (16%). Reported biographer values correlated with meter glucose values measured 11 to 20 minutes later (r = 0.90). Of 20 low-glucose alarms with corresponding meter values measured within 20 minutes, there were 10 true-positive alarms, 10 false-positive alarms, and no false-negative alarms. Campers reported sleep disruption 32% of the nights, and 74% found the biographer helpful. Campers reported they would wear the biographer 4 to 5 nights each week.Half of the biographer low-glucose alarms that had corresponding blood meter values were true-positive alarms, and the remaining were false-positive alarms. There was close correlation between the biographer and meter glucose values. The majority of campers found the biographer helpful and would use it at home.

  View details for PubMedID 14702457

• A two center randomized controlled trial of insulin pump therapy in young children with diabetes Wilson, D., Buckingham, B., Kunselman, E., Sullivan, M., Paguntalan, H., Gitelman, S. AMER DIABETES ASSOC. 2003: A402

  View details for Web of Science ID 000183173801733

• Diabetes research in children network (DirecNet) accuracy study of the continuous glucose monitoring system (CGMS) and Gluco Watch (R) G2 (TM) biographer (GWB) in children with type 1 diabetes - A CRC-based study Buckingham, B., Beck, R., Tamborlane, W., Ruedy, K., Boland, E., Chase, P., Wysocki, T., Tsalikian, E., Wilson, D., Mauras, N., Weinzimer, S., Tansey, M., Fiallo-Scharer, R., Booth, A., Kollman, C., DirecNet Study Grp AMER DIABETES ASSOC. 2003: A36

  View details for Web of Science ID 000183173800156

• A 5-center CRC-Based study of the accuracy of the GlucoWatch((R)) G2((TM)) biographer in children and adolescents with type 1 diabetes Wilson, D., Buckingham, B., Beck, R., Ruedy, K., Kollman, C., Tsalikian, E., Wysocki, T., Weinzimer, S., Chase, P., Diabet Res Children Network AMER DIABETES ASSOC. 2003: A101

  View details for Web of Science ID 000183173800430

• A multicenter study of the accuracy of the One Touch Ultra home glucose meter in children with type 1 diabetes. Diabetes technology & therapeutics 2003; 5 (6): 933-941

  Abstract

  Data are not readily available on the accuracy of one of the most commonly used home blood glucose meters, the One Touch Ultra (LifeScan, Milpitas, California). The purpose of this report is to provide information on the accuracy of this home glucose meter in children with type 1 diabetes. During a 24-h clinical research center stay, the accuracy of the Ultra meter was assessed in 91 children, 3-17 years old, with type 1 diabetes by comparing the Ultra glucose values with concurrent reference serum glucose values measured in a central laboratory. The Pearson correlation between the 2,068 paired Ultra and reference values was 0.97, with the median relative absolute difference being 6%. Ninety-four percent of all Ultra values (96% of venous and 84% of capillary samples) met the proposed International Organisation for Standardisation (ISO) standard for instruments used for self-monitoring of glucose when compared with venous reference values. Ninety-nine percent of values were in zones A + B of the Modified Error Grid. A high degree of accuracy was seen across the full range of glucose values. For 353 data points during an insulin-induced hypoglycemia test, the Ultra meter was found to have accuracy that was comparable to concurrently used benchmark instruments (Beckman, YSI, or i-STAT); 95% and 96% of readings from the Ultra meter and the benchmark instruments met the proposed ISO criteria, respectively. These results confirm that the One Touch Ultra meter provides accurate glucose measurements for both hypoglycemia and hyperglycemia in children with type 1 diabetes.

  View details for PubMedID 14709195

• Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. Ethnicity & disease Robinson, T. N., Killen, J. D., Kraemer, H. C., Wilson, D. M., Matheson, D. M., Haskell, W. L., Pruitt, L. A., Powell, T. M., Owens, A. S., Thompson, N. S., Flint-Moore, N. M., Davis, G. J., Emig, K. A., Brown, R. T., Rochon, J., Green, S., Varady, A. 2003; 13 (1): S65-77

  Abstract

  To test the feasibility, acceptability, and potential efficacy of after-school dance classes and a family-based intervention to reduce television viewing, thereby reducing weight gain, among African-American girls.Twelve-week, 2-arm parallel group, randomized controlled trial.Low-income neighborhoods.Sixty-one 8-10-year-old African-American girls and their parents/guardians.The treatment intervention consisted of after-school dance classes at 3 community centers, and a 5-lesson intervention, delivered in participants' homes, and designed to reduce television, videotape, and video game use. The active control intervention consisted of disseminating newsletters and delivering health education lectures.Implementation and process measures, body mass index, waist circumference, physical activity measured by accelerometry, self-reported media use, and meals eaten with TV.Recruitment and retention goals were exceeded. High rates of participation were achieved for assessments and intervention activities, except where transportation was lacking. All interventions received high satisfaction ratings. At follow up, girls in the treatment group, as compared to the control group, exhibited trends toward lower body mass index (adjusted difference = -.32 kg/m2, 95% confidence interval [CI] -.77, .12; Cohen's d = .38 standard deviation units) and waist circumference (adjusted difference = -.63 cm, 95% CI -1.92, .67; d = .25); increased after-school physical activity (adjusted difference = 55.1 counts/minute, 95% CI -115.6, 225.8; d = .21); and reduced television, videotape, and video game use (adjusted difference = -4.96 hours/week, 95% CI -11.41, 1.49; d = .40). The treatment group reported significantly reduced household television viewing (d = .73, P = .007) and fewer dinners eaten while watching TV (adjusted difference = -1.60 meals/week, 95% CI -2.99, -.21; d = .59; P = .03). Treatment group girls also reported less concern about weight (d = .60; P = .03), and a trend toward improved school grades (d = .51; P = .07).This study confirmed the feasibility, acceptability, and potential efficacy of using dance classes and a family-based intervention to reduce television viewing, thereby reducing weight gain, in African-American girls.

  View details for PubMedID 12713212

• The accuracy of the CGMS in children with type 1 diabetes: results of the diabetes research in children network (DirecNet) accuracy study. Diabetes technology & therapeutics 2003; 5 (5): 781-789

  Abstract

  The accuracy of the Continuous Glucose Monitoring System, CGMS (Medtronic MiniMed, Northridge, CA) was assessed in children and adolescents with type 1 diabetes mellitus (T1DM) when compared with reference serum glucose levels during spontaneous fluctuations in glucose levels over 24 h and during acute hyper- and hypoglycemia. Ninety-one subjects with type 1 diabetes (3.5-17.7 years old) wore one or two CGMSs while blood samples were obtained for serum glucose determinations (made at a central laboratory) hourly during the day, every 30 min overnight, and every 5 min during meal-induced hyperglycemia and insulin-induced hypoglycemia tests, resulting in 6778 CGMS-reference glucose pairs. CGMS function was assessed on each of the 3 days of sensor life. The median relative absolute difference (RAD) between the CGMS and reference values was 18% (25th, 75th percentiles = 8%, 34%). Similar results were obtained on each of the 3 days of sensor life. Accuracy was worse during hypoglycemia than during hyperglycemia. Modified sensors that first became available in November 2002 were more accurate than were the original sensors (median RAD = 11% vs. 19%) and had better precision (r = 0.92 vs. r = 0.77) during time periods in which two CGMSs were simultaneously used. The CGMS sensors that have been in clinical use until recently are often inaccurate in quantifying glucose values in children with T1DM. However, recent modifications to the sensor have resulted in substantially better accuracy and reliability. This improved function, if confirmed by additional data, may enhance the clinical utility of the CGMS.

  View details for PubMedID 14633343

• Effects of insulin in relatives of patients with type 1 diabetes mellitus 61st Annual Meeting of the American-Diabetes-Association Skyler, J. S., Brown, D., Chase, H. P., COLLIER, E., Cowie, C., Eisenbarth, G. S., Fradkin, J., Grave, G., Greenbaum, C., Jackson, R. A., Kaufman, F. R., Krischer, J. P., Marks, J. B., Palmer, J. P., Ricker, A., Schatz, D. A., Wilson, D., Winter, W. E., Wolfsdorf, J., Zeidler, A., Dickler, H., Eastman, R. C., Maclaren, N. K., Malone, J. I., Robertson, P. R., Skyler, J. S., Krischer, J. P., Wolfsdorf, J., Cowie, C., Palmer, J. P., Greenbaum, C., Cuthbertson, D., Rafkin-Mervis, L. M., Kaufman, F. R., Chase, H. P., Palmer, J. P., Chase, H. P., Cowie, C., Fradkin, J., Eisenbarth, G. S., Greenbaum, C., Herold, K., Kaufman, F. R., Krischer, J. P., Marks, J. B., Rafkin-Mervis, L., Schatz, D. A., Skyler, J. S., Aneju, B., Conboy, D., Cook, R., Dennis, M. A., Finney, L., Harris, S., Matheson, D., McCulloch-Olsen, M., Smith, T., VALENZUELA, J., Vega, N., Crofford, O. B., deMets, D., Lachin, J. M., Nerup, J., Rossini, A., Schiffrin, A., Steffes, M., Tsiatis, A., Zinman, B. MASSACHUSETTS MEDICAL SOC. 2002: 1685–1691B

  Abstract

  It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes.In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes.Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups.In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.

  View details for Web of Science ID 000175834100002

  View details for PubMedID 12037147

• Progress in the treatment of childhood diabetes mellitus and obesity 15th Annual National-Cooperative-Growth-Study (NCGS) Investigator Meeting Wilson, D. M. FREUND PUBLISHING HOUSE LTD. 2002: 745–749

  Abstract

  The 61st Annual Meeting and Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA, (June 22-26, 2001) presented many topics of interest to pediatric clinicians. Of particular interest were the results of the insulin injection arm of the Diabetes Prevention Trial for type 1 diabetes mellitus (DM) (DPT-1). Over 80,000 relatives of patients with type 1 DM were screened. Ultimately, 339 subjects were randomized either to active therapy (twice daily insulin injections plus an annual insulin infusion) or to close observation. Risk prediction algorithms appeared to be accurate. Unfortunately, however, insulin therapy did not decrease the risk of developing DM. Of note, this was primarily a pediatric study with most of those randomized under 21 years of age. As expected, young subjects (<12 years) progressed toward the development of DM at a faster rate than older subjects (>15 years). The second arm of the DPT-1 trial, testing oral insulin in those with intermediate risk (25-50%) for DM, is still recruiting subjects. The controversial topic of continuous subcutaneous insulin infusion (CSII) in young children was also addressed. Many investigators presented data strongly supporting the successful use of infusion pumps in young children. In general, glycemic control was improved or remained stable, the incidence of severe hypoglycemia was low, and families reported more flexibility in their lifestyle. Obesity, an increasing problem in pediatric patients, was also addressed.

  View details for PubMedID 12092689

• Microvascular abnormalities in pediatric diabetic patients MICROVASCULAR RESEARCH Cheung, A. T., Price, A. R., Duong, P. L., Ramanujam, S., Gut, J., Larkin, E. C., Chen, P. C., Wilson, D. M. 2002; 63 (3): 252-258

  Abstract

  Microvascular abnormalities are associated with and causative of the development of end-stage organ complications in adult diabetic patients. Whether the same microvascular abnormalities are present in pediatric patients is not known and has not been studied because of a lack of real-time technology, methodology to study young patients, and availability of an appropriate noninvasive site for in vivo studies. We hypothesized that microvascular abnormalities should be present in pediatric patients despite their young age and the relatively short durations of the disease. In this study, computer-assisted intravital microscopy (CAIM) was adapted to blindly quantify microvascular abnormalities in 12 pediatric type 1 diabetic mellitus (T1DM) patients (ages = 6-16 years; mean +/- SD = 11.42 +/- 3.42; duration since diagnosis = 2-14 years; mean +/- SD = 6.75 +/- 3.79) in vivo, using the microcirculation of the bulbar conjunctiva as a noninvasive site. Microvascular abnormalities, commonly found in adult patients, existed in the conjunctival microcirculation of all pediatric T1DM patients in varying degrees despite their relatively young age. A severity index (SI) was developed to reflect the cumulative severity of the microvascular abnormalities and was computed as the summation of all microvascular abnormalities found in each patient. SI for the 12 T1DM patients (mean +/- SD = 7.42 +/- 1.88; median = 8; mode = 9) differed significantly from that for the nondiabetic controls (mean +/- SD = 0.67 +/- 0.78; median = 0.5; mode = 0; P < 0.0001). In addition, SI correlated with hemoglobin A1c levels (mean +/- SD = 9.18 +/- 1.57) of T1DM patients but did not correlate with the duration of disease since diagnosis of the same patients. This observation raises the possibility that diabetic pathogenesis may precede the onset of overt disease or clinical diagnosis. This study confirms that CAIM may represent the availability of a useful real-time technology to study conjunctival microvascular abnormalities in vascular diseases in juvenile as well as adult patients.

  View details for DOI 10.1006/mvre.2001.2386

  View details for Web of Science ID 000175496100002

  View details for PubMedID 11969302

• A longitudinal analysis of maternal serum insulin-like growth factor I (IGF-I) and total and nonphosphorylated IGF-binding protein-1 in human pregnancies complicated by intrauterine growth restriction IGFBP 2000 Meeting Bhatia, S., Faessen, G. H., Carland, G., Balise, R. L., Gargosky, S. E., Druzin, M., El-Sayed, Y., Wilson, D. M., Giudice, L. C. ENDOCRINE SOC. 2002: 1864–70

  Abstract

  In cord blood and late gestation maternal serum, IGF-I is positively correlated with birth weight, whereas IGF-binding protein-1 (IGFBP-1) is inversely correlated with birth weight. Our goal was to determine whether maternal serum or amniotic fluid concentrations of IGF-I, IGFBP-1, or nonphosphorylated IGFBP-1 (npIGFBP-1) in early gestation predict later fetal growth abnormalities. Maternal serum was collected prospectively across gestation (5-40 wk) from 749 pregnant subjects. Amniotic fluid was collected after amniocentesis during wk 15-26 from 207 subjects. We compared median serum concentrations of IGF-I, IGFBP-1, and npIGFBP-1 in 38 subjects who delivered growth-restricted infants with the control group of 236 subjects with normal weight infants for each gestational age grouping, wk 5-12, 13-23, and 24-34. In the control group median IGF-I concentrations were 14.8, 11, and 15.6 nmol/liter for wk 5-12, 13-23, and 24-34, respectively, compared with 13.7, 14.3, and 10.6 nmol/liter in the intrauterine growth restriction (IUGR) group. Median IGFBP-1 concentrations were 8.5, 30.4, and 24.4 nmol/liter, respectively, in controls, compared with 11.4, 28.6, and 25.5 nmol/liter in the IUGR group. Median npIGFBP-1 concentrations were 6.9, 22, and 17.4 nmol/liter, respectively, in controls, compared with 5.0, 32.1, and 24.2 nmol/liter in the IUGR group. In the control group the median amniotic fluid IGFBP-1 level was 13,160 nmol/liter, and the median npIGFBP-1 level was 15,970 nmol/liter; in the IUGR group these levels were 13,440 and 18,440 nmol/liter, respectively. No clinically useful differences were found between the IUGR and control groups. Our results do not support the use of maternal serum IGF-I or IGFBP-1 or amniotic fluid IGFBP-1 or npIGFBP-1 early in gestation to predict later fetal growth restriction.

  View details for PubMedID 11932331

• Serum luteinizing hormone rises within minutes after depot leuprolide injection: Implications for monitoring therapy Annual Meeting of the Society for Pediatric Research Bhatia, S., Neely, E. K., Wilson, D. M. AMER ACAD PEDIATRICS. 2002

  Abstract

  To find the time of the serum gonadotropin peak after depot leuprolide injection in children and to show that depot leuprolide therapy can be monitored by measuring serum luteinizing hormone (LH) immediately after injections.We measured concentrations of leuprolide, LH, and follicle-stimulating hormone (FSH) at multiple time points before and after the first dose of depot leuprolide in 14 pubertal children beginning therapy. Gonadotropins and sex steroids were measured again after the fourth dose.Serum leuprolide, LH, and FSH levels rose rapidly after initial injection, reaching sustained elevations at 30 to 120 minutes. The median LH level increased from 2.1 mIU/mL at baseline to a peak of 27.5 mIU/mL at 45 minutes, and FSH increased from 5.2 to 16.5 mIU/mL. After 3 months on therapy, median serum LH after depot leuprolide injection was only 0.83 mIU/mL, similar to levels observed after intravenous or subcutaneous gonadotropin-releasing hormone stimulation in comparable subjects on depot leuprolide.Our pharmacokinetic data demonstrate that free leuprolide present in a depot leuprolide injection is equivalent to gonadotropin-releasing hormone in stimulating a rapid rise in serum gonadotropin concentrations. We propose that a single serum sample for LH obtained 30 to 60 minutes after depot leuprolide injection in children provides a convenient and accurate assessment of treatment efficacy.

  View details for PubMedID 11826240

• Intensive diabetes management in pediatric patients. Current diabetes reports Buckingham, B., Bluck, B., Wilson, D. M. 2001; 1 (1): 11-18

  Abstract

  Intensive diabetes management requires frequent home glucose monitoring, multiple daily insulin injections or chronic subcutaneous insulin infusion, and adjustments of insulin doses in response to changes in blood glucose levels, food intake, and exercise. It also requires a periodic review of previous glucose results to recognize patterns of hyper- or hypoglycemia. The goals of intensive management are age dependent. In young children, avoidance of severe hypoglycemia is the major goal. In older children and adolescents, lowering hemoglobin A(1c) becomes an increasingly important goal. In children of all ages, the ability to have a flexible lifestyle and meal plan is often a priority. This article provides a brief overview of the rationale for implementing intensive diabetes management in pediatric patients, and practical guidelines for implementation.

  View details for PubMedID 12762952

• Continuous subcutaneous insulin infusion (CSD) in children under five years of age Buckingham, B. A., Paguntalan, H., Fassl, B., Wilson, D. M. AMER DIABETES ASSOC. 2001: A107

  View details for Web of Science ID 000168964300432

• Data entry errors in using the minimed continuous glucose sensor (CGS) Buckingham, B. A., Paguntalan, H., Wilson, D. M. AMER DIABETES ASSOC. 2001: A431

  View details for Web of Science ID 000168964301786

• Prevention of type 1a diabetes mellitus*. Pediatric diabetes Wilson, D. M., Buckingham, B. 2001; 2 (1): 17-24

  Abstract

  Type 1 diabetes begins with the progressive autoimmune mediated destruction of the insulin-producing beta cells. When sufficient beta cell function is lost, the endocrine phase, characterized by insulin deficiency and hyperglycemia, supervenes. While a genetic predisposition to diabetes is an important precondition, most believe an environmental factor or factors serve as the trigger for initiating this process. In this paper we review trials designed to prevent or delay the clinical onset of diabetes. In these studies, high-risk individuals are identified by their genetic predisposition to diabetes, and/or by the presence of immune markers indicating activation of the autoimmune process directed against islet cells. The Deutsche Nicotinamide Intervention Study (DENIS) randomized 55 high-risk subjects to either nicotinamide or placebo and found no significant benefit. The European Nicotinamide Diabetes Intervention Trial (ENDIT) completed enrollment in May 1998. ENDIT screened over 40 000 relatives, randomizing 552 to either nicotinamide or placebo. Results are expected in May of 2003. Designed to test if avoidance of cow's milk in infancy will decrease the incidence of diabetes, the Trial to Reduce Type I Diabetes in the Genetically at Risk (TRIGR). High-risk infants are randomly assigned to different supplemental formulas in the first 6 months of life. Initial results suggest that removing cow's milk has a protective effect. The ongoing, NIH funded, multicenter Diabetes Prevention Trial-Type 1 (DPT-1) is testing two antigen-based (insulin) interventions in relatives at high risk for diabetes. Now in its sixth year, the DPT-1 study group has screened over 84,000 individuals. As of November 2000, 339 subjects have been randomized in the parenteral insulin study, completing the enrollment phase. Enrollment continues in the oral insulin study. Results of this trial are not yet available. Different epitopes of insulin and its analogs, monoclonal antibodies, and cytokine-based therapy, among others, have all been proposed as potential new interventional agents. While a great deal of effort will be required to test these approaches, the potential benefits of prevention justify these research efforts.

  View details for PubMedID 15016206

• First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes 59th Annual Meeting of the American-Diabetes-Association Chase, H. P., Cuthbertson, D. D., Dolan, L. M., KAUFMAN, F., Krischer, J. P., Schatz, D. A., White, N. H., Wilson, D. M., Wolfsdorf, J. MOSBY-ELSEVIER. 2001: 244–49

  Abstract

  To determine the relationship between first-phase (1 minute + 3 minutes) insulin production during the intravenous glucose tolerance test (IV-GTT) and risk factors for developing type 1 diabetes.Relatives of persons with type 1 diabetes (n = 59,600) were screened for islet cell antibodies (ICAs). Subjects who had positive screening results underwent IV-GTT (> or =2 times), repeat ICA screening, insulin autoantibody (IAA) screening twice, and an oral glucose tolerance test.Of the 59,600 subjects in the study, 2199 (3.69%) had positive findings on initial ICA test. IV-GTTs were performed in 1622 subjects, with children <8 years having the lowest first-phase insulin release (FPIR) and subjects 8 to 20 years of age having the highest FPIR. The FPIR was lower for subjects with a confirmed positive ICA test result or a positive IAA test result, subjects with higher titers of ICA or IAA, and subjects who had an abnormal (impaired or diabetic) oral glucose tolerance test result.FPIR in the IV-GTT correlates strongly with risk factors for development of type 1 diabetes.

  View details for DOI 10.1067/mpd.2001.111274

  View details for Web of Science ID 000166905800018

  View details for PubMedID 11174623

• Growth hormone and hypophosphatemic rickets 13th Annual Meeting of the National Cooperative Growth Study (NCGS) Wilson, D. M. FREUND PUBLISHING HOUSE LTD. 2000: 993–998

  Abstract

  This review summarizes seven trials of growth hormone (GH) treatment for X-linked hypophosphatemic rickets (XLHR). These trials range in size from 5 to 30 patients; but despite the limited number of patients enrolled, they represent the largest studies to date of growth hormone in this disorder. Conventional treatment in XLHR, oral phosphate and calcitriol, is often unable to normalize serum phosphate concentration fully and many patients fail to reach normal adult height. The studies reviewed report increased growth velocity when exogenous GH is added to conventional therapy, although the independent effect of GH is difficult to evaluate. Younger patients appear to respond better to GH than do older patients. Disproportionate growth of the trunk may be a problem. Some patients with XLHR have received GH for more than 6 years, yet little is known about the impact of GH on adult height. Reported increases in phosphate concentrations following GH in XLHR are of uncertain clinical benefit. While GH appears to be safe in XLHR, long-term benefits remain unclear.

  View details for PubMedID 11086653

• Glucose meters: now what? Diabetes technology & therapeutics Wilson, D. M. 2000; 2 (2): 231-232

  View details for PubMedID 11469263

• Semi-automated entry of clinical temporal-abstraction knowledge JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION Shahar, Y., Chen, H., Stites, D. P., Basso, L. V., Kaizer, H., Wilson, D. M., Musen, M. A. 1999; 6 (6): 494-511

  Abstract

  The authors discuss the usability of an automated tool that supports entry, by clinical experts, of the knowledge necessary for forming high-level concepts and patterns from raw time-oriented clinical data.Based on their previous work on the RESUME system for forming high-level concepts from raw time-oriented clinical data, the authors designed a graphical knowledge acquisition (KA) tool that acquires the knowledge required by RESUME. This tool was designed using Protégé, a general framework and set of tools for the construction of knowledge-based systems. The usability of the KA tool was evaluated by three expert physicians and three knowledge engineers in three domains-the monitoring of children's growth, the care of patients with diabetes, and protocol-based care in oncology and in experimental therapy for AIDS. The study evaluated the usability of the KA tool for the entry of previously elicited knowledge.The authors recorded the time required to understand the methodology and the KA tool and to enter the knowledge; they examined the subjects' qualitative comments; and they compared the output abstractions with benchmark abstractions computed from the same data and a version of the same knowledge entered manually by RESUME experts.Understanding RESUME required 6 to 20 hours (median, 15 to 20 hours); learning to use the KA tool required 2 to 6 hours (median, 3 to 4 hours). Entry times for physicians varied by domain-2 to 20 hours for growth monitoring (median, 3 hours), 6 and 12 hours for diabetes care, and 5 to 60 hours for protocol-based care (median, 10 hours). An increase in speed of up to 25 times (median, 3 times) was demonstrated for all participants when the KA process was repeated. On their first attempt at using the tool to enter the knowledge, the knowledge engineers recorded entry times similar to those of the expert physicians' second attempt at entering the same knowledge. In all cases RESUME, using knowledge entered by means of the KA tool, generated abstractions that were almost identical to those generated using the same knowledge entered manually.The authors demonstrate that the KA tool is usable and effective for expert physicians and knowledge engineers to enter clinical temporal-abstraction knowledge and that the resulting knowledge bases are as valid as those produced by manual entry.

  View details for PubMedID 10579607

• Regular monitoring of bone age is not useful in children treated with growth hormone 12th Annual National Cooperative Growth Study Investigators Meeting Wilson, D. M. AMER ACAD PEDIATRICS. 1999: 1036–39

  Abstract

  Although bone age estimates are traditionally used to monitor children receiving growth hormone therapy, few data support this practice. Bone age determination is fraught with technical difficulties, resulting in high interobserver differences. Longitudinal studies show that an individual's bone age can change erratically over time. The resulting errors in predicted adult heights based on these bone age determinations are large. Moreover, growth hormone therapy appears to accelerate bone maturation. The radiographic evidence of this acceleration can be delayed. In this setting, improvements in predicted adult heights can be artifactually large. Routine monitoring of bone age during GH therapy is unnecessary. Bayley and Pinneau, bone age determination, Greulich and Pyle, predicted height, radiography, Tanner and Whitehouse.

  View details for PubMedID 10506260

• Diabetes simulators: ready for prime time? Diabetes technology & therapeutics Wilson, D. M. 1999; 1 (1): 55-56

  View details for PubMedID 11475305

• A comparison of calcaneus ultrasound and dual X-ray absorptiometry in healthy north American youths and young adults JOURNAL OF CLINICAL DENSITOMETRY Lum, C. K., Wang, M. C., Moore, E., Wilson, D. M., Marcus, R., Bachrach, L. K. 1999; 2 (4): 403-411

  Abstract

  Quantitative ultrasound is the newest noninvasive method to be accepted for assessing bone mineral in adults. Heel ultrasound measurements correlate with bone density measurements by dual X-ray absorptiometry (DXA) and predict fracture risk in adults. Far less is known about the value of calcaneus ultrasound (CUS) in children. We determine spine, femoral neck, and whole-body bone mineral by DXA and heel bone mass by CUS in 125 youths (69 females, 56 males) ages 9-25 yr. CUS and DXA measurements of bone mass increased with age and pubertal development during adolescence in a parallel fashion. Among females, Tanner stage was a stronger predictor than age for all CUS and DXA measurements, and among males, pubertal stage was a stronger predictor for spine bone mineral apparent density (BMAD) and femoral bone mineral density (BMD). CUS measurements correlated moderately well with DXA measurements of the spine, femoral neck, and whole-body BMD and spine BMAD (r = 0.23-0.58, p < 0. 008). CUS warrants further study as a tool for assessing bone mineral acquisition in children.

  View details for PubMedID 10677794

• beta-islet cell specific CD4(+) T cell responses in patients with type 1 diabetes mellitus and healthy controls Olson, J. A., Parry, S. L., Herman, A., Erlich, H., Noble, J., Wilson, D., Sonderstrup, G. AMER DIABETES ASSOC. 1999: A433

  View details for Web of Science ID 000080215401884

• Prospective study of risk factors for the initiation of cigarette smoking JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY Killen, J. D., Robinson, T. N., Haydel, K. F., Hayward, C., Wilson, D. M., Hammer, L. D., Litt, I. F., Taylor, C. B. 1997; 65 (6): 1011-1016

  Abstract

  Risk factors for the initiation of cigarette smoking were examined in 2 consecutive cohorts of teenagers (N = 1,901). Students in Cohort 1 were followed over 4 years from 9th to 12th grade; those in Cohort 2 were followed over 3 years from 9th to 11th grade. Among girls with no history of smoking at baseline, those with more friends who smoked at baseline (p < .001) and those with higher sociability scores (p < .05) were significantly more likely to have tried smoking over the study interval. Among boys with no history of smoking at baseline, those with more friends who smoked at baseline (p < .05) and those with higher depression symptoms scores (p < .01) were significantly more likely to have tried smoking over the study interval. The data suggest that future research is needed to examine potential gender differences that may have implications for the next generation of smoking-prevention programs.

  View details for PubMedID 9420362

• Psychiatric risk associated with early puberty in adolescent girls JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY Hayward, C., Killen, J. D., Wilson, D. M., Hammer, L. D., Litt, I. F., Kraemer, H. C., Haydel, F., Varady, A., Taylor, C. B. 1997; 36 (2): 255-262

  Abstract

  This study prospectively evaluated the relationship between early puberty and the onset of internalizing symptoms and disorders in adolescent girls.The sample was drawn from 1,463 sixth-, seventh-, and eighth-grade girls who participated in a longitudinal school-based study of growth and development. Pubertal stage was determined by self-assessment of Tanner stage. Psychiatric assessments included self-report instruments and structured diagnostic interviews. Survival methods were utilized for data analysis.Girls with onset of internalizing symptoms were on average 5 months earlier in pubertal development than those who were asymptomatic (p < .001). In addition, girls with earlier maturation (earliest quartile) were more likely to develop internalizing symptoms than were nonearly matures (hazard ratio = 1.8, confidence interval = 1.2, 2.7). In a subsample of girls followed into high school, early-maturing girls were at marginally higher risk (p < .10) for developing internalizing disorders by the study's end. The highest risk for internalizing disorders was for those girls with both early puberty and prior internalizing symptoms (odds ratio = 3.3).Early puberty increases the risk of internalizing symptoms and perhaps internalizing disorders in adolescent girls.

  View details for PubMedID 9031579

• Educational video game for juvenile diabetes: Results of a controlled trial MEDICAL INFORMATICS Brown, S. J., Lieberman, D. A., Gemeny, B. A., Fan, Y. C., Wilson, D. M., Pasta, D. J. 1997; 22 (1): 77-89

  Abstract

  Packy & Marlon, an interactive video game designed to improve self-care among children and adolescents with diabetes, was evaluated in a six-month randomized controlled trial. In the game, players take the role of animated characters who manage their diabetes by monitoring blood glucose, taking insulin injections, and choosing foods, while setting out to save a diabetes summer camp from marauding rats and mice who have stolen the diabetes supplies. Study participants were patients aged 8 to 16 from two separate diabetes clinics. Each participant received a Super Nintendo video game system at an initial clinic visit and was randomly assigned to receive either Packy & Marlon (treatment group, N = 31) or an entertainment video game containing no diabetes-related content (control group, N = 28). Participants were interviewed and a parent filled out a questionnaire at baseline, three months, and six months. The findings in this study indicate that well-designed, educational video games can be effective interventions. There was improvement in the treatment group relative to the control group in terms of diabetes-related self-efficacy (p = 0.07), communication with parents about diabetes (p = 0.025), and self-care behaviours (p = 0.003), and a decrease in unscheduled urgent doctor visits (p = 0.08). There were no significant differences between the groups in knowledge about diabetes or in glycated haemoglobin (HbA1c) levels. Since participants in the study were in general well-controlled patients who were receiving excellent medical care, future research is contemplated involving youngsters who are not under good glycaemic control.

  View details for Web of Science ID A1997XH36800006

  View details for PubMedID 9183781

• Ethnicity and body dissatisfaction: Are Hispanic and Asian girls at increased risk for eating disorders? JOURNAL OF ADOLESCENT HEALTH Robinson, T. N., Killen, J. D., Litt, I. F., Hammer, L. D., Wilson, D. M., Haydel, K. F., Hayward, C., Taylor, C. B. 1996; 19 (6): 384-393

  Abstract

  To compare prevalences and correlates of body dissatisfaction among white, Hispanic, and Asian girls.A total of 939 6th and 7th grade girls (mean age 12.4 years) attending four middle schools in northern California completed self-administered assessments of age, ethnicity, desired body shape, parent education levels, mother's and father's body shapes, pubertal stage, and body dissatisfaction. Body dissatisfaction was assessed with the Body Dissatisfaction scale of the Eating Disorder Inventory. Height, weight, triceps skinfold thickness, and waist and hip circumferences were measured by trained examiners.Hispanic girls reported significantly greater body dissatisfaction than white girls, with Asian girls in-between. After adjustment for body mass index (weight/height), normal and overweight white, Hispanic, and Asian girls reported similar levels of body dissatisfaction. However, among the leanest 25% of girls, Hispanics and Asians reported significantly more body dissatisfaction than white girls. Body mass index was the strongest independent predictor of increased body dissatisfaction in all three ethnic groups. Shorter height among white girls and taller height among Asian girls also made significant independent contributions. Parent education level, a measure of socioeconomic status, was not significantly associated with body dissatisfaction.Body dissatisfaction is not limited to white girls in middle and upper socioeconomic strata. These findings suggest Hispanic and Asian girls may be at greater risk for adopting eating disorder behaviors than previously recognized.

  View details for PubMedID 8969369

• Weight concerns influence the development of eating disorders: A 4-year prospective study JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY Killen, J. D., Taylor, C. B., Hayward, C., Haydel, K. F., Wilson, D. M., Hammer, L., Kraemer, H., BLAIRGREINER, A., Strachowski, D. 1996; 64 (5): 936-940

  Abstract

  The authors examined factors prospectively associated with age of onset of partial syndrome eating disorders over a 4-year interval in a community sample (N = 877) of high school-age adolescent girls. Four percent developed a partial syndrome eating disorder over the interval. A measure of weight concerns was significantly associated with onset in a multivariate Cox proportional hazard analysis (p < .001). Girls scoring in the highest quartile on the measure of weight concerns had the highest incidence (10%) of partial syndrome onset, whereas none of the girls in the lowest quartile developed eating disorder symptoms. This finding is consistent with both theoretical and clinical perspectives and may represent a useful step toward the establishment of a rational basis for the choice of a prevention intervention target.

  View details for PubMedID 8916622

• Predicting onset of drinking in a community sample of adolescents: The role of expectancy and temperament ADDICTIVE BEHAVIORS Killen, J. D., Hayward, C., Wilson, D. M., Haydel, K. F., Robinson, T. N., Taylor, C. B., Hammer, L. D., Varady, A. 1996; 21 (4): 473-480

  Abstract

  We report results of a prospective examination of the influence of outcome expectancy variables and inherited temperaments on the onset of drinking over a 12-month period in a sample of 1,164 high school students. While univariate prospective analysis indicated that drinkers and nondrinkers were different both on measures of outcome expectancy and temperament, multivariate analysis supported, most strongly, a social learning account of the processes influencing the onset and maintenance of drinking behavior in this sample. The multivariate analysis revealed that only expectancies for enhanced social behavior were consistently associated with the onset of drinking from baseline to 12-month follow-up (p < .001). Among all nondrinkers at baseline, those entertaining higher expectancies about the positive effects of alcohol on social interaction were more likely to begin drinking between baseline and follow-up. At present, few, if any, alcohol abuse prevention studies with adolescents have explicitly attempted to alter alcohol expectancies or to establish a link between expectancy and behavior change. Our results suggest that it may be useful to do so.

  View details for PubMedID 8830905

• A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty PEDIATRICS Eckert, K. L., Wilson, D. M., Bachrach, L. K., Anhalt, H., Habiby, R. L., Olney, R. C., Hintz, R. L., Neely, E. K. 1996; 97 (4): 517-519

  Abstract

  We compared a rapid, subcutaneous (SQ), single-sample gonadotropin-releasing hormone (GnRH) stimulation test with the standard multiple-sample, intravenous (IV) GnRH stimulation test used in the evaluation of central precocious puberty (CPP).We evaluated 22 patients presenting with evidence of precocious puberty. GnRH (100 microg) was administered subcutaneously in the clinic setting with single serum luteinizing hormone (LH) measured 40 minutes after injection. A standard IV GnRH stimulation test was performed within 2 weeks, with serum LH obtained at 0, 20, 40, and 60 minutes. LH was assayed by immunochemiluminometric assay.The mean peak LH levels after IV and SQ testing were identical. A significant correlation (r = .88) was found between the LH determined by SQ stimulations and the peak LH determined by IV GnRH testing. CPP was diagnosed (LH, >/- 8 IU/L) by both SQ and IV testing in 7 of 22 patients and was excluded by both tests in 14 of 22 patients. A diagnostic discrepancy between peak IV and SQ results was seen in 1 patient.We conclude that mean GnRH-stimulated LH levels from rapid SQ and standard IV testing are indistinguishable and that individual LH levels by each method are strongly correlated. A rapid SQ GnRH test is a valid tool for laboratory confirmation of CPP.

  View details for PubMedID 8632938

• Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4 JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Olney, R. C., Tsuchiya, K., Wilson, D. M., Mohtai, M., Maloney, W. J., Schurman, D. J., Smith, R. L. 1996; 81 (3): 1096-1103

  Abstract

  Osteoarthritis is a disease in which articular cartilage metabolism is altered, leading to cartilage destruction. As insulin-like growth factor-I (IGF-I) is the major anabolic mediator for articular cartilage, and the IGF-binding proteins (IGFBPs) are an integral part of the IGF axis, they may play a role in the pathophysiology of osteoarthritis. Chondrocytes isolated from fibrillated and normal appearing areas of osteoarthritic human cartilage and from normal cartilage were studied for IGF and IGFBP expression. IGF and IGFBP messenger ribonucleic acids were analyzed by a RT-quantitative PCR technique and Northern blotting. In osteoarthritic chondrocytes, IGF-I message was increased 3.5-fold, IGFBP-3 was increased 24-fold, and IGFBP-5 was increased 16-fold over normal chondrocytes. Chondrocytes from normal appearing areas of cartilage from osteoarthritic joints had intermediate levels. Message levels for beta-actin, IGF-II, and IGFBP-4 were unchanged between the cartilage types. IGF and IGFBP production were analyzed by Western ligand blots and RIAs of conditioned medium from cartilage cultured in serum-free conditions. IGF-I was undetectable in conditioned medium from normal cartilage and increased in that from osteoarthritic cartilage. Osteoarthritic cartilage samples produced IGFBP-2, -3, and -4; glycosylated IGFBP-4; and IGFBP-5. IGFBP-2, -3, and -5 production was increased in osteoarthritic cartilage. Proteases with activity against IGFBP-3 and -5 were also produced by osteoarthritic cartilage. The observation that IGFBP-3 and -5 expression and production are elevated in osteoarthritic cartilage suggests that they may be acting as a competitor for IGF-I in osteoarthritic cartilage, thus reducing the anabolic stimulation of this tissue and contributing to the net loss of cartilage in this disease.

  View details for PubMedID 8772582

• Is testing for growth hormone release necessary? 5th Annual North American Pediatric Renal Transplantation Cooperative Study Wilson, D. M. BLACKWELL SCIENCE INC. 1996: S123–S125

  Abstract

  The question of if testing for growth hormone release is necessary in patients with chronic renal failure (CRF) is part of a greater debate. The question of what constitutes growth hormone deficiency (GHD) has become more controversial over the past few years. In some ways, the question has been replaced by the question, "Who will have a meaningful response to growth hormone (GH) therapy?" Since children with CRF generally respond to GH therapy, the question should be recast as, "When is testing for growth hormone release necessary in patients with CRF?" Why is the diagnosis of GHD important? A clear diagnosis of class GHD has many important implications for a patient. GHD is an easily treated cause of neonatal hypoglycemia. The diagnosis alerts the clinician to search for etiologies of GHD such as intracranial tumors and should stimulate a search for other pituitary deficiencies. Another important claim is that patients with classic GHD have a better long-term response to GH therapy. Children in other diagnostic categories, such as renal failure and Turner syndrome, also respond to GH therapy. Do diagnostic studies use to determine the function of the growth hormone-insulin-like growth factor (GH-IGF) axis help in the management of these children? Recently, experts have become increasingly interested in what constitutes a useful diagnostic test. To be a "good" diagnostic test, a procedure should have the following properties: (1.) have a rational connection to the disorder; (2.) good concordance with the diagnosis/outcome; (3.) accurate; and (4.) reproducible. Among tests that share these properties, the best test is generally the easiest and/or the least expensive. Many different tests can be used to evaluate the GH-IGF axis. These include GH stimulation tests, 24-hour GH profiles, IGF-I, and insulin-like growth factor binding protein 3 (IGFBP-3). High quality determinations of IGF-I and IGFBP-3 can be used to evaluate the GH-IGF axis.

  View details for Web of Science ID A1996TQ50600023

• Is testing for growth hormone release necessary? Kidney international. Supplement Wilson, D. M. 1996; 53: s123-5

  Abstract

  The question of if testing for growth hormone release is necessary in patients with chronic renal failure (CRF) is part of a greater debate. The question of what constitutes growth hormone deficiency (GHD) has become more controversial over the past few years. In some ways, the question has been replaced by the question, "Who will have a meaningful response to growth hormone (GH) therapy?" Since children with CRF generally respond to GH therapy, the question should be recast as, "When is testing for growth hormone release necessary in patients with CRF?" Why is the diagnosis of GHD important? A clear diagnosis of class GHD has many important implications for a patient. GHD is an easily treated cause of neonatal hypoglycemia. The diagnosis alerts the clinician to search for etiologies of GHD such as intracranial tumors and should stimulate a search for other pituitary deficiencies. Another important claim is that patients with classic GHD have a better long-term response to GH therapy. Children in other diagnostic categories, such as renal failure and Turner syndrome, also respond to GH therapy. Do diagnostic studies use to determine the function of the growth hormone-insulin-like growth factor (GH-IGF) axis help in the management of these children? Recently, experts have become increasingly interested in what constitutes a useful diagnostic test. To be a "good" diagnostic test, a procedure should have the following properties: (1.) have a rational connection to the disorder; (2.) good concordance with the diagnosis/outcome; (3.) accurate; and (4.) reproducible. Among tests that share these properties, the best test is generally the easiest and/or the least expensive. Many different tests can be used to evaluate the GH-IGF axis. These include GH stimulation tests, 24-hour GH profiles, IGF-I, and insulin-like growth factor binding protein 3 (IGFBP-3). High quality determinations of IGF-I and IGFBP-3 can be used to evaluate the GH-IGF axis.

  View details for PubMedID 8771005

• OXANDROLONE THERAPY IN CONSTITUTIONALLY DELAYED GROWTH AND PUBERTY PEDIATRICS Wilson, D. M., McCauley, E., Brown, D. R., Dudley, R., Ainslie, M., Carey, D., Danney, M. M., Deeb, L. C., DONLAN, M. A., Edidin, D. V., Gonzalez, J., Hansen, I. L., Howard, C. P., Linarelli, L. G., Rubin, K., RUVALCABA, R., Schatz, D., SHULZ, J. S. 1995; 96 (6): 1095-1100

  Abstract

  Male adolescents with constitutional delay of growth and puberty may have significant psychosocial difficulties related to their sexual immaturity and short stature. The purpose of this study was to test the hypothesis that 1 year of oxandrolone therapy would increase growth velocity and thereby improve psychosocial functioning in boys with constitutional delay of growth and pubertal development.Forty boys (ages 11 to 14.7 years) with delayed pubertal development and short stature were recruited from the pediatric endocrine clinics of 14 medical centers. The boys were randomized using a block design stratified for age to receive either oxandrolone (0.1 mg/kg daily for 1 year) or an identical-appearing placebo tablet, using a double-masked design.Growth velocity in the oxandrolone-treated boys was significantly greater than in the control boys (9.5 vs 6.8 cm/y). Likewise, the mean height SD score increased 0.41 in the oxandrolone group, whereas it decreased 0.03 in the control group. Those in the oxandrolone group gained 2.4 kg more than those in the placebo group. Mean predicted adult heights did not change in either group. The mean rates of pubertal progression were equivalent in both groups. Self-image (Piers-Harris Self Concept Scale) and social competence (Child Behavior Profile) were normal at baseline in both groups and did not change significantly over the course of the study in either group. No complications of oxandrolone therapy were identified.This randomized, placebo-controlled trial demonstrates that low-dose oxandrolone can increase both height and weight velocity in boys with delayed puberty safely. Under the conditions of this study, however, the increased growth velocity in the oxandrolone-treated boys was not associated with a greater improvement in psychosocial status compared with the control boys.

  View details for Web of Science ID A1995TJ13300011

• PREDICTION OF DEPRESSION IN PARENTS OF TURNER-SYNDROME ADOLESCENTS AS A FUNCTION OF GROWTH-HORMONES, FAMILY CONFLICT, AND COPING STYLE JOURNAL OF DEVELOPMENTAL AND PHYSICAL DISABILITIES Faust, J., Rosenfeld, R. G., Wilson, D., Durham, L., VARDOPOULOS, C. C. 1995; 7 (3): 221-233

  View details for Web of Science ID A1995RN71100004

• INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA INCREASE INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 (IGFBP-3) PRODUCTION AND IGFBP-3 PROTEASE ACTIVITY IN HUMAN ARTICULAR CHONDROCYTES JOURNAL OF ENDOCRINOLOGY Olney, R. C., Wilson, D. M., Mohtai, M., Fielder, P. J., Smith, R. L. 1995; 146 (2): 279-286

  Abstract

  IGF-I is the major anabolic factor for cartilage matrix production. Chondrocytes and cartilage treated with interleukin-1 alpha (IL-1 alpha), and chondrocytes from several models of inflammatory joint disease, exhibit reduced responsiveness to IGF-I. Since the IGF-binding proteins (IGFBPs) modulate the effects of IGF-I, we examined the effect of IL-1 alpha and tumor necrosis factor-alpha (TNF-alpha) on IGFBP production by normal human articular chondrocytes in primary culture. Western ligand blots and immunoprecipitation of conditioned medium samples showed that articular chondrocytes produced IGFBPs-2, -3 and -4 and glycosylated IGFBP-4. Both IL-1 alpha and TNF-alpha increased chondrocyte production of IGFBP-3, but did not alter IGFBP-4 production. The activity of a neutral metalloprotease with the ability to cleave IGFBP-3 was also increased by IL-1 alpha. These data suggest that the cytokines IL-1 alpha and TNF-alpha may act to reduce IGF-I access to chondrocytes by increasing production of IGFBP-3. This may be a factor in the decreased matrix production in the inflammatory arthritides.

  View details for PubMedID 7561640

• SCHOOL REFUSAL IN YOUNG ADOLESCENT GIRLS WITH NONCLINICAL PANIC ATTACKS JOURNAL OF ANXIETY DISORDERS Hayward, C., Taylor, C. B., BLAIRGREINER, A., Strachowski, D., Killen, J. D., Wilson, D. M., Hammer, L. D. 1995; 9 (4): 329-338

  View details for Web of Science ID A1995RH79500007

• SPONTANEOUS SERUM GONADOTROPIN CONCENTRATIONS IN THE EVALUATION OF PRECOCIOUS PUBERTY JOURNAL OF PEDIATRICS Neely, E. K., Wilson, D. M., Lee, P. A., Stene, M., Hintz, R. L. 1995; 127 (1): 47-52

  Abstract

  We assessed the utility of spontaneous and gonadotropin-releasing hormone (GnRH)-stimulated serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels measured by new immunochemiluminometric assays in the evaluation and monitoring of precocious puberty.We evaluated serum gonadotropin values from intravenous GnRH stimulation tests in 49 girls with clinical signs suggesting central precocious puberty (CPP). Because GnRH-stimulated LH has been considered the standard for diagnosing CPP, we used it as the basis for comparison with GnRH-stimulated FSH levels and spontaneous LH and FSH measured by immunochemiluminometric assay.Twenty-six patients had a peak serum LH value above the +2 SD threshold for normal prepubertal female subjects (LH > 5 IU/L). The GnRH-stimulated FSH values had a narrow range and did not discriminate patients with CPP. In contrast, elevations in spontaneous LH and FSH were found to be specific for CPP. Spontaneous LH levels correlated strongly with peak stimulated LH levels in subjects with precocious puberty (r = 0.79) or in control subjects (r = 0.93, both p (0.0001). Spontaneous LH levels in excess of 0.1 IU/L detected true puberty with 94% sensitivity and 88% specificity. Random LH levels in excess of 0.3 IU/L had 100% specificity for CPP.The GnRH-stimulated FSH levels do not adequately differentiate children with and without CPP and have limited utility in the evaluation of precocious puberty. Spontaneous FSH levels are elevated in CPP with fair sensitivity and marked specificity. Elevated random LH, measured by third-generation assay such as immunochemiluminometric assay, is strongly correlated with and highly predictive of elevated peak GnRH-stimulated LH, and is a useful screening tool for CPP.

  View details for PubMedID 7608810

• NORMAL RANGES FOR IMMUNOCHEMILUMINOMETRIC GONADOTROPIN ASSAYS JOURNAL OF PEDIATRICS Neely, E. K., Hintz, R. L., Wilson, D. M., Lee, P. A., Gautier, T., Argente, J., Stene, M. 1995; 127 (1): 40-46

  Abstract

  We sought to establish normative data for spontaneous and gonadotropin-releasing hormone (GnRH)-stimulated serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels measured by new immunochemiluminometric assays (ICMA) in children and adolescents.Random serum samples were obtained from 375 normal subjects (0.1 to 17.7 years, 230 female subjects). Intravenous GnRH stimulation tests were performed in 41 normal subjects (4.8 to 18 years, 20 female subjects). Normal ranges were calculated by age and Tanner stage. Immunochemiluminometric assays of LH and FSH concentrations were compared with levels obtained by a sensitive immunofluorometric assay and a less sensitive radioimmunoassay.Random gonadotropin concentrations in normal children followed the pattern of transient elevation in infancy, low but measurable prepubertal levels, and markedly increased values at puberty. Spontaneous LH levels were higher in male infants but were not statistically different in boys and girls after infancy. Mean prepubertal LH was 0.04 +/- 0.04 IU/L (n = 66), rising 100-fold during puberty. Spontaneous FSH levels were much higher than LH values, were higher in female infants, and rose threefold at puberty. Peak GnRH-stimulated LH was identical in prepubertal boys and girls (1.8 +/- 1.3 IU/L, n = 17) and increased 20-fold at puberty. Mean peak GnRH-stimulated FSH was highest in prepubertal female subjects. Luteinizing hormone values measured by ICMA and immunofluorometric assay were highly correlated, but radioimmunoassay levels diverged markedly from ICMA levels at lower concentrations. Because absolute levels were higher, FSH values correlated adequately in the three assays throughout the normal physiologic range.Measurement of LH by ICMA is much more sensitive than older assay methods. Spontaneous LH can be accurately measured by ICMA to the very low levels present in normal prepubertal children, providing a potentially important biochemical discriminator of pubertal status. An ICMA GnRH-stimulated LH level greater than 5 IU/L is suggestive of maturing gonadotropin secretion. The ICMA LH assays provide significant enhancement in sensitivity; these assays should be used when levels may be low, and by their accuracy may reduce the time and expense of testing procedures.

  View details for PubMedID 7608809

• A QUANTITATIVE ASSAY FOR IGF-I AND IGF BINDING-PROTEIN MESSENGER-RNAS - EXPRESSION IN MALIGNANT-MELANOMA CELLS MOLECULAR AND CELLULAR ENDOCRINOLOGY Olney, R. C., Anhalt, H., Neely, E. K., Wilson, D. M. 1995; 110 (1-2): 213-223

  Abstract

  The quantification of messenger RNA is central in studies of gene expression. We describe a quantitative assay for specific mRNAs (QASM) that measures mRNAs for insulin-like growth factor-I, IGF binding proteins (IGFBPs) -2, -3, -4, and -5, and beta-actin. The assay utilizes reverse transcription and polymerase chain reaction, followed by an ELISA based DNA assay technique. The use of internal (competitive) quantification standards gave poorly linear results, while external standards gave linear and reproducible results. QASM results correlated with IGFBP protein concentrations in conditioned medium and with mRNA levels determined by Northern blotting. QASM was used to study IGFBP expression in human malignant melanoma cells. Messenger RNA for IGFBP-2, -3, and -5 were present, while IGF-I and IGFBP-4 mRNAs were not detected. IGFBP-2 and -3 expression was increased in a dose dependent manner by treatment with IGF-I. Protein concentrations in conditioned media paralleled mRNA levels. QASM is a sensitive, specific, and reproducible approach to determining mRNA levels.

  View details for PubMedID 7545621

• Endocrinology of growth and growth factors. Connective tissue research Wilson, D. M. 1995; 31 (4): S3-7

  Abstract

  This review discusses normal growth patterns and the appropriate use of preprinted growth curves. The important roles of thyroid and growth hormone in the modulation of growth are delineated. I present an approach to the evaluation and proper management of children and adolescents with short stature and poor growth.

  View details for PubMedID 15612373

• Oxandrolone therapy in constitutionally delayed growth and puberty. Bio-Technology General Corporation Cooperative Study Group. Pediatrics Wilson, D. M., McCauley, E., Brown, D. R., Dudley, R. 1995; 96 (6): 1095–1100

  Abstract

  Male adolescents with constitutional delay of growth and puberty may have significant psychosocial difficulties related to their sexual immaturity and short stature. The purpose of this study was to test the hypothesis that 1 year of oxandrolone therapy would increase growth velocity and thereby improve psychosocial functioning in boys with constitutional delay of growth and pubertal development.Forty boys (ages 11 to 14.7 years) with delayed pubertal development and short stature were recruited from the pediatric endocrine clinics of 14 medical centers. The boys were randomized using a block design stratified for age to receive either oxandrolone (0.1 mg/kg daily for 1 year) or an identical-appearing placebo tablet, using a double-masked design.Growth velocity in the oxandrolone-treated boys was significantly greater than in the control boys (9.5 vs 6.8 cm/y). Likewise, the mean height SD score increased 0.41 in the oxandrolone group, whereas it decreased 0.03 in the control group. Those in the oxandrolone group gained 2.4 kg more than those in the placebo group. Mean predicted adult heights did not change in either group. The mean rates of pubertal progression were equivalent in both groups. Self-image (Piers-Harris Self Concept Scale) and social competence (Child Behavior Profile) were normal at baseline in both groups and did not change significantly over the course of the study in either group. No complications of oxandrolone therapy were identified.This randomized, placebo-controlled trial demonstrates that low-dose oxandrolone can increase both height and weight velocity in boys with delayed puberty safely. Under the conditions of this study, however, the increased growth velocity in the oxandrolone-treated boys was not associated with a greater improvement in psychosocial status compared with the control boys.

  View details for PubMedID 7491227

• Pursuit of thinness and onset of eating disorder symptoms in a community sample of adolescent girls: a three-year prospective analysis. International journal of eating disorders Killen, J. D., Taylor, C. B., Hayward, C., Wilson, D. M., Haydel, K. F., Hammer, L. D., SIMMONDS, B., Robinson, T. N., Litt, I., Varady, A. 1994; 16 (3): 227-238

  Abstract

  Community-based prospective studies are needed to shed light on mechanisms that may influence development of eating disorders and identify variables that could serve as potential targets for prevention efforts. In this paper we examine level of weight preoccupation and other variables prospectively associated with age of onset of eating disorder symptoms over a 3-year interval in a community sample (N = 939) of young adolescent girls. 3.6% (32/887) experienced onset of symptoms over the interval. Only one factor, a measure of Weight Concerns, was significantly associated with onset (p < .001). Girls scoring in the highest quartile on the measure of Weight Concerns had the shortest survival time (12% incidence by age 14.5) and those scoring in the lowest quartile had the highest survival time (2% incidence by age 14.5; p < .001). This finding is consistent with both theoretical and clinical perspectives and represents one of the first prospective demonstrations of a linkage between weight and body shape concerns and later onset of eating disorder symptoms. An understanding of the independent variables that predispose girls to development of symptoms is a useful step towards the establishment of a rational basis for the choice of a prevention intervention target.

  View details for PubMedID 7833956

• PURSUIT OF THINNESS AND ONSET OF EATING DISORDER SYMPTOMS IN A COMMUNITY SAMPLE OF ADOLESCENT GIRLS - A 3-YEAR PROSPECTIVE ANALYSIS INTERNATIONAL JOURNAL OF EATING DISORDERS Killen, J. D., Taylor, C. B., Hayward, C., Wilson, D. M., Haydel, K. F., Hammer, L. D., SIMMONDS, B., Robinson, T. N., Litt, I., Varady, A., Kraemer, H. 1994; 16 (3): 227-238

  Abstract

  Community-based prospective studies are needed to shed light on mechanisms that may influence development of eating disorders and identify variables that could serve as potential targets for prevention efforts. In this paper we examine level of weight preoccupation and other variables prospectively associated with age of onset of eating disorder symptoms over a 3-year interval in a community sample (N = 939) of young adolescent girls. 3.6% (32/887) experienced onset of symptoms over the interval. Only one factor, a measure of Weight Concerns, was significantly associated with onset (p < .001). Girls scoring in the highest quartile on the measure of Weight Concerns had the shortest survival time (12% incidence by age 14.5) and those scoring in the lowest quartile had the highest survival time (2% incidence by age 14.5; p < .001). This finding is consistent with both theoretical and clinical perspectives and represents one of the first prospective demonstrations of a linkage between weight and body shape concerns and later onset of eating disorder symptoms. An understanding of the independent variables that predispose girls to development of symptoms is a useful step towards the establishment of a rational basis for the choice of a prevention intervention target.

  View details for Web of Science ID A1994PN81000002

• RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT, AND MANAGEMENT OF INDIVIDUALS WITH TURNER SYNDROME ENDOCRINOLOGIST Rosenfeld, R. G., Tesch, L. G., RODRIGUEZRIGAU, L. J., McCauley, E., ALBERTSSONWIKLAND, K., Asch, R., Cara, J., Conte, F., Hall, J. G., Lippe, B., Nagel, T. C., Neely, E. K., Page, D. C., Ranke, M., Saenger, P., Watkins, J. M., Wilson, D. M. 1994; 4 (5): 351-358

  View details for Web of Science ID A1994PK06700007

• TIMING AND RATE OF SEXUAL-MATURATION AND THE ONSET OF CIGARETTE AND ALCOHOL-USE AMONG TEENAGE GIRLS ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE Wilson, D. M., Killen, J. D., Hayward, C., Robinson, T. N., Hammer, L. D., Kraemer, H. C., Varady, A., Taylor, C. B. 1994; 148 (8): 789-795

  Abstract

  To test the hypothesis that the patterns of pubertal progression, early vs late puberty and fast vs slow, are associated with the age at which girls start to drink alcohol and smoke cigarettes.The study included 1463 female students, 10.7 to 18.2 years of age, who were assessed five times during the 2.7-year study. Data regarding pubertal stage, alcohol use, and cigarette use were obtained at each assessment. These data were used to calculate two indexes of pubertal development, the age at which the midpoint of puberty was achieved and the rate of progression through puberty, and the ages when each subject first drank, first drank moderate amounts of alcohol, and first smoked.Girls with earlier puberty (midpoint < 12.2 years) first reported drinking any alcohol at a median age of 12.5 years, 0.7 years younger than girls whose puberty was later. Similarly, girls with earlier puberty reported drinking moderate amounts of alcohol at a median age of 13.7 years, 0.9 years younger than girls with later puberty. Girls with earlier puberty further reported first smoking cigarettes at a median age of 12.8 years, 0.6 years younger than girls with later puberty. The rate of pubertal progression was significantly associated only with the age when girls first drank moderate amounts of alcohol.Earlier puberty is associated with a younger age of onset for both drinking and smoking among adolescent girls.

  View details for Web of Science ID A1994PB26400003

  View details for PubMedID 8044254

• FACTORS ASSOCIATED WITH EATING DISORDER SYMPTOMS IN A COMMUNITY SAMPLE OF 6TH AND 7TH GRADE GIRLS INTERNATIONAL JOURNAL OF EATING DISORDERS Killen, J. D., Hayward, C., Wilson, D. M., Taylor, C. B., Hammer, L. D., Litt, I., SIMMONDS, B., Haydel, F. 1994; 15 (4): 357-367

  Abstract

  Nine hundred thirty-nine 6th and 7th grade girls participated in the baseline phase of a prospective study designed to examine a set of potential risk factors for the development of eating disorders. Of the 939,839 girls (89%) completed the bulimia nervosa section of the Structured Clinical Interview for DSM-III-R disorders. One girl received the diagnosis of bulimia nervosa, another 35 were classified as a symptomatic group. Using analysis of covariance (ANCOVA), controlling for age and stage of sexual maturation, symptomatic and asymptomatic groups were compared on the following measures: Eating Disorders Inventory (EDI), BMI, triceps skinfold thickness, waist-to-hip ratio, depression symptoms (CES-D and DSRS), Restraint Scale, and a measure of family adaptability and cohesion (FACES). Symptomatic girls were more developmentally mature, significantly heavier, reported greater fear of weight gain, experienced greater dysphoria, indicated increased body dissatisfaction, and reported greater feelings of inadequacy and personal worthlessness. Their status on these dimensions may indicate potential vulnerability to eating disorders and, ultimately, suggest the choice of targets for intervention. Our future goal is to conduct the prospective analyses needed to confirm the hypothesized linkages.

  View details for PubMedID 8032350

• PRODUCTION AND HORMONAL-REGULATION OF INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS IN BOVINE CHONDROCYTES ENDOCRINOLOGY Olney, R. C., Smith, R. L., Kee, Y., Wilson, D. M. 1993; 133 (2): 563-570

  Abstract

  Linear growth results from proliferation and differentiation of chondrocytes within the growth plates and is regulated, in part, by the insulin-like growth factors (IGFs). IGF binding proteins (IGFBPs) also appear to play a significant, but yet unclear, role. To examine IGFBP production by chondrocytes, we isolated bovine chondrocytes from adult articular, fetal articular, and fetal growth plate cartilage, and maintained them in primary culture as high-density monolayers or encapsulated in alginate beads. Cells were cultured in serum-free conditions with human GH (hGH), insulin, hIGF-I, or hIGF-II. Human IGF-I resulted in higher DNA content in all three of the chondrocyte types. Conditioned medium samples were analyzed for IGFBPs by Western ligand blotting. Chondrocytes released IGFBPs of 24, 29, 33, 39, and 43 kilodaltons (kDa). Deglycosylation and immunoblotting identified the 39/43-kDa doublet as IGFBP-3 and the 33-kDa band as IGFBP-2. All chondrocyte types released 29- and 24-kDa IGFBP bands constitutively. Adult articular chondrocytes increased production all IGFBPs in response to IGF-I, but particularly the 29-kDa band (17-fold increase). Fetal articular chondrocytes showed a similar pattern, but with less of an increase when treated with IGF-I. Fetal growth plate chondrocytes primarily showed increases in IGFBP-3 and the 24-kDa form (4.7- and 2.7-fold, respectively) in response to IGF-I. Although the role of IGFBPs in IGF mediation of articular and growth plate chondrocyte metabolism requires further research, we show here that bovine chondrocytes produce IGFBPs, and the IGFs regulate this production.

  View details for PubMedID 7688290

• AN ATTEMPT TO MODIFY UNHEALTHFUL EATING ATTITUDES AND WEIGHT REGULATION PRACTICES OF YOUNG ADOLESCENT GIRLS INTERNATIONAL JOURNAL OF EATING DISORDERS Killen, J. D., Taylor, C. B., Hammer, L. D., Litt, I., Wilson, D. M., Rich, T., Hayward, C., SIMMONDS, B., Kraemer, H., Varady, A. 1993; 13 (4): 369-384

  Abstract

  This is the first long-term, controlled study evaluating the effectiveness of a prevention curriculum designed to modify the eating attitudes and unhealthful weight regulation practices of young adolescent girls. Nine hundred sixty-seven sixth and seventh-grade girls were randomized to experimental healthy weight regulation curriculum or no-treatment control classes. A prevention intervention was developed around three principal components: (1) Instruction on the harmful effects of unhealthful weight regulation; (2) promotion of healthful weight regulation through the practice of sound nutrition and dietary principles and regular aerobic physical activity; (3) development of coping skills for resisting the diverse sociocultural influences that appear linked to the current popular obsessions with thinness and dieting. The intervention failed to achieve the hoped-for impact. We did observe a significant increase in knowledge among girls receiving the intervention and among high-risk students only, there was a small albeit statistically significant effect on body mass index. These findings question the wisdom of providing a curriculum directed at all young adolescents, most of whom are not at risk to develop an eating disorder. Rather than targeting the entire population, a healthy weight curriculum designed to modify the eating attitudes and unhealthful weight regulation practices of young adolescent girls might better focus on "at risk" students.

  View details for Web of Science ID A1993KZ50300004

  View details for PubMedID 8490639

• DOES TELEVISION VIEWING INCREASE OBESITY AND REDUCE PHYSICAL-ACTIVITY - CROSS-SECTIONAL AND LONGITUDINAL ANALYSES AMONG ADOLESCENT GIRLS PEDIATRICS Robinson, T. N., Hammer, L. D., Killen, J. D., Kraemer, H. C., Wilson, D. M., Hayward, C., Taylor, C. B. 1993; 91 (2): 273-280

  Abstract

  To examine the relationships between hours of television viewing and adiposity and physical activity among female adolescents, a cohort study with follow-up assessments 7, 14, and 24 months after baseline was conducted. All sixth- and seventh-grade girls (N = 971) attending four northern California middle schools were eligible to participate. Six hundred seventy-one students had sufficient data for baseline cross-sectional analyses, and 279 students in a no-intervention cohort had sufficient data for longitudinal analyses. The baseline sample had a mean age of 12.4 years and was 43% white, 22% Asian, 21% Latino, 6% Pacific Islander, 4% black, 2% American Indian, and 2% other. Hours of after-school television viewing, level of physical activity, and stage of sexual maturation were assessed with self-report instruments. Height, weight, and triceps skinfold thickness were measured and body mass index (ratio of weight [in kilograms] to height [in meters] squared) and triceps skinfold thickness were adjusted by level of sexual maturity for the analyses. Baseline hours of after-school television viewing was not significantly associated with either baseline or longitudinal change in body mass index or triceps skinfold thickness. Baseline hours of after-school television viewing was weakly negatively associated with level of physical activity in cross-sectional analyses but not significantly associated with change in level of physical activity over time. All results were essentially unchanged when adjusted for age, race, parent education, and parent fatness. Among adolescent girls, television viewing time appears to have only weak, if any, meaningful associations with adiposity, physical activity, or change in either over time.

  View details for PubMedID 8424000

• Knowledge reuse: temporal-abstraction mechanisms for the assessment of children's growth. Proceedings / the ... Annual Symposium on Computer Application [sic] in Medical Care. Symposium on Computer Applications in Medical Care Kuilboer, M. M., Shahar, Y., Wilson, D. M., Musen, M. A. 1993: 449-453

  Abstract

  Currently, many workers in the field of medical informatics realize the importance of knowledge reuse. The PROTEGE-II project seeks to develop and implement a domain-independent framework that allows system builders to create custom-tailored role-limiting methods from generic reusable components. These new role-limiting methods are used to create domain- and task-specific knowledge-acquisition tools with which an application expert can generate domain- and task-specific decision-support systems. One required set of reusable components embodies the problem-solving knowledge to generate temporal abstractions. Previously, members of the PROTEGE-II project have used these temporal-abstraction mechanisms to infer the presence of myelotoxicity in patients with AIDS. In this paper, we show that these mechanisms are reusable in the domain of assessment of children's growth.

  View details for PubMedID 8130514

• EFFECTS OF ESTROGEN ON GROWTH-HORMONE FOLLOWING CLONIDINE STIMULATION AMERICAN JOURNAL OF DISEASES OF CHILDREN Wilson, D. M., Dotson, R. J., Neely, E. K., Cohen, P., Hintz, R. L., Rosenfeld, R. G. 1993; 147 (1): 63-65

  Abstract

  To test the usefulness of estrogen priming to enhance the growth hormone (GH) response following stimulation with clonidine hydrochloride in short children.Randomized and patient series.Pediatric endocrine clinic in a referral center.Seventy-three children (63% male) between 1.8 and 15.4 years of age (mean age, 8.8 years) with growth problems who underwent clonidine GH stimulation tests were randomly assigned to receive either estrogen pretreatment or no pretreatment. An additional 49 subjects, seen before or after the randomized study and who did not receive conjugated estrogen, are also described.Consecutive sample.Estrogen pretreatment consisted of 2.5 mg of conjugated estrogen (Premarin) to be taken the evening before and the morning of the clonidine GH stimulation test. Growth hormone concentrations were determined before and 60 and 90 minutes after the subjects received oral clonidine hydrochloride (5 micrograms/kg) by a laboratory blinded to the subject's estrogen status. Growth hormone concentrations greater than 10 micrograms/L were considered normal.Eight of the 73 subjects failed both clonidine and arginine-insulin GH stimulation tests. We analyzed the GH data from the 65 GH-sufficient subjects to determine the effect of estrogen pretreatment on the specificity of the clonidine GH stimulation test. There were no statistically significant differences in the mean GH concentrations between the two groups at any time point during the test.Our data demonstrate that estrogen priming does not improve the diagnostic yield of clonidine GH stimulation tests.

  View details for PubMedID 8380310

• 2-YEAR RESULTS OF TREATMENT WITH DEPOT LEUPROLIDE ACETATE FOR CENTRAL PRECOCIOUS PUBERTY JOURNAL OF PEDIATRICS Neely, E. K., Hintz, R. L., Parker, B., Bachrach, L. K., Cohen, P., Olney, R., Wilson, D. M. 1992; 121 (4): 634-640

  Abstract

  We report results from 2 years of therapy with the long-acting form of the gonadotropin-releasing hormone (GnRH) analog leuprolide acetate, which was previously reported in short-term trials to be efficacious in the treatment of central precocious puberty. Thirteen girls and two boys, aged 1.9 to 9.7 years, who satisfied clinical criteria including GnRH-stimulated luteinizing hormone (LH) greater than 10 IU/L (mean radioimmunoassay LH, 29.1 +/- 5.54 IU/L), received depot leuprolide, 6 to 15 mg intramuscularly every 4 weeks. Estradiol (or testosterone), insulin-like growth factor I, and GnRH-stimulated gonadotropins were obtained at baseline, at 2 months, and at 6-month intervals with bone age determinations. Pubertal progression ceased in all patients, and menses did not occur. Mean increase in height during therapy was 5.77 +/- 2.0 cm/yr. Predicted adult height increased over baseline by 5.52 +/- 1.16 cm at 18 months. Mean estradiol values in the girls declined from 3.3 +/- 0.6 to 0.60 +/- 0.03 ng/dl, with no overlap of baseline and treatment values. The mean basal LH value was unchanged by therapy; mean basal and peak LH values for all follow-up GnRH stimulation tests were 4.05 +/- 0.57 and 4.95 +/- 0.70 IU/L, respectively. Basal and peak follicle-stimulating hormone (FSH) values were suppressed from 4.10 +/- 0.62 and 10.06 +/- 1.34 IU/L, respectively, to generally undetectable levels (< 1). Comparison with untreated control patients suggested that basal LH did not completely return to prepubertal levels, whereas FSH levels were suppressed below prepubertal levels. Estradiol, FSH, and LH levels reached their nadir by 2 months; in contrast, mean serum levels of insulin-like growth factor I progressively declined from +0.57 +/- 0.19 SD score to -0.06 +/- 0.22 SD score at 24 months. Two girls were withdrawn from the study because of reactions at injection sites, with apparent sterile abscess formation in one patient. This study provides evidence that (1) long-term treatment with depot leuprolide is characterized by immediate and sustained laboratory and clinical suppression, (2) GnRH-stimulated LH and random FSH and estradiol concentrations are useful laboratory measures of efficacy, and (3) the progressive increase in predicted adult height is temporally associated with decreased serum levels of insulin-like growth factor I and striking deceleration of bone age advancement.

  View details for PubMedID 1403402

• CLINICAL ACTIONS OF GROWTH-HORMONE ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA Wilson, D. M. 1992; 21 (3): 519-537

  Abstract

  Although biotechnology has provided physicians with essentially unlimited supplies of growth hormone (GH), there are currently only a few clear-cut indications for exogenous GH therapy. Data now support the use of GH in the treatment of children with GH deficiency and short girls with Turner syndrome. Tantalizing preliminary data suggest that GH therapy has a role in the management of short, poorly growing children with other causes for their growth failure. Recent studies have examined the utility of GH therapy in GH-deficient adults, whereas other studies suggest that GH improves the clinical status of GH-sufficient older adults. This article explores the recent data underlying these claims.

  View details for PubMedID 1521510

• PUBERTAL STAGE AND PANIC ATTACK HISTORY IN 6TH-GRADE AND 7TH-GRADE GIRLS INTERNATIONAL CONGRESS ON SCHIZOPHRENIA RESEARCH Hayward, C., Killen, J. D., Hammer, L. D., Litt, I. F., Wilson, D. M., SIMMONDS, B., Taylor, C. B. AMER PSYCHIATRIC ASSOCIATION. 1992: 1239–43

  Abstract

  Although the incidence of first panic attacks appears to peak during adolescence, little is known about which features of adolescence contribute to the risk of a first panic episode. The purpose of this study was to compare the relative importance of age and pubertal stage in explaining the occurrence of panic attacks in adolescents.From a school-based sample of sixth- and seventh-grade girls, 754 subjects completed both a structured clinical interview determining history of one or more panic episodes and a self-assessment of Tanner stages of pubertal development. A multiple logistic regression analysis was performed with panic attack history as the dependent variable and pubertal stage, age, and their interaction as the independent variables.A history of one or more four-symptom panic attacks was found in 5.3% of the girls (N = 40). After age was controlled for, pubertal stage was significantly related to panic attack history. At each age, higher rates of panic attacks were found in the more physically mature girls.Pubertal stage, after adjustment for the effects of age, appears to predict panic attack occurrence in young adolescent girls. Understanding the link between puberty and panic may offer clues regarding the onset and etiology of panic attacks.

  View details for PubMedID 1503139

• Cardiovascular evaluation in Turner syndrome: utility of MR imaging. Australasian radiology Dawson-Falk, K. L., Wright, A. M., Bakker, B., Pitlick, P. T., Wilson, D. M., Rosenfeld, R. G. 1992; 36 (3): 204-209

  Abstract

  Forty patients with karyotypically proven Turner syndrome were prospectively studied using magnetic resonance imaging (MRI) and echocardiography in order to determine the frequency of cardiovascular anomalies and to assess the utility of both imaging modalities as methods for cardiovascular evaluation in Turner syndrome. Cardiovascular anomalies were found in 45% of patients. A high absolute prevalence of bicuspid aortic valve (17.5%) and aortic coarctation (12.5%) were observed relative to comparable series. Of clinically significant abnormalities, three of five aortic coarctations and four of five ascending aortic dilatations were solely MRI detected and not evident at echocardiographic examination. MRI is thus seen as a valuable adjunct to echocardiography in the cardiovascular evaluation of Turner syndrome patients. The usefulness of MRI primarily relates to its ability to provide excellent visualisation of the entire thoracic aorta where a large proportion of clinically significant anomalies occur in Turner syndrome.

  View details for PubMedID 1445102

• INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 IN NORMAL PUBERTAL GIRLS ACTA ENDOCRINOLOGICA Wilson, D. M., STENE, M. A., Killen, J. D., Hammer, L. D., Litt, I. F., Hayward, C., Taylor, C. B. 1992; 126 (5): 381-386

  Abstract

  IGFBP-3 concentrations rise in the second decade of life. To test the hypothesis that the stage of pubertal development, independent of chronological age, was associated with these increases we measured serum IGFBP-3 concentrations by radioimmunoassay in 324 sixth and seventh grade girls (12.3 +/- 0.7 years) at the beginning of a multisite school-based health curriculum. The mean (+/- SD) serum IGFBP-3 among the 242 girls with complete data was 4.0 +/- 0.7 mg/l. Pubertal stage was significantly associated with IGFBP-3 (p less than 0.0001, ANOVA). Mean concentrations rose from 3.5 +/- 0.7 mg/l among those with the earliest pubertal stages to 4.2 +/- 0.7 mg/l among the mature girls. IGF-I and IGFBP-3 concentrations were significantly correlated (Spearman's r = 0.43, p less than 0.0001). After controlling for the association between pubertal development and IGFBP-3 concentrations, only the waist/hip ratio, among the various measures of body composition, was significantly associated with IGFBP-3 concentration (Spearman's r = -0.23, p = 0.0002). Likewise, none of the measures of nutrition: intake of total calories, protein, fat and carbohydrate; serum iron; red cell mean corpuscular volume; or cholesterol; were significantly associated with IGFBP-3 concentrations. There was, however, a small, but significant association between IGFBP-3 concentrations and both serum transferrin and blood hemoglobin concentrations. Pubertal stage has a significant impact on IGFBP-3 concentrations and those attempting to utilize IGFBP-3 concentrations during adolescence should be cognizant of the subject's pubertal stage.

  View details for PubMedID 1377853

• THE OVERLAP SYNDROME - AN UNUSUAL PRESENTATION AMERICAN JOURNAL OF DISEASES OF CHILDREN Gregory, J. L., Wilson, D. M., Parker, B., Wood, B. P. 1992; 146 (4): 421-422

  View details for Web of Science ID A1992HM32200004

• IS PUBERTY A RISK FACTOR FOR EATING DISORDERS AMERICAN JOURNAL OF DISEASES OF CHILDREN Killen, J. D., Hayward, C., Litt, I., Hammer, L. D., Wilson, D. M., Miner, B., Taylor, B., Varady, A., Shisslak, C. 1992; 146 (3): 323-325

  Abstract

  To examine the association between stage of sexual maturation and eating disorder symptoms in a community-based sample of adolescent girls.All sixth- and seventh-grade girls (N = 971) enrolled in four northern California middle schools. MAIN VARIABLES EXAMINED: Pubertal development measured using self-reported Tanner stage and body mass index (kg/m2). The section of the Structured Clinical Interview for DSM-III-R Disorders (SCID) discussing bulimia nervosa was used to evaluate symptoms of bulimia nervosa.Girls manifesting eating disorder symptoms, while not significantly older than their peers without such symptoms, were more developmentally advanced as determined with Tanner self-staging. The odds ratio for the association between sexual maturity and symptoms was 1.8 (95% confidence interval, 1.2 to 2.8); ie, at each age, an increase in sexual maturity of a single point was associated with a 1.8-fold increase in the odds of presenting symptoms. The odds ratio for the association between body mass index (adjusted for sexual maturity) and symptoms was 1.02 (95% confidence interval, 1.0 to 1.05). There was no independent effect of age or of the interaction between age and the sexual maturity index.These results suggest that (1) puberty may be a risk factor for the development of eating disorders, and (2) prevention efforts might best be directed at prepubertal and peripubertal adolescents.

  View details for Web of Science ID A1992HG92400016

  View details for PubMedID 1543180

• Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth factors De Leon, D. D., Wilson, D. M., Powers, M., Rosenfeld, R. G. 1992; 6 (4): 327-336

  Abstract

  It has been shown previously that MCF-7 cells proliferate in response to nanomolar concentrations of IGF-I and IGF-II. It has also been reported that the actions of both peptides are mediated through the IGF-I receptor. To further characterize these observations, we used MCF-7 and Hs578T cell lines in the serum-free/phenol red-free system developed by Ogasawara and Sibarsku, 1988. Cell proliferation was studied in the presence of insulin, IGF-I and -II and a series of growth factor receptor antibodies. No effect was observed on Hs578T cell proliferation with any of the growth factors. However, MCF-7 cells were stimulated 4-5 fold with IGF-I and insulin, while IGF-II was only slightly less potent. alpha IR3, a monoclonal antibody directed against the IGF-I receptor, was stimulatory when added alone. However, alpha IR3 blocked approximately 50% of the IGF-I response, only 5% of the insulin response, and did not block the IGF-II effect on cell proliferation. These data suggest that alpha IR3 and IGF-I are acting as agonists through the IGF-I receptor, but that insulin and IGF-II are acting through other receptors. Two different IGF-II/M-6-P receptor antibodies and an insulin receptor antibody failed to significantly block IGF-II actions. All three antibodies were stimulatory when added alone. beta-gal inhibited 27% of the IGF-II response and had no effect when added alone. Since beta-gal decreases the binding affinity of the IGF-II/M-6-P receptor for IGF-II and does not bind to the IGF-I or insulin receptor, these data suggest the possibility that IGF-II mitogenic action is mediated through the IGF-II/M-6-P receptor. In summary, these data indicate that nanomolar concentration of insulin, IGF-I and IGF-II are potent mitogens in MCF-7 cells and can potentially stimulate cell proliferation through all three receptors.

  View details for PubMedID 1340210

• Radiological case of the month. The overlap syndrome: an unusual presentation. American journal of diseases of children (1960) Gregory, J. L., Wilson, D. M., Parker, B., Wood, B. P. 1992; 146 (4): 421–22

  View details for PubMedID 1558073

• INSULIN-LIKE GROWTH FACTOR-I AS A REFLECTION OF BODY-COMPOSITION, NUTRITION, AND PUBERTY IN 6TH AND 7TH GRADE GIRLS JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Wilson, D. M., Killen, J. D., Hammer, L. D., Litt, I. F., VOSTI, C., Miner, B., Hayward, C., Taylor, C. B. 1991; 73 (4): 907-912

  Abstract

  Large variations in nutritional intake have profound effects on the GH-insulin-like growth factor-I (IGF-I) axis in children and adults, but the effect of normal variations in nutrition on IGF-I concentrations is largely unstudied, particularly during puberty. We measured serum IGF-I concentrations in 325 sixth and seventh grade girls (12.4 +/- 0.7 yr) at the beginning of a multisite school-based health curriculum. The mean serum IGF-I level among the 243 girls with complete data was 573 +/- 244 micrograms/L. Pubertal stage was significantly associated with IGF-I (P less than 0.0001, by analysis of variance). Mean concentrations rose from 427 +/- 198 micrograms/L among those at the earliest pubertal stages to 639 +/- 219 micrograms/L among the mature girls. After adjusting for the association with the stage of pubertal development, serum IGF-I was not significantly associated with measures of body composition (body mass index, triceps skin fold thickness, waist/hip ratio, height, and weight). Additionally, IGF-I concentrations were not associated with nutritional intake (total calories, total protein, total fat, and total carbohydrate) or such measures of nutrition as serum iron, hemoglobin, red cell mean corpuscular volume, white cell count, and cholesterol. IGF-I concentrations, however, were significantly correlated with transferrin concentrations, another possible index of nutritional status (r = 0.29; P less than 0.0001). IGF-I is not a clinically useful index of nutritional status among normal pubertal girls.

  View details for PubMedID 1890162

• GROWTH-HORMONE THERAPY IN HYPOPHOSPHATEMIC RICKETS AMERICAN JOURNAL OF DISEASES OF CHILDREN Wilson, D. M., Lee, P. D., Morris, A. H., Reiter, E. O., Gertner, J. M., Marcus, R., QUARMBY, V. E., Rosenfeld, R. G. 1991; 145 (10): 1165-1170

  Abstract

  The effects of growth hormone therapy on the biochemical measures of bone metabolism were studied in 11 children aged 3.5 to 17 years who had familial hypophosphatemic rickets; five were male. Subjects were maintained on a regimen of stable doses of conventional therapy (calcitriol and phosphate). Subjects were studied at baseline receiving conventional therapy and during three sequential treatment periods: no therapy (4 weeks), growth hormone only (0.05 mg/kg per day for 4 weeks), and conventional therapy plus growth hormone (2 weeks). The nine youngest subjects were continued on a regimen of triple therapy for an additional 24 weeks. Serum phosphate averaged 0.93 +/- 0.13 mmol/L (mean +/- SD) at entry and decreased when the subjects were not receiving any therapy. During the 4 weeks of growth hormone only treatment, phosphate rose in all 11 subjects (0.70 +/- 0.08 mmol/L to 0.83 +/- 0.08 mmol/L). With triple therapy, phosphate remained higher than with no therapy. Calcitriol, osteocalcin, and parathyroid hormone increased as the subjects received growth hormone alone. Insulinlike growth factor I z scores rose significantly in response to growth hormone therapy alone. All nine subjects receiving 6 months of triple therapy increased their growth rate z scores. Exogenous growth hormone therapy may be useful in familial hypophosphatemic rickets.

  View details for PubMedID 1928011

• DIFFERENTIAL REGULATION OF THE INSULIN-LIKE GROWTH-FACTORS (IGF-I AND IGF-II) AND IGF BINDING-PROTEINS DURING MALNUTRITION IN THE NEONATAL RAT ENDOCRINOLOGY Donovan, S. M., Atilano, L. C., Hintz, R. L., Wilson, D. M., Rosenfeld, R. G. 1991; 129 (1): 149-157

  Abstract

  Insulin-like growth factor (IGF)-I and -II are known to play a major role in fetal and early postnatal growth. The IGF binding proteins (IGFBPs) are thought to be important in modulating the actions of the IGFs. In this paper, the effect of malnutrition in the neonatal rat on serum IGFs and IGFBPs and hepatic IGFBP messenger (m) RNA was examined. Control (C) dams (n = 9) were allowed ad libitum intake, whereas restricted (R) dams (n = 9) were limited to 50% of ad libitum intake throughout lactation, which results in decreased milk production and malnutrition of pups suckling on restricted dams. A subset of pups were cross-fostered from the R-dams to the C-dams from days 15-19 postpartum (PP) to investigate the effect of nutritional repletion (refed). Pups were killed on days 8, 12, 15, and 19 PP and liver and blood collected. Serum IGF-I and -II concentrations were measured by RIA after acid-chromatography to remove IGFBPs. Serum IGFBPs were characterized by Western ligand blot. Hepatic mRNA for IGFBP-1, -2, and -3 were determined by northern analysis. Body weight (BW) of R-pups was significantly less than C-pups by day 10 PP (P less than or equal to 0.05), and mean BW at day 19 was 56% of the C-pups. Refeeding from days 15-19 resulted in a significantly greater rate of growth vs. R-pups (3.2 vs. 0.9 g/day), and mean BW of refed pups at day 19 PP was 75% of C-pups. Malnutrition caused a significant reduction in both serum IGF-I and -II after day 12 PP, while causing an elevation in serum IGFBP-2. IGFBP-1 and IGFBP-2 mRNA expression were not significantly affected at days 8 and 12, but were elevated in livers of day 15 and 19 pups. Malnutrition caused a delay in the development shift from IGFBP-2 to IGFBP-3, which normally occurs between day 15 and 19 in the rat. Refeeding raised serum IGF-I and -II levels to those found in the C-pups and a trend toward normalization of IGFBP profiles. In conclusion, IGFs and IGFBPs are differentially regulated during neonatal malnutrition. The decrease in IGF peptide and induction of IGFBP-1 and -2 may provide protective mechanisms by inhibiting growth during malnutrition.

  View details for PubMedID 1711459

• IMPACT OF PUBERTAL DEVELOPMENT ON BODY-FAT DISTRIBUTION AMONG WHITE, HISPANIC, AND ASIAN FEMALE ADOLESCENTS JOURNAL OF PEDIATRICS Hammer, L. D., Wilson, D. M., Litt, I. F., Killen, J. D., Hayward, C., Miner, B., VOSTI, C., Taylor, C. B. 1991; 118 (6): 975-980

  Abstract

  Variation in the waist/hip ratio (WHR) may be related to changes in hormonal secretion associated with pubertal maturation. We therefore studied the effects of race, pubertal development, and body fatness on WHR during adolescence in a multiethnic population. A total of 688 white, Asian, and Hispanic female adolescents (mean (+/- SD) 12.4 +/- 0.7 years), participating in the evaluation of a multisite school-based health education program, were included in these analyses. Self-assessed stage of puberty and measurements of height, weight, waist circumference, and hip circumference were obtained from each participant. The WHR and age-adjusted body mass index were calculated. Analysis of covariance demonstrated that puberty significantly affects hip circumference and WHR but not waist circumference among female adolescents. Age and fatness, as reflected by age-adjusted body mass index, contributed significantly to both circumferences and to the WHR. There was a significant effect of ethnicity on hip circumference but not on waist circumference or the WHR. These results confirm that pubertal stage exerts a significant effect on the hip circumference and WHR in female adolescents, even after the effects of fatness and age are controlled. Studies of body fat distribution during late childhood and adolescence should include assessments of pubertal maturation.

  View details for PubMedID 2040937

• STANDARDIZED PERCENTILE CURVES OF BODY-MASS INDEX FOR CHILDREN AND ADOLESCENTS AMERICAN JOURNAL OF DISEASES OF CHILDREN Hammer, L. D., Kraemer, H. C., Wilson, D. M., Ritter, P. L., DORNBUSCH, S. M. 1991; 145 (3): 259-263

  Abstract

  Weight-for-height indexes are often used in the clinical assessment of obesity in children and adolescents. The direct measurement of adiposity, using hydrostatic weighing and other techniques, is not feasible in studies involving young children or with large numbers of older subjects. Ratios of weight relative to height, such as the body-mass index (weight/height), may be used as indirect measures of obesity and correlate with more direct measures of adiposity. Using data from the First National Health and Nutrition Examination Study, 1971 to 1974, standardized percentile curves of body-mass index for white children and adolescents were developed. These curves may be used to monitor the body-mass index of white children and adolescents longitudinally and for comparing an individual with others of the same sex and age.

  View details for PubMedID 1750869

• INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II AND THEIR BINDING-PROTEINS IN RAT MILK PEDIATRIC RESEARCH Donovan, S. M., Hintz, R. L., Wilson, D. M., Rosenfeld, R. G. 1991; 29 (1): 50-55

  Abstract

  IGF-I and -II are peptide growth factors that may be important contributors to the growth-promoting properties associated with milk. IGF in extracellular fluids, including serum and milk, are carried by specific high-affinity binding proteins (IGFBP). In this study, the levels of IGF-I and -II in rat serum and milk were quantified by specific RIA, and the IGFBP were characterized using Western ligand blotting and autoradiography throughout lactation. The levels of IGF-I in both milk and maternal serum decreased during lactation. Serum IGF-I decreased from 743 +/- 187 micrograms/L on d 1 to 391 +/- 106 (mean +/- SD) on d 21 of lactation, and milk IGF-I levels fell from 30 +/- 10 to 13 +/- 8 micrograms/L. Levels of IGF-II in serum and milk were much lower than IGF-I, and were unaffected by lactation. In maternal serum, several IGFBP were identified: IGFBP-3, which migrates as four glycosylated bands with apparent Mr from 38 to 42 kD and one to two nonglycosylated bands with apparent Mr of 28 to 29 kD, and an IGFBP with an apparent Mr of 24 kD. In milk, IGFBP-3, the 24-kD binding protein, and a third IGFBP with an apparent Mr of 29 kD were identified. Treatment of milk and serum with Endoglycosidase F reduced the four glycosylated IGFBP-3 bands (38-42 kD) to two bands with apparent Mr of 35 and 32 kD. In rat milk, but not adult rat serum, the IGFBP with an apparent Mr of 29 kD was immunoprecipitable by an antibody that recognizes IGFBP-2.(ABSTRACT TRUNCATED AT 250 WORDS)

  View details for PubMedID 1705696

• INSULIN-LIKE GROWTH-FACTORS ARE MITOGENIC FOR HUMAN KERATINOCYTES AND A SQUAMOUS-CELL CARCINOMA JOURNAL OF INVESTIGATIVE DERMATOLOGY Neely, E. K., Morhenn, V. B., Hintz, R. L., Wilson, D. M., Rosenfeld, R. G. 1991; 96 (1): 104-110

  Abstract

  Normal adult human keratinocytes in monolayer culture and SCL-1, a skin-derived squamous-cell carcinoma cell line, were investigated for the expression of receptors for insulin-like growth factors (IGF) and insulin. As demonstrated by affinity crosslinking, radiolabeled IGF-1, IGF-2, and insulin bound specifically to both cell types. Each cell expressed type I IGF receptors, with affinity for IGF-1 greater than IGF-2 much greater than insulin. Insulin receptors, with highest affinity for insulin, were also present on both cells. However, keratinocytes and SCL-1 cells differed in 125I-IGF-2 binding. 125I-IGF-2-bound to both type I and type II IGF receptors in normal keratinocytes, but bound predominantly to membrane-associated IGF binding proteins in SCL-1. IGF-1 was slightly more potent than IGF-2 in stimulating growth of both keratinocytes and SCL-1 cells. In keratinocytes, concentrations of IGF-1 ranging from 5-100 ng/ml, and of IGF-2 from 50-100 ng/ml, resulted in a significant increase in cell number. At the maximum dose of 100 ng/ml, either IGF-1 or IGF-2 caused a 2.3-times increase in cell number. In SCL-1 cells, IGF-1 was more potent than IGF-2 or insulin at lower concentrations, but either IGF-1 or IGF-2 at the maximal concentration of 333 ng/ml stimulated a 4.7-times increase in thymidine incorporation. The stimulatory effect of insulin in SCL-1 was 10-50 times less potent than that of the IGF. The effect of either IGF on SCL-1 was completely inhibited by the type I IGF receptor antibody alpha IR-3, suggesting that both IGFs are mitogenic through the type I IGF receptor. Insulin action was partially blocked by alpha IR-3, suggesting that insulin can act through both the insulin and type I IGF receptors. It thus appears that IGF-1 and IGF-2 are mitogens for normal and transformed human keratinocytes and that their actions are primarily mediated through the type I IGF receptor, whereas insulin is a mitogen through both the IGF-1 receptor and the insulin receptor.

  View details for PubMedID 1846163

• PLASMA PRORENIN ACTIVITY AND COMPLICATIONS IN CHILDREN WITH INSULIN-DEPENDENT DIABETES-MELLITUS NEW ENGLAND JOURNAL OF MEDICINE Wilson, D. M., LUETSCHER, J. A. 1990; 323 (16): 1101-1106

  Abstract

  Renin, secreted into the blood by the juxtaglomerular cells of the kidneys, is derived from a larger precursor, prorenin. Plasma prorenin activity is increased in patients with insulin-dependent (Type I) diabetes mellitus who have microvascular complications of their disease. We undertook this study to determine prospectively whether rising prorenin activity can predict the development of complications in young patients with Type I diabetes.Plasma prorenin was measured in 135 children and adolescents with Type I diabetes. The mean (+/- SE) plasma prorenin activity among the 32 patients over the age of 10 years who had had uncomplicated diabetes for 0.1 to 5 years was 8.43 +/- 0.58 ng of angiotensin I per liter.second, as compared with 7.06 +/- 0.32 in 37 control subjects of the same age (P less than 0.05). In the 9 patients older than 10 who had retinopathy or overt albuminuria, the mean plasma prorenin activity was 13.09 +/- 1.43 ng of angiotensin I per liter.second (P less than 0.0001). In 34 patients 10 years old or older with uncomplicated diabetes, 3 to 13 measurements of plasma prorenin activity were taken during a follow-up period of 6 to 39 months. Urinary albumin was determined at each visit, and the patients had regular retinal examinations. Only 1 of the 20 patients who had consistently normal plasma prorenin values had overt albuminuria (ratio of urinary albumin to creatinine, greater than 0.017) or retinopathy, whereas one or both of these complications appeared in 8 of the 14 who had at least one high prorenin value. The plasma prorenin value was significantly higher in these eight patients at least 18 months before a complication was found.Increased plasma prorenin activity identifies a group of young patients with diabetes who are at high risk for retinopathy or nephropathy.

  View details for PubMedID 2215578

• GROWTH-HORMONE RESPONSE TO GROWTH-HORMONE RELEASING HORMONE IN DEPRESSION AND SCHIZOPHRENIA PSYCHIATRY RESEARCH Peabody, C. A., Warner, M. D., Markoff, E., Hoffman, A. R., Wilson, D. M., Csernansky, J. G. 1990; 33 (3): 269-276

  Abstract

  Growth hormone releasing hormone, a 44-amino acid peptide (GHRH-44), was administered (1 micrograms/kg i.v.) to 6 normal controls, 10 schizophrenic subjects, and 7 depressed subjects. A significantly lower growth hormone (GH) response was found in the schizophrenic and depressed groups. Two molecular forms of GH, 22K GH and 20K GH, were also measured but did not further differentiate the three groups of subjects.

  View details for Web of Science ID A1990EA31200006

  View details for PubMedID 2243902

• INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS IN HUMAN BREAST-CANCER CELLS - RELATIONSHIP TO HIGFBP-2 AND HIGFBP-3 JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM DeLeon, D. D., Bakker, B., Wilson, D. M., Lamson, G., Rosenfeld, R. G. 1990; 71 (2): 530-532

  Abstract

  Human breast cancer cells (HBCC) secrete at least four different forms of IGFBPs. We have previously demonstrated that hIGFBP-1 is a minor component of IGFBPs secreted by Hs578T cells and is absent in CM from MCF-7 cells. In our present report, we describe the immunological and structural relationship of HBCC IGFBPs to hIGFBP-2 and hIGFBP-3. Analysis of conditioned media (CM) from Hs578T by Western ligand blotting revealed three IGFBPs of apparent Mr = 38K, 28K, and 24K; CM from MCF-7 revealed only two IGFBPs, of apparent Mr = 31K and 24K. Immunoprecipitation studies with polyclonal antibodies raised against hIGFBP-2 and hIGFBP-3 demonstrated that the 38K IGFBP in Hs578T CM is immunologically related to hIGFBP-3, while the 31K IGFBP in MCF-7 cells is related to the hIGFBP-2. Analysis by Northern blot demonstrated that MCF-7 cells contained mRNA for hIGFBP-2, while Hs578T cells contained the mRNA characteristic of the hIGFBP-3. The identity of the 24K IGFBP remains unknown, and may represent a distinct IGFBP. Of note, assay of CM following removal of BPs by acid chromatography demonstrated no detectable IGF-I or -II. The role of these IGFBPs in HBCC is of interest in view of the potential modulation of IGF actions by these proteins.

  View details for PubMedID 1696278

• EFFICACY OF INSULIN-LIKE GROWTH FACTOR-I LEVELS IN PREDICTING THE RESPONSE TO PROVOCATIVE GROWTH-HORMONE TESTING PEDIATRIC RESEARCH Lee, P. D., Wilson, D. M., ROUNTREE, L., Hintz, R. L., Rosenfeld, R. G. 1990; 27 (1): 45-51

  Abstract

  Clinical testing of growth hormone (GH) sufficiency is a controversial area in endocrinology. Due to the episodic nature of endogenous GH secretion, diagnosis of GH deficiency has been defined as a failure to achieve normal GH levels in response to at least two stimuli. This testing is associated with significant patient morbidity and cost. We analyzed our experience over a 4-y period to determine whether clinical or biochemical variables could be used to predict the results of a specific GH testing procedure. Of 180 cases analyzed (67% male, mean age 8.89 +/- 4.39 y, range neonate-16 y), eight cases had incomplete GH testing results. Of the remaining 172, 19 were GH deficient (GH level less than 7 ng/mL). Younger age, higher body mass index and a greater degree of bone age delay were characteristic of the GH-deficient population; however, none of these variables alone was of diagnostic utility. Serum IGF-I level was below the normal range for 81% of the GH deficient and 47% of the GH-sufficient children; and was the only single variable that provided a reasonable between-group distinction. Discriminant analysis resulted in development of a new variable, based on IGF-I z scores, chronologic age, degree of bone age delay, and body mass index, which would have allowed exclusion of GH deficiency without provocative testing for 58% of the GH sufficient population, whereas permitting the diagnosis of GH deficiency for all GH-deficient subjects. Our data are dependent on the IGF-I assay method and the clinical definition for GH deficiency; therefore, the calculated predictive values are not applicable to all clinical populations.(ABSTRACT TRUNCATED AT 250 WORDS)

  View details for Web of Science ID A1990CF57900010

  View details for PubMedID 2296471

• PRORENIN AND VASCULAR COMPLICATIONS OF DIABETES AMERICAN JOURNAL OF HYPERTENSION LUETSCHER, J. A., Kraemer, F. B., Wilson, D. M. 1989; 2 (5): 382-386

  Abstract

  A high plasma prorenin is a marker of microvascular complications of diabetes. We have followed 56 adults and 120 children with uncomplicated insulin-dependent (type 1) diabetes. When plasma prorenin rises above the normal range in an adolescent or adult with type 1 diabetes, signs of nephropathy, retinopathy, or neuropathy follow within one to two years. The earliest sign may be intermittent microalbuminuria, which can often be abolished by improved control of hyperglycemia. The association between increased plasma prorenin and complications of noninsulin-dependent (type 2) diabetes is less reliable in patients with hypertension and in those receiving medication that affects plasma prorenin. The oral hypoglycemic agent, glipizide, lowers plasma prorenin, but its effect on prognosis is unknown. Plasma prorenin and renin decline as blood pressure rises, whereas the prevalence of micro- and macroalbuminuria increases. Many drugs used to control hypertension affect the level of prorenin. In the majority of our patients with type 2 diabetes who are hypertensive or are taking a medication that affects plasma prorenin, microalbuminuria may prove to be a more reliable warning of vascular complications.

  View details for PubMedID 2655663

• SOMATIC AND INTELLECTUAL-DEVELOPMENT IN A PATIENT WITH 47,XX,PSU DIC(X)(P11.2) CHROMOSOME CONSTITUTION AMERICAN JOURNAL OF MEDICAL GENETICS OCRANT, I., Bangs, C. D., Johnston, K. M., Wilson, D. M., Hintz, R. L., Rosenfeld, R. G., Donlon, T. A. 1989; 32 (4): 536-539

  Abstract

  An unusual form of X chromosome aneuploidy, 47,XX,psu dic(X)(p11.2), was found during an evaluation for short stature of a prepubertal girl. Unlike 45,X, 47,XXX, 48,XXXX, and 49,XXXXX females, this patient is phenotypically normal except for her short stature, which appears to be unrelated to her chromosome abnormality. X chromosome inactivation studies disclosed inactivation (late replication) of one normal X and the abnormal X chromosome in all cells examined from this patient. Therefore, she is disomic for early-replicating distal Xp loci, found in inactivated X chromosomes, and thought to remain active after lyonization. These data suggest that the presence of three or more copies of the early-replicating, active Xp loci may be responsible for the cognitive deficits and other phenotypic abnormalities seen in and other phenotypic abnormalities seen in polysomy X females.

  View details for PubMedID 2773999

• INSULIN-LIKE GROWTH FACTOR-I IN PREDICTING RESPONSE TO PROVOCATIVE GROWTH-HORMONE TESTING LEE, P. D., WILSON, D. M., ROUNTREE, L., HINTZ, R. L., ROSENFELD, R. G. WILLIAMS & WILKINS. 1989: A87

  View details for Web of Science ID A1989T947100509

• CHARACTERIZATION OF INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEINS FROM HUMAN-BREAST CANCER-CELLS MOLECULAR ENDOCRINOLOGY DeLeon, D. D., Wilson, D. M., Bakker, B., LAMSOM, G., Hintz, R. L., Rosenfeld, R. G. 1989; 3 (3): 567-574

  Abstract

  The insulin-like growth factor binding proteins (IGF-BPs) are structurally and immunologically distinct from the IGF type 1 or type 2 receptors and are characterized by two major forms: a large, GH-dependent BP found in human plasma (Mr = 150 k) and a small GH-independent BP (Mr = 28-42 k) present in human plasma, amniotic fluid, and HEP G2 cells. Using affinity cross-linking techniques, we have identified several binding proteins secreted by human breast cancer cell lines (Hs578T, MDA-231, T-47D, and MCF-7). Under nonreducing conditions these proteins migrated at an apparent Mr = 35, 28, 27, and 24 k, while reducing conditions revealed bands of apparent Mr = 35, 32, 27, and 24 k. Competitive binding studies in T-47D-conditioned media demonstrated that these BPs bound more IGF-II than IGF-I, and that IGF-II potently inhibited binding of either IGF-I or -II. Immunological studies using a polyclonal antibody against the HEP G2 small BP revealed no immunoreactive BP in conditioned media from MCF-7 and T-47D and only slight immunoreactivity in conditioned media from Hs578T and MDA 231. Analysis by Northern blot, using a probe from the cDNA sequence of the HEP G2 BP, demonstrated that Hs578T and MDA-231 cell lines contained small amounts of the 1.65 kilobase mRNA characteristic of the HEP G2 BP, while MCF-7 and T-47D tested negative.(ABSTRACT TRUNCATED AT 250 WORDS)

  View details for PubMedID 2473392

• A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF EFFECTS OF DEXAMETHASONE ON HYPOTHALAMIC-PITUITARY-ADRENAL AXIS IN PRETERM INFANTS JOURNAL OF PEDIATRICS Wilson, D. M., Baldwin, R. B., Ariagno, R. L. 1988; 113 (4): 764-768

  Abstract

  As part of a blinded, randomized, placebo-controlled study of dexamethasone therapy in 27 preterm infants with bronchopulmonary dysplasia, we investigated the effect of 7 days of high-dose glucocorticoid therapy on the hypothalamic-pituitary-adrenal axis. Before therapy the median basal cortisol concentration in all infants was 8.2 micrograms/dl (226 nmol/L). After stimulation with 1-24 ACTH, the serum cortisol concentration rose in all infants to a median concentration of 23.5 micrograms/dl (649 nmol/L), resulting in a median rise of 13.4 micrograms/dl (37 nmol/L). Immediately after 7 days of glucocorticoid therapy basal and peak cortisol concentrations were significantly decreased in the dexamethasone group. The rise in serum cortisol following 1-24 ACTH, however, remained equivalent in both groups. Ten days after the end of therapy basal and peak cortisol concentrations in the dexamethasone group had returned to levels equivalent to those seen in the placebo group. Weight gain was markedly diminished while the infants were receiving dexamethasone. Weight gains were, however, equivalent 10 days after the end of treatment. These data indicate that 7 days of dexamethasone therapy has significant but short-term effects on cortisol secretion and possibly on weight gain.

  View details for PubMedID 3050006

• PLASMA PRORENIN AND RENIN IN CHILDHOOD AND ADOLESCENCE AMERICAN JOURNAL OF DISEASES OF CHILDREN Wilson, D. M., Stevenson, D. K., LUETSCHER, J. A. 1988; 142 (10): 1070-1072

  Abstract

  We studied 108 subjects (age range, 4 to 76 years) to determine the effect of age on prorenin (inactive renin), active renin, and plasma renin activity in normal children, adolescents, and adults. Children and adolescents had lower prorenin concentrations and higher plasma renin activity and active renin concentrations than did adults. Prorenin concentrations were positively correlated with age over the range of 4 to 76 years, while plasma renin activity and active renin concentration were negatively correlated with age. Plasma prorenin and active renin concentrations from umbilical cord blood samples obtained from 11 newborns and arterial samples obtained from five infants were higher than those in samples obtained from children or adults.

  View details for PubMedID 3052031

• STRUCTURAL AND IMMUNOHISTOCHEMICAL CHARACTERIZATION OF INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II RECEPTORS IN THE MURINE CENTRAL NERVOUS-SYSTEM ENDOCRINOLOGY OCRANT, I., Valentino, K. L., Eng, L. F., Hintz, R. L., Wilson, D. M., Rosenfeld, R. G. 1988; 123 (2): 1023-1034

  Abstract

  The description of the cellular localization of insulin-like growth factor (IGF) receptors in the central nervous system (CNS) remains incomplete, as do the descriptions of changes in their characteristics with respect to different developmental stages. We, therefore, performed affinity labeling studies in microsomal membrane preparations of adult and fetal rat brain and liver tissues with [125I]IGF-I and [125I]IGF-II. These studies demonstrated tissue- and developmental stage-specific structural variants of type I receptor alpha-subunits as well as type II receptors. The adult rat brain type I alpha-subunit had an apparent mol wt (Mr) of 127,000, whereas those of adult and fetal rat liver measured 140,000. Fetal rat brain microsomes, however, had two types of type I receptor alpha-subunits measuring 130,000 and 120,000 Mr. The larger subunit from fetal brain consistently migrated at an apparent Mr of 3,000, greater than subunits from adult brain. Both type I and II receptors were more abundant in fetal liver and brain than in adult tissues. Affinity labeling was also performed directly to monolayers of cultured fetal brain neurons and newborn astrocytes. These studies detected both type I and II receptors on the surfaces of both types of cells. However, only the high Mr (140,000) form of the type I alpha-subunit was detected in cultured CNS cells, suggesting that expression of low Mr variant receptors is altered in vitro. Type II receptors were demonstrated by immunohistochemistry in adult rat hypothalamic neurons. However, the majority of neurons did not react with type II receptor antibody. This finding implies that only a minority of hypothalamic neurons are capable of responding to IGF-II via type II receptors. On the other hand, all astrocytes had striking type II receptor immunoreactivity. This signifies a more general biological role for this receptor in astrocytes compared with neurons. These results suggest that different tissue-, developmental stage-, and cell-specific processes are mediated by IGF receptors and suggests new directions in which to explore potential biological actions for these receptor-ligand systems in the CNS.

  View details for PubMedID 2969324

• DEMONSTRATION OF INSULIN-LIKE GROWTH-FACTOR (IGF-I AND IGF-II) RECEPTORS AND BINDING-PROTEIN IN HUMAN-BREAST CANCER CELL-LINES BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS DeLeon, D. D., Bakker, B., Wilson, D. M., Hintz, R. L., Rosenfeld, R. G. 1988; 152 (1): 398-405

  Abstract

  The insulin like growth factors (IGFs), potent mitogens for a variety of normal and transformed cells, have been reported to be secreted by several human breast cancer cell lines (BC). We have investigated the binding characteristics of IGF-I and -II in four human BC: MCF-7, T-47D, MDA 231 and Hs578T. Binding studies in microsomal membrane preparations detected high specific binding for both IGF in all four BC studied. Cross-linking with 125I-IGF-I, followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reduced conditions, revealed the presence of an alpha subunit of apparent Mr = 130,000 in MCF-7, T-47D and MDA 213 cells. When 125I-IGF-II was cross-linked, a major band of apparent Mr = 260,000 was seen in all BC. This band was inhibited by IGF-II, but not by insulin. Cross-linking of 125I-IGF-I to conditioned media from BC demonstrated the presence of three binding proteins of apparent Mr = 45,000, 36,000 and 29,000 in all BC but T-47D, in which the 36,000 band was not seen. These data demonstrate that BC possess classical receptors for both IGF-I and -II and, furthermore, that BC produce specific binding proteins for these growth factors.

  View details for PubMedID 2451917

• CARBOHYDRATE AND LIPID-METABOLISM IN TURNER SYNDROME - EFFECT OF THERAPY WITH GROWTH-HORMONE, OXANDROLONE, AND A COMBINATION OF BOTH JOURNAL OF PEDIATRICS Wilson, D. M., Frane, J. W., Sherman, B., Johanson, A. J., Hintz, R. L., Rosenfeld, R. G. 1988; 112 (2): 210-217

  Abstract

  To evaluate the effects of growth-promoting therapy on carbohydrate metabolism in girls with Turner syndrome, we determined glucose and insulin concentrations during oral glucose tolerance tests (OGTTs) at baseline and after 5 days, 2 months, and 12 months of treatment with growth hormone (GH), oxandrolone, or a combination of GH and oxandrolone, or after the same intervals with no therapy. Before therapy, subjects had a significantly greater glucose response during OGTT than published normal control values. There were no significant changes in mean fasting glucose, cholesterol, or triglyceride concentrations in any of the treatment groups. The integrated glucose concentrations rose significantly over baseline values in the oxandrolone group at 2 and 12 months and in the combination group at 5 days. There were significant increases in the mean integrated insulin concentrations at 2 and 12 months for the group receiving oxandrolone alone and at all three times for the group receiving combination therapy. Thus oxandrolone, alone or in combination with GH, had significant effects on carbohydrate metabolism in subjects with Turner syndrome, whereas GH alone did not.

  View details for PubMedID 3276862

• EFFECTS OF TESTOSTERONE THERAPY FOR PUBERTAL DELAY AMERICAN JOURNAL OF DISEASES OF CHILDREN Wilson, D. M., Kei, J., Hintz, R. L., Rosenfeld, R. G. 1988; 142 (1): 96-99

  Abstract

  We reviewed the effects of a brief course of testosterone enanthate (four intramuscular injections of 200 mg at three-week intervals) on pubertal advancement and final adult height in 50 male patients with delayed puberty. Although those treated with testosterone were slightly older than a group of 38 untreated subjects, the two groups had similar baseline mean bone age delays, height z scores, Tanner stages, predicted adult heights, growth rates, and midparental heights. Four months after baseline, the treated group had a significantly greater mean increase in the height z score and sexual maturation index. At 12 months, the mean increase in the sexual maturation index remained greater in the treated group. Among treated and untreated subjects older than 17 years, there was no significant difference in the absolute height z score. Over 95% of treated subjects were satisfied with the effects of therapy.

  View details for Web of Science ID A1988L526200031

  View details for PubMedID 3341306

• LINEAR GROWTH-RESPONSE TO EXOGENOUS GROWTH-HORMONE IN PRADER-WILLI SYNDROME AMERICAN JOURNAL OF MEDICAL GENETICS Lee, P. D., Wilson, D. M., ROUNTREE, L., Hintz, R. L., Rosenfeld, R. G. 1987; 28 (4): 865-871

  Abstract

  Linear growth retardation and adult short stature are usual characteristics of Prader-Willi syndrome. Several lines of evidence suggest that a deficiency in growth hormone (GH) secretion may contribute to this abnormal growth pattern. We have recently reported observations in 4 children with Prader-Willi syndrome treated with GH. This report extends our observations in 2 of these cases. Both cases had abnormally low growth rate, normal stimulated GH levels, and low somatomedin-C levels prior to therapy. GH treatment led to significant increases in linear growth rate and somatomedin-C levels. An additive effect of oxandrolone therapy on linear growth rate was demonstrated in one case. Our results support the possibility of a neuro-secretory GH deficiency in Prader-Willi syndrome and suggest a need for further investigations.

  View details for Web of Science ID A1987K914200010

  View details for PubMedID 3688024

• TREATMENT OF SHORT STATURE AND DELAYED ADOLESCENCE PEDIATRIC CLINICS OF NORTH AMERICA Wilson, D. M., Rosenfeld, R. G. 1987; 34 (4): 865-879

  Abstract

  The treatment of growth failure in children with documented GH deficiency remains the only noncontroversial indication for GH therapy. There are increasing data suggesting that GH may be useful in treating some children with Turner's syndrome and with NVSS. Further studies, however, are necessary to evaluate the long-term efficacy and safety of GH therapy in these children. The treatment of non-GH deficient children whose heights are within two standard deviations of the mean height for age is clearly inappropriate and should be avoided, despite parental protests.

  View details for Web of Science ID A1987J442600004

  View details for PubMedID 3302896

• GROWTH-CURVES AND ADULT HEIGHT ESTIMATION FOR ADOLESCENTS AMERICAN JOURNAL OF DISEASES OF CHILDREN Wilson, D. M., Kraemer, H. C., Ritter, P. L., Hammer, L. D. 1987; 141 (5): 565-570

  Abstract

  Using data from the large number of adolescents studied in cycle III of the National Health Examination Survey, we utilized a sexual maturity index to develop a set of growth curves that reduce the distortion caused by commingling height data from adolescents maturing at different rates. We also created a set of correction tables to be used with these curves to permit the calculation of an adjusted height percentile that compensates for the effects of the differing rates of pubertal maturation. These adjusted height percentiles should remain more constant throughout puberty than height percentiles obtained from traditional growth curves; they may thus be used to estimate final adult height with only data obtained during routine physical examinations, by assuming that subjects maintain their adjusted height percentile through adolescence to adulthood. Height predictions made in this manner compare favorably with predictions made using two clinically tested algorithms.

  View details for Web of Science ID A1987H069200039

  View details for PubMedID 3578172

• TRANSPLANTATION OF INSULIN-LIKE GROWTH FACTOR-II-SECRETING TUMORS INTO NUDE RODENTS ENDOCRINOLOGY Wilson, D. M., Thomas, J. A., Hamm, T. E., Wyche, J., Hintz, R. L., Rosenfeld, R. G. 1987; 120 (5): 1896-1901

  Abstract

  Restricted supplies of insulin-like growth factor II (IGF-II) have severely limited investigation of the in vivo actions of this hormone. To circumvent this problem, we have developed an in vivo rodent model in which rat (r) IGF-II-secreting cells (18, 54-SF) are transplanted into congenitally immunodeficient (nude) rats and mice. These cells proliferate and form discrete tumors that contain rIGF-II and abundant IGF-II receptors. The tumors also secrete rIGF-II into the circulation, resulting in plasma rIGF-II concentrations many-fold greater than those in control rodents (81 +/- 19 vs. less than 10 ng/ml, rats; 159 +/- 28 vs. 18 +/- 5 ng/ml, mice; P less than 0.05, both groups). There was no significant difference between the tumor-bearing and control rodents in either body weight or tail length. The tumor-bearing rodents did have significantly lower concentrations of IGF-I (296 +/- 23 vs. 527 +/- 67 ng/ml, rats; 300 +/- 26 vs. 482 +/- 70 ng/ml, mice; P less than 0.05, both groups), suggesting that the increased concentrations of rIGF-II may have inhibited IGF-I production or secretion. This animal model may be used to explore the biological effects of increased plasma IGF-II concentrations.

  View details for Web of Science ID A1987H165300027

  View details for PubMedID 3569119

• ACROMEGALY AND PHEOCHROMOCYTOMA - A MULTIPLE ENDOCRINE SYNDROME CAUSED BY A PLURIHORMONAL ADRENAL-MEDULLARY TUMOR JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Roth, K. A., Wilson, D. M., Eberwine, J., Dorin, R. I., Kovacs, K., Bensch, K. G., Hoffman, A. R. 1986; 63 (6): 1421-1426

  Abstract

  A 42-yr-old man with congestive heart failure and diabetes mellitus was found to have acromegaly and a pheochromocytoma. Serum GH-releasing hormone (GHRH) levels were elevated (2.34 ng/dl; normal, less than 0.02 ng/dl), suggesting that the acromegaly was caused by ectopic secretion of GHRH. Postmortem examination revealed that the right adrenal gland contained a pheochromocytoma in which GHRH was demonstrated by immunohistochemical studies. Gel permeation chromatography combined with the use of two GHRH antisera showed that GHRH-(1-44)-NH2 was a predominant form of the hormone. When the RNA from the tumor was extracted and analyzed by Northern gel blotting, two mRNA species were identified, with transcripts corresponding to 1600 and 780 base pairs. The pituitary gland was enlarged, but no distinct adenoma was found. Diffuse and nodular hyperplasia of somatotrophs in some areas resembling adenoma was identified on histological examination. These findings indicate that GH excess accompanied by somatotroph hyperplasia and acromegaly were secondary to a pheochromocytoma which secreted not only catecholamines but also GHRH.

  View details for Web of Science ID A1986E916800028

  View details for PubMedID 3097056

• GROWTH AND INTELLECTUAL-DEVELOPMENT PEDIATRICS Wilson, D. M., Hammer, L. D., Duncan, P. M., DORNBUSCH, S. M., Ritter, P. L., Hintz, R. L., Gross, R. T., Rosenfeld, R. G. 1986; 78 (4): 646-650

  Abstract

  Data from the National Health Examination Survey (cycles II and III) provided a representative sample of 13,887 US youths (6 to 17 years of age) with which to examine the relationship between height (normalized for age and sex) and measures of intellectual development (Wechsler Intelligence Scale for Children) and academic achievement (Wide Range Achievement Test). Additionally, 2,177 subjects were studied first in cycle II and 2 to 5 years later in cycle III, forming a well-selected longitudinal study group in which to examine any association between linear growth and change in IQ scores. Wechsler Intelligence Scale for Children and Wide Range Achievement Test scores were significantly correlated with height in both cycle II and cycle III. However, no significant association between change in relative height and change in IQ scores could be detected in the longitudinal group. These data suggest that therapies designed to increase height are unlikely to alter measures of intellectual development or academic achievement.

  View details for Web of Science ID A1986E252900018

  View details for PubMedID 3763275

• REDUCTION OF PITUITARY SIZE BY THE SOMATOSTATIN ANALOG SMS 201-995 IN A PATIENT WITH AN ISLET CELL TUMOR SECRETING GROWTH-HORMONE RELEASING-FACTOR ACTA ENDOCRINOLOGICA Wilson, D. M., Hoffman, A. R. 1986; 113 (1): 23-28

  Abstract

  Acromegaly is rarely caused by the ectopic secretion of growth hormone releasing factor (GRF) from peripheral neuroendocrine tumours. We evaluated the ability of a recently developed somatostatin analogue (SMS 201-995, Sandoz) to reduce hormone levels and pituitary size in a young woman with acromegaly and Zollinger-Ellison syndrome secondary to a metastatic pancreatic islet cell tumour secreting GRF and gastrin. Gastrin, GRF, and growth hormone (GH) levels declined dramatically following the initiation of therapy with the analogue by continuous iv infusion. Although intermittent sc therapy was not effective in suppressing hormone levels, continuous sc infusion of SMS 201-995 has provided good control of both GRF and GH levels for nine months. Moreover, treatment with SMS 201-995 was associated with a substantial reduction in pituitary enlargement and an improvement in her gastric symptoms. Continuous sc infusion of SMS 201-995 may be useful in treating enlarged pituitaries resistant to other modes of therapy.

  View details for Web of Science ID A1986E141000005

  View details for PubMedID 2876570

• INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II IN EVALUATION OF GROWTH-RETARDATION JOURNAL OF PEDIATRICS Rosenfeld, R. G., Wilson, D. M., Lee, P. D., Hintz, R. L. 1986; 109 (3): 428-433

  Abstract

  Plasma samples from 68 growth hormone (GH)-deficient children (provocative serum GH level less than 7 ng/ml), 44 normal short children, and 197 children with normal height were assayed by specific radioimmunoassays for the somatomedin peptides, insulin-like growth factors (IGF)-I and -II. Eighteen percent of the GH-deficient children had IGF-I levels within the normal range for age, whereas 32% of normal short children had low IGF-I levels. Low IGF-II levels were found in 52% of GH-deficient children, but also in 35% of normal short children. However, only 4% of GH-deficient children had normal plasma levels of both IGF-I and IGF-II. Furthermore, only 0.5% of normal children and 11% of normal short children had low plasma levels of both IGF-I and IGF-II. We conclude that plasma levels of either IGF-I or IGF-II overlap in GH-deficient and normal short children, but that the combination of radioimmunoassays may permit better discrimination among normal, normal short, and GH-deficient children.

  View details for Web of Science ID A1986D885600006

  View details for PubMedID 3746530

• TESTICULAR-TUMORS WITH PEUTZ-JEGHERS SYNDROME CANCER Wilson, D. M., Pitts, W. C., Hintz, R. L., Rosenfeld, R. G. 1986; 57 (11): 2238-2240

  Abstract

  The case of a 6-year-old boy with Peutz-Jeghers syndrome (PJS), gynecomastia, and multifocal and bilateral testicular tumors is described. Females with PJS are known to be at increased risk for developing gonadal tumors. This case and other reports from the literature suggest that males, as well as females, with PJS are at risk for developing gonadal tumors.

  View details for Web of Science ID A1986C312100027

  View details for PubMedID 3697923

• SEX-CHROMOSOME FRAGMENT IN A PHENOTYPICALLY NORMAL FEMALE - SIGNIFICANCE OF OCCULT Y-RELATED MATERIAL CLINICAL PEDIATRICS Wilson, D. M., Hintz, R. L., Ross, J. C., Rosenfeld, R. G. 1986; 25 (1): 36-39

  Abstract

  The authors report a 15-year-old short, nonvirilized, prepubertal female whose peripheral karyotype revealed a mosaicism in which 62 percent of the cells had a karyotype of 45X, and the other 38 percent had a karyotype of 46X plus a small unidentified marker chromosome. Since the authors were unable to determine from the karyotype whether this marker was derived from an X or a Y chromosome and because of the high risk for neoplasia in abnormal gonads containing Y material, she underwent surgical exploration, with removal of gonadal tissue. Microscopic examination of the streak gonads revealed a mixture of dysgenetic ovarian and testicular type tissues. The presence of testicular-like tubules strongly implied the presence of Y material in the genotype. Review of the literature reveals at least 19 similar cases in which presumed sex chromosomal markers or fragments were found in phenotypically normal females. Because of the risk of gonadal neoplasia in patients with occult Y chromosomal material, gonadectomy is indicated when the origin of the marker chromosome is uncertain.

  View details for Web of Science ID A1986AYY2000005

  View details for PubMedID 3455908

• THE MEASUREMENT OF ARTERIAL SMOOTH-MUSCLE CELL MITOGENS IN THE BLOOD OF ORAL-CONTRACEPTIVE USERS ATHEROSCLEROSIS Bagdade, J. D., Subbaiah, P. V., Hintz, R. L., Wilson, D. M. 1985; 56 (2): 149-155

  Abstract

  We have previously shown that serum from young women receiving the same combined mestranol-norethindrone containing oral contraceptive (OC) preparation accelerated the proliferation of arterial smooth muscle cells (SMC) in tissue culture, and this in vitro effect was not a direct action of either of its estrogenic or progestogenic constituents. To identify the substance(s) which might contribute to this potentially atherogenic action, blood was obtained from 20 OC users and control women for the measurement of growth hormone, insulin, somatomedins (insulin-like growth factor IGF-I and IGF-II), and the platelet alpha-granule constituents platelet-derived growth factor (PDGF), beta-thromboglobulin, and platelet factor 4 (PF4). No difference was demonstrable between OC users and controls in the levels of any of these growth-promoting hormones, nor in plasma concentrations of any of the platelet alpha-granule proteins. These studies indicate that the enhanced mitogenicity found in OC sera is probably not attributable directly to these hormones or PDGF, and may instead result from an in vivo OC-induced alteration in other as yet unidentified mediators of cellular growth.

  View details for Web of Science ID A1985APA1100003

  View details for PubMedID 2934071

• REGULATION OF GROWTH-HORMONE RELEASE FROM CULTURED HUMAN PITUITARY-ADENOMAS BY SOMATOMEDINS AND INSULIN JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Ceda, G. P., Hoffman, A. R., Silverberg, G. D., Wilson, D. M., Rosenfeld, R. G. 1985; 60 (6): 1204-1209

  Abstract

  GH secretion is stimulated by hypothalamic GH-releasing factor (GHRH) and inhibited by somatostatin. Since GH induces the production of insulin-like growth factors (IGF) in liver and other tissues, it is of interest to learn whether IGF alters GH release through long loop feedback inhibition. Pituitary adenomas which had been removed from six acromegalic patients were processed for dispersed cell cultures and/or cell membrane preparations. Binding studies using 125I-labeled IGF-I, IGF-II, and insulin revealed specific hormone binding for each ligand to cell membranes derived from four somatotropinomas. A partially purified somatomedin preparation inhibited basal and/or GHRH-stimulated GH release from cultured pituitary cells derived from three of four adenomas; there was no effect of somatomedin in one tumor. In a single tumor, insulin also partially inhibited GHRH-stimulated GH release. Additionally, in one nonadenomatous pituitary removed from a patient with diabetes mellitus, insulin and somatomedin inhibited GHRH-stimulated GH release, and insulin inhibited basal GH secretion. These results indicate that specific cell membrane receptors for somatomedin peptides and insulin may be found on cell membranes from GH-secreting tumors, and that somatomedins and insulin can inhibit GH release in cultured human somatotropinoma cells. Thus, these data suggest that somatomedins may exert feedback inhibition of GH secretion in some patients with acromegaly.

  View details for Web of Science ID A1985AHM2400025

  View details for PubMedID 3889029

• INCREASED PLASMA INACTIVE RENIN IN DIABETES-MELLITUS - A MARKER OF MICROVASCULAR COMPLICATIONS NEW ENGLAND JOURNAL OF MEDICINE LUETSCHER, J. A., Kraemer, F. B., Wilson, D. M., Schwartz, H. C., Bryerash, M. 1985; 312 (22): 1412-1417

  Abstract

  Plasma renin exists in an active form or as an inactive zymogen that resembles a prorenin present in homogenates of human kidneys. We examined the relation of diabetes and its microvascular complications with the level of plasma inactive renin activated by dialysis to pH 3.3. Plasma inactive renin was measured in 235 diabetic patients and 90 nondiabetic controls. In the controls, the level of plasma inactive renin increased slightly with age but was never above 50 ng per milliliter per hour. In young diabetic patients studied within three years of the onset of diabetes the concentration of inactive renin was normal, and in some older diabetics without complications it remained within the age-adjusted normal range for many years. However, in patients with retinopathy or albuminuria, plasma inactive renin was above the normal range with few exceptions, reaching levels 50 to 200 per cent above the upper limits of normal in patients with nephropathy. The frequency of neuropathy was also significantly higher among patients with levels above the normal range. In 37 per cent of the diabetics followed during one to three years of conventional treatment, plasma inactive renin increased significantly, but in another group of diabetics under intensive treatment, the level rose in only 7 per cent and fell in 43 per cent. We conclude that there is a close association between a high level of plasma inactive renin and the presence of microvascular complications, and that the level of inactive renin can be modified by intensive treatment of diabetes.

  View details for Web of Science ID A1985AHZ2600002

  View details for PubMedID 3887168

• HYPERTENSION CAUSED BY AN ALDOSTERONE-SECRETING ADENOMA - OCCURRENCE IN A 7-YEAR-OLD CHILD AMERICAN JOURNAL OF DISEASES OF CHILDREN Bryerash, M., Wilson, D. M., Tune, B. M., Rosenfeld, R. G., Shochat, S. J., LUETSCHER, J. A. 1984; 138 (7): 673-676

  Abstract

  A 7-year-old girl had hyperaldosteronism due to an adrenal cortical adenoma, a rare, surgically remediable cause of hypertension. Although the plasma potassium concentration was only slightly below normal, and the plasma aldosterone concentration was in a high normal range, the consistently suppressed plasma renin activity suggested primary aldosteronism. This diagnosis was confirmed by the failure of saline infusion to lower the plasma aldosterone concentration. Glucocorticoid-remediable hyperaldosteronism was excluded when dexamethasone did not reduce the high plasma aldosterone concentration. An enlarged left adrenal gland was observed in the computed tomographic scan, and blood from the left adrenal vein contained much more aldosterone than blood from the right adrenal vein. Surgical excision of the left adrenal gland, containing an adenoma, was followed by a return of BP and biochemical measurements to their normal ranges. This case demonstrated the importance of a rational systematic approach in the evaluation of children with sustained unexplained hypertension and the need to obtain plasma renin activity values when either hypokalemia is present or initial investigations fall to provide a diagnosis.

  View details for Web of Science ID A1984SY11300015

  View details for PubMedID 6375348

• RECEPTORS FOR INSULIN-LIKE GROWTH-FACTORS ON CULTURED PITUITARY-CELLS CEDA, G. P., HOFFMAN, A. R., WILSON, D. M., DOLLAR, L. A., ROSENFELD, R. G. SLACK INC. 1984: A19

  View details for Web of Science ID A1984RZ82200115

• ACUTE SOMATOMEDIN RESPONSE DURING SUBCUTANEOUS AND INTRAMUSCULAR HUMAN GROWTH-HORMONE THERAPY WILSON, D. M., BAKER, B. K., HINTZ, R. L., ROSENFELD, R. G. SLACK INC. 1984: A54

  View details for Web of Science ID A1984RZ82200324

• ACROMEGALY AND ZOLLINGER-ELLISON SYNDROME SECONDARY TO AN ISLET CELL TUMOR - CHARACTERIZATION AND QUANTIFICATION OF PLASMA AND TUMOR HUMAN GROWTH HORMONE-RELEASING FACTOR JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Wilson, D. M., Ceda, G. P., Bostwick, D. G., Webber, R. J., Minkoff, J. R., Pont, A., Hintz, R. L., Bensch, K. G., Kraemer, F. B., Rosenfeld, R. G., Hoffman, A. R. 1984; 59 (5): 1002-1005

  Abstract

  A young woman with acromegaly and Zollinger-Ellison syndrome associated with a GH-releasing factor (GRF)- and gastrin-secreting metastatic islet cell carcinoma was studied by means of specific antisera which recognize various regions of the GRF molecule. Using specific immunohistochemical techniques, the tumor cells were shown to contain GRF, gastrin, and gastrin-releasing peptide, but not GH. During a 4-h period, plasma GRF levels averaged 5.6 +/- 1.4 ng/ml (+/- SD), while GH levels averaged 148 +/- 71 ng/ml. GH secretion was pulsatile and increased after TRH administration. GRF RIAs may be useful in establishing the diagnosis of acromegaly secondary to the ectopic secretion of GRF.

  View details for Web of Science ID A1984TP17300031

  View details for PubMedID 6090497

• PROSPECTIVE CLINICAL-TRIAL OF HUMAN GROWTH-HORMONE IN SHORT CHILDREN WITHOUT GROWTH-HORMONE DEFICIENCY JOURNAL OF PEDIATRICS Gertner, J. M., Genel, M., GIANFREDI, S. P., Hintz, R. L., Rosenfeld, R. G., Tamborlane, W. V., Wilson, D. M. 1984; 104 (2): 172-176

  Abstract

  Ten unselected, apparently healthy short children who were capable of normal growth hormone secretion were given human growth hormone (0.1 U/kg 1M thrice weekly) for 6 months to determine whether such treatment might lead to an increase in growth velocity. During treatment, all patients increased their growth rate (from 4.3 +/- 0.3 cm/yr to 7.4 +/- 0.5 cm/yr P less than 0.001). No adverse effects were detected. During the four-day IGF generation test, IGF I and IGF II levels rose significantly from 0.32 +/- 0.04 U/ml to 0.62 +/- 0.13 U/ml and from 279 +/- 36 ng/ml to 434 +/- 49 ng/ml, respectively. However, the growth response was not predicted by either the acute rise in IGF I or that in IGF II. Human growth hormone in standard doses may be capable of inducing accelerated growth in some short children without growth hormone deficiency. Measurements of IGF I and II cannot be used to predict which children will respond.

  View details for Web of Science ID A1984SC70100002

  View details for PubMedID 6363657

• CHARACTERIZATION OF HIGH-AFFINITY RECEPTORS FOR INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II ON RAT ANTERIOR-PITUITARY CELLS ENDOCRINOLOGY Rosenfeld, R. G., Ceda, G., Wilson, D. M., DOLLAR, L. A., Hoffman, A. R. 1984; 114 (5): 1571-1575

  Abstract

  Primary cultures of rat anterior pituitary cells were assessed for the presence of specific receptors for insulin and for the somatomedin peptides, insulin-like growth factors I and II (IGF-I and IGF-II). Specific binding per 100,000 pituitary cells averaged 9.45 +/- 1.69% (mean +/- SD) for [125I]IGF-II, 0.83 +/- 0.06% for [125I]IGF-I, and only 0.11% for [125I]insulin, IGF-II was twice as potent as IGF-I in displacing [125I]IGF-II, while insulin was totally nonreactive, IGF-I was 5-fold more potent than IGF-II at displacing [125I]IGF-I and 1000-fold more potent than insulin. Scatchard analysis of [125I]IGF-II binding revealed a curvilinear plot, which could be resolved into a high affinity receptor with a Ka of 7.0 X 10(8) M-1 and 120,000 receptor sites/cell, and a low affinity receptor with a Ka of 1.1 X 10(8) M-1 and 720,000 receptor sites/cell. The existence of abundant high affinity somatomedin receptors (especially for IGF-II) on rat anterior pituitary cells is consistent with a potential role for these peptides in the regulation of GH secretion.

  View details for Web of Science ID A1984SP24200014

  View details for PubMedID 6325123

• COMPUTED TOMOGRAPHIC FINDINGS IN SEPTO-OPTIC DYSPLASIA - DISCORDANCE BETWEEN CLINICAL AND RADIOLOGICAL FINDINGS NEURORADIOLOGY Wilson, D. M., Enzmann, D. R., Hintz, R. L., Rosenfeld, G. 1984; 26 (4): 279-283

  Abstract

  The clinical and radiological findings in four children with septo-optic dysplasia are reported. All four had growth retardation associated with growth hormone deficiency, as well as varying degrees of ophthalmologic dysfunction. The CT scan findings spanned a spectrum from normal to the expected abnormalities involving the ventricular system and orbits. Only two of the four had an absent septum pellucidum. A third patient had normal CT scans except for optic nerve hypoplasia, while the fourth had entirely normal CT scans of both the brain and orbits. Because the anatomic defects of septo-optic dysplasia may be subtle, an apparently normal CT scan does not invalidate the clinical diagnosis of septo-optic dysplasia.

  View details for Web of Science ID A1984SZ02800005

  View details for PubMedID 6462434

• SOMATOMEDINS IN ADOLESCENCE - A CROSS-SECTIONAL STUDY OF THE EFFECT OF PUBERTY ON PLASMA INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II LEVELS JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Luna, A. M., Wilson, D. M., Wibbelsman, C. J., Brown, R. C., Nagashima, R. J., Hintz, R. L., Rosenfeld, R. G. 1983; 57 (2): 268-271

  Abstract

  To explore the effect of puberty on the somatomedins (SMs), a group of insulin-like peptides which mediate the action of GH on skeletal tissue, we measured SM-C/insulin-like growth factor-I (SM-C/IGF-I) and IGF-II by specific RIAs in 110 adolescents between the ages of 10 and 18 yr. All subjects were in good health and between the 5th and 95th percentiles for height. In both females and males, SM-C/IGF-I levels rose during puberty to a peak approximately 3-fold higher than the average adult level. The rise in SM-C/IGF-I levels corresponded better with the Tanner stage of the adolescents than with their chronological age. IGF-II levels did not rise during puberty and were slightly below adult levels. The dramatic rise in SM-C/IGF-I levels during puberty suggests a role for this SM peptide in the adolescent growth spurt. Furthermore, these data indicate that proper interpretation of SM-C/IGF-I levels during adolescence must include a knowledge of the patient's pubertal development.

  View details for Web of Science ID A1983QZ90300005

  View details for PubMedID 6345568

• SOMATOMEDINS IN ADOLESCENCE - THE EFFECT OF PUBERTY ON PLASMA-LEVELS OF INSULIN-LIKE FACTOR-I AND FACTOR-II WILSON, D. M., LUNA, A. M., HINTZ, R. L., ROSENFELD, R. G. SLACK INC. 1983: A61

  View details for Web of Science ID A1983PU88600368

• INTER-SPECIES COMPARISON OF SOMATOMEDIN STRUCTURE USING IMMUNOLOGICAL PROBES JOURNAL OF ENDOCRINOLOGY Wilson, D. M., Hintz, R. L. 1982; 95 (1): 59-64

  View details for Web of Science ID A1982PN26100009

  View details for PubMedID 6752325

• EVALUATION OF SERUM FREE-THYROXINE LEVELS IN TERM, PRETERM, AND SICK INFANTS HOPPER, A. O., WILSON, D. M., MCDOUGALL, I. R., BAYER, M. F., HINTZ, R. L., ROSENFELD, R. G., STEVENSON, D. K. SLACK INC. 1982: A113

  View details for Web of Science ID A1982MX91200665

• SERUM FREE-THYROXINE VALUES IN TERM, PREMATURE, AND SICK INFANTS JOURNAL OF PEDIATRICS Wilson, D. M., Hopper, A. O., McDougall, I. R., BAYER, M. F., Hintz, R. L., Stevenson, D. K., Rosenfeld, R. G. 1982; 101 (1): 113-117

  Abstract

  Free thyroxine concentrations were determined by radioimmunoassay in 96 infants within an intensive care nursery and in 32 healthy term infants. Sera for free T4 levels were drawn simultaneously with the filter paper specimens for T4 obtained to screen these infants for congenital hypothyroidism. The mean free T4 level in 20 adults was 1.38 +/- 0.03 ng/dl (mean +/- SEM). The mean in the ICN infants was 3.48 +/- 0.18 ng/dl and in healthy term infants, 4.24 +/- 0.23 ng/dl. Like T4, free T4 correlated positively with increasing gestational age and birth weight, and was lower in infants with RDS. Although 66% of the ICN infants had T4 levels below the statistically selected screening level (fifth percentile), all of these infants had free T4 levels greater than 0.8 ng/dl. Two additional infants with untreated congenital hypothyroidism has free T4 levels of 0.3 and 0.4 ng/dl. The measurement of free T4 appears to be an accurate indicator of thyroid function in these infants.

  View details for Web of Science ID A1982NX34400029

  View details for PubMedID 7086610

• SOMATOMEDINS IN PREGNANCY - A CROSS-SECTIONAL STUDY OF INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II AND SOMATOMEDIN PEPTIDE CONTENT IN NORMAL HUMAN PREGNANCIES JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Wilson, D. M., Bennett, A., Adamson, G. D., Nagashima, R. J., Liu, F., DENATALE, M. L., Hintz, R. L., Rosenfeld, R. G. 1982; 55 (5): 858-861

  Abstract

  To explore the role of the somatomedins (SM) during human pregnancy, we have measured plasma levels of insulin-like growth factor I (IGF-I), IGF-II, and SM peptide content (SMPC) in 79 women in various stages of normal pregnancies. IGF-I and IGF-II were measured by specific RIAs, and SMPC was measured by a radioreceptor assay using human placental membranes. IGF-I and SMPC rose during pregnancy, showing a significant positive correlation with the length of gestation. Plasma levels of IGF-I in the third trimester averaged 324 ng/ml, a 33% increase over the first trimester average of 243 ng/ml (P less than 0.05). Although IGF-II did not correlate with the length of gestation, the third trimester average was significantly higher than the first trimester average (780 vs. 630 ng/ml; P less than 0.05). After delivery, both IGF-I and IGF-II levels rapidly dropped to levels significantly below those seen in the third trimester. The gestational rise in SMPC and plasma levels of both IGF-I and IGF-II supports the hypothesis that SM play a role in the regulation of fetal growth.

  View details for Web of Science ID A1982PM14600006

  View details for PubMedID 6749878

• BIOSYNTHETIC METHIONYL HUMAN GROWTH-HORMONE IS BIOLOGICALLY-ACTIVE IN ADULT MAN LANCET Hintz, R. L., Wilson, D. M., FINNO, J., Rosenfeld, R. G., Bennett, A., MCCLELLAN, B. 1982; 1 (8284): 1276-1279

  Abstract

  The acute effects of synthetic methionyl human growth hormone produced by recombinant DNA technology were compared with those of pituitary human growth hormone in 22 healthy male volunteers. Both caused increases in somatomedin and triglycerides and decreases in blood urea nitrogen and cholesterol. By all indices measured, synthetic methionyl human growth hormone was equipotent with pituitary human growth hormone. The ability to make biologically active synthetic human growth hormone creates an essentially unlimited supply of growth hormone for the treatment of hypopituitarism and for the study of additional therapeutic indications.

  View details for Web of Science ID A1982NT14800005

• BOTH HUMAN PITUITARY GROWTH-HORMONE AND RECOMBINANT DNA-DERIVED HUMAN GROWTH-HORMONE CAUSE INSULIN RESISTANCE AT A POSTRECEPTOR SITE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Rosenfeld, R. G., Wilson, D. M., DOLLAR, L. A., Bennett, A., Hintz, R. L. 1982; 54 (5): 1033-1038

  Abstract

  We have investigated the effects on carbohydrate metabolism of human GH produced by recombinant DNA technology (methionyl-hGH) compared with pituitary hGH. Twelve normal adult male subjects received four daily im injections of either methionyl-hGH or pituitary hGH in a double blind, crossover study. Oral glucose tolerance tests and assays of insulin binding to peripheral monocytes were performed before th initial administration and 12 h after the fourth injection of both hGH preparations. Both methionyl-hGH and pituitary hGH resulted in significant carbohydrate intolerance, with a rise in fasting plasma glucose from 96.6 +/- 2.9 to 105.9 +/- 3.0 mg/ml (mean +/- SEM) after pituitary hGH and from 96.2 +/- 1.5 to 107.5 +/- 3.3 mg/dl after methionyl-hGH (P less than 0.01). The area under the glucose tolerance curve increased by 34% after pituitary hGH and by 37% after methionyl-hGH. With both hGH preparations, carbohydrate intolerance was associated with marked hyperinsulinemia, with a rise in fasting plasma insulin levels from 9.4 +/- 1.2 to 33.2 +/- 7.8 microU/ml after pituitary hGH and from 7.4 +/- 1.1 to 45.8 +/- 11.1 microU/ml after methionyl-hGH (P less than 0.01). The integrated plasma insulin levels during the oral glucose tolerance test tripled after both hGH preparations. The pronounced insulin resistance could not be attributed to an alteration in insulin receptor concentrations. Both hGH preparations were associated with small reductions in insulin binding to monocytes at tracer concentrations, but the decline in binding was not statistically significant. The calculated binding sites per cell and Ke were not significantly altered by hGH administration. We conclude that methionyl-hGH and pituitary hGH are indistinguishable in their ability to induce insulin-resistant carbohydrate intolerance. This decrease in insulin sensitivity cannot be attributed to an alteration in insulin binding, and presumably represents a postreceptor defect in insulin action.

  View details for Web of Science ID A1982NK24700024

  View details for PubMedID 7037819

• ULTRADIAN CARDIAC RHYTHMS IN SURGICAL INTENSIVE-CARE UNIT PATIENTS PSYCHOSOMATIC MEDICINE Wilson, D. M., Kripke, D. F., MCCLURE, D. K., Greenburg, A. G. 1977; 39 (6): 432-435

  Abstract

  Several reports have suggested that heart rate may be regulated by an ultradian biological rhythm with a period of about 90--100 min. Blood pressure and heart rate were collected from 10 Surgical Intensive Care patients at 5-min intervals and analyzed by computer. No 90-min rhthms were found, indicating this rhythm has no significant influence on heart rate or blood pressure in postsurgical patients.

  View details for Web of Science ID A1977EE81400006

  View details for PubMedID 594287